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Thesis Abstract 
The vasculitides are a wide spectrum of disorders which are characterised by vascular 
inflammation. Endothelial injury can occur as a consequence of inappropriate 
inflammation and is central to the pathogenesis of these varied diseases.  This thesis 
documents the development of assays for detection of novel biomarkers of endothelial 
injury and/or activation and subsequent reparative responses in children with primary 
systemic vasculitis.  It focuses in particular on circulating endothelial cells, cellular 
microparticles, growth factors involved in angiogenesis/vasculogenesis and endothelial 
progenitor cells.   
 
Circulating endothelial cells are mature endothelial cells which have become detached 
from the vessel wall and represent a highly damaged vasculature and were found to be 
significantly higher in children with active primary systemic vasculitis compared to 
healthy child controls and patients in remission.  Microparticles are released from 
activated cells, including the endothelium and leukocytes.  In this study endothelial and 
monocyte derived microparticles were found to be elevated during active vasculitis.  
Growth factors released in response to endothelial injury regulate reparative responses, 
of which endothelial progenitor cells may play a key role.  In this study, patients at 
disease onset prior to treatment were found to have significantly higher levels of growth 
factors and endothelial progenitor cells, which decreased with remission inducing 
therapy.  Overall this thesis has investigated the changes in these interlinked biomarkers 
of injury and repair during active disease, remission and disease flare.  
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1 Introduction 
 
1.1. The endothelium and its functions 
 
1.2. Vasculitis – a clinical perspective 
 
1.3. The pathogenesis of vasculitis 
 
1.4. Assessment of disease activity in vasculitis – the need for reliable 
biomarkers 
 
1.5. Aims of this thesis 
 
17 
 
1.1 The endothelium and its functions 
The term “vasculitis” refers to inflammation affecting blood vessels.  The endothelium, 
which forms the inner layer of all blood vessels, is both central to the pathogenesis of 
the disease and can be directly damaged by the inflammatory processes, resulting in 
impairment of function.  This thesis therefore begins with a brief introduction to the 
endothelium, hilighting some of its key functions that are essential for health but may be 
impacted upon in vasculitis.  
 
In an adult human the endothelial monolayer consists of approximately 10
13
 cells 
covering an area of 1-7m
2
 (Cines et al., 1998).   Endothelial cells are supported by a 
basement membrane that is surrounded by varying thicknesses of smooth muscle and 
connective tissue depending on vessel type and function.  In the microvasculature where 
smooth muscle is absent, pericytes also sit within the basement membrane and surround 
the endothelium with long cytoplasmic processes (Allt and Lawrenson, 2001).  Prior to 
the discovery of the vasodilator prostacyclin in 1976 (Bunting et al., 1976) the 
endothelium was considered to be an inert barrier that separated blood and tissue.  
However, it is now apparent that the endothelium plays a role in many vital functions 
including: regulation of vessel tone and blood flow, fluid and solute exchange, 
haemostasis and coagulation, vasculogenesis and angiogenesis and inflammatory 
responses.   
 
1.1.1 Control of vessel tone 
In response to stimulation by substances in the blood (e.g. histamine, angiotensin, 5HT) 
or mechanical stimuli endothelial cells can release a number of vasoactive factors that 
relax (e.g. prostacyclin, nitric oxide (NO), hydrogen peroxide (H2O2)) or contract (e.g. 
18 
 
thromboxane A2, endothelin, angiotensin II) surrounding smooth muscle (Feletou and 
Vanhoutte, 2006).  Endothelial cells can also signal directly with smooth muscle via 
myoendothelial gap junctions, allowing the spread of membrane potential and small 
molecules and ions such as calcium (Ca
2+
) which in turn can alter vascular tone (Feletou 
and Vanhoutte, 2006).  
 
Global rise in intracellular Ca
2+
 directly influences the contractile state of vascular 
smooth muscle (VSM) (House et al., 2008).  This occurs via its binding of calmodulin 
and subsequent activation of myosin light chain kinase (MLCK), which results in the 
phosphorylation of myosin, allowing interaction with actin and the initiation of 
contraction (Rang et al., 1999).  The ability of the endothelium to activate/inhibit 
signalling pathways that crosstalk with this system, means that although Ca
2+
 is 
important for contraction, the relationship between Ca
2+
 concentration and the extent of 
contraction is not as clearly defined in VSM as it is in skeletal or cardiac muscle (Rang 
et al., 1999).  
 
1.1.2 Fluid and solute exchange 
The endothelium acts as a semi-permeable barrier and tightly controls the passage of 
large molecules and fluids between the blood and interstitial space.  Small molecules 
such as urea, glucose and ions easily pass across in a paracellular manner through 
interendothelial gap junctions (Lum and Malik, 1994).   However, larger molecules such 
as albumin cannot do this and, in the quiescent endothelium, they pass in an 
intracellular manner via vesicular transport.  Calveolae (pits) in the surface of the 
endothelium, develop into vesicles which pass across the cell, either independently via 
fluid-phase uptake or in a receptor dependent manner (Lum and Malik, 1994).  In 
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response to certain stimuli (such as histamine or vascular endothelial growth factor 
(VEGF)) interendothelial gap junctions become disrupted and larger molecules can pass 
through.  This transvascular flux of liquid and solutes from the circulation can rapidly 
lead to the oedema formation that is often associated with inflammation (Mehta and 
Malik, 2006).     
 
1.1.3 Haemostasis 
Damage to the luminal vessel wall can result in blood loss and haemostasis refers to the 
process by which it is stopped.  It is associated with vasoconstriction, adhesion and 
activation of platelets at the site of injury and a complex enzymatic activation cascade 
which culminates in the formation of a stable fibrin plug, effectively sealing the vessel 
(Hoffman and Monroe, 2007).   
 
Exposure to the blood of tissue factor (TF), the transmembrane receptor for factor VII, 
initiates this proteolytic clotting cascade, which ultimately results in the downstream 
activation of thrombin and its subsequent conversion of fibrinogen to the clot stabilizing 
polymer fibrin.  TF is constitutively expressed on a number of cells in the vessel wall 
(e.g. pericytes, fibroblasts and smooth muscle) (Camerer et al., 1996) but not on the 
endothelium, and thus under normal physiological conditions clotting should not be 
instigated.  However, TF can be expressed on tumour derived endothelium (Engelmann 
et al., 2003) and on endothelial cells in response to inflammation (Randolph et al., 
1998).  It is also found on activated monocytes and is associated with platelets and 
microparticles in the circulation (Muller et al., 2003).  On microparticles in healthy 
individuals it is thought to be in an inactive form (Furie and Furie, 2008).   
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Platelets are activated on contact with exposed collagen in the vessel wall and along 
with leucocytes form part of the thrombus, propagating the enzymatic cascade by acting 
as a surface upon which TF is exposed and where fibrin generating pathways can occur 
(Hoffman and Monroe, 2007).  Pathological thrombosis can occur in the absence of 
substantial endothelial damage, and platelet activation independent of collagen exposure 
may be an initiating event in this.           
 
During haemostasis the endothelium acts to influence both pro and anticoagulant 
pathways.  It synthesizes and secretes key components of the clotting cascade (e.g. von 
Willebrand factor (vWF) and plasminogen activator inhibitor-1(PAI-1)) (Becker et al., 
2000).  Conversely the endothelium also generates NO and prostacyclin (inhibiting 
platelet function), and activates a number of anticoagulant pathways that limit the 
thrombus formed.  These anticoagulant pathways are essential for preventing 
unnecessary pathological haemostasis and include expression of the surface 
glycoprotein heparan sulfate, which is a cofactor for the serine protease inhibitor 
antithrombin III (which can inhibit many of the clotting cascade enzymes) and 
thrombomodulin, a thrombin receptor which activates the anticoagulant protease protein 
C (Adams and Huntington, 2006). Tissue factor pathway inhibitor (TFPI) is 
constitutively released by the endothelium and interferes in the TF-activated factor VII 
complex (Lwaleed and Bass, 2006) Tissue plasminogen activator, released in response 
to procoagulant activity catalyses the conversion of plasminogen to plasmin - a key 
player in dissolution of the clot once injury has healed (Emeis, 1992).    
 
1.1.4 Angiogenesis and Vasculogenesis 
Once  haemostasis  has prevented blood loss from the vessel wall,  repair must  occur  to  
21 
 
prevent long term dysfunction.  In health, the integrity of the endothelium is maintained 
by a continuous renewal of cells.  Turnover of the endothelium is low, with replication 
rates in the region of 0.1% per day in adults (Hunting et al., 2005), although in healthy 
growing children it could well be higher.  
 
Until relatively recently angiogenesis, whereby mature endothelial cells already present 
within the vessel proliferate and migrate, was considered to be the mechanism by which 
growth, remodeling and repair of damage occurred.  Vasculogenesis, whereupon bone 
marrow derived progenitor cells are recruited to form new vasculature, was considered 
to occur only during early embryonic development.  The concept of post-embryonic 
vasculogenesis gained impetus in 1997 when Asahara et al described a population of 
CD34+ cells which circulated within the peripheral blood, had the potential to form 
endothelial-like cells in vitro and enhanced repair in an ischaemia-reperfusion model 
(Asahara et al., 1997).  These cells were termed endothelial progenitor cells (EPCs) and 
have been the subject of much research in recent years. 
 
Whether EPCs are true endothelial progenitors with the ability to form permanent long 
lasting endothelium is still open to debate a decade later.  One alternative hypothesis is 
that they promote a localized pro-angiogenic state and are only found transiently at sites 
of injury (Fazel et al., 2006), although this requires further confirmation.  Regardless of 
the exact mechanisms which contribute to repair, the regulators of these pathways 
(growth factors, chemokines and cytokines) a number of which act directly on or are 
released from the endothelium, are frequently the same in angiogenesis and 
vasculogenesis and thus these processes are likely to be highly interdependent. 
Angiogenesis and vasculogenesis are discussed in more detail in subsequent chapters.      
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1.1.5 Inflammatory responses and the endothelium 
The endothelium responds rapidly to pathological conditions being both affected by and 
contributing to the inflammatory process, secreting inflammatory cytokines and 
chemokines and upregulating adhesion molecules, facilitating leukocyte recruitment.  In 
health, these responses are reversible and localized, however sustained or inappropriate 
activation is associated with endothelial dysfunction and contributes to the development 
of cardiovascular diseases such as atherosclerosis (Loppnow et al., 2008).   
 
A wide number of cytokines and chemokines can be released from the endothelium in 
response to inflammatory stimuli such as treatment with lipopolysaccharide (LPS) or 
tumour necrosis factor-α (TNFα) in vitro, and shear stress, infection or hypoxia in vivo 
(Krishnaswamy et al., 1999).  These include acute phase response cytokines such as IL-
1 and IL-6, which are responsible for a number of the characteristic manifestations of 
inflammation including fever, generation of acute-phase reactants by hepatocytes and 
activation of lymphocytes (Marceau et al., 1992,Ala et al., 1992).  Chemokines 
produced include IL-8, which can recruit and activate neutrophils (Sica et al., 1990a), 
MCP-1 (monocyte chemoattractant protein-1) which recruits monocytes, activated T 
cells, dendritic cells, and natural killer (NK) cells (Sica et al., 1990b) and 
CCL5/RANTES (regulated upon activation normal T cell expressed and secreted), 
which recruits eosinophils.  Colony stimulating factors (CSF) released from endothelial 
cells such as GM-CSF (granulocyte-macrophage-CSF), M-CSF (macrophage-CSF) and 
G-CSF (granulocyte-CSF) alter the differentiation, activation, proliferation and 
migration of macrophages and granulocytes and may even promote the in situ longevity 
of these recruited inflammatory cells (Rajavashisth et al., 1990). 
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Leukocyte recruitment to the tissue from the circulation requires cells to migrate 
through the vessel wall.  The endothelium plays a key role in this by upregulating 
adhesion molecules which interact with leukocytes aiding their recruitment.  Endothelial 
E and P selectins acting on their carbohydrate ligands on leukocytes result in the 
leukocytes slowing down and rolling along the endothelial surface.   Rolling leukocytes 
rapidly become activated via immobilized chemokines on the endothelium (Johnston 
and Butcher, 2002) with upregulation of integrins on their surface.   Integrins on 
leukocytes contribute both to the rolling process (Ley et al., 2007) and to firm adhesion 
by binding members of the immunoglobulin superfamily on endothelial cells such as 
intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 
(VCAM-1) (Petri and Bixel, 2006). Subsequently leukocytes engage other adhesion 
molecules such as platelet/endothelial cell adhesion molecule-1 (PECAM-1), 
endothelial cell-selective adhesion molecule (ESAM), CD99 and members of the 
junctional adhesion molecule family (JAM) and cross the endothelial layer (Ley et al., 
2007).   
 
Studies utilizing neutralising antibodies indicate that different adhesion molecules 
mediate leukocyte transmigration depending on stimulus, leukocyte cell type or 
location.  In rat mesenteric arteries for example IL-1β but not FMLP induced leukocyte 
transmigration can be inhibited by the use of PECAM blocking antibodies (Thompson 
et al., 2000).  Leukocytes can cross the endothelium in a paracellular or transcellular 
manner (Feng et al., 1998). It remains to be determined whether both pathways are of 
equal physiological relevance or if, as has been observed in vitro, paracellular 
mechanisms are primary route of migration (Vestweber, 2007). 
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1.1.6 Conclusions 
The endothelium is a dynamic and heterogeneic organ system, with significant 
differences in response between endothelium of different vessels and even between cells 
in a similar location to certain stimuli.  With such a wide ranging and tightly regulated 
functionality preservation of a healthy endothelium is crucial to the maintenance of 
health and normal physiological homeostasis.  Inappropriate and sustained 
inflammatory responses (such as those seen in the vasculitides) are associated with 
endothelial dysfunction.  Endothelial dysfunction is a phenomeneon that is considered 
to be central to the pathogenesis of the vasculitides and hence this group of disorders 
will now be discussed in more detail.  
 
 
1.2 Vasculitis – a clinical perspective 
The vasculitides are a group of disorders characterised by the presence of inflammatory 
cellular infiltrates (neutrophilic, eosinophilic, or mononuclear) in the walls of blood 
vessels, with resultant tissue ischaemia and necrosis. Vasculitis can affect blood vessels 
of all sizes and can occur as the primary disease manifestation or secondary to other 
conditions, such as infection, malignancy or autoimmune diseases such as rheumatoid 
arthritis (RA), scleroderma, Sjogrens syndrome and systemic lupus erythematosus 
(SLE) amongst others. 
 
1.2.1 Primary systemic vasculitis 
Classification of the vasculitides has proved difficult because of the absence of sensitive 
and specific diagnostic tests and an incomplete understanding of the aetiology of most 
vasculitic syndromes.  Patients often have constellations of symptoms and findings that 
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overlap the clinical features of the various individual diseases.  Although many attempts 
have been made to classify primary systemic vasculitis (PSV) according to type of 
inflammation, causative mechanisms or associated autoantibodies, the most commonly 
used system for classifying disease is based on the size of the smallest vessel 
predominantly involved in the disease process - the Chapel Hill Consensus Criteria 
(Jennette et al., 1994).   
 
While the Chapel Hill criteria and the American College of Rheumatology (ACR) 
criteria (Appendix 1) for classification of vasculitis are widely used, they have never 
been validated in children.  In this context the recently described European League 
Against Rheumatism (EULAR)/Paediatric Rheumatology European Society (PRES) 
endorsed consensus criteria for the classification of childhood vasculitides may be more 
appropriate (Appendix 1) (Ozen et al., 2006), and are currently undergoing formal 
validation (Brogan, personal communication).  This is based on the Chapel Hill 
consensus criteria with modifications suggested by consensus relevant to paediatric 
disease.  For the purposes of this thesis which is focused on the downstream 
consequences of vasculitis (i.e. endothelial injury and repair), classification is perhaps 
somewhat arbitrary as endothelial injury occurs in PSV irrespective of disease aetio-
pathogenesis (Brogan et al., 2004a).  In addition overlap in the size of vessels affected 
occurs (“polyangiitis overlap”), for example in Wegener’s granulomatosis (WG), which 
is classified as a small vessel disease vasculitis can be detected in small and medium-
sized arteries and occasionally larger vessels, including the renal artery and aorta 
(Shitrit et al., 2002).  Therefore in this thesis when data was analysed the cohort was 
first examined as a whole, and then by subgroup analysis of individual diseases where 
appropriate.  Diseases were classified predominantly using the Chapel Hill Consensus 
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Criteria, however the ACR and EULAR/PRES consensus criteria were used (out of 
necessity) as additional classification tools by clinicians experienced in the 
classification of vasculitis at Great Ormond Street Hospital (GOSH).   
 
The individual vasculitic diseases of the young which have been studied within this 
thesis will now be described in more detail.  The predominant diseases observed in this 
study have been Polyarteritis Nodosa (PAN) and Wegener’s Granulomatosis (WG), 
followed by Kawasaki disease (KD) and Takayasu’s Disease (TD).  An additional group 
of patients had definite but “unclassified” vasculitis. Epidemiological evidence suggests 
that KD and Henloch Schönlein-Purpura (HSP) are the most common vasculitic 
diseases of childhood.  In 2002 incidences for KD and HSP were estimated to be 8.2 per 
100 000 children under the age of five (Harnden et al., 2002) and 20.8 per 100 000 
children (Gardner-Medwin et al., 2002) respectively, with 0.24 per 100 000 children for 
all other primary systemic vasculitic conditions (Gardner-Medwin et al., 2002).  This is 
not reflective of the GOSH cohort however, as GOSH is a specialist centre for 
paediatric vasculitis dealing with more complex cases that are referred from secondary 
and other tertiary care trusts 
 
1.2.2 Polyarteritis Nodosa and associated diseases 
In its  classical form,  PAN, is  a  necrotizing  vasculitis  associated  with  aneurysmal 
nodules along the walls of medium-sized muscular arteries, and was first described in 
detail in 1866 by Kussmaul and Maier (Dillon, 1998).  Although overlap occurs with 
smaller vessel disease, it is distinct from microscopic polyangiitis (see below), and in 
children occurs more commonly than the anti neutrophil cytoplasmic antibody (ANCA) 
associated vasculitides (Brogan and Dillon, 2000b).  The main clinical features of PAN 
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are malaise, fever, skin rash, abdominal pain and arthropathy, although testicular pain, 
myalgia, hypertension, neuropathy, renal failure, organic psychosis and myocardial 
ischaemia can also occur (Besbas et al., 2000,Brogan and Dillon, 2000b).  
 
PAN can occur in a predominantly cutaneous form, associated with painful skin 
nodules, livedo reticularis, and often following upper respiratory tract infection (Ozen et 
al., 2004).  While cutaneous PAN is generally a milder condition that responds well to 
non-steroidal anti inflammatory drugs (although in some cases corticosteroids are 
necessary) and/or antibiotics if infection is suspected, the cutaneous disease can develop 
into the more serious systemic condition (Till and Amos, 1997).  Relapses are common 
(up to 25%) and prophylactic penicillin is sometimes used, as infection may be 
associated with relapse.  Those with relapsing disease may have a higher risk of 
developing systemic vasculitis (Till and Amos, 1997). 
 
Microscopic polyangiitis (MPA, formerly microscopic polyarteritis) differs from classic 
PAN by having extensive glomerular involvement and/or pulmonary haemorrhage.  It 
can be defined as a small vessel vasculitis with focal segmental pauci-immune 
glomerulonephritis, sometimes with alveolar haemorrhage but without granulomatous 
disease of the respiratory tract (Puechal, 2007).  MPA is one of the ANCA-associated 
vasculitides (AAV), associated with perinuclear ANCA (pANCA) positivity, typically 
directed against myeloperoxidase (MPO-ANCA) (Bosch et al., 2006). 
 
1.2.3 Wegener’s Granulomatosis 
WG  is a necrotizing granulomatous vasculitis of the upper and  lower  respiratory  tract,  
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associated with glomerulonephritis and variable small vessel vasculitis.  Upper airway 
disease can include granulomatous involvement of the trachea leading to stenosis, and 
of the nasal septum, leading to collapse of the bridge of the nose and “saddle nose” 
deformity.  Lower airway disease can often masquearade as infection (Stegmayr et al., 
2000), but it due to necrotising vasculitis of the pulmonary capillaries.  WG is another 
ANCA associated disease, although it is predominantly cytoplasmic ANCA staining 
(cANCA) that is observed (Bosch et al., 2006), typically against proteinase-3 (PR3-
ANCA), although MPO-ANCA are sometimes observed (Brogan, 2007).  
 
1.2.4 Takayasu disease 
World-wide, TD is the third commonest vasculitis of childhood, and some have 
suggested that it may be related to tuberculosis infection (Dillon, 1998).  TD is a giant 
cell arteritis, a term that relates to the infiltration of giant cells (multinucleated cells 
formed by the fusion of many cells) seen in biopsies of diseased tissue.  TD causes 
stenosis and aneurysmal dilatation of large arteries, such as the aorta and its major 
branches. Its clinical features include fever, anorexia, weight loss, arthritis, and later the 
development of hypertension, heart failure and loss of pulse in some limbs (Kerr et al., 
1994).  The disease is often delayed in its diagnosis, especially in the young, and they 
can be confused with other causes of occlusive vasculopathy such as fibromuscular 
dysplasia (Tullus et al., 2008). 
 
1.2.5 Kawasaki disease 
KD was first described in 1967 by Tomisaku  Kawasaki who described 50 Japanese 
children with an illness characterised by fever, rash, conjunctival injection, erythema 
and swelling of hands and feet, and cervical lymphadenopathy (Kawasaki, 1967).  KD 
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is more common in children of oriental background, with peak incidence at around 9-11 
months of age (Newburger et al., 2003).  KD is associated with development of 
systemic vasculitis complicated by coronary and peripheral arterial aneurysms, and 
myocardial infarction in some patients.  KD is the commonest cause of acquired heart 
disease in children in the UK and USA (Shulman et al., 1995)   
 
1.2.6 Henoch-Schönlein purpura  
HSP (anaphylactoid purpura) is the commonest vasculitis seen in childhood with peak 
incidence occurring at 4-5 years of age, more commonly in males.  It is a multi-system 
small vessel systemic vasculitis with a prominent cutaneous component, that can also 
affect joints, gastrointestinal tract and the kidney (Yang et al., 2008). Other organs less 
frequently involved include the central nervous system, gonads and the lungs.  HSP 
often occurs following an upper respiratory tract infection and the onset of the disorder 
may be accompanied by systemic symptoms including malaise and mild pyrexia 
(Saulsbury, 1999).  Of the childhood vasculitides HSP has the most favourable 
outcome, with the large majority of children requiring no treatment. Recurrence of 
symptoms occurs in around one third of cases, generally within four months of 
resolution of the original symptoms and more frequently in those with renal 
involvement (Saulsbury, 1999). 
 
1.2.7 Churg-Strauss syndrome 
Churg-Strauss syndrome (CSS) or allergic granulomatosis is extremely rare in 
childhood (Boyer et al., 2006).  It is described as AAV, although there is no 
predominant cANCA or pANCA association (Bosch et al., 2006) and in the small 
number of published studies in children, frequency of ANCA positivity is lower than in 
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adults (Boyer et al., 2006).   The disease can affect the lungs, GI tract and nervous 
system and often presents initially as severe asthma.  Other clinical features include 
eosinophilia, infiltrates on chest X-ray and extra-vascular granulomata on biopsy (Boyer 
et al., 2006). 
 
1.2.8 Other vasculitic disorders 
According to the EULAR/PRES consensus criteria relating to the classification of 
paediatric vasculitis the following conditions fall into the category of disease described 
as “other” (Ozen et al., 2006).  No specific definitions are described for these entities in 
the proporsed EULAR/PRES criteria, thus Chapel Hill consensus or ACR criteria were 
applied where appropriate. 
 
1.2.8.1 Behçet’s disease 
Behçet’s disease (BD) occurs rarely in children.  In studies of adults incidence is much 
higher in the Mediterranean, Middle East and Far East compared to Northern Europe 
(Reynolds, 2008). Incidence in adults in Turkey is estimated at 110-370 per 100 000 
(Idil et al., 2002,Yurdakul et al., 1988), whereas in the UK it is 0.64 per 100 000 
(Chamberlain, 1977).  BD is associated with recurrent oral and genital ulcers, relapsing 
uveitis, skin lesions, arthritis and CNS and GI manifestations.  It is recognised that a 
vasculitic component is an important feature of the disease (Reynolds, 2008,Kutlay et 
al., 2008).   
 
1.2.8.2 Cogan’s syndrome 
Cogan’s syndrome is a rare condition that predominantly affects young adults, although 
has been reported in children (Olfat and Al-Mayouf, 2001).  The syndrome mainly 
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affects the eyes with inflammation of the cornea (keratitis) leading to eye redness, 
blurred vision, pain and photophobia and the vestibuloauditory system causing tinnitus, 
dizziness, hearing loss and nausea and vomiting.  Systemic vasculitis can also occur, in 
predominantly  large and medium vessels, typically associated with aortic involvement 
(St Clair and McCallum, 1999). 
 
1.2.8.3 Vasculitis secondary to connective tissue diseases 
Secondary systemic vasculitis associated with autoimmune connective tissue diseases is 
a well recognised phenomenon.  The extent to which it occurs at a subclinical level may 
be much more widespread, than previously appreciated, and in children and adults is 
likely to have long term implications relating to cardiovascular outcomes such as 
premature atherosclerosis (Bacon et al., 2002).  
 
Autopsy studies in adult patients suffering from RA indicate that a significant 
proportion have evidence of systemic vasculitis (ranging from 15-31%) (Bely et al., 
1992,Salvarani et al., 1992,Suzuki et al., 1994) however in living patients detection is at 
much lower levels (<1%) (Watts et al., 2004,Wattiaux et al., 1987,Genta et al., 2006).  
The relationship between rheumatic disease and risk of adverse cardiovascular events 
independent of traditional risk factors is now well recognized.  RA doubles the risk of 
cardiovascular disease and is associated with early mortality (Van et al., 2002,bou-Raya 
and bou-Raya, 2006) while SLE has a 5-6 times higher risk of a significant coronary 
event, rising to up to 50 times higher than the general population in young women 
(Manzi et al., 1997).  The presence of subclinical vasculitis in these patients is an 
attractive hypothesis to explain this phenomenon, however as discussed in more detail 
later in this chapter monitoring disease activity in primary systemic vasculitis is fraught 
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with difficulties in routine clinical practice.  Thus assessing subclinical vasculitis in 
patients with inflammatory disease remains a major challenge, but is likely to be of 
great importance in view of the poor cardiovascular outcomes associated with 
autoimmune diseases (Bacon et al., 2002).   
 
1.2.8.4  Vasculitis secondary to infection 
Infectious agents such as viruses, bacteria and fungi have been repeatedly proposed as 
triggering agents for vasculitis, and are more frequently associated with conditions that 
are ANCA negative (Pagnoux et al., 2006).  Some infections are directly responsible for 
causing vasculitis by their action on the endothelium, either by directly infecting 
endothelial cells or binding to them, resulting in bystander injury to the surrounding 
vessel wall.  Other infections misdirect the host immune response towards self: if the 
infecting pathogen expresses structures similar to that seen in the endothelium, 
molecular mimicry may occur whereby host responses are directed towards the 
endothelium as well as the pathogen.  Complementary peptides (which contain 
sequences that match the antisense DNA strand of a host peptide) can also induce a host 
autoimmune response (discussed in more detail in the context of AAV) (Pendergraft, III 
et al., 2004).  Superantigens have also been implicated in vasculitis, particularly KD 
(Brogan et al., 2008).  These pathogen derived peptides have the ability to activate large 
proportions of the T cell population (5-30%) by crosslinking MHC class II on antigen 
presenting cells (APCs) and the T cell receptor (TCR) independent of conventional 
antigen processing pathways. 
 
Viral infections that have been implicated in vasculitis include hepatitis B, hepatitis C, 
human immunodeficiency virus, erythrovirus B19, cytomegalovirus (CMV), varicella-
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zoster virus (VZV) and human T-cell lymphotropic virus-1 (HTLV-1) (Pagnoux et al., 
2006).  Bacterial infections that have been proposed as potential causative agents 
include strains of Pseudomonas, Legionella, Neisseria, Rickettsiae, Staphylococcus and 
Mycobacterium tuberculosis (Pagnoux et al., 2006).  Fungal infections of the lung can 
mimic WG or Churg Strauss syndrome by causing a granulomata to form in vessel 
walls (El-Zammar and Katzenstein, 2007).  In a number of these infection related 
vasculitides, if the vasculitis is a direct effect of the infective agent (e.g. the necrotizing 
vasculitis of the lung sometimes seen in Pseudomonas aeruginosa infections) rather 
than as a downstream consequence after the immune system has been misdirected 
towards self, then effective treatment of the underlying infection with antimicrobial 
agents is necessary, and may be sufficient without additional immunosuppression 
(Pagnoux et al., 2006).   
 
1.2.8.5 Vasculitis secondary to malignancy 
Vasculitis associated with malignancy is extremely rare in children (Pelajo et al., 2007), 
however it can occur and there a number of ways in which this happens.   Vasculitis can 
occur as the result of an infectious complication in an already immunocompromised 
patient.  Vasculitis can also be triggered directly by the presence of malignancy or 
metastases invading blood vessels (Racanelli et al., 2008).  Alternatively, it can occur as 
a paraneoplastic phenomenon as a consequence of abeherent immune responses, 
whereupon treatment of the inciting malignancy can resolve the vasculitis.  Often 
paraneoplastic vasculitis is a cutaneous form that is detected prior to clinical detection 
of the malignancy.  Lastly, it remains possible that both malignancy and vasculitis are 
triggered by the same environmental stimuli in some cases (Racanelli et al., 2008). 
  
34 
 
1.2.9 Treating vasculitis 
Treatment for systemic vasculitis comprises aggressive immunosuppression and 
consists of combined corticosteroid and cytotoxic agents such as cyclophosphamide 
(oral or pulsed intravenous), azathioprine or methotrexate as well as antiplatelet agents 
(usually aspirin), and in some forms of vasculitis pooled human intravenous 
immunoglobulin (IVIG, particularly for KD (Newburger et al., 1986)) in an attempt to 
bring the disease into remission (Watts et al., 2005).  Plasma exchange may also prove a 
useful therapy, particularly for severe fulminant forms of small vessel vasculitis (Jayne 
et al., 2007). The exact regime used depends on the disease and the individual patient.  
In some of the milder conditions such as HSP or cutaneous PAN, treatment may only 
consist of symptomatic relief with analgesics or non steroidal anti inflammatory drugs 
(Palit and Inamadar, 2006).   
 
Newer biological agents may be necessary if conventional treatment is ineffective.  
These include (amongst others) anti TNFα (Burns et al., 2005a,Booth et al., 
2004a,Brogan et al., 2009), anti IL-1 (Eleftheriou et al., 2009),  B cell depletion 
(Eleftheriou et al., 2009) or lymphocyte depletion using anti-CD52 (Campath) 
(Lockwood et al., 2003).  These novel approaches have only been used in relatively 
small numbers of patients and thus their usage is based on largely anecdotal evidence.  
That said, biologic therapy holds promise for recalcitrant disease.  If remission is still 
not achieved, autologous stem cell transplantation may be an option and indeed was 
performed successfully in one child included in this thesis.   
 
With the more agressive forms of therapy there is significant morbidity associated with 
long term use of these agents which includes diabetes, infection, bladder cancer, 
35 
 
haemorrhagic cystitis, bone marrow toxicity and infertility.  Thus treatment should be 
tailored to the minimum required to control disease whilst at the same time limiting 
these unfavourable side effects (Brogan and Dillon, 2000a).  Following successful 
induction of remission, maintenance of remission is achieved using therapy including 
anti-platelet doses of aspirin and low dose corticosteroids combined with 
immunosuppressants such as azathioprine, mycophenolate mofetil, or methotrexate 
sometimes for months or years (Brogan and Dillon, 2000a).   
 
Despite these aggressive therapeutic approaches, there is still a significant mortality and 
morbidity associated with PSV, including treatment related complications such as 
opportunistic infections.  However it is worth noting that without treatment mortality is 
extremely high.  Historically for patients with WG there was 80% mortality within the 
first year (Walton E.W, 1958).  Thus treatment outcomes for children and adults with 
vasculitis are vastly improved but require further refinement, a programme of work 
currently being performed by the EUVAS group (European vasculitis study group). 
 
Lastly it is important to emphasise that many of the treatment protocols for PSV in 
children, with the exception of KD are based on evidence from clinical trials in adults.  
Importantly, however for the first time children with ANCA associated vasculitis have 
recently been included in EUVAS trials (Brogan, personal communication).  
 
1.2.10 Prognosis 
Overall  outlook  is  good  for  patients  who  urvive the initial vasculitic insult  and  any 
subsequent disease flares, however the long term consequences of vasculitis in 
childhood are still not clear.  Recent studies indicate that there is increased subclinical 
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atherosclerosis in adult patients with small vessel vasculitis (Chironi et al., 2007) and 
whether children with these diseases have similar consequences remains to be 
determined.  Coronary artery lesions (including aneurysms and stenoses) in KD 
predispose to premature coronary atherosclerosis, and peripheral arteries remain stiffer 
than in healthy controls for years after disease remission in PAN, possibly being 
indicative of fibrotic changes (Cheung et al., 2002,Suzuki et al., 1986)  and/ or ongoing 
subclinical vascular inflammation (Mitani et al., 2005).   So although now most children 
survive vasculitis, it appears that there could be implications for their cardiovascular 
health in the longer term (Nakamura et al., 2002).    
 
1.2.11 Conclusions relating to clinical perspectives on vasculitis 
There is a wide spectrum of vasculitic disease affecting children.  The distinction from 
other conditions, especially those associated with infection is often difficult, but it is 
possible to categorise the disorders into clinico-pathological entities even though there 
is a substantial degree of overlap. Treatment for systemic disease is aggressive 
immunosuppression, aimed at inducing remission, rather than targeting upstream casual 
pathology (described in Section 1.3).  Outlook for patients on the whole is good, 
however in the long term, cardiovascular complications may lead to reduced life 
expectancy, however much work remains to be done in order to identify those patients 
at greatest risk.  
 
 
1.3 The pathogenesis of vasculitis 
In most patients the definitive upstream causes of vasculitis are unknown, however 
there are a number of well described inflammatory pathways that culminate in injury to 
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the endothelium that are beginning to be understood.  The predominant theory as to how 
vasculitis is initiated is the combination of an environmental trigger occurring in an 
individual with a background genetic susceptibility (Brogan, 2007). 
 
1.3.1 Environmental triggers 
A number of epidemiological studies support the hypothesis that an environmental 
trigger is involved in the development of vasculitis.  In the two commonest vasculitic 
diseases of childhood, HSP and KD, epidemiological evidence points to an infectious 
cause.  Both conditions have seasonal variations in incidence, with KD peaking in the 
winter and spring months (Bronstein et al., 2000)  and HSP in autumn and winter (Yang 
et al., 2005) often following a respiratory tract infection.  WG occurs more commonly 
in Northern Europe than Southern Europe.  In one study by Watts et al although there 
were significant differences in the incidence of WG between Spain and the UK, there 
was little variation in HLA-DRB1 region genetics (the human leucocyte antigen region 
of the genome which is associated with a number of autoimmune diseases) leading the 
authors to suggest that environmental factors may be more important than genetic risk 
factors for triggering WG (Watts et al., 2001).   
      
While infections and malignancies (discussed above) may be triggers of vasculitis, there 
a number of other potential non-infectious environmental factors which have been 
implicated in disease onset.  In 2003 Lane et al demonstrated increased risk of 
developing PSV (all forms) in Norfolk with exposure to silica, solvents and 
interestingly farming, which undoubtedly exposes the individual to many chemicals 
(pesticides, fertilizers etc) and possible infectious agents from livestock (Lane et al., 
2003).  Other studies have also implicated silica and solvents (Tervaert et al., 1998,Pai 
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et al., 1998) as well as heavy metal exposure (Albert et al., 2004) , a number of different 
vaccinations (including influenza and hepatitis B) (Somer and Finegold, 1995,Schattner, 
2005), many different classes of drugs (Wiik, 2008), corticosteroid withdrawal 
(Kinoshita et al., 1999) and allergy desensitisation procedures (Cabrera et al., 1993).  A 
background of allergy or asthma is also associated with increased risk of PSV (all 
forms) (Lane et al., 2003).  
 
1.3.2 Genetics of vasculitis 
In recent years there have been a number of studies examining the genetic background 
of the different vasculitic diseases.  Table 1.1 (adapted from Brogan, 2007) highlights a 
number of these studies.  What is immediately apparent is that the genetic factors which 
predispose individuals to developing vasculitis are complex and there are a wide variety 
of candidate genes that may be involved.  These genes include those  involved  in  
inflammation  such  as  cytokines, chemokines, and their receptors as well as those 
relating to regulation of the vasculature such as growth factors and NO synthase.  
Caveats to these genetic studies include the large numbers of patients with these rare 
diseases which are required for adequate powering, and the difficulty of robust 
classification.  This has resulted in a number of potentially underpowered studies in KD, 
HSP, BD and AAV.  However, considerable advances in genome wide association 
studies hold the promise of major advances in the understanding of complex diseases 
such as the vasculitides if adequate patient numbers can be studied (numbers in the 
1,000s are necessary (McCarthy et al., 2008)).  This will ultimately require international 
cooperation. 
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Table 1-1: Genetic studies in vasculitis 
 
 
Gene of 
interest 
Disease 
studied 
Effect 
Angiotensin 
converting 
enzyme 
KD 
 
 
HSP 
 
 
 
BD 
Higher expression of ACE insertion allele associated with increased disease susceptibility 
(Shim et al., 2006) 
 
No association found with ACE, but angiotensinogen (angiotensin precursor) associated with 
disease susceptibility (Ozkaya et al., 2006) 
ACE DD genotype predicts persistent proteinurea (Yoshioka et al., 1998) 
 
Higher expression of ACE deletion allele than in controls (Turgut et al., 2005) 
VEGF 
KD 
 
 
HSP 
Polymorphisms associated with development of disease (Breunis et al., 2006), a more recent 
study demonstrated no associations (Huang et al., 2008) 
 
Polymorphisms associated with development of renal complications (Rueda et al., 2006) 
Nitric oxide 
synthase 
(NOS) 
HSP 
 
 
KD 
Polymorphism in iNOS promotor associated with renal involvement (Martin et al., 2005) 
although no associations with eNOS polymorphisms (Amoli et al., 2004b) 
 
No association of eNOS or iNOS polymorphisms with susceptibility or coronary artery 
lesions (Khajoee et al., 2003) 
IL-1/IL-1Ra 
KD 
 
HSP 
 
 
WG 
Polymorphisms in Il-1ra but not IL-1β associated with susceptibility (Wu et al., 2005) 
 
Polymorphisms in both Il-1ra and  IL-1β associated with renal involvement (Amoli et al., 
2002,Amoli et al., 2004a) 
 
No associations found (Zhou et al., 2004) 
TNFα 
KD 
 
 
WG 
Polymorphisms associated with susceptibility (Cheung et al., 2008) and IVIG resistance 
(Yang et al., 2003) 
 
Polymorphisms associated with susceptibility (Spriewald et al., 2005) although another study 
showed no association (Huang et al., 2000) 
IL-6 
 
 
KD 
 
HSP 
 
BD 
No associations found (Sohn et al., 2001) 
 
No associations found (Amoli et al., 2007) 
 
Polymorphisms associated with susceptibility (Chang et al., 2005) 
IL-10 
KD 
 
 
AAV 
 
BD 
Association of promoter polymorphism with increased risk of coronary artery aneurysm 
(Yang et al., 2003) 
 
Polymorphisms associated with CSS but not WG (Wieczorek et al., 2008) 
 
Polymorphism associated with susceptibility in UK patients  (Wallace et al., 2007) 
Inositol 1,4,5-
trisphosphate-3 
kinase C 
(ITPKC) 
KD 
Polymorphism in ITPKC ( a negative regulator of T cell signalling) associated with both 
susceptibility to KD and coronary artery lesions (Onouchi et al., 2008) 
CCR5 KD 
Polymorphisms in CCR5 and its ligand CCL3LI associated with susceptibility (Burns et al., 
2005b) 
Human 
leucocyte 
antigens 
(HLA) 
AAV 
 
KD 
HLA-DRB4 associated with CSS development (Vaglio et al., 2007) 
 
HLA-B and C polymorphisms associated with susceptibility in Korean cohort (Oh et al., 
2008). No association with HLA DRB1 (Huang et al., 2007) 
 
Mannose 
binding lectin 
(MBL) 
KD 
 
 
 
AAV 
 
BD 
In Children <1 year old polymorphisms in MBL2 (resulting in low MBL levels) were 
associated with increased risk of coronary artery aneurysms, however conversely at >1 year 
of age wild type (normal MBL levels) were at increased risk (Biezeveld et al., 2006) 
 
No associations found (Kamesh et al., 2007) 
 
MBL2 HYPA haplotype associated with severity and susceptibility (Park et al., 2005b) 
Matrix 
metallo-
proteinases 
KD 
MMP3 promotor (6A/6A) genotype associated with higher frequency of coronary artery 
aneurysms, no associations found with MMP9 polymorphisms (Park et al., 2005a). In a 
second study no association was found with a different MMP3 promoter polymorphism (-
439C/G) (Hong et al., 2008) 
Proteinase 3 
(PR3) 
WG 
Polymorphism in promoter of PR3 associated with WG susceptibility (Gencik et al., 2000) as 
is a polymorphism in the inhibitor of PR3 α-1-antitrypsin which causes deficiency (Elzouki et 
al., 1994) although other studies suggest its influence  is minor (Lhotta et al., 1994) 
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1.3.3 Immunological pathways in vasculitis  
1.3.3.1 Autoantibodies  
Numerous autoantibodies are associated with vasculitis, however the pathological 
consequences of antineutrophil cytoplasmic antibodies (ANCA) and anti-endothelial 
cell antibodies (AECA) have been studied extensively and require mention in detail. 
 
1.3.3.2 Antineutrophil cytoplasmic antibodies 
ANCA are detected in 85-95% of adult patients with MPA, WG, CSS, and the localized 
forms of these diseases (Bosch et al., 2006).  The frequency of ANCA positivity may be less 
for children with these vasculitides however (Akikusa et al., 2007,Belostotsky et al., 2002).  
These predominantly IgG autoantibodies target antigens found within neutrophil 
granules and also within the lysosymes of monocytes (Braun et al., 1991).  Although a 
number of other antigenic targets have been identified the most clinically relevant are those 
targeting PR3 and MPO.  Typically, PR3-ANCA is seen as diffuse staining  of  the  
neutrophil  cytoplasm (cANCA)  whereas MPO-ANCA gives a perinuclear staining 
(pANCA) pattern on immunofluorescent microscopy.  Table 1.2 summarises the type of 
ANCA found in the difference ANCA associated vasculitides in adults.   
 
Table 1-2: ANCA distribution in the ANCA associated vasculitides  
 
 Data from (Van Paassen P. et al., 2007) 
Disease 
% of patients with 
MPO-ANCA 
% of patients with 
PR3-ANCA 
Churg Strauss syndrome (CSS) 30-70 <10 
Wegener’s Granulomatosis (WG) 10-30 >70 
Microscopic Polyangiitis (MPA) 30-70 10-30 
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In comparison to patients positive for MPO-ANCA patients with PR3-ANCA have 
more organs involved, a faster decline in renal function, more frequent relapses of the 
disease, and granulomatous necrotizing inflammation in the airways (Franssen et al., 
2000), suggesting different pathological pathways may be involved. 
 
Development of ANCA 
The upstream events which lead to development of ANCA remain unknown, however 
there are a number of hypothesese as to how ANCA develop.  As AAV can be initiated 
by infection, molecular mimicry is one possibility (Benoist and Mathis, 1998), another 
is autoantigen complementarity a phenomenon described by Pendergraft et al, whereby 
peptides complementary to PR3 (encoded by the corresponding antisense strand of 
DNA) initiate production of antibodies against PR3 (Pendergraft, III et al., 2004).  The 
generation of PR3-ANCA occurs via a 2-stage immune response, the initial response is 
directed against the complementary peptide, the secondary response again the 
antibodies generated to the complementary peptide (these will also act on PR3).  
Interestingly peptides complementary to PR3 are found in a number of infectious 
agents, including Staphylococcus Aureus, human herpes virus 4 and rickettsia 
prowazekii (Pendergraft, III et al., 2004).   
 
A non-infection related hypothesis for ANCA generation relates to neutrophil apoptosis.  
When neutrophils undergo apoptosis, their granule contents translocate to the cell 
surface (Gilligan et al., 1996), incomplete or inappropriate phagocytosis may allow 
exposure of these self antigens to antigen presenting cells (APCs).  However, while 
injection of apoptotic neutrophils into mice (Rauova et al., 2002) or rats (Patry et al., 
2001) induced ANCA expression, neither species developed vasculitis.  Evidence from 
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in-vitro experiments is conflicting.  Although immature dendritic cells can take up 
apoptotic and necrotic neutrophils, with corresponding increases in maturation markers 
such as CD83 and MHC class II, the costimulatory molecules (CD86, CD80 and CD40) 
necessary for T cell activation are downregulated.  Thus the overall effect of 
apoptotic/necrotic neutrophils in this study is tolerogenic, although this was partially 
reversed by TNFα treatment (Clayton et al., 2003).  Thus the exact mechanisms by 
which defective neutrophil apoptosis could lead to ANCA generation remain poorly 
defined. 
 
Are ANCA pathogenic? 
Regardless of how ANCA production is initiated, there is much evidence to implicate 
this autoantibody in the pathogenesis of vasculitis from observations made in humans 
and animal models.  Recently animal models have provided some of the most 
compelling evidence that ANCA are indeed directly pathogenic manner, while in vitro 
experiments have provided more details at a cellular level on mechanisms by how this 
can occur.   
 
Proof of concept – do ANCA cause vasculitis in vivo? 
As yet only MPO-ANCA have been shown to induce significant vasculitis in animal 
models.  Studies have been performed using PR3-ANCA however it is apparent that the 
disease pathogenesis in PR3-ANCA associated conditions may be more complicated 
than just an autoantibody mediated vasculitis (Kallenberg, 2008), corresponding with 
the differences observed in disease severity between MPO-ANCA and PR3-ANCA in 
humans (Franssen et al., 2000).   
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Rats injected with human MPO, generate anti-MPO antibodies and developed a small 
vessel vasculitis (Little et al., 2005).  The IgG isolated from these rats was shown (like 
human ANCA) to enhance leukocyte-endothelial interactions in vitro.  In other studies, 
injecting MPO knockout mice with mouse MPO allowed generation of anti-mouse 
MPO IgG (removing the potential confounding factor of using a human peptide) (Xiao 
et al., 2002).  When these antibodies were injected into wildtype or recombinase 
activating gene-2 (RAG2-/-) knockout mice (which have no mature B or T cells) they 
developed a disease similar to AAV with focal necrotizing and crescentic 
glomerulonephritis, and in some mice a systemic small vessel vasculitis (Xiao et al., 
2002).  The presence of disease in RAG-/- mice indicated that T cells were not required 
to induce the acute lesions.  Neutrophils however were necessary as prior injection of a 
neutrophil depleting antibody prevented disease (Xiao et al., 2005). Correspondingly, 
priming neutrophils with LPS prior to the IgG dose exacerbated the disease (Huugen et 
al., 2005).  Interestingly, the non classical complement activation pathway is also 
implicated in this model as C4 (classical) but not C5 (common) or factor B (non-
classical) knockout mice develop disease after transfer of anti-mouse-MPO IgG (Xiao et 
al., 2007a).   
 
In contrast, evidence that PR3-ANCA are directly pathogenic is so far conflicting.  
When mice were injected with human PR3-ANCA, they developed antibodies to PR3 in 
a two stage immune response similar to that described for complimentary peptides.  
Mice initially develop antibodies to human PR3-ANCA, followed by antibodies against 
these (anti-anti-human-PR3-ANCA) which have the ability to bind PR3 (Tomer et al., 
1995).  These mice developed lung disease but not glomerulonephritis.  However, when 
PR3-ANCA was generated in PR3 knockout mice (using mouse PR3), the injection of 
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these antibodies into wild type mice did not result in spontaneous vasculitis (Pfister et 
al., 2004).  The only difference observed was an exacerbated response to localised 
TNFα injection (Pfister et al., 2004).   Rats injected with human/mouse chimeric PR3, 
also generated PR3-ANCA, however, despite this being able to bind rat PR3, vasculitis 
did not develop (van der Geld et al., 2007). 
 
Perhaps the most robust evidence yet that ANCA can cause vasculitis in humans comes 
from two reports that have documented trans-placental transfer of IgG MPO-ANCA 
from mothers with active MPA.  The two neonates described developed pulmonary 
renal syndrome soon after birth (Bansal and Tobin, 2004,Schlieben et al., 2005).    
 
How do ANCA cause vascular injury? 
The predominant mechanism by which ANCA induce endothelial injury is via 
neutrophil activation and adhesion to the endothelium, followed by neutrophil 
degranulation and subseqeunt dyseregulated apoptosis (Bosch et al., 2006).  ANCA can 
also activate other cell types involved in the inflammatory processes, although these 
pathways are less well defined (Ralston et al., 1997).   
 
Although MPO and PR3 are not found on the surface of resting neutrophils (Gilligan et 
al., 1996), priming of neutrophils with substances such as TNFα or LPS (at a 
concentration that does not induce full activation) or even isolated purified ANCA 
results in their translocation to the cell surface (Csernok et al., 1994,Hattar et al., 2001).  
In patients with active AAV circulating neutrophils are primed; they have enhanced 
expression of surface PR3 (Muller Kobold et al., 1998a), the activation markers CD66b, 
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CD63, and CD64 (Muller Kobold et al., 1998b) and increased basal superoxide 
production (Harper et al., 2001).  
 
When ANCA bind their target antigens on the neutrophil surface, they also crosslink 
with Fc receptors causing cell activation (Porges et al., 1994).  Neutrophil-endothelial 
adhesion changes from rolling to firm in an integrin dependent manner, followed by 
respiratory burst and degranulation.  Degranulation releases potentially damaging 
reactive oxygen species, chemokines, cytokines and proteolytic enzymes in close 
vicinity to the endothelium (Harper et al., 2004). NO generated independent of classical 
NO synthase (NOS) pathways is also released (Tse et al., 2001), although the 
consequences of the increased availability of NO is unclear.  While NO is a potent 
vasodilator and has been shown to reduce neutrophil endothelial interactions, it is also 
cytotoxic, increases vascular permeability, forms free radicals and can modulate 
cytokine production in leucocytes, thus could conceivably be contributing to endothelial 
injury in this context (Tripathi et al., 2007).  
    
Neutrophil activation by ANCA is followed by apoptosis, however in vitro experiments 
indicate this is accelerated and dysregulated; while neutrophils showed typical features 
of apoptosis such as shrunken nuclei and internucleasomal cleavage of DNA 
phosphatidylserine (PS) does not become externalized (Harper et al., 2000). The 
externalisation of PS is essential for recognition of apoptotic cells by phagocytes, which 
engulf and safely remove them preventing release of damaging cell contents.  This poor 
clearance explains the leucocytoclasia (accumulation of unscavenged apoptotic or 
necrotic neutrophils or their fragmented nuclei in the tissues around the vessels) often 
seen in vasculitic lesions. 
46 
 
As well as neutrophil activation ANCA have the potential to initiate endothelial injury 
by other mechanisms.  Both PR3-ANCA and MPO-ANCA can act directly on their 
target enzymes altering their function.  PR3 degrades extracellular matrix proteins such 
as elastin and collagen type IV.  Its natural inhibitor is α1-antitrypsin which forms 
complexes with PR3 causing it extensive structural reorganization and irreversible loss 
of function.  PR3-ANCA inhibits both the proteolytic activity of PR3 and its complex 
formation with α1-antitrypsin (van der Geld et al., 2002,Dolman et al., 1993) which 
may impair both regulation and clearance of PR3 (Dolman et al., 1993).  MPO is 
involved in the reaction between hydrogen peroxide and chloride ions which generates 
hypochlorous acid (HOCl), one of the reactive oxygen species that contributes to the 
neutrophil oxidative burst.  In vitro, MPO-ANCA can activate MPO and may directly 
initiate neutrophil oxidative burst, resulting in the release of a number of EC damaging 
ROS (Guilpain et al., 2007).   
 
PR3-ANCA  can  act  directly  on  the  endothelium,  despite  endothelial  cells  not 
expressing it (or MPO either) and the mechanism by which this occurs remains elusive 
(Pendergraft et al., 2000).  Consequences include activation and upregulation of 
adhesion molecules such as ICAM-1 (de et al., 1997a) and VCAM-1 (Mayet et al., 
1996), expression of TF and release of IL-1 (de et al., 1997b).  Both PR3-ANCA and 
MPO-ANCA can activate monocytes, resulting in production of IL-8 (Ralston et al., 
1997) and increasing expression of CD14 (LPS receptor) and CD18 (a 2 integrin 
receptor)(Nowack et al., 2000).  Interestingly glomerular epithelial cells are also 
reported to express PR3 mRNA, raising the possibility of direct glomerular epithelial 
injury by ANCA (Schwarting et al., 2000) 
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1.3.3.3 Anti-endothelial cell antibodies 
A number of autoantibodies directed against the endothelium have been detected in 
vasculitis.  The antigens targeted by AECA encompass a broad spectrum and remain 
poorly identified; AECA positive sera displays a broad reactivity against EC from many 
different locations (Praprotnik et al., 2001) and different species (reacting with bovine 
and murine endothelial cells) (Shoenfeld, 2002) as well as a number of other targets, 
including extracellular matrix (Belizna and Tervaert, 1997).  IgG, IgM, and IgA 
isotypes of those antibodies have all been reported (Praprotnik et al., 2001).  
 
AECA from the sera of patients with WG are able to activate endothelial cells directly, 
up-regulating expression of adhesion molecules such as E-selectin and inducing 
production of proinflammatory cytokines and chemokines including IL-1, IL-6, IL-8, 
and MCP-1 (Del et al., 1996) via NFκB activation (Blank et al., 1999). AECA have also 
been shown to  induce apoptosis of endothelial cells (Bordron et al., 1998) and 
upregulate TF (Tannenbaum et al., 1986). 
 
Mice immunized with IgG from the sera of patients with WG after any ANCA present 
has been depleted, develop a vasculitic disorder characterized by lymphocytic 
infiltration in vessel walls, particularly in the lungs and kidney (Damianovich et al., 
1996).  As in the previously described ANCA models injection of human IgG results in 
an idiopathic response, whereby antibodies are initially generated against the human 
IgG, then a second response generates antibodies against these.  The second stage 
antibodies have the ability to bind to the target endothelial antigens. 
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1.3.3.4 T cells 
T cells are activated when APCs present specific antigen to them via the MHC 
molecules on their surface, in combination with co-stimulatory signals.  T cells can 
broadly fall under the categories of T helper cells (CD4+), whereby they release 
cytokines promoting the immune response, cytotoxic T cells (CD8+) whereby their 
function is to remove altered-self cells, or regulatory T cells whereupon they suppress 
immune responses (Goldsby RA et al., 2003a).  Memory cells of these subtypes are also 
found, as are natural killer cells, a T cell subtype which recognizes and eliminates host 
cells missing MHC class I molecules (Krzewski and Strominger, 2008).  CD4+ T helper 
cells can secrete different profiles of cytokines. Th1 type cells produce TNFα and IFNγ 
which are responsible for promoting the cellular immune system, activating 
macrophages and cytotoxic cells, whilst Th2 type cells release IL-4, IL-6, IL-10 which 
activates the humoral immune system, inducing B cell proliferation and antibody 
production (Goldsby RA et al., 2003a).  A recently described population of T helper 
cells, Th17s produce Il-17, IL-21 and IL-22.  IL-17 in particular is a potent 
chemoattractant of neutrophils and can induce production of other inflammatory 
cytokines and chemokines (Kolls and Linden, 2004).  There has been much interest in 
this novel T cell population, with evidence indicating that IL-17 is involved in the 
pathogenesis of many autoimmune conditions (Bettelli et al., 2007).  
 
In AAV T cells can be activated by MPO and PR3 (King et al., 1998) and in patients 
there is evidence of activated T cells irrespective of phase of disease or therapy as 
demonstrated by reduced CD28 (co-stimulatory molecule) and increased CD69 (an 
early T-cell activation marker) on CD3 T cells, and CD38 on CD8+ cytotoxic T-cells 
(present on mitogen stimulated T cells) (Christensson et al., 2000).  In WG activated 
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CD4+ cells have a predominantly Th1 cytokine profile (Ludviksson et al., 1998), 
although in disease remission CD4+ cells are skewed towards a Th2, Th17 response 
(Abdulahad et al., 2008).  In WG there is also evidence of a PR3 specific Th17 
population (Abdulahad et al., 2008).  Both CD4+ and CD8+ T cells are found in lesions 
in AAV, as are the adhesion molecules and cytokines that are required for their 
recruitment.   In pauci-immune glomerulonephritis (so called because of lack of 
immune complex deposition) cellular infiltrates at the site of injury include activated T 
cells, indicative of a casual role in this particular disease manifestation (Cunningham et 
al., 1999).   
 
In KD activated T cells have been found in skin biopsies and coronary vascular lesions 
(Terai et al., 1990), however there are conflicting reports regarding whether peripheral 
blood T cells are activated in acute KD.  While some indicate increased activation 
(Barron et al., 1988), others have demonstrated no overall difference from controls, 
although subfamilies of T cells bearing particular Vβ segments may be activated 
preferentially (Brogan et al., 2008). 
 
T cells also play a pivotal role in giant cell arteritis (not a disease of childhood, however 
the mechanism bears mention) and are believed to direct a response to arterial antigens - 
T cells in the arterial wall have identical sequences at the third complementary 
determining region (CDR3) of their T-cell receptors suggesting a common antigen 
(Weyand et al., 1994). 
 
Regulatory T cells are a topic of great interest in the context of autoimmune disease.  
They are characterised by expression of CD4, CD25, and the transcription factor 
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FOXP3, are anergic to proliferative responses in vitro and do not express key cytokines, 
such as IL-2 or IFN-γ in response to stimulation.  Functionally, they suppress 
proliferation of effector T cells, which in vitro requires activation and cell contact but is 
not via  IL-4, IL-10, or transforming growth factor-β (TGF-β) production (Torgerson, 
2006).  Studies in KD indicate that regulatory T cells are reduced in acute disease 
(Furuno et al., 2004), while in BD (Hamzaoui et al., 2006) and WG they are elevated, 
however their functional capacity to suppress proliferation was found to be decreased in 
WG (Abdulahad et al., 2007).  
 
1.3.3.5 Immune complexes, complement and cryoglobulins 
Immune complexes occur when antibodies bind to soluble antigen – the mechanism of 
type III hypersensitivity reactions.  Once formed immune complexes can be deposited 
in various tissues, instigating an inflammatory response.  Immune complexes are found 
in a number of small vessel vasculitides including HSP, PAN and cryoglobulinaemia 
and are a major cause of associated glomerulonephritis (Guillevin and Dorner, 2007).  
 
Endothelial injury mediated by immune complexes involves recruitment of 
inflammatory cells and also activation of classical complement pathways (Claudy, 
1998). C1q, the first component of complement, binds to the Fc portion of IgG or IgM 
antibodies in the deposited immune complexes resulting in activation of other 
components of the enzymatic cascade which culminates in the formation of a membrane 
attack complex and subsequent cell lysis (Goldsby RA et al., 2003b). Some components 
(such as C5a) have chemotactic properties and can recruit neutrophils, monocytes and 
lymphocytes (Guo and Ward, 2005).  C5a can also activated neutrophils, inducing 
oxidative burst and degranulation (Guo and Ward, 2005).  The deposition of immune 
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complexes in the vessel wall can therefore target these activated inflammatory cells to 
the endothelium. 
 
Cryoglubulins are immunoglobulins that persist in the serum, precipitate with cold 
temperature, and resolubilize when rewarmed (Cacoub et al., 2002).  They are 
associated with some forms of vasculitis and also induce immune complex deposition 
with resultant vascular injury (Cacoub et al., 2002). 
 
1.3.3.6 Endothelial immune interactions – amplifying inflammation? 
As previously mentioned, endothelial cells play a pivotal role in inflammatory processes 
and it is thus not surprising that they can play a role in amplifying the vasculitic process.   
Activation of the endothelium induces upregulation of adhesion molecules to facilitate 
leukocyte recruitment and adhesion (Rao et al., 2007) and release of pro-inflammatory 
cytokines which act in both an autocrine and paracrine manner; increasing endothelial 
activation and activating surrounding cells such as neutrophils to induce further injury 
(Krishnaswamy et al., 1999). 
 
In PAN it has been shown that while early on in lesional formation there is increased 
expression of E-selectin and VCAM-1 at the site of lesions, as disease progresses 
adhesion molecules are downregulated in the lesion but upregulated on surrounding new 
formed microvasculature (Coll-Vinent et al., 1998).  Interestingly animal models 
indicate that upregulation of adhesion molecules occurs normally in newly formed 
vessels (Vallien et al., 2000).   Thus reparative responses such as angiogenesis could 
exacerbate disease if inflammation is not controlled by facilitating in recruitment of 
more inflammatory cells to the site of injury (Coll-Vinent et al., 1998). 
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1.3.4 Conclusions regarding the pathogenesis of vasculitis 
Complex pathways involving immune cells, immune complexes and pro-inflammatory 
pathways as well as the endothelium itself are involved in the pathogenesis of vasculitis, 
although the upstream mechanisms which initiate and maintain endothelial injury 
remain to be fully elucidated.  Whatever the exact mechanisms involved in different 
vasculitis syndromes, the common end result is injury to the endothelium.  This concept 
will be examined in further detail in the subsequent chapters of this thesis. 
 
 
1.4  Assessment of disease activity in vasculitis – the 
need for reliable biomarkers 
After initial disease is brought into remission, it is not uncommon in a number of the 
vasculitides for repeated recurrent flares of the disease to occur.  This is a particular 
problem for PAN and the AAV (Gayraud et al., 2001).  In this context it is thus 
important clinically to be able to distinguish between vasculitic disease activity in 
which escalation of immunosuppression is required or treatment related manifestations 
such as opportunistic infection, where further immunosuppresion is unneccessary or 
could be detrimental. 
 
In the late 1990s, an expert working group at the NIH (National Institutes of Health, 
USA) was established to define the concept of biomarkers and their role in defining 
clinical outcomes and endpoints for trials.  They defined a biomarker as: "a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” (Biomarkers definitions working group, 2001). In the context of vasculitis 
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there is great interest in finding novel biomarkers that could be used to routinely assess 
disease activity in a minimally invasive manner, a number of which are discussed in 
detail below.   
 
It would have been virtually impossible to assess all the potential biomarkers described 
herein within the vasculitis cohort at GOSH.  Therefore this thesis focuses on 
biomarkers associated with endothelial injury, a phenomenon common to all of the 
vasculitides, irrespective of causal pathology as discussed in Section 1.3.  Biomarkers 
that reflect endothelial activation and injury therefore have the potential to monitor 
disease activity over a heterogeneous cohort (Brogan et al., 2004a).  While it is difficult 
to access the tissue directly, any factors released by the endothelium enter the blood, 
thus providing a window to the affected organ.  Before consideration is given to these 
novel biomarkers, some description of routine clinical assessment of vasculitis disease 
activity is required.   
 
1.4.1 Routine clinical tests for diagnosis and assessment of disease activity 
1.4.1.1 Initial diagnosis 
The symptoms of vasculitis are shared with a wide number of other conditions and 
therefore numerous investigations are performed in order to distinguish it from other 
diseases. In the first instance these include haematological tests such as blood counts, 
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), assessment of 
renal, liver and thyroid function, screens for infectious diseases, screening for 
prothrombotic clotting factors and certain genetic mutations as well as a multitude of 
immunological tests, including autoantibodies (antinuclear antibodies (ANA), anti 
double stranded DNA antibodies (DS-DNA), rheumatoid factor (RF),  antibodies to 
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extractable nuclear antigens such as Ro and La (ENAs), anticardiolipin antibodies, anti-
glomerular basement membrane antibodies (GBM)), immunoglobulins, cryoglobulins, 
factors involved in the complement pathways (MBL, C3/C4/C5a) and cytokines 
(Damianovich et al., 1996,Rees et al., 2007).   Radiological investigations, biopsy and 
further testing to exclude rare conditions (such as malignancy) and to further confirm 
the presence or absence of vasculitis would then be dependent on the individual patient 
symptoms and organ involvement (Rees et al., 2007). 
 
Radiological investigations are most useful in the medium to large vessel vasculitides, 
in smaller vessel diseases the techniques may not be sufficiently sensitive to detect 
abnormalities.  At GOSH digital subtraction arteriography, magnetic resonance imaging 
and angiography (MRI/MRA) and positron emission tomography (PET) may be used 
for initial diagnostic assessment.  Of these, arteriography is the most invasive, 
whereupon a contrast agent is injected into the arteries at the site of interest (selective 
visceral and/or cerebral arteriography), via a catheter and guide wires usually inserted 
through the femoral artery (Brogan et al., 2002).  This allows X-rays to be taken which 
will show changes within the vessel lumen, demonstrating aneurysms occlusions and 
stenosis (Brogan et al., 2002). 
 
MRI and MRA are  relatively  non-invasive  techniques  which  can  provide  additional  
information about the vessel wall (MRI) and lumen (MRA).    MRI can give indication  
of thickening of the vessel walls including oedema which may be indicative of 
inflammation (Pipitone et al., 2008).  MRA is used to assess aneurysms, occlusions and 
stenosis, however it can overestimate the degree of stenosis and thus have higher false 
positives than conventional areriography (Gotway et al., 2005).  Conversely MRA lacks 
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sufficient sensitivity for the detection of changes affecting smaller muscular arteries 
frequently observed in PAN (Brogan et al., 2002). 
 
PET scanning utilizes a radiolabelled glucose analogue (
18
fluorodeoxyglucose (
18
FDG)) 
to highlight cells which have a higher level of glucose uptake due to increased 
metabolic activity.  At sites of active vasculitis uptake is high (Belhocine et al., 2003), 
however although it is unlikely to be as large a confounding factor in paediatric cohorts 
as it is in adults, atherosclerotic lesions are also sites of high metabolic activity (Yun et 
al., 2001) and thus great care must be taken when interpreting the scans.  Co-registration 
of PET with computed tomography (PET-CT) vastly improves anatomical resolution 
and is useful for TD, although radiation exposure is very high (Henes et al., 2008).   
 
Evidence of vasculitic disease activity on a tissue biopsy is frequently referred to as the 
“gold standard” for confirming active disease (Mukhtyar et al., 2006).  However due to 
the localised nature of the disease, a negative result on biopsy does not indicate that 
disease is absent.  For example in patients with well-documented active WG, only 
around 50% of nasal biopsies demonstrated evidence of active vasculitis (Del Buono 
and Flint, 1991).  Ultimately diagnosis is based on the ability to assimilate the evidence 
pointing to vasculitis and to exclude other conditions that may mimic it through a broad  
array of clinical investigations. 
  
1.4.1.2 Routine assessment of disease activity following diagnosis 
As treatment for vasculitis is often toxic, a well defined diagnosis at outset is essential.  
In addition, the ability to monitor disease activity is equally important due to the 
relapsing nature of a number of the vasculitides and the need for rapid intervention if  or 
56 
 
when disease returns.  Careful clinical evaluation of individual patients, with assessment 
of changes in symptoms and biological and radiological markers is the only way in 
which disease activity and response to treatment can be assessed.  This is the principle 
behind the Birmingham Vasculitis Activity Score (BVAS) (Appendix 2, discussed in 
Section 2.2.2) which is now routinely used to quantify disease activity in clinical trials 
and increasingly in routine clinical practice as well (Luqmani et al., 1994). 
 
Commonly used biological markers of inflammation such as ESR and CRP are non 
specific and cannot easily distinguish between infection or disease activity.  During 
active disease, levels of these inflammatory markers may also remain normal, 
particularly in episodes of localised disease and granulomatous flares (Salvarani et al., 
2003,Sproson et al., 2007), so caution must be taken when interpreting such 
information.   
 
In the ANCA-associated vasculitides routine monitoring of ANCA levels is 
commonplace, both PR3 and MPO-ANCA can be detected using ELISA or indirect 
immunofluorescence (Hagen et al., 1996).  However, the usefulness of ANCA as a 
biomarker remains controversial; while transient rises in ANCA often occur during 
relapse many patients who have a rise in ANCA remain well (Mukhtyar et al., 2008).  
  
Although  histopathological  evidence  on biopsy  is  a  reliable  confirmation  of  active  
disease in vasculitis, it is not a practical measure for routinely assessing disease activity 
due to its invasive nature.  The same applies for radiological investigations, while 
changes in radiological images are indicative of ongoing disease activity, the techniques 
can be extremely invasive and are also expensive, time consuming and in some 
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instances carry a significant radiation level.  Moreover, contrast agents used in 
MRI/MRA protocols have recently been associated with nephrogenic systemic fibrosis 
in patients with renal impairment (Agarwal et al., 2008,Penfield, 2008).  Thus it is with 
caution that MRI/MRA should be performed in patients with renal vasculitis.      
 
1.4.2 Novel Biomarkers in vasculitis 
Due to the complexity of diagnosing and assessing vasculitis there has been much 
interest in finding novel biomarkers which may prove useful in this context.  Possible 
biomarkers for vasculitis that have been investigated range from autoantibodies, to 
soluble adhesion molecules, cytokines, growth factors and cellular fragments.  
 
1.4.2.1 Autoantibodies  
Anti-endothelial cell antibodies  
As described in Section 1.3 AECA may have a pathological role in vasculitis.  AECA 
are commonly detected using a cell based ELISA with HUVEC as the substrate and 
their presence has been observed in a number of the vasculitides, including WG (Savage 
et al., 1991), PAN and BD (Navarro et al., 1997), TD (Park et al., 2006) and KD 
(Fujieda et al., 1997).  However some studies completely contradict these findings with 
no difference in the proportion of samples positive for AECA in patients or controls 
(Dinc et al., 2003,Varagunam et al., 1993).  A small number of studies have shown 
AECA levels fluctuate correspondingly with disease activity in vasculitis (Park et al., 
2006), however other groups have shown no such relationship (Sebastian et al., 2007).  
The discrepancies in findings have been in part attributed to the non standardised 
methodologies used to detect AECA; while the majority of groups use variations on 
cellular ELISA, flow cytometry and a number of other methods have also been 
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employed (Belizna and Tervaert, 1997).  While experimental evidence points to AECA 
as a potential mechanism of endothelial activation both in vivo and in vitro, the 
contrasting observations in patients do not currently support its role as a biomarker of 
disease activity.   
 
Anti-heat shock protein antibodies 
Heat shock proteins (HSPs) are highly evolutionary conserved proteins that are 
upregulated in response to a number of environmental stresses (including, hypoxia, 
heat-shock and inflammation) (Tsan and Gao, 2004).  Many family members also 
function constitutively, acting as molecular chaperones – stabilizing in folding and 
assisting in the intracellular trafficking of peptides, including complex formation.  
Under stress, their increased expression is protective assisting in cellular repair and 
inhibiting a number of apoptotic signalling pathways (Lanneau et al., 2008).   
 
Because of the highly conserved structure of HSPs throughout species, the presence of 
antibodies to bacterial and human homologue HSPs in vasculitis has been proposed as 
evidence of molecular mimicry causing disease, particularly in KD (Sireci et al., 2000) 
and BD (Tanaka et al., 1999).  As HSPs can bind with cell membrane peptides, it has 
been suggested that HSPs may be a target of AECA (Jamin et al., 2005).  As with other 
autoantibodies in vasculitis the evidence regarding anti-HSPs is conflicting, while some 
studies show elevated levels of antibodies to specific HSPs in patients with vasculitis 
such as alpha-enolase in KD (Chun et al., 2008) others show no differences in 
expression from controls (Sherer et al., 2008).  As yet no study has examined the 
changes in anti-HSPs with treatment and thus the lack of reproducible data and the 
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possibility that it may only be relevant in a small proportion of patients indicates this 
may not prove a suitable biomarker in a varied cohort. 
 
Other autoantibodies 
Other  autoantibodies  that  have  been  shown  to  be  elevated  in  vasculitis  include  
antiphospholipid antibodies and anti glomerular basement membrane antibodies.  
Neither of these are specific for vasculitis, nor have been studied in the context of 
disease progression, however both may influence the type of disease complications 
which occur.  Antiphospholipid antibodies are a heterogenous groups of autoantibodies 
specific for anionic phospolipids (including anti-cardiolipin, lupus anticoagulant and 
anti-β2 glycoprotein), and have been documented in WG (Hergesell et al., 1993) and 
PAN (de la Fuente and Grana, 1994), with a small number of studies suggesting an 
association with adverse thrombotic events (Morelli et al., 1998).  Antibodies targeting 
the glomerular basement membrane are rare, but their presence is associated with renal 
and pulmonary complications (Goodpasture’s disease). While these may not provide a 
direct assessment of disease activity, their presence or absence could provide useful 
insight for treatment in certain vasculitides, albeit the vast minority of cases (Rutgers et 
al., 2005). 
  
1.4.2.2 Soluble adhesion molecules 
Adhesion molecules mediate the attachment of cells to each other, playing a pivotal role 
in the recruitment of inflammatory cells to the site of injury in vasculitis.  Proteolytic 
cleavage of the extracellular portion of cell membrane expressed adhesion molecules 
results in a soluble form being released into the circulation and explains in part the 
transient expression of adhesion molecules on activated cells (Gearing and Newman, 
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1993).  There is also evidence that some adhesion molecules (such as P-selectin) may 
have alternatively spliced forms which lack a trans-membrane domain and thus are 
produced in a soluble form (Ishiwata et al., 1994).    
 
L-selectin  is  constitutively  expressed  on  leukocytes, but  is  rapidly shed from the  
surface of activated cells.  In-vitro the soluble form can inhibit lymphocyte-endothelial 
interactions (Schleiffenbaum et al., 1992).  In patients with active AAV (Ara et al., 
2001), PAN (Coll-Vinent et al., 1997) and KD (Takeshita et al., 1997) L-selectin levels 
were lower than in controls, however in KD levels rose during the convalescent stages 
of the disease (Takeshita et al., 1997). 
 
P-selectin is a preformed molecule which is stored in the granules of platelets and the 
Weibel-Palade bodies of the endothelium, and is involved in the interaction between 
platelets, the endothelium and leukocytes, thus playing a key role in vascular 
inflammation.  The soluble form has been shown to be upregulated in active BD 
(Turkoz et al., 2005), and in the subacute phase of KD, correlating with platelet count 
(Takeshita et al., 1997).  In AAV and PAN P-selectin levels did not differ from controls 
(Ara et al., 2001,Coll-Vinent et al., 1997).  
 
E-selectin is highly selective, only being found on activated endothelial cells in a 
transient manner.  Its soluble form is detected in the supernatants of TNFα and IL-1 
stimulated ECs (Pigott et al., 1992).  Correspondingly it is upregulated in active 
vasculitis, in AAV (Ara et al., 2001), PAN (Coll-Vinent et al., 1997) and KD (Takeshita 
et al., 1997) and declines with remission inducing treatment.  In KD it showed 
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correlation with disease activity and was highest in patients with coronary artery lesions 
(Furui et al., 2002).  
 
 Both ICAM-1 and VCAM-1 are released in a soluble form from activated ECs in vitro 
(Pigott et al., 1992).  Unlike E-selectin their expression is not specific to the 
endothelium, however they are both upregulated in vasculitis (Wang et al., 
2006,Stegeman et al., 1994,Verity et al., 1998) and in some studies have shown 
correlation with disease activity (Stegeman et al., 1994), although not in all (Wang et 
al., 2006,Ara et al., 2001).   
 
While soluble adhesion molecules have been widely studied in the vasculitides the data 
is ambiguous, with good correlation with disease activity reported in some studies(Furui 
et al., 2002,Stegeman et al., 1994), but not in others (Ara et al., 2001).  The predominant 
methodology for detection of these molecules is ELISA, which may not distinguish 
between biologically active and inactive forms of the adhesion molecules and may also 
be detecting adhesion molecules associated with membrane fragments (microparticles) 
rather than true soluble molecules. 
   
1.4.2.3 Other peptides – cytokines, chemokines, clotting and growth factors 
Unsurprisingly   a   number   of   the   vasculitides  are  associated   with   elevations   in  
inflammatory cytokines such as IL-1, TNFα, IFNγ Il-17, Il-23 and Il-6 (Ohlsson et al., 
2004,Chi et al., 2008,Grau et al., 1989) and chemokines such as RANTES, fractalkine, 
eotaxin, MCP-1 and IL-8 (Torheim et al., 2005,Bjerkeli et al., 2007,Dhawan et al., 
2006). Both are produced by a wide variety of cell types, including the endothelium and 
recruited leukocytes.  The actual cytokine profile in individual patients is extremely 
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varied and as in the case of elevated ESR and CRP, cytokines and chemokines are not 
specific to vasculitis and can be upregulated in inflammation without the presence of 
active vasculitic disease. Thus their use as a biomarker for disease activity would 
require careful interpretation.  However with the increasing use of biological therapies 
to Il-1 and TNFα in patients refractory to other treatments, the presence of high levels of 
these cytokines may provide valuable clinical insight regarding indication for treatment 
with these agents.  Interestingly in AAV at least, although anti-TNFα therapy 
(infliximab) induced remission in 10 patients with active disease, levels of serum TNFα 
were not significantly different to controls, nor was there a significant change observed 
with treatment in individual patients (Booth et al., 2004b).  Further studies will be 
necessary to clarify any diagnostic potential of these cytokines.    
   
Von Willebrand Factor (VWf) is released in large amounts from Weibel-Palade bodies 
by activated and damaged endothelium.  It is important in coagulation, binding exposed 
collagen in the vessel wall, platelet receptors to form complexes even under high shear 
stress, and clotting factor VII preventing its inactivation (Ruggeri, 2007).  In vasculitis a 
number of studies have assessed its potential as a biomarker of disease activity with 
promising results.  VWf correlates with disease activity in WG (D'Cruz et al., 1999) and 
HSP (Yilmaz et al., 2005), although in acute KD despite being elevated compared to 
healthy controls there were no differences to febrile controls (Lin et al., 2005) 
suggesting a lack of specificity for vasculitis.  Another peptide involved in haemostasis 
is thrombomodulin which acts as a receptor for thrombin and functions as a natural 
anticoagulant.  It is found on endothelial cells and is cleaved on cellular activation. In 
vasculitis it has been to shown to correlate with disease activity in WG and MPA 
63 
 
(Hergesell et al., 1996) (Boehme et al., 1996) although like VWf is unlikely to be 
specific for vasculitis and is upregulated in infection (Van de Wouwer M. et al., 2004). 
 
In response to vascular injury, the endothelium secretes numerous growth factors to 
assist in repair.  This important topic is discussed in more detail in Chapter 5.  In 
vasculitis a number of studies have examined VEGF levels in patient plasma or sera and 
found it to be upregulated in active disease in HSP (Topaloglu et al., 2001), BD (Shaker 
et al., 2007) and in KD (Terai et al., 1999), which decreased on recovery.  Data also 
suggests in KD that high VEGF may be a risk factor for development of coronary artery 
lesions (Ohno et al., 2000).  Interestingly in KD the antiangiogenic growth factor 
endostatin was shown to be lower in active disease (Takeshita et al., 2005).     
 
1.4.2.4 Cells and cellular fragments 
When cells become activated, membrane blebs or microparticles (MPs) are shed and 
can be detected in the circulation (Piccin et al., 2007).  Thus cellular MPs could provide 
valuable information about activated cell populations and hypothetically may be able to 
predict disease flare prior to significant vascular injury by early detection of activated or 
primed cells before irreversible vascular injury occurs.  MPs are discussed in detail in 
Chapter 4 where they are assessed as a potential biomarker of disease activity in 
vasculitis. 
 
If endothelial cells become sufficiently activated, they may become apoptotic or 
necrotic and whole cells may become detached from the vessel wall.  Circulating 
endothelial cells (CECs) have been detected in a number of conditions associated with 
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vascular injury (Blann et al., 2005) and are discussed in detail in Chapter 3, where they 
have been assessed as a potential biomarker of vasculitic disease activity.  
 
Conversely endothelial injury must be followed by endothelial repair in order to 
maintain health, and markers of putative reparative response such as endothelial 
progenitor cells (EPCs) and the growth factor signalling pathways involved in their 
recruitment may also provide insight into disease activity.  This important area is 
discussed in more detail in Chapters 5 and 6.   
 
While these markers of endothelial activation and injury are of particular relevance in 
the vasculitis cohort, they also have significance in a number of other conditions 
affecting the vasculature, including atherosclerosis.  Although this latter condition is not 
so relevant in paediatric cohorts (where atherosclerotic changes are rare), it may be of 
greater significance in adult cohorts.  That said, as will be discussed later in this thesis, 
both endothelial MPs and CECs have been studied in adults with vasculitis with 
promising results (Erdbruegger et al., 2008). 
 
  
65 
 
1.5 Aims of this thesis 
The aim of this thesis is to evaluate novel putative biomarkers of disease activity in 
primary systemic vasculitis.  As the endothelium is the target organ of the disease, this 
objective has been addressed by focusing on surrogate markers of endothelial activation 
and injury and subsequent reparative responses.  The biomarkers studied in subsequent 
chapters of this thesis include circulating endothelial cells and endothelial 
microparticles, growth factors associated with angiogenesis and vasculogenesis and 
endothelial progenitor cells.  A major factor of work involving children is the small 
volumes of blood available on which to perform such tests and thus much care was 
taken to minimise blood volumes necessary for study.        
 
66 
 
2 Methods and Materials 
 
2.1. Introduction 
 
2.2. Patients, vasculitis classification and assessment of disease activity 
 
2.3. Materials  
 
2.4. Preparation of blood and tissue samples 
 
2.5. Assessment of endothelial activation and injury 
 
2.6. Assessment of potential endothelial repair responses 
 
2.7. Statistics 
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2.1 Introduction 
This section details materials and methods which are used in more than one chapter.  
Where methodologies have been adapted or developed specifically for this study, they 
are discussed in greater detail in the relevant chapter. 
 
 
2.2 Patients, vasculitis classification and assessment of 
disease activity 
All patients enrolled in the study were assessed by rheumatologists at GOSH.  Full 
informed consent was obtained for all patients and controls (parental) and children’s 
assent was sought where appropriate on enrolment in the study.   
     
2.2.1 Classification of the vasculitic syndromes 
As discussed in Section 1.2 vasculitis was classified predominantly according to the 
Chapel Hill Consensus Criteria (Jennette et al., 1994), however the American College of 
Rheumatology (ACR) criteria (Fries et al., 1990) and the EULAR/PRES endorsed 
consensus criteria (Ozen et al., 2006) for vasculitis of the young were applied as 
additional classification tools.  The Chapel Hill criteria classifies vasculitis on the size 
of the vessel predominantly affected and also forms the basis of the EULAR/PRES 
criteria, which contains further modifications relating to the paediatric population.  
These include; the exclusion of diseases not relevant in childhood and inclusion of 
diseases that are not addressed by the adult system, an extra category of disease entitled 
“other diseases” and the use of vessel “predominantly affected” to categorise patients 
whose disease overlaps vessel sizes (Ozen et al., 2006). Appendix 1 lists all criteria. 
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2.2.2 Assessment of disease activity 
Disease activity was assessed using a modified paediatric version of the Birmingham 
Vasculitis Activity Score (BVAS) (Luqmani et al., 1994), a scoring system that is used 
to give an overall view of disease activity in vasculitis patients (Appendix 2).  It has 
never been formally validated in children.  However, in a previous report from our 
group a modified paediatric version of BVAS was found to significantly correlate with 
the conventional acute phase marker CRP (as in adults) (Brogan et al., 2004a,Luqmani 
et al., 1994).   
 
The aim of the BVAS scoring system is to give a uniform assessment of current disease 
activity in groups of patients with different forms of vasculitis and is not specifically 
designed for any single vasculitic syndrome, although a specific form of BVAS for 
Wegener’s Granulomatosis has been described for use in adult patients (Jayne, 
2001,Stone et al., 2001).   At time of scoring, disease activity is only considered for 1 
month previously.  The score is weighted more heavily towards biochemical and 
objective evidence of active vasculitis (such as organ involvement e.g. gut or kidneys) 
rather than symptoms which have a subjective element (e.g. myalgia, arthralgia).  
Despite the inherent potential limitations and scorer subjectivity of the BVAS this 
system does provide an overall clinical score of vasculitic disease activity and has 
proved a successful tool for use in clinical trials (Jayne, 2001).  
 
In this study, active vasculitis was defined as a BVAS score greater than 0, where the 
scored criteria were newly appearing or worse in the preceding 4 weeks and attributable 
to vasculitis, having excluded other causes such as infection.  The maximum score 
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attainable was 63.  Disease remission was defined as a score of 0/63.   The modified 
BVAS used in this thesis is shown in Appendix 2. 
 
 
2.3   Materials 
2.3.1 Reagents for blood collection 
After blood was obtained it was aliquoted into one or more of the following collection 
bottles depending on use; 1.4ml 3.2% trisodium citrate (Sarstedt), 5ml EDTA 
(International scientific supplies), 5ml polypropylene containing no anticoagulant or 
sterile 20ml Universal bottles containing 40µl of preservative-free heparin (Monoparin, 
CP Pharmaceuticals Ltd, 1000 U/ml). 
 
2.3.2 Fluorochrome conjugated antibodies for flow cytometry 
The fluorochrome conjugated antibodies used are listed in Table 2.1.  Antibodies were 
diluted using 0.01M PBS + 0.1% azide for staining of peripheral blood mononuclear 
cells (PBMCS) and Human umbilical vein endothelial cells (HUVEC) and sterile 
filtered RPMI 1640 with 5% FCS for staining of microparticles (MPs).  Where 
antibodies were used in whole blood they were added neat to give the final dilution 
given in Table 2.1.  All antibodies were titrated alongside their manufacturers 
recommended isotype control to determine their optimal concentration and minimise 
non-specific binding. FC receptor blocking reagent (Miltenyi biotech) was used to 
further reduce non specific antibody binding. 
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Table 2-1: Fluorochrome conjugated antibodies for flow cytometry 
 
Use in this thesis E = endothelial progenitor cells, C = Circulating endothelial cells, M = 
microparticles, EC = in vitro endothelial activation, N = in vitro neutrophil experiments    
Specificity Isotype Conjugate Clone Dilution Source Usage 
 
 
CD34 IgG1 PERCP 8G12 1:10 BD E,EC,C 
CD133 IgG1 PE AC133 1:10 Miltenyi E 
CD14 IgG1 FITC Mem-18 1:20 Serotec E 
CD14 IgG1 PE Mem-18 1:20/1:15 Serotec E,M 
CD144 Poly 
IgG 
FITC - 1:15 Serotec E 
CD144 I 1 PE 16B1 1:20/1:15 eBiosciences E,M 
CD45 IgG1κ FITC HI30 1:20 eBiosciences C 
CD146 IgG1 κ PE P1H12 1:20 BD E,EC,C 
CD3 IgG1 CY UCHT1 1:20/1:15 BD E,M 
KDR IgG1 BIOTIN KDR-2 1:10 Sigma E 
CD105 IgG1 PE SN6 1:15 Serotec M 
CD62e IgG1κ PE 68-5H11 1:15/1:10 BD M,EC 
CD62p IgG1κ PE AK4 1:15 BD M 
CD62L IgG1κ PE-CY5 DREG-56 1:15/1:20 BD M, N 
CD11b IgG1κ PE ICRF44 1:15/1:20 BD M,N 
CD15 IgG1κ PE HLDA8 1:15/1:20 Biolegend M,N 
CD54 IgG1κ PE-CY5 HA58 1:15 BD M 
CD66b IgG1 PE Birma17C 1:40/1:25 IBGRL M,N 
CD42a IgG1κ Percp Beb1 1:15 BD M 
TF IgG1κ PE HTF-1 1:15 BD M 
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2.3.3 Tissue culture media 
The following tissue culture media was used: RPMI-1640 culture medium containing 
2mM L-glutamine (Invitrogen), MCDB-131 (Invitrogen) and the EGM-2 (endothelial 
growth media) bullet kit (Cambrex).  The EGM-2 bullet kit consisted of EBM-2 
(endothelial basal media) with the following supplementation (concentrations were not 
given) human recombinant Epidermal Growth Factor (hEGF), human Fibroblast 
Growth Factor - Basic (hFGF-B), Vascular Endothelial Growth Factor (VEGF),  
Ascorbic Acid (Vitamin C), Hydrocortisone,  Long human Recombinant Insulin-like 
Growth Factor (R3-IGF-1), Heparin, Fetal Bovine Serum (FBS), Gentamicin and 
Amphotericin. 
 
Further supplementation to the culture media depended on the culture conditions as 
described in the individual methodologies, however the following were also used; 
penicillin and streptomycin (10,000U and 10,000µg, diluted 1:100, Invitrogen), 
antibiotic-antimycotic liquid 100x (10,000U penicillin, 10,000 µg streptomycin, 25 µg 
amphotericin B, diluted 1:100, Invitrogen), Vascular Endothelial Growth Factor 
(VEGF, R&D), basic human fibroblast growth factor (bFGF, R&D), heparin and fetal 
calf serum (FCS, Invitrogen).  In most experiments FCS was heat inactivated at 56
o
 C 
for 60 minutes to destroy complement.  Variations in batch quality of FCS can 
dramatically influence HUVEC growth, therefore batches of FCS used for HUVEC 
culture were tested prior to purchase and bought in large quantities.  To enhance cell 
attachment or to act as a growth scaffold the following were used: Attachment factor 
(PAA systems), fibronectin (100ng/ml, Calbiochem), Matrigel
TM
, phenol red free (BD). 
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2.3.4 Cytokine and protein reagents 
The following cytokines were used: recombinant TNF- (100ng/ml, Autogen Bioclear), 
recombinant Il-1β (100ng/ml, Autogen Bioclear).  The following peptides were used: N-
formyl-methyl-leucyl-phenylalanine (FMLP) (1uM, Sigma), LPS (100ng/ml, Sigma). 
The following fluorochrome-conjugated proteins were used: annexin-V (FITC; 1:100 
dilution, BD); Ulex europaeus I Agglutinin (UEA-I FITC, 10mg/ml, Sigma), 
Streptavidin (FITC, 1:150 dilution, Serotec).  Type II collagenase (Sigma) was used for 
isolation of HUVEC from umbilical cords.  Trypsin-EDTA (10x, 0.5%, Invitrogen) was 
used for detachment of HUVEC from culture.   
 
2.3.5 Bead based extraction reagents 
DYNAL bead technology (Invitrogen) was used for isolation of CECs: Dynabeads Pan 
Mouse IgG were labeled with an unconjugated IgG1 antibody to CD146, clone s-endo 1 
(BioCytex). The Dynal MPC-L magnet which holds 1-8ml tubes was also used. 
 
2.3.6 ELISA kits 
The following ELISA kits were used to determine levels of growth factors in patients 
plasma and serum: Angiopoeitin-1 (R&D), Angiopoeitin-2 (R&D), Vascular endothelial 
growth factor VEGF) (R&D), Thymosin β4 (immundiagnostik).  All test kits were used 
as per manufacturer recommendation. 
 
2.3.7 Other reagents 
For isolation of PBMCs from blood samples, the density centrifugation separation 
reagent Lymphoprep (Axis-Shield) was used.  To isolate neutrophils a similar product 
Polymorphprep was used (Axis-Shield). The following latex beads were used to 
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investigate forward and side scatter (FSC/SSC) flow cytometric characteristics of small 
particles: 0.3, 0.8, 3µm latex beads, (Sigma).  Countbright beads
TM
 (Invitrogen) were 
used as in an internal standard for absolute enumeration of circulating endothelial cells 
and endothelial progenitor cells in whole blood samples. 
 
 
2.4 Preparation of blood and tissue samples 
All human blood and tissue samples were collected with full ethical approval and 
informed consent. 
 
2.4.1 HUVEC 
2.4.1.1 Isolation of HUVEC  
Umbilical cords were collected from the maternity unit at the West Middlesex hospital, 
London with ethical approval and informed consent.  HUVEC were isolated from 
freshly collected cords in the following manner:  Using tweezers cords were removed 
from the collection bottle (containing RPMI 1640 + 100U/ml Penicillin + 100 µg /ml 
Streptomycin + 0.25 µg/ml Amphotericin) and sprayed liberally with IMS.  Any blood 
inside the cord was squeezed out and discarded.  One end was clamped approximately 
2cm in and the end cut off.  At the other end, a further 1-2cm was removed and a Kwill 
(Universal Hospital Supplies) was inserted into the umbilical vein and clamped into 
position.  A syringe filled with RPMI 1640 (with antibiotics and antimycotic as above) 
was squeezed into the cord via the Kwill and used to fill it.  The clamped end of the 
cord was then released and the vein contents washed out into a clean waste beaker.  The 
vein was then filled with warm (37
o
C) collagenase type II solution (0.1%, dissolved in 
RPMI-1640 and passed through a 0.2µm tissue culture filter, aliquoted and stored at -
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20°C).  Both ends were clamped and the cord left for 10 minutes in the incubator.  The 
contents of the vein were then emptied into a sterile collection bottle and a further wash 
through with RPMI (containing antibiotics only + 5% heat inactivated FCS) was 
performed.  The collected vein contents containing HUVEC were then centrifuged for 8 
minutes at 450g creating a cell pellet. 
 
2.4.1.2 HUVEC culture 
Pelleted HUVEC were resuspended in MCDB131 (containing 20% heat inactivated 
FCS + antibiotics) and placed in a 25 cm
2
 flask, precoated (30 minutes prior to use) with 
attachment factor for optimal cell attachment.  Cells were cultured at 37
o
C with 5% CO2 
and inspected each day for growth. The media was changed every 3 days until cells 
were required, passaging as necessary at about 80% confluence.   Initally HUVEC were 
easily identifiable as small clusters of oval adherent cells when inspected under phase-
contrast microscopy (Figure 2.1a).  As they reached confluence their appearance was 
characteristically “cobblestone” (Figure 2.1b).  In some cultures there was significant 
overgrowth of smooth muscle-like or fibroblast-like cells (which are characteristically 
spindle-shaped), cultures containing these and those that had not grown well were 
discarded. 
 
2.4.1.3 HUVEC culture passage 
HUVEC that were near-confluent were washed three times in warmed PBS to remove 
non-adherent cells and any FCS. Cells were then washed once in 0.5ml 0.05% Trypsin-
EDTA solution (per 25 cm
2
 flask) which was then removed and a further 1ml Trypsin- 
EDTA solution added. Cells were inspected under phase-contrast microscopy, and when 
rounding  and  becoming  dislodged  (typically after 30 seconds),  the  flask  was  tapped 
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Figure 2-1: Cultured HUVEC  phenotype 
 
 
 
 
 
Figure 2.1a: Soon after they were placed in culture HUVEC were easily identifiable as small 
clusters of oval adherent cells when inspected under phase-contrast microscopy.   Figure 2.1b: As 
HUVEC reached confluence their appearance was characteristically “cobblestone” .  Scale bars 
represent 50µm  
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against the bench top to aid removal.  If cells did not detach, flasks were placed in the 
incubator for a further 30 seconds. The detached cells were quickly resuspended in 
warmed HUVEC culture medium and transferred to a 50-ml sterile conical tube. These 
were then seeded into 6 or 12 well flat-bottom tissue culture plates, precoated in 
attachment factor. Tissue culture plates were then incubated as before. 
 
When cord supply was plentiful HUVEC at passage 1 and 2 were frozen down, to 
provide a continous supply of endothelial cells if fresh cords were unavailable.  After 
passage, viable HUVEC were counted with trypan blue (to exclude dead cells) in a 
haemocytometer.  A minimum of 5 x 10
6
 cells were resuspended in heat inactivated 
FCS containing 10% DMSO and frozen in a freezing container placed in a -80
o
C 
freezer.   For use, cells were defrosted rapidly at 37
o
C and decanted straight into a T25 
flask precoated with attachment factor and containing EGM-2 media with all additives. 
 
Details of specific conditions used to grow HUVEC for various experimental 
procedures are described in the relevant sections in subsequent chapters. HUVEC 
morphology and phenotype, especially in terms of induction of cell adhesion molecules 
in response to pro-inflammatory stimuli may alter after serial passages. The cells used 
throughout this study were therefore always first to third sub-culture passage.  
 
2.4.1.4 Spiking of whole blood samples and PBS with HUVEC  
In these experiments HUVECs at passage 1 or 2 were detached as described above 
using 0.05% trypsin-EDTA and resuspended in PBS + 5% heat inactivated FCS + 0.1% 
azide.  Cells were centrifuged to a pellet, resuspended in a small volume of PBS 
(additives as above) and counted as described above.  The HUVEC were serially diluted 
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to give stock concentrations from which 100l of cells could be added to 1ml blood or 
1ml PBS.  Whole blood or PBS was spiked with 0, 100, 1000, 10000 and 100000 
HUVECs/ml. Cells were carefully mixed in the blood or PBS sample by gentle 
pipetting.  Equal volumes of spiked whole blood or PBS were used for flow cytometry 
or immunomagnetic bead extraction in the comparative experiments described in 
Chapter 3.     
 
2.4.2 Isolation of PBMCS 
PBMCs were isolated using density gradient media (Lymphoprep).  10ml of blood 
collected in preservative free heparin was mixed with 10ml RPMI 1640 containing L-
glutamine with added antibiotics (penicillin 100U/ml and streptomycin 100g/ml) and 
layered over 10ml of lymphoprep in a 50ml conical tube.  The sample was then 
centrifuged at room temperature for 25 minutes at 700g with no brake.   A wide tipped 
Pasteur pipette was used to aspirate PBMCs from the buffy coat layer formed into a 
fresh 50ml conical tube, which was then washed with RPMI 1640 containing L-
glutamine (with 10% heat inactivated FCS and antibiotics as before).  Cells were 
centrifuged at 500g for 10 minutes and the pellet re-suspended in RPMI 1640 (with FCS 
and antibiotics). Cells were counted as described previously.  To allow batch analysis 
aliquots of cells (concentration 5-10x10
6
 cells/ml) were resuspended in heat inactivated 
FCS with 10% DMSO and frozen in a freezing container placed in a -80
o
C freezer for 
use in later experiments.  
 
2.4.3 Isolation of neutrophils 
Neutrophils were also isolated using density gradient media (Polymorphprep). 6ml of 
blood was layered directly over 6ml of polymorphprep in a 15ml falcon tube. The 
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sample was then centrifuged at 500g for 30minutes.  The different gradient preparation 
resulted in a separation of 2 bands of cells, the lower of which constituted neutrophils 
with the upper band corresponding to PBMCs.  A wide tipped Pasteur pipette was used 
to remove the upper band first, allowing better access to the lower band of interest, 
which was then removed in the same way.  To reduce neutrophil activation, cells were 
resuspended in PBS and kept on ice until use. 
 
2.4.4 Separation of platelet poor plasma 
Blood collected in 3.2% trisodium citrate was spun at 5000g for 5 minutes in a  
microcentrifuge in 1.5ml polypropylene tubes.  The supernatant was decanted and then 
respunded in order to obtain platelet poor plasma (PPP).  The PPP was then aliquoted 
and stored at -80
o
C until use.  PPP was used for detection of microparticles as described 
in 2.5.3 and in ELISAs for detection of Angiopoetin-1 and Angiopoetin-2. 
 
2.4.5 Separation of serum  
Uncoagulated blood was allowed to stand for 2-4 hours.  The sample was then 
centrifuged at 1500g for 10mins, the supernatant aliquoted and samples stored at -80
o
C 
until future use.   Serum was used in ELISAs for detection of VEGF and Thymosin β4. 
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2.5 Assessment of endothelial activation and injury 
2.5.1 Detection of circulating endothelial cells using immunomagnetic 
beads 
2.5.1.1 Preparation of immunomagnetic beads 
Dynabeads (pan mouse IgG) were resuspended and 350µl was added to a 5ml 
polypropylene tube.  The tube was then placed into the magnet (MPC-L) for 2 minutes 
to allow the beads to attach to the side of the tube.  The supernatant was discarded using 
a Pasteur pipette and the beads resuspended in 1ml PBS (+0.1% BSA).  The tube was 
placed in the magnet again and the supernatant discarded as before.  The beads were 
resuspended in 950ul of PBS (+ 0.1% BSA) and 400ul of s-endo-1 antibody were added 
(25µg/ml concentration).  The tube was sealed and the sample mixed on a roller mixer 
for 2 hrs at 4
o
C.   Beads were washed as before three times and resuspended in a final 
volume of 1ml, ready for use. 
 
2.5.1.2 CEC extraction from peripheral blood 
CECs were detected using the consensus protocol as described by Woywodt et al 
(Woywodt et al., 2006a).  Briefly 1ml of venous blood collected into a blood bottle 
containing EDTA was mixed with 1ml buffer (phosphate buffered saline (PBS) 
containing 0.1% bovine serum albumin (BSA) and 0.6% sodium citrate) and 20μl Fc 
receptor (FcR) blocking reagent and incubated for 5 minutes at room temperature. 50μl 
of anti-CD146 coated immunomagnetic beads was then added and the sample incubated 
at 4
o
C whilst rotating for 30 minutes. Bead-bound cells were separated using the magnet 
as described above and washed three times with buffer. Cells were then re-suspended in 
100μl of buffer containing 10μl of 2mg/ml FITC labelled Ulex Europeus lectin and 
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incubated in the dark at room temperature for one hour. Cells were then washed again 
three times and re-suspended in a final volume of 200μl buffer. 
 
2.5.1.3 Counting CECS 
CECs in the sample were counted using a Nageotte chamber on a fluorescent 
microscope and were defined as the following;  Ulex bright cells, greater than 10μm in 
size with more than 5 magnetic beads attached, a definition put forward in the 2006 
consensus paper (Woywodt et al., 2006a).  A Nageotte counting chamber is designed 
for counting of rare events and holds 50µl of sample over a grid consisting of 40 lines.  
CECs were counted over 20 lines of the grid (corresponding to 25µl or 1/8 of the 
sample) if there were high numbers, which made it difficult to count or over all 40 lines 
(corresponding to 50µl or 1/4 of the sample) if there were low numbers.  Counts were 
then multiplied by the appropriate factor to get a total value per ml of whole blood.  
 
2.5.2 Detection of circulating endothelial cells using flow cytometry  
Enumeration of CECs has been carried out using both the immunomagnetic bead 
extraction as described above and flow cytometry (FC), however only one publication 
has demonstrated whether they give comparable results and this was not in patients with 
vasculitis (Goon et al., 2006).  Thus both methods were used in this thesis for 
comparison.  The flow cytometric definition of CECs definition of  putative CECs as 
suggested by Goon et al in their comparative paper and other groups was thus: cells 
falling within a mononuclear cell gate that express both CD146 and CD34, but which 
are negative for CD45 (Goon et al., 2006,Bertolini et al., 2006,Del et al., 2004,Khan et 
al., 2005).   
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2.5.2.1 Preparation of blood samples for flow cytometry of CECs 
1ml of blood collected in EDTA was lysed using 10ml of FACS lysis solution (1:10 
dilution of 10x FACS lyse, BD). After centrifugation to a pellet and decantation of the 
supernatant, non-specific antibody binding was blocked using 20l FcR blocking 
reagent (Miltenyi) and 200l of mouse serum (Sigma-Aldrich) for 20 minutes at room 
temperature.  Cells were then incubated with the following fluorochrome labelled anti-
human antibodies: CD45 FITC, CD146 PE and CD34 Percp for 30 minutes.  Cells were 
washed once using PBS + 5% heat inactivated FCS + 0.1% azide, centrifuged to pellet 
the cells and then re-suspended in 200l of fixative with 10% formaldehyde and 1% 
azide (BD, cellFIX
tm
) and made up to 1ml with buffer immediately prior to FC.  
 
2.5.2.2 Flow cytometry instrument settings 
Samples were run on a Becton Dickinson FACSCalibur flow cytometer.  FC was 
performed using FSC and SSC instrument settings optimised for detection of PBMCs as 
previously described (Goon et al., 2006), using a linear FSC/SSC scale with FSC 
voltage set at E00.  After the optimisation steps described in Chapter 3 FC was also 
performed as for larger cells such as HUVEC, using a logarithmic FSC scale and a 
linear SSC, with a FSC voltage set at E00 as previously described (Brogan et al., 
2004b). CECs were gated firstly on their FSC and SSC characteristics and then on cells 
negative for CD45 staining.  CECs were then considered to be all events bright for 
CD146 and CD34 in this region.  Non-stained samples and fluorochrome matched 
isotype controls (IgG1 FITC (eBiosciences), IgG1 PE (BD) and IgG1 Percp (BD)) 
were used to define positivity.  The gating strategy used is shown in Chapter 3 in 
Figures 3.1 and Figure 3.11.  
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2.5.2.3 Absolute enumeration of CECs using flow cytometry 
In order to obtain absolute CEC counts, samples were either spiked with Countbright
TM
 
absolute counting beads as per manufacturer’s instructions, run to completion or had the 
flow rate calculated prior to the sample being run using 3µm latex beads (see below).   
 
To enumerate using countbright
TM
 beads 50µl was spiked into the sample.  50µl 
contained approximately 50,000 beads (depending on batch).  Therefore absolute cell 
count could be determined by calculating the volume of sample analysed by calculating 
the proportion of beads run through the system using the following equation: 
 
 
 
In order to estimate the flow rate of the machine 3µm latex beads were diluted in sterile 
filtered distilled water to give a final concentration of 20,000 beads/µl.  10 µl of this 
stock was then added to 240µl of distilled water.  The number of beads acquired in a set 
time at a set flow speed (usually medium flow) was used to estimate the flow rate (in 
µl/second) using the following calculation: 
 
 
 
 
 
Once the flow rate was estimated the number of CECs in a sample could be calculated 
by working out the volume of sample that would be run in a set time at that flow rate 
and then calculating how many CECs would be in the whole sample.  
Beads added (50,000) 
Beads counted 
x CECs counted = CECs/ml 
÷ Time (s)  = Flow rate (µl/s) Beads counted 
Beads added 
(200,000) 
x Volume (250µl) 
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2.5.3 Detection of cellular microparticles 
Samples of platelet poor plasma (PPP) were thawed rapidly at 37
o
C and a known 
volume was spun at 15000g for 60 minutes to pellet the microparticles (MPs) at room 
temperature in a temperature controlled centrifuge. The supernatant was decanted and 
the MPs resuspended in annexin V buffer (BD).  35µl was then added to wells on a 96 
well plate (polypropylene) containing 5µl of annexin V FITC diluted 1:10 (BD) and 
10µl of a PE conjugated, PerCP conjugated or PE-CY5 conjugated antibody diluted to 
give a final concentration in 50µl as in Table 2.1 (1 in 3 for most antibodies, 1 n 5 for 
CD144 and 1 in 8 for CD66b).  MPs were stained, rocking gently, in the dark at room 
temperature for 10 minutes.  200µl of Annexin V buffer was then added to each well to 
end the incubation and samples were then transferred to FACS tubes.   The FC plans 
used for MP detection are shown in Appendix 3.  A 22 tube plan was used for samples 
with a volume greater than 300µl, while smaller samples were run using 12 tubes. 
 
2.5.3.1 Flow cytometry instrument settings for microparticle detection 
Samples were analysed on a BD Facscalibur, using a logarithmic scale with FSC 
voltage set at E01.  Instrument settings were initially optimised using 0.3, 0.8 and 3µm 
latex beads, this process is described in detail in Chapter 4.  As described previously 
(Combes et al., 1997) MPs were gated on their Annexin V (AnV) positivity as 
demonstrated in Figure 4.3.  As AnV is a protein and not an antibody, it therefore does 
not have an isotype control so unlabeled MPs were used to establish positivity cutoff.  
In order to determine whether observed noise in the system leading to high event rate in 
some samples had a significant effect on MP detection, MPs were analysed with and 
without a threshold based on AnV binding (discussed in Chapter 4).  Histograms based 
on the gated AnV positive population were obtained for the fluorochrome conjugated 
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antibody binding and positivity was defined by the isotype control using 2.5 % 
positivity as a cutoff.  
 
2.5.3.2 Absolute enumeration of microparticles 
MP samples were run at a medium flow rate for 45 seconds, with a known number 
(200,000) of 3µm latex beads run for 45 seconds at the same flow rate before and after 
each patient’s samples, allowing absolute MP enumeration. By using the equation 
below, which incorporates the beads run in 45 seconds and the exact volume of plasma 
used the absolute number of annexin V binding microparticles per ml of plasma was 
determined: 
 
 
 
 
 
2.5.4 Detection of activated parent cells 
When MPs were generated from isolated cell populations during setup experiments 
activation of the parent cell was confirmed in the following manner.  After the cells 
were pelleted and the supernatant was decanted for MP enumeration, the parent cells 
were resuspended in PBS (containing 0.1% azide and 5% heat inactivated FCS) to a 
concentration of 2 x 10
6
 cells/ml.  100µl of cell suspension was added to wells on a 96 
well plate.  The plate was then spun at 500g for 5 minutes at 4
o
C.  The supernatant was 
flicked off and the plate blotted.  10µl of diluted antibody or control (final concentration 
as in table 2.1) was added to the pelleted cells.  Cells were stained for 30 minutes at 
4
o
C, then washed 3 times with PBS using the spin down, flick and blot technique 
MPs/ml of 
plasma 
x x 
no of FACs tubes 
sample divided into 
Annexin V +ve 
events 
Beads added (200,000) 
Average beads counted 
x 
1000 
Vol of plasma  
spun down (µl) 
= 
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described above. After the final wash cells were resuspended in 200µl of Cellfix.  The 
phenotype of the MPs generated from different cell populations and their activated 
parent cells is shown in Appendix 4. 
  
 
2.6 Assessment of potential endothelial repair 
responses 
2.6.1 Measurement of endothelial growth factors  
Growth factors associated with endothelial reparative responses were measured using 
then following ELISA kits: VEGF (R&D), Angiopoetin 1 (R&D), and 2 (R&D), and 
thymosin beta 4 (immunodiagnostik).  The three R&D kits were based on the sandwich 
ELISA principle while the thymosin beat 4 kit was based on a competitive ELISA 
principle. 
 
In a sandwich ELISA a monoclonal antibody specific to the peptide of interest is coated 
onto each well of a 96 well plate.  Standards and samples are then pipetted into the 
wells in duplicate and any peptide of interest becomes immobilised.  Unbound sample is 
then washed away and an enzyme linked secondary monoclonal specific for the peptide 
of interest is added.  This then binds the immobilised peptide and after a wash step, the 
introduction of a substrate for the enzyme allows a colour to develop, the reaction is 
stopped and the plate then read at a specific wavelength to determine the colour 
intensity (Figure 2.2).  The intensity of colour (measured as optical density (OD)) of the 
standards allows a standard graph to be plotted so the test samples can be compared to it 
and have their concentration calculated.  Examples of the standard graphs obtained 
86 
 
using these kits can be seen in Appendix 5.  VEGF was measured in serum (100µl per 
well, undiluted), Angiopoetin 1 was measured in platelet poor plasma (50µl per well, 
diluted 1 in 15) as was Angiopoeitin-2 (50µl per well diluted 1 in 5).   
 
In a competition ELISA (Figure 2.3) the peptide of interest is coated onto the wells of 
the 96 well plate and competes with the peptide in the standards and samples to bind an 
enzyme linked substrate.  In the case of thymosin β4, the substrate was monomeric 
actin.  Thus in samples which have a high OD the substrate had bound the plate and 
thus there was a low concentration of thymosin β4 in the sample, conversely samples 
with low OD have high thymosin β4.  The standards with a known concentration for 
thymosin beta 4 were used to generate a standard curve with which to compare the test 
samples.  Unfortunately although the kit purchased claimed to be fully optimised for 
measurement of TB4 in human serum, children had in some cases 10 fold high 
thymosin β 4 level than adults and were off the standard curve.  Further dilution of the 
sample was necessary and demonstrated that all samples required a 1 in 5 dilution 
before running on the plate.  Examples of the standard curves generated are in Appendix 
5. 
 
2.6.2 Flow cytometry for detection of endothelial progenitor cells  
Frozen PBMCs were thawed rapidly at 37
o
C, then transferred to warmed FCS, to which 
warm RPMI 1640 (with antibiotics) was added to give a final FCS concentration of 10-
20%.  PBMCs were then counted and diluted to 2 x 10
6
 cells per ml (in some samples a 
pelleting step was necessary to concentrate cells), 50µl of FcR blocking agent was 
added per ml and the cells incubated for 10 minutes at room temperature. 150µl of the 
cell suspension was added to wells on a 96 well plate, subsequently the plates were spun 
at 500g for 5 mins at 4
o
C and the supernatant flicked off and the plate blotted. 
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Figure 2-2: Methodology of Sandwich ELISA 
 
  
 
 
 
 
 
 
Figure 2.2:  Sandwich ELISAs for VEGF and Angiopoietins-1 and 2 were performed using the 
above protocol, adapted from R&D instruction manuals. 
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Figure 2-3: Methodology of Thymosin-β 4 competition ELISA 
 
 
 
 
 
 
 
Figure 2.3: Thymosin beta-4 competition  ELISA methodology was performed as described in the 
protocol above, adapted from Immunodiagnostik instruction manual.  Although the kit was 
optimised for adult samples, it became apparent that children have much higher levels of  TB4 and 
thus serum samples had to be diluted 1 in 5 before they could be analysed using this kit  
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Cells were then stained with 10µl of diluted antibody (diluted using PBS + 0.1% azide; 
table 1a) and incubated for 30 minutes at 4
o
C.   Cells were washed using 200µl of FACs 
wash (PBS + 0.1% azide + 5% heat inactivated FCS) and spun down and the 
supernatant flicked off as before.  The secondary antibody for KDR, Streptavidin FITC 
was then added to the required wells and incubated for 10mins at 4
o
C.  Cells were then 
washed twice as before and finally resuspended in 150µl of fixative with 10% 
formaldehyde with 1% azide (BD, cellFIX
tm
). 
 
Using flow cytometry the endothelial progenitor cell (EPC) markers KDR, CD133 and 
CD34 were examined alongside the endothelial markers CD144, CD146 and the 
lymphocyte marker CD3, the monocyte marker CD14 and the pan leukocyte marker 
CD45. Non stained samples and fluorochrome matched isotype controls were used to 
define positivity.  EPCs were expressed as a percentage of the mononuclear cell gate, as 
a percentage of total CD34+ cells  and in the vasculitis patients as an estimate of 
absolute EPC number based on the full blood count obtained from the clinical labs as 
described in Chapter 6.  Briefly the leukocyte count is multiplied by the % of viable 
cells expressing CD34.  It is important to note that this was not used as an absolute 
count of EPCs but as a crude tool to estimate absolute EPC numbers in order to 
determine whether trends observed in individual patients were reflected when the 
different ways of expressing EPC number were compared.  
 
2.6.3 Endothelial progenitor cell colony culture   
Hill et al described a methodology for counting colonies believed to be derived from 
EPCs.  In a large study these colonies correlated with flow mediated dilatation (a 
measure of endothelial function) (Hill et al., 2003).  This technique was thought to be 
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dependent on the batch of FCS used, which was developed into the commercially 
available colony counting assay – EndocultTM (Stemcell technologies).  This technique 
has now become widely used in clinical studies and is thought to predict cardiovascular 
mortality (Hill et al., 2003).  Work done previously within our group by Dr Francesca 
Arrigoni had resulted in a growth factor supplemented media which emulated the 
growth characteristics of endocult, independent of FCS batch.  Thus this media was 
used for assessment of EPC colonies as follows: PBMCs were isolated as described in 
2.4.4 and 5 x 10
6
 cells were cultured in RPMI 1640 (with 20% FCS (not heat 
inactivated) and antibiotics as before) for 2 days per well on a fibronectin coated 6 well 
plate.  The non-adherent cells (hypothesized to contain the non differentiated stem cell 
population) were then removed and replated onto a fibronectin coated 24 well plate at a 
concentration of 1 x 10
6
 cells per well.  The replated cells and the adherent population 
remaining on the 6 well plate were cultured in MCDB131 containing the following 
additives L-glutamine (50ng/mL),  endothelial cell growth serum (50µg/ml,Sigma), 
VEGF (20ng/mL), bFGF (5ng/mL), 20% FCS (not heat inactivated), heparin (5U/mL) 
and penicillin (100 U/mL) and streptomycin (100µg/ml).  Media was changed every 3 
days until day 7 when colonies were counted.  Colonies consisted of a central core of 
rounded cells surrounded by spindle like outgrowth cells (Figure 2.4a). 
 
2.6.4 Endothelial progenitor cell outgrowth culture   
Although a number of groups have used colony counting as a measure of EPC function, 
other groups have derived endothelial-like monolayers from adherent cell populations, 
in much longer cultures (20+ days)  and these have been termed late outgrowth EPCs 
(Lin et al., 2000). In line with most studies which have grown these late outgrowths, the 
commercially available endothelial media EGM-2 was used.  PBMCs were isolated as 
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described in Section 2.4.4 and in order to grow late outgrowths 10 x 10
6
 cells were 
added to fibronectin coated wells on a 6 well plate.  Cells were cultured in EGM-2 with 
supplements as described in Section 2.3.3. After the first 4 days, media was changed 
every 3 days.  As with the Hill protocol described above colonies formed between 4-7 
days in culture (Figure 2.4b).  In some experiments cells were replated on fresh 
fibronectin using trypsin as described for passage of HUVEC to determine optimal 
conditions for growth of monolayers (Figure 2.4c and d). 
 
2.6.5 Matrigel - assessment of endothelial progenitor cell function 
A number of studies have shown that EPCs can incorporate into tubule networks formed 
by endothelial cells on extracellular matrix formulations (Matrigel
TM
) (Bompais et al., 
2004,Hur et al., 2004).  The following protocol used for assessing incorporation of 
PBMCs into tubule networks is based on work previously established by Dr Francesca 
Arrigoni and Dr Neil Halliday within the group.   
 
Isolated PBMCs were cultured for 9 days in EGM-2 on a fibronectin coated 24 well 
plate with 5 x 10
6
 cells added per well as described above. EGM-2 cultures were thus 
the same age as the non-adherent colony cultures when lifted.  At day 9 cells were 
stained with Di-I-acetylated low density lipoprotein (DiI-AC-LDL) 1.6µl/well for 4 hrs 
at 37
o
C.  An hour before the cells were ready, 100µl of defrosted matrigel (defrosted for 
3+ hours at 4
o
C) was added using cold (left overnight at -20
o
C) pipette tips into each 
well of a cold (-20
o
C overnight) 24 well plate on ice, taking care to spread evenly across 
the well.  The matrigel was left to set at room temperature for 1 hour.  After 1 hour, 1ml 
of EGM-2 (without hydrocortisone) was added to each well.  EGM-2 cells and HUVEC 
were then lifted using trypsin as previously described and 4 x 10
4
 EGM-2 cells and 4 x 
92 
 
Figure 2-4: EPC colony culture 
 
 
 
 
 
 
Figure 2.4a: After 7 days in culture after the preplating step the EPCS had formed colonies which 
consisted of a central cluster of rounded cells surrounded by spindle-like outgrowths. Figure 2.4b: 
cells cultured for 7 days in EGM-2 had a similar phenotype.  Figure 2.4cd: When these EGM-2 cells 
were left for longer, they went on to form “late outgrowth” EPCS which resembled a HUVEC-like 
monolayer at around 18-20 days in culture.  Scale bars represent 50µm. 
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10
4 
HUVEC or 4 x 10
4
 HUVEC alone were added to each well.  Tubule growth and 
PBMC incorporation was assessed after 18 hours in culture, using the HUVEC alone as 
a control (Figure 2.5ab). 
 
 
 
2.7 Statistics 
A number of parametric and non-parametric statistical analyses were used in this thesis.  
Description of individual tests and their applications is given in the relevant chapters.  
While parametric tests were used whenever possible, there were a number of instances 
where data were not normally distributed (and could not be easily transformed to 
normality) and thus non-parametric tests were used.  Parametric tests used were 
student’s t-test and paired t-tests. Non-parametric tests used were the Kruskall-Wallis 
test, the Wilcoxon signed-ranks test, and Spearman rank correlation coefficient. Bland-
Altman statistics were performed where comparison of methodology was required, 
including assessment of interuser variability.  In several chapters of this thesis multiple 
comparisons were performed simultaneously, so in order to reduce the risk of falsely 
finding tests positive a post-hoc Holm-Bonferroni correction was performed.   Graphs 
were plotted using Microsoft Excel 2007 and Graphpad Prism version 4. All statistics 
were calculated using Microsoft Excel 2007, and SPSS versions 15. 
 
As the cohort described herein is highly heterogenous, data was colour coded dependent 
on disease classification, in all the graphs within this thesis the following coding 
applies:  
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Figure 2-5: Matrigel, incorporation of PBMCS into HUVEC tubules 
 
 
 
 
 
 
Figure 2.5a: When HUVEC alone are cultured on matrigel, they form characteristic lattices. Scale 
bar represents 100µm. Figure 2.5b: When cells cultured for 9 days in EGM-2 are added alongside 
HUVEC they adhere/incorporate in the tubules formed the extenct of incorporation is assesssed 
using DiI acetylated LDL to visualise these cells.  Scale bar represents 50µm. 
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3.1 Summary 
As discussed in the introduction to this thesis, assessment of disease activity in 
vasculitis can be challenging.  The gold standard technique for detecting active 
inflammatory disease (tissue biopsy) is invasive and impractical for repeated 
assessment, particularly due to the patchy nature of the disease where false negative 
results can occur.   This chapter describes the methodology used to detect circulating 
endothelial cells (a novel biomarker of endothelial injury) and demonstrates which of 
the two commonly used techniques is more appropriate for patients with vasculitis.  The 
latter part of this chapter then examines the relationship between circulating endothelial 
cells and disease activity in children with primary systemic vasculitis.  Some of the data 
presented herein are now published (Clarke et al., 2008,Shantsila and Lip, 2008).    
 
 
3.2 Introduction 
Circulating endothelial cells (CECs) are mature endothelial cells which have become 
detached from the vessel wall.  In health, these cells are found in low levels in the 
circulation and are believed to represent physiological endothelial turnover 
(Erdbruegger et al., 2006), however in conditions associated with endothelial injury 
they are elevated (Woywodt et al., 2006a). 
 
3.2.1 Detecting CECs 
The concept that mature endothelial cells can be detected within peripheral blood is not 
new.  CECs were first described in the 1950s in blood smears (Li et al., 
1958,Shanberge, 1955) and were considered likely to be the result of traumatic 
venepuncture and not of pathological consequence.  The CECs described by Li et al 
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occurred both singly and in sheets of cells and their detection relied on observations of 
morphology and size under light microscopy.  In the early 1970s the link between these 
CECs in blood smears and vascular injury was proposed and these cells were 
subsequently identified in various conditions including myocardial infarction (Hladovec 
et al., 1978) and hypertension (Hladovec and Prerovsky, 1989).  All these early studies 
were reliant on morphology alone and were technically difficult and subjective.   
 
Further refinement of the blood smear methodology included the use of fluorescent 
antibodies to endothelial markers such as Von Willebrand factor (VWf) or cell adhesion 
molecules (Percivalle et al., 1993).  However there remained a lack of specificity of cell 
surface antigens and the use of more specific intracellular antigens required cell 
permeabilisation, which increased the potential for cell loss from samples.  By the early 
1990s antibodies to more specific surface markers for ECs had been developed, 
including the monoclonal S-endo-1 against CD146, a highly expressed constitutive EC 
cell surface marker associated with the cytoskeleton.  CD146 is more specific for ECs 
(although it is found on some activated T cells and melanoma cells) than other EC 
surface markers such as CD31 (PECAM-1, also found on platelets, monocytes, 
neutrophils and T cells), CD54 (ICAM-1, also found on monocytes and lymphocytes) or 
CD105 (endoglin, also found on activated monocytes, macrophages and erythrocyte 
precursers) and soon became the antibody of choice for CEC detection.  Its high 
expression on most ECs importantly allowed the use of immunomagnetic beads for 
enrichment of CECs from blood samples (George et al., 1992). 
 
In 2006 Woywodt et al described a consensus protocol for detection of CECs using 
immunomagnetic bead extraction (IBE) and it is described in detail in Section 2.5.1 
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(Woywodt et al., 2006a).  After CECs are extracted from peripheral blood using CD146 
bound to immunomagnetic beads they are stained with a fluorescently labelled lectin 
Ulex Europeus (Ulex).  Ulex selectively binds alpha-L-fucose containing glycoproteins, 
that can be found on the surface of human ECs and is more sensitive than vWF as it can 
bind ECs shown to be vWF negative (Holthofer et al., 1982).  As with CD146, Ulex is 
not endothelial specific and has been shown to bind many cell types including gut 
epithelial cells (Narita and Numao, 1992) and megakarocytes (Liu and Liu, 1990) as 
well as the blood type H(O) antigen on red blood cells (Ito et al., 1990).   Therefore 
CECs must be identified by the expression of both of these two endothelial markers to 
discriminate from other cell populations.  Microscopy also allows discrimination of 
CECs based on size and morphology from smaller cells such T cells (which can express 
CD146) and endothelial progenitor cells (EPCs) (CD146 and ULEX can both stain 
EPCs) (Delorme et al., 2005,Porat et al., 2006).       
 
Using the IBE methodology high levels of CECs have been detected in a number of 
conditions associated with vascular injury including vasculitis in adults, as 
demonstrated in Table 3.1.  In AAV, CECs correlated with disease activity (BVAS 
score) (Woywodt et al., 2003b) and in studies in patients with coronary artery disease it 
was noted that the highest levels of CECs occurred in those patient with the most severe 
and acute disease (Mutin et al., 1999).  Low levels have been documented in healthy 
individuals of all ages in all studies, suggesting that high levels of CECs may be a 
marker of extreme EC injury.    
 
A commonly used alternative methodology to IBE for enumeration of CECs uses flow 
cytometry (FC),  although  as  yet the consistent reproducibility seen with  IBE  has  not  
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Table 3-1: CEC detection in human disease 
 
Median CEC value (range used where given) 
 
been demonstrated with this technique.  Widely differing reference ranges have been 
reported in healthy individuals across different laboratories (Table 3.1) and moreover no 
consensus has been reached for FC methodology, including the choice of cell surface 
markers examined to evaluate CECs.  FC quantification, however, offers a number of 
potential advantages over IBE including: multiple CEC surface markers can be 
Condition Method Case Control Study 
Sickle cell anaemia IBE 13.2-22.8 2.6 (Solovey et al., 1997) 
Septic Shock IBE 30 2 (Mutunga et al., 2001) 
Rickettsial infection IBE 5-1600 <3 (George et al., 1993) 
Renal transplantation IBE 24-72 6 (Woywodt et al., 2003a) 
Bone marrow transplantation IBE 16-44 8 (Woywodt et al., 2004) 
Acute MI IBE 7.5 0 (Mutin et al., 1999) 
Diabetes IBE 35-126 10 (McClung et al., 2005) 
Stroke IBE 10.8-20.7 2.7 (Nadar et al., 2005), 
Hypertension IBE 10 7 (Boos et al., 2007) 
AAV IBE 20-5700 5 (Woywodt et al., 2003b) 
KD IBE 15 6 (Nakatani et al., 2003) 
Breast cancer 
& lymphoma 
FC 
6800-
39100 
1200-
7900 
(Mancuso et al., 2001) 
Systemic sclerosis FC 243-375 69-110 (Del et al., 2004) 
SLE FC 89 10 (Rajagopalan et al., 2004) 
Acute coronary syndrome FC 8-20 6-10 (Goon et al., 2006) 
Breast cancer FC 6-16 6-10 (Goon et al., 2006) 
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examined simultaneously; exclusion of leukocytes using the pan leukocyte marker 
CD45; and further characterisation of sub-populations of CECs such as those in either 
an activated, or apoptotic state.  Consequently attempts to optimise FC methodology for 
CEC detection in different health and disease states are clearly of considerable 
importance.  In this context, a recent FC protocol for CEC enumeration has been 
described that demonstrated agreement between CEC counts measured using FC 
methodology and IBE in healthy adults and patients with primary breast cancer and 
acute coronary syndromes (Goon et al., 2006). 
  
In order to determine which methodology would be most appropriate for the paediatric 
vasculitis cohort, both the IBE consensus protocol (Woywodt et al., 2006a) and an FC 
protocol based on the aforementioned paper (Goon et al., 2006) was established.  As 
described in the methods chapter, the FC definition of a CEC that was used has been 
described by a number of studies: cells that express both CD146 and CD34, but are 
negative for CD45 (Del et al., 2004,Goon et al., 2006,Bertolini et al., 2006,Khan et al., 
2005) (Figure 3.1a-c).  The definition of a CEC using IBE was as follows; Ulex bright 
cells, greater than 10m in size with more than 5 CD146 conjugated magnetic beads 
attached, (Figure 3.1d-f) (Woywodt et al., 2006a). 
 
3.2.2 Where do CECs come from and does this influence phenotype? 
CECs can be detected in both the arterial and venous circulation without significant 
differences in values obtained (Woywodt et al., 2006a).  This observation raises 
interesting questions as to the origins of CECs and whether  they  can  pass  through  the 
capillary beds (unlikely, in the opinion of this author, when considering the size of the 
capillary lumen and the size of CECs), or whether CECs represent widespread (arterial 
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Figure 3-1: Flow cytometric (FC) and immunomagnetic bead (IBE) 
definitions of CECs 
 
 
 
Figure 3.1a-c: CECs as defined by FC are mononuclear cells (figure 3.1a, R1) which are negative 
for CD45, (figure 3.1b, R2) and positive for CD34 and CD146 (figure 3.1c, R3).  FC data shown is 
from a patient with active Wegener’s Granulomatosis.  Figure 3.1d-f CECs as defined by IBE are 
ULEX bright, have greater than 5 beads attached and are greater than 10µm in size. These CECs 
are from 2 patients with active disease, the first (figure 3.1d) with Wegener’s granulomatosis, the 
second (figure 3.1e) with PAN. Figure 3.1f Demonstrates how several CECs may clump together.  
Although it is apparent that a number of cells make up this sheet, it is still only counted as 1 CEC.  
This CEC is from the same patient with PAN in (figure 3.1e).  
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and venous) or whether CECs represent widespread (arterial and venous) endothelial 
dysfunction or even elevated systemic turnover originating from a localised disease.  
Interestingly the vessel site of origin of CECs may vary between different conditions.  A 
number of studies have used the proposed microvascular specific antigen CD36 
(Solovey et al., 1997,Swerlick et al., 1992) to assess the extent to which CECs have 
come from microvasculature.  In healthy adult controls half the CECs had a 
microvascular phenotype, whereas in sickle cell anaemia this was higher at 78% 
(Solovey et al., 1997).  Interestingly in acute coronary syndrome no CD36 staining was 
observed, suggesting a macrovascular origin (Mutin et al., 1999).  Neither of these 
findings in disease is unexpected when the nature of the two diseases is considered. 
 
CECs have also been shown to have widely differing phenotypes.  Relating to size and 
morphology CECs consist of both sheets of cells or individual cells, and in some 
samples there are numerous brightly staining fragments, which are too small to consider 
whole cells but are of endothelial origin (Woywodt et al., 2006a).  As Figure 3.2 
demonstrates such findings have all been demonstrated in the GOSH vasculitis cohort 
described in this thesis.  The majority of CECs detected using IBE in adults with 
vasculitis are of a necrotic or apoptotic nature (Woywodt et al., 2003b).  In other 
conditions this may not be the case.  Both Lin et al and Mutunga et al were able to 
culture CD146+ CECs isolated from peripheral blood from healthy controls and 
Mutunga et al demonstrated that CECs from a proportion of patients with septic shock 
could also be cultured (Lin et al., 2000,Mutunga et al., 2001).   
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Figure 3-2: Phenotype of CECs in vasculitis 
 
 
 
 
 
Figure 3.2a: CECs from patients with PSV can include sheets of many endothelial cells.  Figure 
3.2b: CECS were also seen as single cells Figure 3.2cd: Frequently samples from PSV patients 
contain many CD146 bead bound and Ulex bright events that were too small to be counted as CECs 
- shown at low magnification (figure 3.2c: arrows indicate bright events large enough to be counted 
as CECs) and at higher magnification (figure 3.2d).  These may be fragments of whole cells or 
endothelial microparticles. 
  
104 
 
3.3 Detection of CECs using immunomagnetic bead 
extraction  
CECs were isolated and stained as described in Chapter 2.5.1.  Each sample where 
practical, was counted by two individuals blinded to the patients clinical state.  CEC 
enumeration is reliant on user observation and therefore has an element of subjectivity.  
Whilst strict counting guidelines as described above will minimize this, duplicate 
counting by two independent observers is advised, particularly for validation of the 
technique.   
 
3.3.1 Reproducibility of the technique 
In order to evaluate the reproducibility of the IBE technique, CECs from 1 healthy adult 
control and 1 patient with active WG were prepared from 3 individual 1ml samples.  As 
a positive control, blood was spiked with 1000 HUVEC/ml and again 3 samples were 
prepared from this.  Figure 3.3 demonstrates that there was greater variation in count for 
samples with high CECs (i.e. from the HUVEC spiked into blood and from the patient) 
and little variation in absolute CEC count in healthy adult control samples.  Despite this 
variation at high counts, results were all consistantly high and thus a single sample was 
considered a sufficiently robust representation of clinical CEC counts from patients in 
subsequent studies. 
 
3.3.2 Interobserver variability 
As mentioned previously, due to subjectivity in CEC counting bias relating to 
interobserver variability could occur.  In samples counted by more than one observer, 
Bland-Altman   analysis  was   performed  to  determine   the  degree   of  interobserver  
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Figure 3-3: Reproducibility of IBE for detection of CECs  
 
 
 
 
 
 
Figure 3.3: Blood samples from 1 healthy adult control and 1 patient with active Wegener’s 
granulomatosus were divided into 3 and CECs enumerated in each sample.  As a further positive 
control a sample of the healthy control blood was spiked with 1000 HUVEC/ml.    The mean CEC 
count in the healthy adult control was 1 CECs/ml  SD 2;  in the patient with active Wegener’s 
granulomatosis the mean was 768 CECs/ml SD 128; and in the HUVEC spiked sample the mean 
was 757 CECs/ml SD 72.  
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variability between myself and four other individuals who had been trained to count 
CECs.  Figure 3.4a demonstrates that there was greater interobserver variability 
between samples which had high CEC counts (overall mean difference -26.7, 95% CI 
+/- 331.5), however this is undoubtedly influenced by the multiplication factor used as 
part of the nageotte chamber counting protocol.   
 
As described in Chapter 2 (section 2.5.1.3) when samples have high CECs less lines are 
counted on the nageotte chamber (since counting the full 40 lines would be 
prohibitively time consuming and impractical for routine clinical used) and therefore the 
multiplication factor is greater.  Thus in figure 3.4b when the absolute nageotte count 
was considered, the interobserver variability was low, the mean difference was 0.2 
CECs counted (95% CI, +/- 36.2).  While there was higher interobserver variability at 
the high range of the CEC counts, the ability to enumerate exactly in this disease 
context is somewhat less relevant than the ability to distinguish between grossly 
elevated and low CEC counts, where agreement was much better.  Particularly when 
monitoring individuals for disease activity in clinical studies. 
 
3.3.3 The effect of traumatic venepuncture 
As has previously been documented (Woywodt et al., 2006a) if venepuncture is 
traumatic then CECs may appear falsely elevated.  This is of particular relevance in 
paediatric cohorts as it is often technically more difficult to obtain peripheral blood 
from small children than from adults.  In order to reduce the effect of venepuncture, 
many groups discard the first 5ml of blood taken, however this may not be appropriate 
or possible for paediatric samples, which are typically of smaller volume.  The influence 
of traumatic venepuncture was investigated in 1 healthy adult control (a sample size of 3  
107 
 
Figure 3-4: Bland-Altman plots for testing interobserver variability of IBE 
for detection of CECs 
 
 
Figure 3.4a Primary observer (LC = myself) CEC counts compared to 4 different individuals 
trained to count CECs. Each different observer is indicated by a different coloured cross. CECs 
were counted in 18 patients with vasculitis and 13 healthy child controls.  Overall, the mean 
difference between the CEC counts I obtained and those obtained by others was -26.7, 95% CI +/- 
331.5.  Notably levels of agreement was better at low CEC counts and the wide confidence interval 
influenced by 3 outliers. This analysis does not take into account differences in the multiplication 
factor used to calculate the final count, therefore any differences are amplified in samples with high 
CEC counts.  Figure 3.4b thus compares absolute nageotte count which gives a mean difference of 
0.2, 95% CI +/- 36.3.  
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would have been desirable, however volunteers were not forthcoming) with ethical 
approval and informed consent.  Blood was collected first using 3 x 5ml syringes from 
the control arm.  Traumatic venepuncture was then achieved in the other arm by 
scraping the needle backwards and forwards in the vessel, once it had been inserted.  As 
in the contralateral control arm, blood was then collected in 3 x 5ml syringes.  
 
Although traumatic venepuncture elevated CECs from the 16 cells/ml seen in the 
contralateral arm to a maximum of 128 cells/ml (Figure 3.5),  CECs did not increase to 
the levels observed in adult active vasculitis patients (up 5,000 CECs/ml) (Woywodt et 
al., 2003b).  It was therefore concluded that as long as child controls were age matched 
the effect of the more traumatic venepuncture expected in children would not detract 
from the elevations seen in active disease, although could account for more 
“background noise” in both paediatric controls and vasculitis patients.  Also it can be 
seen in this individual that discarding the first 5mls of blood after traumatic 
venepuncture did not make a difference to the CEC count as both the second and third 
syringes of blood gave a similar CEC count to the first 5mls sampled (Figure 3.5).  
However, this may have been a consequence of the excessive trauma occurring in this 
individual case.  Thus in line with other studies (Woywodt et al., 2006a) for all future 
blood samples the first 5mls of blood were not used for CEC quantification (where 
possible) but rather for other assays described in this thesis, minimizing waste of 
precious paediatric blood samples. 
 
3.3.4 The effect of storage and time to preparation on CEC enumeration 
In the same individual who had kindly agreed to consent to traumatic venepuncture, 
after  the  1ml  of blood required for IBE was  removed  the  remainder of the  first  5ml 
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Figure 3-5: Factors influencing CEC counting – traumatic venepuncture. 
 
  
 
 
 
 
 
 
Figure 3.5 demonstrates the effect of traumatic venepuncture on CEC enumeration in 1 individual. 
15 mls of blood was taken in 3 x 5ml syringes from both arms.  In the second arm, venupuncture was 
traumatic.   CEC count was much higher under traumatic conditions than in the control arm, 
however notably, discarding the first 5 mls of blood would not have made a difference to the CEC 
count under highly traumatic conditions as the second and third samples from each arm were of 
similar levels to the first.  
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sample was divided into 2 and left at RT or 4
o
C.  CECs were then counted in 0.5ml of 
blood at 2hrs, 4hrs and 24hrs to demonstrate any alterations in CEC count caused by 
sample storage time (Figure 3.5a and b, represented by diamonds).   
 
The same time course experiment was also performed on 3 vasculitis patient samples 
(Figure 3.5 a and b, represented by crosses).  As can be seen in Figures 3.6 a and b, as 
has previously been described CEC counts had declined by 24hrs in all individuals 
studied (Woywodt et al., 2006a).  The temperature at which the sample was stored did 
not appear to influence this, although room temperature samples were more difficult to 
read, with higher background noise possibly due to greater fragmentation/degradation of 
cells than samples stored at 4
o
C.  Thus, where possible all bloods were processed 
immediately, usually within a 2 hour window and kept cold at 4
o
C if they could not be 
processed straight away.   
 
 
 
3.4 Detecting CECS using flow cytometry  
For the purposes of this thesis the methodology as described by Goon et al was closely 
followed, as described in Section 2.5.2. (Goon et al., 2006)  
 
3.4.1 The effect of lysis on staining of CD34/CD146/CD45 
In  the  protocol  described  by  Goon et al, 1ml  of whole blood underwent red cell lysis 
prior  to  addition  of  antibodies (to  reduce  the  volume  of  antibody  required for each 
sample).  This is a recognized but uncommon methodology for whole blood FC and 
thus in order to make sure the cells were stained optimally experiments were performed 
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Figure 3-6: Factors influencing CEC counting – sample storage time and 
storage temperature 
 
 
 
Figure 3.6a and b: 3 samples of blood from active vasculitis patients and one from the healthy adult 
control who had undergone traumatic venupuncture were left at room temperature (Figure 3.6a) or 
4
o
C (Figure 3.6b) for 0, 2, 4 and 24 hrs before they were prepared for CEC detection.  By 24 hrs  
CEC counts were decreased in all individuals. Thus blood was prepared as close to time of sampling 
as possible for all future clinical studies.  
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to determine whether the lysis step was influencing staining of these cell surface 
markers.  Figures 3.7a-c demonstrate that there were no significant differences in the 
percentage expression of CD45, CD146 or CD34 within the FC mononuclear cell gate 
in 3 patients if cells were stained before or after lysis confirming the validity of this 
methodology.  
 
3.4.2 Using endothelial cells as a positive control for CECs 
HUVEC had provided a useful positive control while establishing the IBE assay.  It was 
therefore ascertained whether HUVEC could be used as a positive control in FC 
protocols for CEC detection. Unfortunately HUVEC detached from cultured 
monolayers and resuspended in PBS as described in section 2.4.3 could not be detected 
using the previously published flow cytometric instrument settings for CECs.  This was 
because HUVEC had greater forward and side scatter (FSC and SSC) than peripheral 
blood mononuclear cells.  However when gated optimally HUVEC were detected by FC 
and were negative for the pan leukocyte marker CD45 (Figure 3.7d) and expressed high 
levels of CD146 (Figure 3.7e) and at first passage CD34 (although this diminished with 
later passage) (Figure 3.7 f and g).  Thus HUVEC could be used as a positive control for 
assessment of sensitivity and reproducibility of FC as long as the FSC SSC setting were 
optimized to incorporate them.  This important observation has significant implications 
for the detection of CECs using FC (Clarke et al., 2008) and will be discussed in more 
detail later in this chapter. 
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Figure 3-7: The effect of red cell lysis on flow cytometric protocols for 
HUVEC detection 
 
 
 
Figure 3.7 a-c demonstrates that the pre-staining red cell lysis protocol as described by Goon et al, 
does not significantly alter the % of monunuclear cells expressing the 3 CEC markers: CD45, 
CD146 and CD34.  Figure 3.7 d-g demonstrates that HUVEC can be used as a positive control for 
the CECs described by Goon et al, as they are negative for CD45 (Figure 3.7d) and express high 
CD146 (Figure 3.7e).  HUVEC only express CD34 when examined at early passage (Figure 3.7f), 
by P3 HUVEC are negative for CD34 (Figure 3.7g).  
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3.4.3 Using counting beads to determine absolute cell number  
In the paper from Goon et al, (Goon et al., 2006) the flow rate of the flow cytometer 
was determined prior to each sample being run using a sample spiked with a known 
number of latex counting beads, a standard technique for cell counting using FC.  This 
allowed a calculation of the quantity of sample analysed in a set time and thus could be 
used to calculate an absolute CEC number.  However, samples have to be run for a long 
period of time as CECs are rare events in peripheral blood and thus variations in flow 
rate may occur, which could significantly affect the result.   
 
To determine whether this would alter results significantly an experiment was 
performed that enumerated HUVEC spiked into whole blood using different methods 
for calculating absolute HUVEC counts. Whole blood was spiked with 100,000 
HUVEC/ml and comparative experiments (n=3) were performed.  In these experiments 
three different counting strategies were investigated: 1. Samples were run to 
completion. 2. The flow rate was calculated prior to samples being run using latex 
beads.  3. An internal standard counting bead was used (Countbright
tm
 beads, 
Invitrogen).  These methods are described in Chapters 2.5.2 and 2.5.3.   
 
Figure 3.8 demonstrates that enumerating samples using Countbright
tm
 beads resulted in 
a higher (but non-statistically significant) percentage recovery than calculating the flow 
rate prior to running the samples (NS, p=0.06).  Running samples to completion also 
gave better recovery than calculating flow rate from latex beads, however this technique 
would not be practical for routine clinical studies - the data files produced were large 
and in order to run a 1ml sample to completion dry it took over an hour, even at a high 
flow rate.  This experiment confirmed that the use of an internal standard such as 
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Countbright
TM
 beads was more accurate over the long period of time required to collect 
sufficient sample for rare event analysis and therefore would be the methodology of 
choice for future studies relating to FC for CEC analysis in this thesis.   
 
3.4.4 Reproducibility of flow cytometry for endothelial cell enumeration 
As described previously whole blood was spiked with 100,000 HUVEC/ml.  The 
sample was then divided into 3 and the number of HUVEC in each sample was again 
enumerated using Countbright
tm
 beads.  The mean recovery of HUVEC was 53% (range 
51-56%) demonstrating the reproducibility of the technique.  However this recovery of 
53% of spiked HUVEC was low.  The reasons for this are explained in more detail later 
in this chapter, but are due to poor optimisation of the FC technique for this particular 
experimental setup.  As the aim of this series of preliminary experiments was to 
evaluate the previously published FC methodology in vasculitis patients we deliberately 
did not change the methodology from that described by Goon et al before evaluating it 
in patients (other than to utilize countbright
TM
 for enumeration as opposed to a 
calculated flow rate) (Goon et al., 2006).     
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Figure 3-8:  Absolute enumeration of HUVEC spiked into whole blood 
 
 
 
 
 
 
 
Figure 3.8 demonstrates the % recovery of 100,000 HUVEC spiked into samples of healthy adult 
controls blood.  Samples were enumerated by 1. Running to completion.  2.By calculating the flow 
rate prior to running the sample using latex beads 3. By using an internal standard added to the 
sample to calculate the proportion run (Countbright 
TM
 beads).  Countbright 
TM
 beads as an internal 
standard gave the best % recovery compared to the other two techniques (NS, vs completion p=0.11 
and vs calculated flow p=0.06).  While not statistically significant, this difference could be clinically 
relevant and thus Countbright 
TM
 beads were used for CEC enumeration in future FC studies.    
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3.5 Clinical study comparing two different methods of 
CEC quantification 
3.5.1 Patients and methods 
3.5.1.1 Patients 
25 children with primary systemic vasculitis were studied for this part of the study. 
These included 12 males and 13 females of median age 13.1 years (range 2.3 -16.4 
years). The vasculitis type (using the Chapel Hill Consensus Criteria) (Jennette et al., 
1994) was PAN n=9, WG n=4, MPA n= 1 and unclassified vasculitis n=11. Disease 
activity was assessed using a modified paediatric Birmingham Vasculitis Activity Score 
(BVAS), with a value of 0/63 defining clinical remission (no clinical disease activity) as 
previously described (Brogan et al., 2004a,Luqmani et al., 1994) (Appendix 2).  To 
establish if the assays compared performed similarly in health and disease, in addition 
to the 25 vasculitis patients 20 healthy adult controls were also recruited (2 males, 18 
females, age range 24-40 years).  All blood used for analysis was drawn using a 21 
gauge needle with minimal trauma and with the first 5 mls discarded if possible as 
previously described (Woywodt et al., 2006a). Blood was processed immediately after 
collection as described below.  
 
3.5.1.2 Detection of CECs using IBE and FC 
This was performed as describe in Chapter 2 (sections 2.5.1 and 2.5.2).  The IBE 
methodology was identical to the previously published consensus paper (Woywodt et 
al., 2006a).  FC was performed using forward and side scatter (FSC/SSC) instrument 
settings optimised for detection of peripheral blood mononuclear cells (PBMCs; Figure 
3.1) as previously described (Goon et al., 2006) (PBMC-FC).  A second FC protocol 
was designed to optimally capture larger cells such as human umbilical vein endothelial 
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cells (HUVEC) as previously described (Brogan et al., 2004b).  This is hereafter 
referred to as the EC-optimised-FC gating protocol.   
 
As previously described, CECs were gated firstly on their FSC/SSC characteristics and 
then on cells negative for CD45 (Figure 3.1).   Non-stained samples and fluorochrome 
matched isotype controls (IgG1 FITC, eBiosciences; IgG1 PE, BD; and IgG1 Percp, 
BD) were used to define positivity. All FC instrument settings were optimised using 
detached HUVEC or pulmonary artery ECs (PAECs) in PBS, or whole blood spiked 
with 100000/ml HUVEC.  The PAECs (first passage) were obtained from the main 
pulmonary artery of the explanted lungs of a child with pulmonary hypertension and 
were a kind gift from Dr Sue Hall (Institute of Child Health, UCL). 
 
3.5.1.3 Statistics 
The Mann-Whitney U test (non-paired samples) or Wilcoxon signed rank test (paired 
samples) were used to compare CEC counts between experiments. Levels of agreement 
for CEC counts between different methodologies were summarised using Bland-Altman 
plots (Bland and Altman, 1986). All blood spiking experiments were repeated in 
triplicate, unless otherwise stated. All statistical analyses were performed in SPSS 
version 15.0. Statistical significance was set at p<0.05. 
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3.5.2 Results 
3.5.2.1 Agreement between IBE and PBMC-FC  
The overall median IBE CEC count in vasculitis patients (n=25) and controls (n=20) 
combined was 32 CECs/ml, range 0-800. In contrast the PBMC-FC CEC count in the 
same individuals (n=45) was significantly lower at 26 CECs/ml, range 0-326 (p=0.014); 
paired analyses in 45 individuals.  The Bland-Altman plot in Figure 3.9 summarises the 
levels of agreement between IBE and PBMC-FC for vasculitis patients (n=25, denoted 
as crosses) and controls (n=20, denoted as circles).  Overall there was poor agreement 
between IBE and PBMC-FC based on these 45 paired observations in the 45 
individuals: the mean difference between the two methods (IBE - PBMC-FC) was 78 
CECs/ml, 95% confidence interval of the difference +/-365 CECs/ml. 
 
Subgroup analysis of these 45 paired analyses revealed that most of this poor agreement 
arose in the vasculitis patients. Measurements from paired samples in these patients 
(n=25; 10 with active vasculitis [BVAS>0]; 15 with vasculitis in remission [BVAS=0]) 
demonstrated significantly higher numbers of CECs with the IBE method than with 
PBMC-FC:  with IBE the median CEC count in the vasculitis patients was 80 CECs/ml, 
range 0-800, and the corresponding median CEC count using PBMC-FC was 31 
CECs/ml, range 4-326 (p=0.004).  Subgroup analysis of healthy adult controls (n=20) 
showed that agreement between IBE and PBMC-FC was better, but remained weak: the 
mean difference in CEC count between the two methods (IBE – PBMC-FC) was 17 
CECs/ml, 95% CI +/-127 CECs/ml.  
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Figure 3-9: Bland-Altman statistics for testing agreement between IBE and 
PBMC-FC for CEC enumeration 
 
 
 
 
 
 
 
Figure 3.9 is a Bland Altman plot to assess the agreement between the two methodologies described 
for detection of CECs.  25 vasculitis patients (denoted as crosses) and 20 healthy adult controls 
(denoted as circles) were studied.  Overall there was poor agreement between IBE and PBMC-FC 
based on these 45 paired observations in the 45 individuals: the mean difference between the two 
methods (IBE - PBMC-FC) was 78 CECs/ml, 95% confidence interval of the difference +/-365 
CECs/ml.   
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3.5.2.2 Optimisation of flow cytometric gating for detection of endothelial cells 
Having demonstrated consistently higher CEC counts with IBE compared to FC in 
patients with vasculitis, it was decided to investigate whether the mononuclear gate used 
in the FC protocol was optimal for detection of CECs.  As had previously been 
observed HUVEC have different FSC SSC characteristics to mononuclear cells, thus in 
order to determine whether CECS might also have different FSC SSC characteristics 
their size was compared to both HUVEC and a second cultured primary endothelial cell 
- pulmonary artery ECS (PAEC) which had been explanted from the pulmonary artery 
of the lungs of a child with pulmonary hypertension.  
 
Cultured ECs are of similar size to CECs obtained from patients with vasculitis 
Phase contrast and immunofluorescent microscopy of HUVEC and PAECs isolated 
using IBE from spiked whole blood or PBS was performed. This demonstrated that 
these cultured ECs overlapped in size and exhibited similar morphology to CECs 
extracted from the peripheral blood of patients with active vasculitis (Figure 3.10a-e).  
The diameter of CECs from patients was determined by measurement of all the CECs in 
5 random fields from 5 patients with active vasculitis (WG=3, PAN=2).  In contrast, 
CD146+ cells extracted from isolated PBMCs using immunomagnetic beads were 
significantly smaller than CECs (median diameter of CD146+ PBMCs and CECs were 
6.8m versus 21.5m respectively (p<0.0001; Figure 1a).  These observations 
emphasised the significant difference in size and morphology between CECs and 
CD146+ PBMCs as defined by light and fluorescent microscopy, which would be likely 
to influence the flow cytometric FSC/SSC characteristics of these cell populations.  
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Figure 3-10: Comparison of cell size CECs vs ECs 
 
 
 
 
Figure 3.10a-e: CECs were compared to pulmonary artery endothelial cells (PAECs), venous 
endothelial cells (HUVEC) and peripheral blood mononuclear cells (PBMCs) isolated from spiked 
blood samples using immunomagnetic beads coated with CD146. Figure 3.10a: Demonstrates the 
comparative cell diameter of CD146+ PBMCs, PAECs, CECs from vasculitis patients (5 children, 5 
random fields, all CECs counted in field) and HUVEC.  Of note was the wider range in diameter of 
CECs compared with detached cultured ECs, overlapping both HUVEC and PAECs.  Figure 3.10b: 
Fluorescent microscopy of a single CD146+ PBMC (arrowed) bound to CD146-coated 
immunomagnetic beads; Figure 3.10c: PAEC with rosette of CD146-coated immunomagnetic 
beads; Figure 3.10d: CEC from a child with active PSV.  CECs are characterised by rosetting of 
immunomagnetic beads and uptake of FITC labelled lectin from Ulex europaeus and are 
significantly larger than PBMCs at approximately 20-40m in size. Figure 3.10e: HUVEC 
demonstrating similar size to CECs (scale bar, 20m).  
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EC forward and side scatter characteristics    
The FSC/SSC characteristics of detached  cultured PAECs and HUVEC were examined 
using the previously described PBMC-FC instrument settings (Goon et al., 2006). 
(Figure 3.1) Using these settings the majority of these ECs (>80% PAEC, >95% 
HUVEC) were detected outside of the previously proposed CEC gate (Figure 3.11). 
Therefore, having demonstrated that CECs from patients were of similar size and 
morphology as both PAECs and HUVEC (Figure 3.10), the FC instrument settings were 
optimised to capture both EC populations and mononuclear events, in order to recover 
all possible CEC events. The EC-optimised-FC gating strategy is illustrated in Figure 
3.11. 
 
3.5.2.3 Comparison of EC-optimised-FC with PBMC-FC  
When the EC-optimised-FC gating strategy was compared with PBMC-FC to detect 
CECs in children with vasculitis (paired observations in n=25 patients) and healthy 
controls (paired observations in n=20 subjects) greater numbers of CECs were detected 
using the EC-optimised protocol: the median EC-optimised-FC count was 39 CECs/ml, 
range 5-331; versus PBMC-FC CEC count 26 CECs/ml, range 0-326 (p=0.000).  There 
was correspondingly poor agreement between the two FC protocols as indicated in the 
Bland-Altman plot in Figure 3.12a.  Mean difference between the two techniques (EC-
optimised-FC – PBMC- FC) was 18 CECs/ml, 95%CI +/-63 CECs/ml.  
 
3.5.2.4 Comparison of EC-optimised-FC with IBE for enumeration of CECs 
The median CEC value obtained with the EC-optimised-FC protocol from all 45 
subjects (25 vasculitis patients; 20 healthy adult controls) was comparable to IBE: the 
the two methods on Bland- Altman analysis: the mean difference (IBE – EC-optimised- 
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Figure 3-11: FSC/SSC characteristics of ECs and optimisation of flow 
cytometric gating to detect ECs 
 
 
 
 
Figure 3.11a demonstrates the FSC SSC profile of whole blood and the mononuclear cell gate.   
When pulmonary artery ECs (PAECs) (Figure 3.11b) and  HUVEC (Figure 3.11c) were examined 
using the same instrument settings the majority of all ECs (>80% PAECs, >95% HUVEC) fall 
outside the previously proposed CEC gate.  Figure 3.11d: EC-optimised-FC gate using logarithmic 
FSC/SSC settings.  When 100000 HUVEC were spiked into whole blood they formed a discrete 
population distinguishable from blood cells. The FC instrument settings were thus adjusted to design 
a FSC/SSC gate that was optimised to capture endothelial cells for both HUVEC (arrowed, 
H=HUVEC); and PAECs(data not shown).  N=neutrophils, M=monocytes, L=lymphocytes.  
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IBE median count was 32 CECs/ml, range 0-800; versus EC-optimised-FC CEC count 
of 39 CECs/ml range 5-331(p=0.25).  Despite this, overall agreement was poor between 
FC) was 60 CECs/ml, 95% CI +/-374 CECs/ml, figure 3.12b. Again much of this poor 
agreement arose from the children with active vasculitis and high CEC counts 
(CECs>100/ml) as shown in the Bland-Altman plot (Figure 3.12b).  
 
When the optimised FC gating strategy was used to detect CECs in children with 
vasculitis (n=24 patients) greater numbers of CECs were detected (median count 39 
CECs/ml, range 9-330) (p=0.023).  However these values remained considerably lower 
than those obtained concurrently using IBE (median count 84 CECs/ml, range 0-800 
CECs/ml) (p=0.018). Again, lower levels of agreement were observed in children with 
more active vasculitis and high CEC counts (CECs > 100/ml) with better agreement 
between the two methods noted at lower CEC counts as shown in the Bland-Altman 
plot (Figure 3.12b).  In healthy adult controls consistently higher numbers of CECs 
were recovered using the optimised FC gating strategy (median count 36 CECs/ml, 
range 5-166) (p = 0.001).  Again there was no significant difference between this and 
the results obtained using IBE (p=0.179).  
 
3.5.2.5 Factors influencing the sensitivity of IBE and FC for recovery of ECs 
A series of in vitro experiments were undertaken to investigate further why there was 
poor agreement between IBE and FC (PBMC-FC and EC-optimised-FC) CEC 
enumeration in the clinical samples, particularly in those patients with active vasculitis. 
PBS or whole blood was spiked serially with 100-100000 HUVEC/ml and the 
sensitivity of EC recovery using IBE or FC was evaluated under different experimental 
conditions.  Using HUVEC spiked into WB was a better model of CEC enumeration, as 
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Figure 3-12: Bland-Altman analysis of agreement between EC-optimised 
FC and PBMC-FC and IBE for CEC enumeration  
 
 
 
Figure 3.12a: shows the agreement between EC-optimised-FC (with FSC/SSC optimised to gate on 
ECs) compared to the previously published PBMC-FC protocol.  The mean difference between EC-
optimised-FC and PBMC-FC was 18 CECs/ml, 95% CI +/-63 CECs/ml. Figure 3.12b: IBE 
compared to EC-optimised-FC.  Again levels of agreement between IBE and FC were poor, 
particularly in patients with high CEC counts. Mean difference between IBE and EC-optimised-FC 
was 60 CECs/ml, 95% CI +/-374 CECs/ml.   
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it would mean that confounding cell populations and non specific binding relevant in 
both FC and IBE would also be present.  However there was concern that the HUVEC 
might suffer complement mediated degradation and thus the PBS control was necessary.  
As expression of CD34 on HUVEC is low (Muller et al., 2002) and also dependent on 
passage (Figure 3.7f and g) all CD45-/CD146+ events were considered to be EC in 
these experiments.    
 
Effect of EC numbers on quantification accuracy of IBE and FC 
The PBMC-FC gating protocol (Goon et al., 2006) failed to detect any ECs when 100 
HUVEC/ml were added to whole blood (Figure 3.13a). EC recovery using this FC 
protocol was also low when between 1000-100 000 EC were added to whole blood: 
mean EC recovery (n=3 experiments) was 0.2-0.9% (Figure 3.13a). Detection of 
HUVEC was similar in both PBS and whole blood using these instrument settings 
(Figure 3.13b).   
 
Using the EC-optimised-FC protocol to recover cultured ECs from PBS or whole blood 
resulted in greater recovery of CD45-/CD146+ cells (Figure 3.13a and b).  Larger 
numbers of HUVEC (100000 HUVEC/ml) added to whole blood were easily identified 
as a distinct population from both the lymphocyte and monocyte populations (Figure 
3.11d) although recovery was low with a mean of 38% (range 8-56%, n=5 
experiments).  Recovery using EC-optimised-FC was greatest at 1000 HUVEC/ml with 
mean recovery of 72% (range 21-154%, n=5 experiments; Figure 4).  However, when 
fewer HUVEC (100 HUVEC/ml) were added considerable variation in recovery (36-
708%) was observed indicating sub-optimal sensitivity and specificity at this level of 
detection. Recovery of spiked HUVEC from PBS using the EC-optimised-FC protocol 
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was better than from whole blood with mean recovery of 63% for 1000 HUVEC/ml, 
90% for 10000 HUVEC/ml and 70% for 100000 HUVEC/ml (n=3 experiments).   
    
In contrast, the sensitivity of EC recovery using IBE in these experiments was between 
25%-112% of the cells added to both whole blood and PBS, with greatest sensitivity at 
1,000 cells per ml in WB (80% recovery from whole blood, range 69-94%, n=3 
experiments) and at 100 cells/ml in PBS (101%, range 88-112%).  IBE demonstrated 
lower recovery at higher EC counts: when 10000 HUVEC/ml were added, recovery was 
44% in WB, (range 27-56%) and 43% in PBS (range 41-47%); and was even lower for 
100000 HUVEC/ml at 28% in WB, range 14-37% and 45% in PBS (range 30-55).  
 
Flow cytometric resolution: counting of rare events and effect of sample dilution 
In order to determine whether the flow cytometer was “missing” HUVEC events in 
whole blood because of a phenomenon known as coincidence the final volume of 
sample for FC analysis was diluted to obtain a lower event acquisition rate.  
Coincidence occurs if the sample is too concentrated and the total cell events acquired 
per second are too great to resolve all individual rare events (Jaroszeski and Radcliff, 
1999).  In case the presence of enumeration beads was influencing this, samples were 
run to completion to evaluate its effect.  As Figure 3.11d demonstrated HUVEC are 
easily distinguished from whole blood on their CD146 expression alone, so in these 
experiments HUVEC were defined as CD146-high cells.  Diluting the final flow volume 
to a concentration of 1/2 or 1/5, then running tubes to completion at medium flow rate 
increased the recovery of CD146-high HUVEC from spiked blood (100,000 cells/ml; 
Figure 3.14).   However, by increasing the final volume of sample the time taken to 
acquire the data was considerably increased, up to 90 minutes.  
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Figure 3-13: The effect of EC number on recovery - sensitivity  
 
 
 
Figure 3.13ab: Whole blood (figure 3.13a) and PBS (figure 3.13b) were spiked with HUVEC and 
the cells recovered using IBE (grey bars, n=3 experiments) and the two different FC protocols (EC-
optimised-FC, black bars, n=5 experiments; or PBMC-FC, white bars, n=3 experiments).  Using FC 
HUVEC were defined as CD45-/CD146+. On the whole HUVEC recovery from whole blood or PBS 
using IBE was comparable to EC-optimised-FC across the range of cells added. EC-optimised-FC 
HUVEC recovery was sub-optimal at 100 HUVEC/ml, however, since the percentage recovery was 
>100% in some experiments. Of note, previously proposed PBMC-FC strategies failed to detect any 
CD45-/CD146+ cells in these experiments. Error bars demonstrate the standard error of the mean.  
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Figure 3-14: Resolution – sample dilution improves recovery  
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Diluting the final flow volume of blood spiked with HUVEC (100,000 cells/ml of blood) 
resulted in increased HUVEC recovery.  This is due to the phenomenon known as coincidence, 
events are missed because the flow cytometer is unable to resolve them as flow rate is too fast.  
Dilution of the sample improved this.  Error bars demonstrate standard error of the mean.  Mean 
recovery of neat sample was 43% which increased to 63% when dilute 1in2 and 66% when diluted 1 
in 5.    
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 Lysis of ECs in flow cytometric protocols limits CEC recovery from vasculitis patients.  
When samples from patients with active vasculitis (n=3) were treated with FC red cell 
lysis buffer prior to enumeration using IBE there was a significant reduction in the 
number of CECs recovered.  This reduction was observed using both BD FACS lyse, 
and a non-fixative ammonium chloride lysis buffer in 3 individual patients with active 
vasculitis.  The median IBE CEC count from these patients for the non-lysed sample 
was 376 CECs/ml (range 216-552) which fell to 152 CECs/ml (range 144-168) for 
samples pre-treated with BD FACS lyse; and 120 CECs/ml (range 64-176) for samples 
pre-treated with ammonium chloride lysis buffer (Figure 3.15ab). Repeating these 
experiments using detached HUVEC added to PBS revealed that pre-treatment with 
lysis buffer did not reduce EC recovery Figure 3.15c.  
 
 
3.6 Conclusions of methodological experiments 
As this series of experiments has demonstrated, considerable optimization of FC 
protocols is still required in order to detect CECs with accuracy.  Technical factors 
inherent to FC which influence CEC quantification include FSC/SSC gating strategy 
which necessarily require optimisation for EC capture; limited FC reliability of rare 
event measurement; variations in FC flow rate during long sample acquisition and loss 
of activated and necrotic CECs during the lysis and washing steps in preparation for FC.    
 
For the purposes of this thesis it was concluded that detection of CECs using IBE 
methodology as described by Woywodt et al in their 2006 consensus paper (Woywodt 
et al., 2006a) would the most appropriate methodology for enumeration of CECs in the 
GOSH vasculitis cohort, described in Section 2.5. 
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Figure 3-15: The effect of lysis on CEC recovery  
 
 
 
Figure 3.15ab: When blood samples taken from children with active vasculitis (n=3) were lysed 
using BD FACs lyse (Figure 3.15a) or an ammonium chloride based lysis (AC lysis) (Figure 3.15b) 
prior to IBE there was a reduction in the number of cells recovered that was not seen when viable 
cells such as HUVEC were lysed prior to IBE at all concentrations of spiked HUVEC (Figure 
3.15c).  
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3.7 Evaluation of CECs in vasculitis 
As described previously, CECs obtained from patients with active vasculitis were 
affected by the lysis stages necessary for flow cytometry.   Thus in this thesis CECs as a 
biomarker of endothelial injury in children with vasculitis were evaluated using IBE.  
 
3.7.1 Patients and methods 
3.7.1.1 Patients 
42 children with primary systemic vasculitis were studied. These included 18 males and 
24 females of median age 10.8 years (range 0.3 -16.6 years). The vasculitis type (using 
the Chapel Hill Consensus Criteria) (Jennette et al., 1994) was polyarteritis nodosa 
(PAN) n=18, Wegener’s granulomatosis (WG) n=8, microscopic polyangiitis (MPA) n= 
1, Kawasaki’s disease (KD) n = 6, Takayasu’s disease (TD) n = 3, Beçhets disease (BD) 
n  = 1 and unclassified vasculitis n=5. Disease activity was assessed using a modified 
paediatric BVAS (Appendix 2).   25 healthy child controls (6 males, 19 females, median 
age 8.9 years, range 1.5-15.8),  13 febrile controls (7 males, 6 females, median age 7.3 
years range 1.5- 14.0) and 20 healthy adult controls were also recruited (2 males, 18 
females, age range 24-40 years).  The febrile control group consisted of patients with a 
variety of autoimmune or other inflammatory disorders (including infection) without the 
presence of vasculitis. 
 
3.7.1.2 Methods 
CECS were isolated from EDTA coagulated peripheral venous blood as described in 
section 2.5.1.  All blood used for analysis was drawn using a 21 gauge needle with 
minimal trauma and where possible the first 5 mls of blood were discarded (and used in 
 other assays).  Blood was processed immediately after collection. 
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3.7.1.3 Statistics 
Median CEC counts were compared between groups using a Kruskall Wallis test to 
check for overall differences.  Individual Mann Whitney U tests for non-parametric data 
were used for specific inter-group comparisons.  The Wilcoxon signed rank test was 
performed to compare groups with paired samples.  Spearman Rank correlation 
coefficiants were examined to determine the levels of correlation between CECs and 
other markers of clinical disease activity.  In all data graphs patient classification was 
denoted using colour coding as indicated below: 
 
 
  
 
3.7.2 Results 
3.7.2.1 CECs are elevated during active disease and decline with treatment 
Kruskall Wallis testing indicated there was an overall significant differences between 
test groups (p<0.0001).  CECs were significantly higher in 32 children with active 
vasculitis (as defined by a BVAS score >0, median value 208 CECs/ml) compared to 13 
febrile disease controls (non-syndromic, inflammatory disorders, median value 36 
CECs/ml, p=0.0009), 25 healthy child controls (median value 32 CECs/ml, p<0.0001) 
and 20 healthy adult controls (median value 20 CECs/ml, p<0.0001).  There were no 
significant differences between 28 patients with inactive vasculitis (median value 32 
CECs/ml) and these control groups.   
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Notably, there were a number of individual patients whose disease was considered 
clinically inactive, yet had elevated CECs, possibly indicative of subclinical endothelial 
injury (Figure 3.16a).  The data shown in Figure 3.16a includes paired samples between 
individual patients with active and inactive disease and thus these groups could not be 
compared without their exclusion.  Only the first observation made in each individual 
patient was included in this analysis. CECs were significantly higher in 32 patients with 
active vasculitis compared to 11 patients in remission (p<0.0001, median CEC count 
was 208 CECs/ml vs 16 CECs/ml).  
 
In 19 individual patients with paired analyses (active vasculitis vs inactive vasculitis), 
CECs were significantly higher during active disease compared to when they were 
considered to be clinically in remission (BVAS score = 0, median time to remission 3.5 
months, p=0.01, Figure 3.16b). Of these 19 patients, 16 had frequent and detailed follow 
up over time for up to 18 months from disease onset and pre-treatment (prior to 
immunomodulatory therapy) or from a flare of their disease while on treatment (10 
patients were followed up from disease onset - solid line, 6 from a disease flare - dotted 
line).  Ultimately CEC numbers declined in all individuals although in some patients 
this took longer than in others (Figure 3.17).  At median followup of 3 and 12 months 
from pretreatment at disease onset (10 individuals) CECs were significantly lower than 
at onset (p=0.005 and p=0.014).  At 12 months 2 patients had flared, with corresponding 
elevation in CEC number (Figure 3.17). 
 
 
 
 
 
136 
 
Figure 3-16: CECs in vasculitis 
 
  
 
 
Figure 3.16a: Circulating endothelial cells were significantly higher in 32 children with active 
vasculitis compared to 13 febrile disease controls (non syndromic, inflammatory disorders) 
(p=0.0009), 25 healthy child controls (p<0.0001) and 20 healthy adult controls (p<0.0001).  There 
were no significant differences between 28 patients with inactive disease and these control groups, 
however it is notable that there are a number of individual patients with inactive disease and 
elevated CECs, possibly indicative of subclinical endothelial injury. Figure 3.16b: In 19 individual 
patients with paired analysis, CECs were significantly higher when patients had active disease 
compared to when they were considered inactive (median time to remission 3.5 months, p=0.01).   
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Figure 3-17: CECs in vasculitis – response to treatment 
 
 
 
 
 
 
Figure 3.17:16 individual patients had their circulating endothelial cells measured from initiation of 
treatment after disease onset or flare  (dotted lines indicate patients followed from a flare while on 
treatment, solid lines indicate patients who were observed from pre-treatment). At median followup 
of 3 and 12 months from pre-treatment CECs were significantly lower than at onset (p=0.005 and 
p=0.014).  At 12 months 2 patients had flared, with corresponding elevation in CEC number.  
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3.7.3 Correlation between CECs and disease activity 
Spearman Rank correlation coefficiant analysis was performed between CEC count and 
the traditional markers of active disease; BVAS, ESR, CRP, platelet count, albumin and 
white cell count.  Correlations were performed on all values obtained from the cohort of 
44 patients.  Table 3.2 summarises the results.  CECs in vasculitis correlated 
significantly with disease activity as determined using a paediatric modified BVAS 
scoring system, although not significantly with other markers.  Figure 3.18 
demonstrates the relationship between CECs, BVAS , ESR and CRP visually.  As can 
be seen in Figure 3.18a-c there were a number of patients with low ESR or CRP and 
low disease activity as defined by BVAS that had high CEC levels, again possibly 
indicative ongoing subclinical endothelial injury (Figure 3.18).  
 
Table 3-2: Spearman Rank correlation coefficiants between CECs and 
conventional markers of disease activity 
 
Marker of disease activity vs CECs  Marker of disease activity vs CECs 
BVAS r = 0.48 
p<0.0001 
n = 110  
 Platelet count r = 0.059 
p = 0.556 
n = 102  
ESR r = 0.12 
p = 0.23 
n = 101  
 Albumin r  = -0.160 
p = 0.11 
n = 99 
CRP r = 0.134 
p = 0.17 
n = 107  
 White cell count r = 0.117 
p = 0.233 
n = 105  
 
Significant correlations highlighted in blue 
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Figure 3-18: Correlation with disease activity 
 
 
 
Figure 3.18a: Circulating endothelial cells correlated with disease activity in vasculitis as 
determined using a paediatric modified BVAS scoring system  (p<0.0001, R=0.47) based on 105 
measurements in 42 patients.  Figure 3.18b and c CECs did not correlate significantly with ESR 
(p=0.09, based on 98 measurements in 41 patients) or CRP  (p=0.2, based on 102 measurements in 
42 patients), as the graphs show there are a number of patients with low inflammation as determined 
by ESR or CRP or disease activity as defined by BVAS that have high CEC levels, indicative of 
subclinical  endothelial injury.  
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Of the 16 patients who had detailed repeated measurements over time, a number had 
flares of active disease during the study period.  Figures 3.19-3.22 hilight 4 interesting 
cases, the first three are patients studied from disease onset, the fourth a patient who 
underwent autologous stem cell transplantation.  Figure 3.19 a-d shows the changes in 
CEC count alongside ESR, CRP and BVAS over time from treatment in a 12 year old 
female with WG.  As can be seen she had a disease flare (arrowed) in which CECs 
mirrored the more traditional methods used for assessing disease activity.  In Figure 
3.20 a-d an 11 year old female with WG was also followed up over time, unfortunately 
her CECs were not observed at the onset of her disease, however she entered an episode 
of severe, localized and (presumed) granulomatus flare (orbital mass) and as can be seen 
her CECs rose, but did not rise to the high levels seen in severe active systemic disease 
(Figure 3.20).  In Figure 3.21 a-d a 10 year old female with PAN was followed closely 
at the initiation of disease.  After initially entering remission her ESR and CRP became 
elevated, however her CECs remained normal.  This was subsequently proven not to be 
a flare of her disease but an associated urinary tract infection. Figure 3.22 a-d shows the 
changes in CEC number that occured in one individual who underwent autologous stem 
cell transplantation for recalcitrant vasculitic disease occurring secondary to a familial 
fever.  CEC numbers declined from 3,136 to 20 after a week of pre-conditioning 
treatment (Campath®).  CEC numbers remained low after the transplant, until the 
patient contracted a cytomegalovirus (CMV) infection, which corresponded with a rise 
in CEC count.  CECs infected with CMV have been documented by a number of groups 
in patients with CMV infections (Pooley, Jr. et al., 1999,Percivalle et al., 1993).  Other 
examples of the changes in CECs in individual patients with other markers of disease 
activity over time from treatment are found in Appendix 6. 
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Figure 3-19: Patient with WG - CECs and disease activity – predictive of 
disease flare? 
 
 
 
Figure 3.19a indicates the change in CEC number over time from treatment in a 12 year old female 
with WG. Figures 3.19 b-d indicate the changes in disease activity as determined using BVAS 
scoring and the changes in the inflammatory markers ESR and CRP.  CEC levels mirrored the 
changes seen in the more traditional clinical methods of assessing disease activity in this individual. 
Rx = treatment, BVAS = Birmingham vasculitis activity score, ESR = erythrocyte sedimentation 
rate, CRP = c reactive protein. 
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Figure 3-20: Patient with WG – CECs and disease activity in orbital 
granuloma  
 
 
 
Figure 3.20a indicates the change in CEC number during a granulomatus flare in an 11 year old 
female with WG. Figures 3.20 b-d indicates the changes in disease activity as determined using 
BVAS scoring and the changes in the inflammatory markers ESR and CRP. Although CECs 
increased slightly, they were within the healthy child range. 
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Figure 3-21: Patient with PAN – CECs and disease activity 
 
 
 
 
 
Figure 3.21a-d indicates the changes in CEC number and traditional markers of disease activity 
after treatment in a 10 year old female with PAN. At 6 months into her disease she experienced a 
spike in ESR and CRP (Figures c and d) subsequently proven to be due to a urinary tract infection 
(UTI), not active disease – BVAS and CECS remained low.  
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Figure 3-22: CECs during autologous stem cell transplantation 
 
 
 
 
Figure 3.22a-d indicates the changes in CEC number and traditional markers of disease activity in 
a patient who underwent autologous stem cell transplantation for recalcitrant vasculitic disease 
occurring secondary to a familial fever.  CECs were high, prior to Campath® pre-conditioning and 
remained low during the transplant, until the patient contracted a CMV infection.  Unfortunately 
ESR and CRP were not measured as frequently in this patient as the research bloods as they are not 
part of the routine bloods performed in transplantation patients.  
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3.7.4 CECs in individual vasculitic syndromes 
When the combined cohort of vasculitis patients was subdivided into individual 
diseases, the results, although based on small numbers were worthy of some comment.  
During active disease patients with KD and TD (diseases predominantly affecting large 
and medium vessels) had lower CECs than patients with PAN or WG (disease 
predominantly affecting small to medium vessels) (Figure 3.22a).  This interesting 
result which warrants further investigation, could indicate that this biomarker could 
depend on how widespread the overall surface area of the endothelium affected by the 
disease is.  Bearing in mind that by far the largest surface area of endothelium is made 
up of smaller vessel endothelium (Ganong WF, 2001) this explanation may not be an 
oversimplification. During clinically defined remission (BVAS =0, Figure 3.22b) the 
majority of patients had low CECs.  There were two notable exceptions: in the WG 
group, three patients had high CECs despite clinical remission; the single patient with 
KD had coronary artery aneurysms and although systemic inflammation had subsided, 
was likely to be undergoing extensive vascular remodeling.   
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Figure 3-23: Subdivision into individual diseases - CECs in different 
vasculitic conditions 
 
 
 
Figure 3.23a: When the patient cohort was divided into the different disease classifications, 
although the numbers were low, patients with Takayasu’s disease (TD) and Kawasaki disease (KD) 
had lower levels of CECs in active disease than those patient with Polyarteritis nodosa (PAN) or 
Wegener’s granulomatosis (WG). Figure 3.23b: Interestingly in those patients in clinical remission, 
the group with the highest proportion of individuals who had elevated CECs was the WG group, a 
disease affecting predominantly small vessels and notorious for its relapsing nature and poor 
clinical outcome. 
Active 
Disease 
Clinical 
Remission 
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3.8 Discussion 
Circulating endothelial cells are elevated at times of active disease in PSV and correlate 
with disease activity although inconsistently with routine clinical markers of 
inflammation. In individual patients, CECs were elevated during active disease and 
declined over time with remission inducing treatment (Figures 3.16 and 3.17).  CECs 
tended to be higher in patients with diseases affecting predominantly smaller vessels, 
although this observation was preliminary (Figure 3.18).  In the small number of 
patients who entered a flare of systemic vasculitic disease while on treatment, CECs 
correspondingly increased (Figure 3.19, Appendix 6 patients 3,4,7,10 and 13), although 
in localised flare this was not to the high levels seen in systemic disease (Figure 3.20, 
Appendix 6 patients 6 and 8), a finding that has also been observed in adults with WG 
(Woywodt et al., 2006b).   
 
The significant differences in CEC number between active disease and healthy age 
matched and febrile controls, suggest that CECs may be a reliable marker of active 
vasculitis and endothelial injury.  Vasculitis patients are a highly heterogeneous group 
and it is thus not surprising that some patients with active disease do not have high 
elevation of CECs, perhaps related to the time of sampling in relation to initiation of 
treatment and the location and extent (systemic versus localised) of the vasculitic injury.  
As discussed in the introduction to this chapter, it remains unclear where CECs 
originate and how they enter the venous circulation.  Of some concern in this patient 
population was the small number of patients who had elevated levels of CECs but no 
clinical signs of disease activity.  It may be that this is indicative of an increased 
endothelial turnover and vascular remodeling rather than acute injury, an hypothesis that 
makes sense considering the time it takes CECs to return to normal levels in some 
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individual patients, despite bringing the inflammation under control.  A less optimistic 
hypothesis, however is that in these patients endothelial injury is ongoing, despite the 
clinical impression of disease remission.  
 
The poor correlation with clinical markers of inflammation is consistant with the 
conflicting results observed in previous studies in adult, whereby strong correlations 
have been observed between CECs and BVAS in ANCA associated disease (Woywodt 
et al., 2003b,Woywodt et al., 2006b) but only a weak correlation was been observed 
with CRP (Woywodt et al., 2006b).  As discussed in the introduction to this thesis, 
levels of ESR and CRP may remain normal during active vasculitis, particularly in 
episodes of localised disease and granulomatous flares (Salvarani et al., 2003,Sproson et 
al., 2007) and thus this result is unsurprising, indicating as mentioned above that 
endothelial injury can occur in the absence of inflammation.      
 
Unfortunately the technique used in this thesis for detection of CECs is not yet suitable 
for large scale automated routine clinical testing, because of its time consuming nature 
and the training required to reliably read samples.  Development of a flow cytometry 
based assay optimised for detection of necrotic cell populations was not a direction in 
which this project went due to time constraints and the availability of a well established 
and reproducible assay for reliable detection of CECS.   However flow cytometry 
protocols can be relatively simply automated and future work based on this would be of 
considerable interest.  A multiparametric approach for detection of CECs would allow a 
much more defined population, that could provide more understanding of the exact 
nature of CECs.  
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As red cell lysis used in FC was one of the major causes of loss of the fragile CEC 
population, the use of similar techniques to those used for examination of apoptotic and 
necrotic cells using FC such as no wash/no lyse protocols (Darzynkiewicz et al., 1997) 
could overcome this limitation.  However without red cell lysis there is much 
background noise due to non removal of red cells, and in order to distinguish cells of 
interest from erythrocytes, a threshold based on fluorescence must be used.  As yet 
these techniques are only described for rare event analysis based on very bright staining 
populations with metabolic dyes rather than antibody staining (Rehse et al., 1995) and 
thus may not be suitable for detection of CECs.  Another potential method for 
overcoming these problems (in order to benefit from the multiparametric potential of 
FC) would be to enrich the CEC population prior to preparation for FC, thus removing 
the majority of superfluous cells and much of the background noise.  This could be done 
using FC compatible magnetic beads as described recently by Widemann et al.  
Interestingly, although this protocol gave comparable values to IBE, statistically the 
results were consistently higher when healthy individuals, patients who had undergone 
coronary angioplasty or renal transplantation were studied (Widemann et al., 2008).  
The authors attributed this to the loss of fragile cells populations during the washing 
steps required for IBE and thus this finding is extremely promising for future studies in 
vasculitis, whereby conventional FC methodology resulted in considerable loss on 
handling of CECs (Clarke et al., 2008).   
 
An alternative multiparameter identification technique which has been developed into a 
commercially available CEC counting system involves automated microscopy 
(Celltracks endothelial cell kit, Immunicon). CECs are isolated from peripheral blood 
using CD146 immunomagnetic beads then stained with DAPI, anti-CD105-PE and anti-
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CD45-APC.  The stained cells are transferred to a counting chamber and are scanned 
with an automated microscope.  Events positive for DAPI and CD105 and negative for 
CD45 have composite images taken which an operator can then distinguish on 
morphology.  Not surprisingly the setup costs for this kind of system are prohibitively 
expensive.  However, with the right software and using a microscope with a motorised 
stage and filter set, it may be possible to emulate the technology at a fraction of the cost.  
Unfortunately time restraints did not permit the development of either of these avenues 
of work and thus for the purposes of this thesis and to examine CECs within the 
vasculitis patient cohort, IBE as described by the 2006 consensus paper was therefore 
the methodology of choice (Woywodt et al., 2006a).   
 
While IBE has proved to be more reproducible and robust than FC for assessment of 
CECs in vasculitis, excluding a single study in KD (Nakatani et al., 2003) this is the 
first study to examine a paediatric cohort with necrotising vasculitis in detail.  Thus 
potential paediatric related sources of error needed to be considered.  In particular the 
effect of traumatic venepuncture and the inability to guarantee that all samples would 
have the first 5 mls of blood discarded due to the small samples typically obtained for 
research in children.  Although the data is preliminary, due to lack of willing volunteers, 
traumatic venepuncture did considerably elevate the CECS in a single healthy adult 
volunteer above the median values normally obtained in healthy adult controls (20 
CECs/ml in this study, comparable with previous studies of around 10-20 CECs/ml) 
(Blann et al., 2005).  However the range seen in active AAV (20-5700 CECs/ml) 
(Woywodt et al., 2003b) was much higher than this and the experimental venepuncture 
performed in this study was far more traumatic than would be hoped under normal 
conditions.   Interestingly discarding the first 5 mls of blood in this individual, would 
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not have influenced the CECs enumerated.  Although it is difficult to draw firm 
conclusions from these preliminary findings, as long as the same conditions are applied 
to the control group as to the patient group it is possible that these child related 
confounding issues will not affect our the results, because CECs are so grossly elevated 
in children and adults with active vaculitis.  
 
In conclusion it appears that in vasculitis in children CECs reflect the extreme 
endothelial damage associated with this condition and are a useful tool for assessing 
disease activity.  Further development of the methodology towards a routine clinical test 
would be an obvious future direction of this work. 
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4.1 Summary 
This chapter describes the methodology used to detect cellular derived microparticles.  
Like CECs this technique can provide insight into the activation state of the 
endothelium, and may be an appropriate biomarker of disease activity in vaculitis.  
However, due to the multiparametric nature of the technique used, insight can be gained 
at the same time relating to the activation state of a number of different cells (eg 
neutrophils, monocytes) which are also pivotal to disease activity in vasculitis.  The 
latter part of this chapter examines in detail the relationship between microparticles and 
disease activity in children with primary systemic vasculitis and further expands on 
previously published data from the group (Brogan et al., 2004a).  
  
 
4.2 Introduction 
Microparticles (MPs) are membrane derived vesicles 0.1-2µm in size that are released 
during physiological or pathological cell or platelet activation (Piccin et al., 2007).  MPs 
can express surface markers of their cell of origin and in contrast to quiescent cells can 
express phosphatidylserine (PS) on their outer leaflet (Hugel et al., 2005), a 
consequence of the membrane remodelling or in more pathological situations the loss of 
integrity necessary for their formation.   
 
4.2.1 Formation of MPs 
Cellular and platelet plasma membranes consist of a phospholipid bilayer, which in 
unstimulated cells has an asymmetrical distribution of its components.  Uncharged 
phospholipids such as phophatidylcholine (PC) and sphyingomyelin (SM) are 
predominantly expressed on the outer leaflet and negatively charged phospholipids such 
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as PS and phosphatidylethanolamine (PE) found on the inner leaflet.  Membrane 
remodelling and subsequent PS expression on the outer leaflet of cells promotes the 
activation of clotting factors (Bevers et al., 1982) and recognition of the cell by 
phagocytes and is considered to be a key stage in apoptosis (Fadok et al., 1992).   
 
Membrane composition is tightly regulated by enzymes, known as flippases, floppases 
and scramblases (Piccin et al., 2007).  Flippases inwardly direct the negatively charged 
phospholipids in an ATP dependent manner, whereas floppases act in an outward 
manner (Daleke, 2003).  Scramblases degrade the bilayer phospholipid gradients, acting 
in both directions.  A Ca
2+
 activated scramblase has been described which plays an 
important role in membrane reorganization in response to cell stimulation (Daleke, 
2003), the resultant membrane disorganisation results in PS expression on the surface of 
the cell.  As transient rises in Ca
2+
 can alter the membrane asymmetry and activate 
enzymes involved in cytoskeleton remodeling, such as calpain, it is believed to play a 
key role in MP formation (Wiedmer et al., 1990). Thus Ca
2+
 ionophores can be used to 
generate MPs.   
 
In vitro it is relatively easy to stimulate isolated cell populations to generate MPs by the 
use of cytokines of ionophores.  In vivo the stimuli which generate MPs and their 
functions remains unclear, however it is apparent that they are a consequence of cell 
activation, apoptosis and necrosis and are the product of remodeling of the cytoskeleton 
and loss of membrane asymmetry.    
 
4.2.2 Detection of MPs 
The majority of studies which have detected MPs have used flow cytometry (FC) based  
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protocols.  This allows for a multi-parameter based assessment of the MP population. 
However there is much variation in methodology and no consensus protocol has been 
described (Enjeti et al., 2007).  An alternative technique utilizes sandwich ELISA, 
whereupon MPs are immobilized on the ELISA plate by PS binding.  However this does 
not provide as much information relating to phenotype as FC allows, and also does not 
allow analysis of PS negative MPs.  Thus in this thesis FC was employed to study MPs. 
 
4.2.3 Function of MPs 
The phenotype and function of MPs from different cellular origins remains to be fully 
elucidated, however it is apparent that different cellular MPs and the circumstances 
under which they are generated can exert different functional effects.  MPs are 
generated in response to numerous stimuli and while some groups hypothesise that their 
role is in inter-cellular signaling, others suggest it is a consequence of cell survival.  The 
expression of high levels of PS on the outer surface of all phenotypes of MPs indicates 
widespread procoagulant potential, as PS promotes the coagulation cascade (Hugel et 
al., 2005,Toti et al., 1996).  Elevated levels of MPs from endothelium, platelets, 
mononuclear cells and neutrophils have been documented in a number of diseases 
associated with cardiovascular injury, including vasculitis in both adults (Daniel et al., 
2006,Erdbruegger et al., 2008) and children (Brogan et al., 2004a) and will now be 
discussed in more detail.  
  
4.2.4 Endothelial MPs 
Endothelial  MPs  (EMPs)  were  first  described  by  Hamilton  et  al  in  1990,  being 
produced in response to complement mediated attack on HUVEC (Hamilton et al., 
1990).  The resultant MPs generated were less than 1µm in size and bound activated 
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factor V a key component of the coagulation pathway (Hamilton et al., 1990).  Cultured 
ECs have subsequently been shown to produce MPs in response to various stimuli 
including inflammatory cytokines such as TNFα (Combes et al., 1999) and IL-1α (bid 
Hussein et al., 2003), CRP (Wang et al., 2007), thrombin (Sapet et al., 2006) and serum 
from patients with antiphospholipid syndrome (APS) (Combes et al., 1999), thrombo-
cytopenic purpura (Jimenez et al., 2001) and multiple sclerosis (Minagar et al., 2001).   
 
Elevated levels of EMPS have been detected in many diseases associated with vascular 
injury including vasculitis (Brogan et al., 2004a), acute coronary syndrome (Bernal-
Mizrachi et al., 2003), multiple sclerosis (Minagar et al., 2001) and type 2 diabetes 
where they are predictive of associated coronary artery disease (Koga et al., 2005).  
Thus are not specific to the vasculitides, but reflect activation and injury.   
 
4.2.4.1 Phenotype of EMPs 
There is no agreed consensus as to what defines an EMP other than the presence of 
endothelial cell membrane antigens on the surface of a MP.  More often than not MPs 
are defined by the presence of PS (shown by binding of AnnexinV (AnV)) on the 
surface of particles with low FSC, however some groups consider AnV negative 
populations as well. EC markers that have been examined on MPs include CD144, 
CD146 (Faure et al., 2006), CD31, CD105, CD51, ICAM-1, E-selectin and CD106 
(Jimenez et al., 2003). 
 
Jimenez  et al  demonstrated that when ECs were deprived of growth factors  to induce  
apoptosis the MPs generated expressed CD31 and CD105 (Jimenez et al., 2003), 
however after cellular activation with TNFα the MPs produced had much higher 
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expression of the inducible activation markers E-selectin, ICAM-1 and CD106 (Jimenez 
et al., 2003).  Thus examining a combination of markers may give insight into the 
circumstances of MP generation.  For the purposes of this thesis, the constitutive 
endothelial markers CD144 and CD105 and the inducible endothelial markers ICAM-1 
and E-selectin were examined.   
 
CD144 is specific for ECs in adults, however can be found on haematopoeitic stem cells 
in the foetus (Kim et al., 2005) and endothelial progenitor cells post-natally (Rehman et 
al., 2004).  It is involved in maintaining the tight cell-cell contact between ECs, thus 
significant EC disruption would necessitate it being exposed.  CD105 or endoglin is part 
of the TGFβ receptor complex on endothelial cells and like CD144 it is not frequently 
found on cells circulating in the blood, other than leukaemic cells (Duff et al., 2003).  It 
is upregulated in hypoxia (Sanchez-Elsner et al., 2002) and on proliferating ECs (Duff 
et al., 2003).  Although CD31 and CD146 are alternative EC constitutive markers, they 
are found on haematopoietic cell types which are more prevalent and may generate MPs 
in inflammatory conditions; CD146 is found on activated T cells and CD31 is found on 
platelets, neutrophils, T cells and NK cells.  E-selectin is highly specific for activated 
ECs and has only been observed on other cell types in vitro; TNFα stimulated foetal 
astrocytes (Hurwitz et al., 1992) or on CD4+ T cells after antibody stimulation of 
membrane-bound TNF (Harashima et al., 2001).  In vitro its expression is transient, 
peaking at 4hrs after stimulation (Pober et al., 1986).  ICAM-1 is constitutively 
expressed on EC, but is also upregulated on activation, peaking at 4hrs after IL-1 
stimulation (Dustin et al., 1986).  It is less EC specific though and is also expressed on 
activated leucocytes. 
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4.2.4.2 Functional significance 
Microparticles generated in vitro from cultured endothelial cells such as HUVEC or 
microvascular endothelial cells (MVEC) have been shown to activate monocytes (Jy et 
al., 2004b) and enhance monocyte-endothelial adhesion (Huber et al., 2002), suppress 
HUVEC growth in a matrigel angiogenesis assay (Mezentsev et al., 2005) and promote 
coagulation in vitro and in vivo (bid Hussein et al., 2008).  In isolated perfused human 
microvessels, the addition of EMPs reduced acetylcholine induced endothelium 
dependent vasodilation and in the same study, when EMPs were injected into both rats 
and mice acute lung injury occurred (Densmore et al., 2006).   
 
4.2.5 Platelet MPs 
Platelet MPs (PMPs) are the population which have been most extensively studied to 
date and make up the predominant MP population in healthy individuals (Diamant et al., 
2004).  Stimulation of platelets by a wide variety of agents (such as thrombin, collagen 
or ADP) induces the aggregation necessary for haemostasis and can also result in MP 
release (Diamant et al., 2004).  PMPs are also released in vitro by shear stress 
(Miyazaki et al., 1996).   
 
Elevated levels of PMPs have been found in patients suffering thrombotic complications 
or vascular injury including acute myocardial infarction (Matsumoto et al., 2002), 
peripheral arterial disease (Zeiger et al., 2000), vasculitis (Brogan et al., 2004a), 
hypertension (Preston et al., 2003) and in malignancy (Kim et al., 2003).  Conversely 
patients with bleeding disorders, such as Castamann’s disease have reduced PMPs 
(Castaman et al., 1997) and in the rare genetic disease Scott’s syndrome where PS is 
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unable to be exposed on the surface of cells, PMPs cannot be generated at all (Toti et 
al., 1996). 
 
4.2.5.1 Phenotype of PMPs     
As with EMPS, PMPs have been assessed based on their expression of PS in 
combination with a platelet surface marker such as; CD42a, CD42b, CD41, CD61, 
CD63 or P-selectin (Piccin et al., 2007).  For the purposes of this thesis CD42a, which 
is constitutive and selectively expressed on platelets and the adhesion molecule P-
selectin which is found on platelets although less selectively (it is also expressed on 
endothelial cells (Merten and Thiagarajan, 2004)) were chosen.  CD42a or glycoprotein 
IX is part of the vWF receptor complex (consisting of 4 subunits – gp1bα and β, gpIX 
and gpV) which is involved in mediating the tethering of platelets to exposed vWF on 
the subendothelium.  The complex also interacts with thrombin, P-selectin and 
coagulation factors (Du, 2007).   P-selectin mediates rolling of platelets and leukocytes 
on activated endothelium and intereactions between platelets and leukocytes (Merten 
and Thiagarajan, 2004).  
 
4.2.5.2 Function of PMPs 
In vitro PMPs have been shown to initiate and propagate coagulation (Warkentin et al., 
1994), activate neutrophils (Jy et al., 1995), monocytes (Barry et al., 1998) and 
endothelial cells (Barry et al., 1997) and mediate the cell-cell interactions between them 
(Barry et al., 1998).  PMPs have been shown to transfer platelet antigens (Majka et al., 
2007) and other receptors between cell types such as CXCR4, which can make cells 
susceptible to the HIV virus (Rozmyslowicz et al., 2003). In lung cancer PMPs can 
induce metastasis (Janowska-Wieczorek et al., 2005).  Conversely under some 
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conditions PMPs have demonstrated anticoagulant properties, via acceleration of 
inactivation of activated factor V by protein C (Tans et al., 1991) and by their 
expression of proteins which inhibit coagulation, such as TF pathway inhibitor 
(Steppich et al., 2005), suggesting a complex role in the balance of haemostasis.  
  
4.2.6 Leukocyte MPs – Neutrophils, monocytes and lymphocytes 
As neutrophils play a key role in the pathogenesis of AAV, it is perhaps not surprising 
that elevated levels of neutrophil derived MPs (NMPs) have been described in vasculitis 
(Daniel et al., 2006).  Elevated levels of NMPS have been also been documented in 
sepsis (Joop et al., 2001).  Both studies examined the immunoglobulin surface marker 
CD66b.  For the purposes of this thesis CD15, CD11b, and L-selectin were examined in 
addition to CD66b.  CD15 is a constutively expressed adhesion molecule found in high 
levels on neutrophils and is involved in phagocytosis and chemotaxis (Skubitz et al., 
1989).  CD11b is an integrin involved in neutrophil and monocyte adhesion with the 
endothelium and is upregulated on stimulation of neutrophils (Finn et al., 1994).  L-
selectin is involved in leucocyte-endothelial interactions and is downregulated on 
neutrophil stimulation (Finn et al., 1994).   
 
Microparticles derived from monocytes (MMPs) have previously been detected by their 
high expression of CD14 in combination with AnV (Kanazawa et al., 2003). CD14 is 
part of the LPS receptor complex and is found on a small proportion of neutrophils. 
Stimulated monocytes can synthesis high levels of tissue factor (TF).  While both 
endothelial cells and platelets can release TF from intracellular granules on stimulation, 
it is hypothesized that monocytes may be the predominant source of TF positive MPs, 
which have the potential to form complexes with platelets and PMPs, propagating 
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coagulation (Osterud, 2001).  Elevated levels of CD14+ MPs have been documented in 
lung cancer (Kanazawa et al., 2003) and type 2 diabetes (Omoto et al., 2002).  
 
Elevations in lymphocyte microparticles (LMPs) have been documented in pre-
eclampsia (VanWijk et al., 2002) and HIV(Aupeix et al., 1997) and has been postulated 
to be associated with high levels of lymphocyte apoptosis in these conditions.  CD4 and 
CD8 MPs were examined in these studies. For the purposes of this thesis CD3 positive 
MPs were assessed.  CD3 is part of the T cell receptor complex and is constitutively 
expressed on mature T cells (Goldsby RA et al., 2003a).  
 
4.2.6.1 Function of leukocyte MPs 
Leukocyte derived MPS have been less well studied than those derived from 
endothelium or platelets.  It is apparent that they are associated with inflammation and 
infection and there is evidence accumulating that they may also have functional 
significance.  MMPs express high levels of TF, which can be transferred to other cell 
populations (Osterud, 2001) indicating a role in coagulation.  LMPs have been shown to 
activate monocytes (Scanu et al., 2008) propagating inflammation. The data relating to 
NMPs is more complex; while NMPs can stimulate endothelial cells to release IL-6 
(Mesri and Altieri, 1998), perhaps potentiating inflammatory reponses, conversely they 
can act in an anti-inflammatory manner.  In vitro NMPs generated from N-formyl-
methyl-leucyl-phenylalanine (FMLP) stimulated adherent neutrophils (cocultured with 
HUVEC),can inhibit neutrophil-endothelial interactions (Dalli et al., 2008).  In vivo, 
mouse NMPs generated in the same manner (using mouse endothelium) inhibited IL-1β  
induced inflammatory infiltrate in a mouse air pouch model (Dalli et al., 2008). 
 
162 
 
4.2.7 Microparticles in vasculitis 
To date, there have been 3 studies and one case study examining MPs in vasculitis, the 
first by Brogan et al demonstrated an elevation in E-selectin and CD105 expressing 
EMPs and CD42a (although not P-selectin) expressing PMPs in children with active 
PSV compared to healthy controls (Brogan et al., 2004a). Daniel et al demonstrated an 
elevation in NMPs expressing CD66b and PMPs expressing CD41a in adult patients 
with AAV during active disease compared to controls.  During remission patients also 
had higher NMPs than controls (Daniel et al., 2006). Recently Erdbruegger et al 
examined EMPs in adults with AAV and demonstrated an elevation E-selectin and 
CD105 EMPs during active disease compared to patients in remission and healthy 
controls (Erdbruegger et al., 2008).  The case study described by Kumpers et al, 
demonstrated eleveated EMPs, PMPs and leucocyte MPs (CD45+) at onset of Churg-
Strauss syndrome that declined with treatment (Kumpers et al., 2008).   
 
While Erdbruegger et al followed changes in EMPs for 6 months from treatment and 
demonstrated a rapid decline, the two other studies only examined a small number of 
patients before and after treatment.  Thus a comprehensive study relating to changes in 
MPs in relation to treatment and disease flare has yet to be performed.  The study 
described herein will begin to examine MPs in this context. 
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4.3 Detection of MPs – methodological optimisation 
4.3.1 Preparation of samples 
The methodology described is based on work previously optimized and published by 
the group (Brogan et al., 2004a) and thus few changes to the basic protocol were 
required.  Platelet poor plasma was generated as described in Section 2.4.7.  Figure 4.1 
demonstrates the extent to which platelets were removed from the sample after each 
spin.  50µl samples of blood prior to spinning, plasma after 1 x 5 mins spin at 5,000g 
and after 2x 5 mins spins at 5,000g were diluted in 200µl of sterile filtered (0.22µm) 
FACS buffer and run for 45 seconds on a BD Facscalibur, using logarithmic instrument 
settings, with FSC amplitude of E01.  As can be seen in Figure 4.1a-c while 1 spin 
removes a large proportion of platelets (Figure 4.1b), 2 spins removes almost all of 
them (Figure 4.1).  The removal of platelets from plasma is an important step in the 
protocol as to (some extent) they have overlapping FSC/SSC profiles to MPs making 
FC analysis more difficult in the presence of platelet contamination.  Moreover, the 
freeze thawing of platelets may disrupt their membrane and could result in false positive 
MP events (see section of effect of freeze-thawing below).    
 
4.3.2 Preparation of positive controls for setup experiments 
In order to detect the different MP populations in vasculitis patients MPs were 
generated from activated parent cells of different types.  For EMPs HUVEC were 
isolated and cultured as described in section 2.4.1.  After first passage they were grown 
on 6 well plates until 80% confluence, whereupon they were serum starved overnight 
and then stimulated with 100ng/ml TNF for 24hrs.  To generate NMPs neutrophils were 
isolated using polymorphprep as described in section 2.4.5 and stimulated for 30 mins-
4hrs using FMLP (10ng/ml), TNFα (100ng/ml) or  LPS  (10ng/ml)  or  combinations  of 
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Figure 4-1: The removal of platelets for generation of platelet poor plasma 
 
 
 
 
 
 
 
 
Figure 4.1a-c: Using instrument settings  optimised for MP detection (Voltage E01, logarithmic 
scale) the platelet population can be easily seen within whole blood. (Figure 4.1a, circled).  After 1 
and 2 x 5000g spins, 50µl samples of  the plasma obtained  were diluted with 200µl of sterile filtered 
PBS + 0.1% azide and run for 45seconds at low flow. Figure 4.1b: After 1 x 500g spin some 
platelets are removed.  Figure 4.1c:  After 2 spins most platelets are removed.  Absolute platelet 
count dropped from 250 to 27 after the second spin in this representative experiment.  
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FMLP with another reagent.  To generate MMPS and LMPs, PBMCs were isolated as 
described in Section 2.4.4 and stimulated using 100ng/ml TNF for 30 mins-4hrs.  To 
detect a mixed population of MPs, including platelet, monocyte, lymphocyte and 
neutrophil whole blood was stimulated with LPS 100ng/ml. All stimulation experiments 
of blood and cells in suspension were carried out in polypropylene tubes to prevent MPs 
sticking to the plasticware.  Activation of parent cells was confirmed using FC as 2.5.4.  
The phenotype of the MPs generated and their activated parent cells is shown in 
Appendix 4. 
 
4.3.3 Staining of MPs for flow cytometry 
A known and exact volume of sample containing MPs – either platelet poor plasma or 
culture media from experiments (which had been centrifuged at 500g for 5 mins to 
remove cells) was centrifuged at 13000g for 60 mins to pellet the MPs.  This was 
necessary to allow samples to be resuspended in AnV buffer (containing 2.5mM CaCl2) 
as AnV binding is Ca
2+
 dependent and thus there must be optimal Ca
2+
 present to allow 
binding to occur.  Once the supernatant had been carefully decanted the MPs were 
resuspended in sufficient Annexin V buffer to allow 35µl to be added to wells on a 96 
well plate containing 5 µl of Annexin V FITC and 10 µl of a PE/PE-CY5 or Percp 
conjugated antibody as described in Chapter 2.5.3. After 10mins of staining at room 
temperature 200µl of Annexin V buffer was added to stop staining and allow flow 
cytometry of sample.  The full MP staining plan is shown in Appendix 3. 
 
4.3.4 Flow cytometry of MPS 
MPs were analysed on a BD Facscalibur using logarithmic instrument settings with a 
FSC voltage of E01.   
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4.3.4.1 Optimisation of instrument settings using latex beads 
To establish the limits of detection and appropriate instrument settings 0.3, 0.8 and 3µm 
latex counting beads were used.  It is important to note that while these beads give an 
approximate estimate of size they are not directly comparable with MP size as they are 
of different composition and therefore have different optical properties (the refraction 
and reflection of the laser beam in the flow cytometer which contribute to FSC and SSC 
will be different when considering latex particles to cell membranes).  Thus MPs should 
be FSC/SSC gated based on their discrete populations and not based entirely on where 
beads fall on the FC (Furie and Furie, 2006).   As can be seen in Figure 4.2a, 3µm latex 
beads lie within a similar FSC location to platelets when whole blood was examined 
and thus could be used as an approximate upper boundary of the FC region of interest.     
 
In order to investigate the lower limits of detection, 0.8µm, 0.3µm beads and sterile 
filtered water alone were also examined.  Sterile filtered water was used to examine the 
absolute limits of detection.  The noise detected using 0.2µm filtered water was 
presumed to be electrical noise and therefore a FSC threshold was established to 
exclude the peak of this (Figure 4.2b).  Once this threshold was established the 0.8 µm 
and 0.3µm beads were examined.  As can be seen from the histograms, while the 0.8µm 
beads are easily distinguishable from noise (Figure 4.2c) the 0.3µm beads are not 
(Figure 4.2d).  Thus, as MPs are close to the limits of detection of the flow cytometer, it 
is apparent that they cannot be entirely distinguished from this noise based on their FSC 
and SSC characteristics alone, emphasizing the importance of using AnV as a 
constitutive MP marker.  Figure 4.3 shows the gating strategy used for detection of 
MPs. As can be seen a number of events positive for AnV fall within this overlapping 
noise region. 
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Figure 4-2: Optimisation of MP gating using 0.3µm, 0.8µm and 3µm latex 
beads  
 
 
 
 
 
 
Figure 4.2a demonstrates the FSC profile of 3µm latex beads and shows that they sit at the upper 
end of the platelet region that was described in figure 3.16a-c. This was used as the upper limit of 
the region of interest.  Figure 4.2 b indicates the lower limits of detection by using sterile filtered 
distilled water only and highlights the extent of background electrical noise within the system.  The 
blue line indicates the FSC threshold used to remove the peak of the background noise  Figure 4.2c 
shows that 0.8µm beads can be easily distinguished from both the noise and the 3µm bead 
population.  0.3µm beads however cannot be distinguished from the background noise (figure 4.2d)   
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4.3.4.2 Absolute enumeration of MPs 
As described previously in Chapter 3 there are 3 commonly used methods for absolute 
enumeration of flow cytometric events: 1. Allowing samples to run to completion; 
2.Using an internal standard such as counting beads; or 3.calculating the flow rate for a 
set collection time prior to running the samples.  While using an internal standard had 
proved more accurate for enumerating CECs, the presence of beads within the MP 
sample might influence the level of back ground noise making it more difficult to 
reliably count MPs accurately.   Thus this issue needed further clarification.  
 
Optimisation of detection of 3µm latex beads 
In previous studies, 3µm latex beads had been used as an internal standard (Brogan et al., 
2004a).  In the first instance it was important to establish that these counting beads were 
being detected with accuracy.  3µm latex beads were diluted in sterile filtered distilled 
water to give a final concentration of 20,000 beads/µl.  10 µl of this stock (200,000 
beads) was then added to 240µl of sterile filtered water.  Samples (n=3) were then run 
to completion at a medium flow rate using the instrument settings as established in 
Figures 4.2 and 4.3.  Using these instrument settings beads recovery was poor, with 
mean recovery of only 8.9% (range 6.7-11.4%).   
 
The manufacturer’s recommendations for the use of latex beads suggested that the use 
of a detergent may prevent beads clumping together, a phenomenon which could 
explain this poor recovery.   Thus an experiment was performed to determine if this 
could be the cause of poor recovery. Bead clumping can occur over time, so all bead 
samples used in these experiments were prepared immediately prior to use in FC 
experiments.  Beads were diluted in sterile filtered distilled water or 0.05 % TWEEN to  
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Figure 4-3: MP gating strategy, based on Annexin V positivity 
 
 
   
 
 
Figure 4.3a shows the FSC vs Annexin V positivity of MPs from a patient with active vasculitis.  The 
MPs form a discrete population at the lower end of the FSC axis that can be gated on, notably a 
number of events fall within the electrical noise region described in Figure 4.2.  When a histogram 
is drawn based on this gating, (figure 4.3b) this gated MP populations sample can be seen to have 
high numbers of CD144 positive MPs. The black line represents the negative isotype control 
antibody,  and the red line the CD144 antibody staining.  The marker was set at 2.5% positivity of 
the isotype control alone, the non-specific 2.5% being subtracted from the CD144% staining to 
obtain the final value of 38% in this example. 
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give a stock solution of 20,000 beads/µl.  10µl of each stock solution (200,000) was 
then added to 240µl of sterile filtered distilled water, 0.05% TWEEN or AnV buffer.  
As Figure 4.4b demonstrates the recovery of beads was poor under all conditions, which 
indicated that bead clumping may not be the reason for poor recovery.  Alternative 
explanations thus included suboptimal instrument settings.   
 
The aforementioned phenomenon of flow cytometric “coincidence”, whereby too many 
individual events are occurring simultaneously to detect with accuracy, could 
conceivably influence recovery.   As Figure 4.4a demonstrates, the flow cytometric 
instrument settings are at the limits of detection and there is much background noise 
(circled) which contributes to the events occuring.  In order to determine if this 
phenomenon was influencing the ability to recover beads a FSC threshold was set 
(Figure 4.4c). As Figure 4.4d shows, this increased the average bead recovery from 
8.9% to 111% (range 89-133%).  Thus in order to enumerate counting beads accurately 
the instrument settings must be optimised to the counting beads.  This was problematic 
as using the FSC threshold show in figure 4.4c would mean that the majority of the MPs 
would go undetected: as can be seen in figure 4.3a the MP population has a low FSC.  
Thus it was apparent that the use of these 3µm beads as an internal standard was not 
appropriate in this experimental setting for reliable MP quantification.   
 
As the background noise was having such a detrimental effect on bead enumeration 
(possibly via coincidence or another undefined mechanism) this observation raised 
questions regarding the effect of “noise” on MP counts.  MPs are detected using AnV 
positivity to define them, so using a threshold based on the MP AnV phenotype could 
reduce  background  noise and may allow a FITC labeled counting bead to be used as an  
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Figure 4-4: Recovery of 3µm counting beads 
 
  
 
 
 
Figure 4.4: When 200,000 latex beads were spiked into 240µl of sterile distilled water and acquired 
using MP flow cytometric instrument setting (Figure 4.4a) recovery was poor with mean recovery 
8.9% (range 6.7-11.4%).  To assess if this was due to bead clumping the stock sample of beads was 
diluted in the presence of detergent as recommended by the manufacturer (0.05% TWEEN)  - white 
bars (Figure 4.4b) and spiked into distilled water, Annexin V buffer or more detergent.  This had no 
affect on bead recovery.   There was much background noise in the sample (circled in Figure 4.4a) 
so a FSC threshold to cut out the noise was set (Figure 4.4c).  This resulted in good recovery of 
beads (Figure 4.4d, white bar) mean recovery 111% (range 89-133%).  
Using fluorescence thresholds to reduce background noise 
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internal standard.  As had been established for the non-labelled latex counting beads it 
was important to determine that the FITC labelled beads (3µm flouresbrite yellow green 
microparticles, Polysciences) were being recovered with accuracy.  As before the beads 
were diluted in sterile distilled water to give a final concentration of 20,000 beads/µl, of 
which 10µl (200,000 beads) was added to 240µl of sterile filtered distilled water.   
 
Figure 4.5a-c demonstrates that when instrument settings were optimised to beads 
(figure 4.5a) and noise (circled) was excluded using an FL1 threshold (figure 4.5b) bead 
recovery was good (mean recovery 106%, range 96-111%) (figure 4.5c).  In order to 
determine if this could be used as an internal standard 10µl of the stock solution was 
added to 240µl of a sample containing MPs stained with AnV only.  As Figures 4.6a 
and b indicate, the bright fluorescence of the beads required the FL1 voltage to be 
decreased, making the MP population appear compressed (Figure 4.6b).  Thus it was 
decided that the most appropriate method for MP enumeration was to use the 3µm latex 
counting beads with FSC threshold applied (as in Figure 4.4c) to determine the flow rate 
of the FACS machine before and after each patient sample was run and thus calculate a 
mean value.   
 
While fluoresbright beads could not be used as an internal standard due to their high 
signal when compared to MPs, in order to determine whether the use of an FL1 
threshold improved the recovery of AnV positive MPs, all samples were run using the 
previously published instrument settings (Brogan et al., 2004a) and then again using an 
FL1 threshold.  Figure 4.7 demonstrates the total Annexin V MP results obtained in 20  
healthy child controls.  
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Figure 4-5: Detecting Flouresbrite beads – recovery of beads alone 
 
  
 
 
Figure 4.5a-c demonstrates that when FC instrument settings were optimised to include fluoresbrite 
beads (figure 4.5a) and the noise (circled) was excluded using an FL1 threshold (figure 4.5b) bead 
recovery was good  (mean value 106%, range 96-111%) (figure 4.5c).  
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Figure 4-6:Fluoresbrite beads in relation to MPs 
 
 
 
  
 
 
 
Figure 4.6: When beads were used as an internal standard in the presence of Annexin V positive 
MPs, if instrument settings were optimised to the MPs the beads were off the FL1 scale (Figure 
4.6a, arrowed).  In order to recover beads at the same time as MPs FL1 voltage was reduced 
(Figure 4.6b, beads circled).  However this shifted the MP population considerably. 
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Figure 4-7:Using an FL1 threshold for MP enumeration 
 
 
  
 
 
 
Figure 4.7: When an FL1 threshold was used to remove background noise from the system, (figures 
4.7a and b) the calculated number of Annexin V positive MPs per ml of plasma was increased 
(figure 4.7c).  Figure 4.7c shows the recovery of AnnexinV MPs in 20 healthy child controls.  When 
an FL1 threshold was used, the total number of MPs recovered was significantly higher   
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It is apparent that the use of an FL1 threshold increases the sensitivity of the technique 
by removing the majority of the noise within the system.  It does however prevent 
analysis of AnV negative events.  While phosphatidylserine (PS) is widely thought to be 
found on all MPs it has been suggested that there are large populations within the 
circulation which do not express PS (Horstman et al., 2004).  Therefore for the purposes 
of this thesis it was decided to enumerate MPs using a modification of the settings 
described by Brogan et al, with the addition of an FL1 threshold as described above.  
However data was also collected using the previously published instrument settings to 
allow future study of the AnV negative population (Brogan et al., 2004a). Use of 
fluorescence thresholds have been previously described by others for detection of MPs 
(Jimenez et al., 2001). 
 
It is important to note that these instrument settings are entirely dependent on the 
particular flow cytometer (in this case a FACscalibur, BD) used for assaying these MPs.  
It is possible that the use of a different machine would not need all of the rigorous steps 
taken above to reduce background noise.  However, when MP samples were run on a 
second flow cytometer (FACSscan, BD) to investigate this, it was found that the use of 
an FL1 threshold still increased the number of AnV positive events recovered and thus 
hilighted that the steps taken to optimize this assay are of important consideration when 
performing rare event analysis under any circumstances. 
 
4.3.5 The effect of plasma freeze-thaw on MP quantification 
As mentioned previously the removal of platelets from plasma is an important step in 
the protocol as all samples were frozen.  While desirable (and possible with this 
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technique) to get same day results, the staining process is time consuming, and storage 
of frozen plasma for analysis in batches is more efficient.  
 
In order to determine if freeze-thawing altered the MPs obtained from patients a 
comparison between fresh and frozen platelet poor plasma was performed.  As figure 
4.8 demonstrates there was no difference between fresh and frozen total MP number 
based on experiments in 5 samples.  MPs were stained and enumerated as described 
above and in chapter 2.5.3, but only with AnV.  This finding is in keeping with other 
groups who found no difference due to freeze thaw (Enjeti et al., 2007).  There is one 
study that indicates the freeze thaw process may be detrimental to EMPs (Jy et al., 
2004a), however in order to establish this finding with certainty a much greater sample 
size, including different MP generation conditions, different MP populations and the 
concentrations frozen must be considered.  Time restraints meant that this investigation 
could not be performed to such a detailed level.   
 
4.3.6 Reproducibility of the technique from different plasma volumes 
Platelet poor plasma from 1 healthy adult control was frozen in 3 separate aliquots, each 
with a different volume (range 150-500µl).  As Figure 4.9 demonstrates each aliquot 
gave similar mean results for total MP enumeration (based on 5 sample tubes analysed 
using flow cytometry as described above), verifying acceptable reproducibility of the 
technique of different volumes of frozen plasma.  
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Figure 4-8: The effect of freeze thaw on MP enumeration 
 
 
 
 
 
 
 
Figure 4.8: MPs were enumerated from 5 individual patients, on freshly isolated platelet poor 
plasma and platelet poor plasma that had been frozen for 24hrs at -80
o
C.   Freeze thawing of 
platelet poor plasma gave no significant differences in absolute Annexin V positive MP number 
(n=5). 
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Figure 4-9: Reproducibility of MP enumeration  
 
 
 
 
 
 
 
 
 
Figure 4.9: Platelet poor plasma was obtained from one healthy individual.  3 plasma aliquots of 
different sizes (range 150-500µl) were frozen down and the MPs enumerated, based on 5 individual 
flow cytometric sample readings. There was no significant difference between the samples for total 
AnnexinV positive MP events.  
  
180 
 
4.4 Conclusions of methodological experiments 
What is apparent from this series of experiments is that detection of MPs is fraught with 
problems relating to the sensitivity of FC, as it involves using the machine at the limits 
of its detection. However, MP populations can be detected and phenotyped with careful 
and systematic optimisation of FC instrument settings.  
 
To determine whether the MP populations of interest could be detected by FC, MP 
controls from different parent populations as positive controls were generated. For all 
the cell surface markers used in this study MPs expressing them were able to be 
generated in vitro (staining profiles are in Appendix 4), thus if they were present in 
patients, then their expression should be detectable.  However, the MPs thus generated 
may not be representative of pathophysiological conditions and thus may not be entirely 
representative results of the MPs found within the peripheral blood in health and 
disease.  While this is a point for consideration it does not detract from the validity of 
the FC work as FC is the only technique with which a multiparametric approach can be 
taken to enumerate subtypes of MPs and has been used widely in different states of 
health and disease.  
 
For the purposes of this thesis MP samples were run twice, once using an FL1 threshold 
to reduce background noise, (the data which is presented in the next section of chapter) 
and once using previously published instrument settings (Brogan et al., 2004a) so that 
they could be compared with previously published data from within our group (this data 
is not included within this thesis). 
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4.5 Evaluation of cellular MPs in vasculitis 
4.5.1 Patients and methods 
4.5.1.1 Patients 
40 children with primary systemic vasculitis were studied.  These patients were the 
same individuals described in Chapter 3, allowing MPs to be compared to CECs.  These 
included 17 males and 23 females of median age 11.1 years (range 1 -16.6 years). The 
vasculitis type (using the Chapel Hill Consensus Criteria) (Jennette et al., 1994) was 
polyarteritis nodosa (PAN) n=18, Wegener’s granulomatosis (WG) n=8, microscopic 
polyangiitis n= 1, Kawasaki’s disease = 5, Takayasu’s disease (TD) = 2, Beçhets 
disease  = 1 and unclassified vasculitis n=5. Disease activity was again assessed using a 
modified paediatric BVAS (Appendix 2).   20 healthy child controls (8 males, 12 
females, median age 8.5 years, range 1.5-15.8),  10 febrile controls (6 males, 4 females, 
median age 6.8 years, range 1.5-13.5) and 20 healthy adult controls were also recruited 
(2 males, 18 females, age range 24-40 years).  As with the vasculitis patients, the 
control individuals were the same as those studied in Chapter 3.   
 
4.5.1.2 Methods 
MPs were analysed as described above and in Chapter 2.5.3.  Depending on the volume 
of platelet poor plasma obtained samples were either analysed using the 22 tube FC plan 
or the 12 tube FC plan shown in Appendix 3.  As platelet and endothelial microparticles 
have particular relevance in the vasculitides, these were prioritised in the 12 tube plan.  
Other markers are less well defined in MP populations and thus these were analysed in a 
smaller cohort, where plasma sample size was not a limiting factor.  Adult healthy 
controls were only analysed on the 12 tube plan due to time constraints. 
182 
 
4.5.1.3 Statistics 
Median MP counts were compared between groups using the Kruskall Wallis test to 
check for overall differences.  Individual Mann Whitney U tests for non parametric data 
were performed to compare between specific groups.  The Wilcoxon signed rank test 
was performed to compare medians of paired samples.  Spearman Rank correlation 
coefficiants were performed to assess correlation between MPs and other markers of 
disease activity, including CECs.  In all data graphs patient classification was denoted 
using colour coding as indicated below: 
 
 
 
4.5.2 Results 
4.5.2.1 Total Annexin V positive MPs  
These data are presented in Figure 4.10a-c.  Kruskall Wallis testing indicated there was 
an overall significant difference between groups (p=0.005).  Total AnnexinV positive 
MPs were significantly higher in 30 patients with active vasculitis (median value 0.98 x 
10
6
 MPs/ml) compared to 20 healthy child controls (median value 0.65 x 10
6
 MPs/ml, 
p=0.03) and 20 healthy adult controls (median value 0.30 x 10
6
 MPs/ml, p<0.001), 
although there was no significant difference compared 10 febrile controls (median value 
0.70 x 10
6
 MPs/ml p=0.09).   There were no significant differences between 27 patients 
with inactive vasculitis (median value 0.65 x 10
6
 MPs/ml) and febrile controls or 
healthy child controls.  Healthy adults also had significantly lower MPs than children 
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with inactive vasculitis (p=0.007) and child controls (p=0.04) (Figure 4.10a).  When 
paired data between active and inactive vasculitis was excluded (the first observation 
made in individual patients was used in this analysis) there was no significant difference 
between 30 patients with active disease and 11 patients in remission (median value 0.86 
x 10
6
 MPs/ml, data not shown).  In 17 individual patients there was no significant 
difference between total MP number during active disease and remission (median time 
to remission 4.5 months) (Figure 4.10b). Of these 17 patients, 13 had frequent and 
detailed follow up for up to 18 months from pre-treatment at disease onset (10 patients, 
solid line) or from flares of their disease (3 patients, dotted line). At median followup of 
3 and 12 months AnV+ MPs were not significantly different from pretreatment levels 
(Figure 4.10c).   
 
4.5.2.2 MPs of endothelial origin 
These data are presented in Figures 4.11-4.14.  Kruskall Wallis testing indicated that 
there was an overall significant difference between groups for MPs expressing CD144 
(p=0.002).  No other endothelial marker showed overall significance, CD105 (p=0.1) E-
selectin (p=0.2), ICAM-1 (p=0.06) (Figure 4.11-4.14a).  Direct comparisons between 
individual patient and control groups will be presented below.   
 
CD144+ EMPs 
MPs expressing the constitutive marker CD144, were significantly higher in 30 patients 
with active vasculitis (median value 0.35 x 10
6 
MPs/ml) compared to 20 healthy child 
controls (median value 0.09 x 10
6 
MPs/ml, p=0.02) and 20 healthy adult controls 
(median value 0.04 x 10
6 
MPs/ml, p=0.007), but were not significantly different when 
compared with 10 febrile controls (median value 0.15 x 10
6 
MPs/ml).    
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Figure 4-10: Total AnV MPs  
 
  
Figure 4.10a: Kruskall Wallis testing indicated there was an overall significant difference between 
groups (p=0.005).  Total AnnexinV positive MPs were significantly higher in 30 patients with active 
vasculitis compared to healthy child controls (n=20, p=0.03) and healthy adult controls (n=20, 
p<0.001), there were no significant differences compared 10 febrile controls (p=0.09).   There were no 
significant differences between 27 patients with inactive vasculitis disease and febrile controls or healthy 
child controls.  Healthy adults also had significantly lower MPs than patients with inactive vasculitis 
(p=0.007) and child controls (p=0.04).  Figure 4.10b:In 17 individual patients paired analysis revealed 
there was no significant difference between total AnV+ MPs during active disease and  remission 
(median time to remission 4.5 months). Figure 4.10c: 13 individual patients were followed from disease 
onset (n=10, solid line) or flare (n=3, dotted line).  At median followup of 3 and 12 months from disease 
onset AnV+ MPs were not significantly different from pretreatment levels. Rx = treatment.  
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There were no significant differences in CD144+ MPs between 27 patients with inactive 
disease (median value 0.03 x 10
6 
MPs/ml) and these control groups (Figure 4.11a).  
When paired data between active and inactive vasculitis were excluded (the first 
observation made in each individual patient was used in this analysis) there was no 
significant difference between 30 patients with active disease and 11 patients in 
remission (median value 0.23 x 10
6
 MPs/ml, data not shown).  In 17 individual patients 
however, paired analysis revealed CD144 MPs were significantly higher during active 
disease compared to remission (p=0.001, median time to remission 4.5 months, Figure 
4.11b).  Of these 17 patients, 13 were followed up for up to 18 months from initiation of 
treatment at disease onset (10 patients, solid line) or from flare (3 patients, dotted line).  
At median followup of 3 and 12 months from disease onset there was no significant 
difference from pretreatment levels of CD144+ MPs (Figure 4.11c).  
 
CD105+ EMPs 
MPs expressing CD105 (endoglin), were not significantly different in the same 30 
patients with active disease (median value 0.11 x 10
6
MPs/ml) compared to 20 healthy 
child controls (median value 0.11 x 10
6
MPs/ml), 10 febrile child controls (median value 
0.13 x 10
6
MPs/ml or 20 adult controls (median value 0.03 x10
6
MPs/ml). However, MPs 
expressing CD105 were significantly higher in 27 patients with inactive disease (median 
value 0.22 x10
6
MPs/ml) compared to healthy child (p=0.038) and adult (p=0.028) 
controls (Figure 4.12a).  When paired data between active and inactive vasculitis were 
excluded (the first observation made in each individual patient was used in this analysis) 
there was no significant difference between 30 patients with active disease and 11 
patients in remission (median value 0.20 x 10
6
 MPs/ml, p=0.09, data not shown).   
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Figure 4-11: MPs of endothelial origin – CD144 
 
 
Figure 4.11a: Kruskall Wallis testing indicated there was an overall significant difference between 
groups (p=0.002).  CD144+ MPs were significantly higher in 30 patients with active disease compared 
to healthy child controls (n=20, p=0.02) and healthy adult controls (n=20, p=0.007), but not febrile 
controls (n=10).  Figure 4.11b:  In 17 individual patients, paired analysis revealed CD144 MPs were 
significantly higher during active disease compared to when patients were in remission (p=0.001, median 
time to remission 4.5months). Figure 4.11c: 13 individual patients were followed from disease onset 
(n=10, solid lines) or flare(n=3, dotted lines).  At median followup of 3 and 12 months from disease onset 
(n=10) CD144+ MPs were not significantly different from pretreatment levels. Rx = treatment.   
187 
 
Figure 4-12: MPs of endothelial origin CD105 
 
Figure 4.12a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.1). However when individual analysis was performed although CD105+ MPs were not 
significantly different between 30 patients with active vasculitis and control groups, they were 
significantly higher in 27 patients with inactive vasculitis compared to healthy child (n=20, p=0.04) and 
adult controls (n=20, p=0.03) although not febrile controls (n=10). Figure 4.12b:  In 17 individual 
patients, paired analysis revealed CD105+ MPs were not significantly different during active disease 
compared to when patients were in remission (p=0.3, median time to remission 4.5months). Figure 
4.12c: 13 individual patients were followed from disease onset (n=10, solid lines) or flare (n=3, dotted 
lines).  At median followup of 3 and 12 months from disease onset (n=10) CD105+ MPs were not 
significantly different from pretreatment levels. Rx = treatment.  
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In 17 individual patients paired analysis revealed no significant difference between 
active and inactive disease (p=0.3, median time to remission 4.5 months, Figure 4.12b).  
13 of these patients were followed up from initiation of treatment at disease onset 
(n=10, solid line) or from flare (n=3, dotted line). At median followup of 3 and 12 
months from disease onset (n=10) there was no significant difference from pretreatment 
levels of CD105+ MPs (Figure 4.12c).   
 
E-selectin+ EMPs 
MPs expressing the inducible activation marker E-selectin were significantly higher in 
30 patients with active disease (median value 0.075 x 10
6
MPs/ml) compared to 20 
healthy adult controls (p=0.015, median value 0.004 x 10
6
MPs/ml), although not child 
controls, febrile (median value 0.07 x 10
6
MPs/ml) or healthy (median value 0.04 x 
10
6
MPs/ml).  There were no significant differences between patients with inactive 
vasculitis and these control groups (Figure 4.13a). When paired data between active and 
inactive vasculitis was excluded (the first observation made in each individual patient 
was used in this analysis) there was no significant difference between 30 patients with 
active disease and 11 patients in remission  (median value 0.049 x 10
6
 MPs/ml, data not 
shown).  There was also no significant differences between active and inactive disease 
in 17 individual patients where paired samples were available for analysis (Figure 
4.13b).  13 of these 17 individuals were followed up for up to 18 months from disease 
onset and initiation of treatment (n=10, solid lines) or disease flare (n=3, dotted lines).  
At median followup of 3 and 12 months from disease onset (n=10) there was no 
significant difference from pretreatment levels of E-selectin+ MPs (Figure 4.13c).   
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Figure 4-13: MPs of endothelial origin – E-selectin 
 
 
 
Figure 4.13a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.1). However when individual analysis was performed E-selectin + MPs were significantly 
higher in 30 patients with active disease compared to 20 healthy adult controls (p=0.015), although not 
child controls, febrile or healthy. Figure 4.13b:  In 17 individual patients paired analysis revealed there 
was no significant differences between active and inactive disease (p=0.17, median time to remission 6 
months). Figure 4.13c: 13 individual patients were followed from disease onset (n=10, solid lines) or 
flare (n=3, dotted lines).  At median followup of 3 and 12 months from disease onset (n=10) E-selectin+ 
MPs were not significantly different from pretreatment levels. Rx = treatment.  
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ICAM-1+ EMPS 
There were no significant differences in MPs expressing the inducible activation marker 
ICAM-1 between 26 patients with active vasculitis (median value 0.05 x 10
6
 MPs/ml)  
compared to 20 healthy child controls (median value 0.02 x 10
6
 MPs/ml) or 3 febrile 
controls(median value 0.16 x 10
6
 MPs/ml) .  There were no significant differences 
between 18 patients with inactive vasculitis (median value 0.06 x 10
6
 MPs/ml)   and 
these controls groups either (Figure 4.14a).  When paired data between active and 
inactive vasculitis was excluded (the first observation made in each individual patient 
was used in this analysis) there was no significant difference between 26 patients with 
active disease and 4 patients in remission (median value 0.06 x 10
6
 MPs/ml).  Paired 
analysis in 14 individual patients showed no significant differences between and 
inactive disease (Figure 4.14b).  13 individuals were followed from pre-treatment at 
disease onset (n=10, solid lines) or diseaseflare (n=3, dotted lines).  At median followup 
of 3 and 12 months from disease onset (n=10) there was no significant difference from 
pretreatment levels of ICAM-1+ MPs (Figure 4.14c).   
 
 
4.5.2.3 MPs of platelet origin 
These data are presented in figures 4.15-16. Kruskall Wallis testing indicated that there 
were no overall significant differences between groups for MPs expressing CD42a 
(p=0.7) or P-selectin (p=0.4).  Direct comparisons between individual patient and 
control groups will be presented below. 
 
CD42a+ PMPs 
When individual analysis was performed between groups there were no significant 
differences  in  the number of CD42+ MPs between  30  patients  with  active  vasculitis   
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Figure 4-14: MPs of endothelial origin – ICAM-1 
 
 
Figure 4.14a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.06). When individual analysis was performed ICAM-1+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
no significant differences between inactive vasculits and these control groups.Figure 4.14b:  In 14 
individual patients paired analysis revealed there was no significant differences between active and 
inactive disease (p=0.3, median time to remission 6 months). Figure 4.14c: 13 individual patients were 
followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 
12 months from disease onset (n=10) ICAM-1+ MPs were not significantly different from pretreatment 
levels. Rx = treatment.  
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(median value 0.12 x 10
6
 MPs/ml) compared to 10 febrile controls (median value 0.04 x 
10
6
 MPs/ml), 20 healthy child controls (median value 0.16 x 10
6
 MPs/ml) or 20 healthy 
adult controls (median value 0.15 x 10
6
 MPs/ml).  There were no significant differences 
between patients with inactive vasculitis (median value 0.18 x 10
6
 MPs/ml) and these 
controls groups (Figure 4.15a).  When paired data between active and inactive vasculitis 
was excluded (the first observation made in each individual patient was used in this 
analysis) there was no significant difference between 30 patients with active disease and 
11 patients in remission (median value 0.26 x 10
6
 MPs/ml, data not shown).  Paired 
analysis in 17 individual patients showed no significant differences between and 
inactive disease (Figure 4.15b).  13 of these 17 individuals were followed up for up to 
18 months from disease onset and initiation of treatment (n=10, solid lines) or disease 
flare (n=3, dotted lines).  At median followup of 3 and 12 months from disease onset 
(n=10) there was no significant difference from pretreatment levels of CD42a+ MPs 
(Figure 4.15c).    
 
 
P-selectin+ PMPs 
There was also no significant differences for P-selectin+ MPs between 26 patients with 
active vasculitis (median value 0 x 10
6
 MPs/ml) compared to child controls (3 febrile, 
median value 0 x 10
6
 MPs/ml and 20 healthy median value 0 x 10
6
 MPs/ml).  There 
were no significant differences between 18 patients with inactive disease (median value 
0.1 x 10
6
 MPs/ml) and these control groups (Figure 4.16a). When paired data between 
active and inactive vasculitis was excluded (the first observation made in each 
individual patient was used in this analysis) there was no significant difference between 
26 patients with active disease and 4 patients in remission (median value 0.01 x 10
6
 
MPs/ml, data not shown).  Paired analysis in 14 individual patients indicated P-selectin+   
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Figure 4-15: MPs of platelet origin – CD42a 
 
Figure 4.15a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.06). When individual analysis was performed ICAM-1+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
no significant differences between inactive vasculitis and these control groups.Figure 4.15b:  In 14 
individual patients paired analysis revealed there was no significant differences between active and 
inactive disease (p=0.3, median time to remission 6 months). Figure 4.15c: 13 individual patients were 
followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 
12 months from disease onset (n=10) CD42a+ MPs were not significantly different from pretreatment 
levels. Rx = treatment.  
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PMPs were signficiantly higher during remission than during active disease (p=0.01, 
Figure 4.16b).  13 of these 17 individuals were followed up for up to 18 months from 
disease onset and initiation of treatment (n=10, solid lines) or disease flare (n=3, dotted 
lines).  At median followup of 3 and 12 months from disease onset (n=10) there was no 
significant difference from pretreatment levels of P-selectin+ MPs (Figure 4.15c). 
 
4.5.2.4 MPs of leukocyte origins 
These data are presented in Figures 4.17-4.23.  Kruskall Wallis testing indicated that 
there was no overall significant differences between groups for MPs expressing the 
neutrophil markers CD15 (p=0.3), CD11b (p=0.2), L-selectin (p=0.4), or CD66b 
(p=0.8), the monocyte markers TF (p=0.2) and CD14 (p=0.2) or the T cell marker CD3 
(p=0.1).  Comparison between individual patient and control groups are presented 
below.   
 
CD15+ NMPs 
When individual analysis between specific groups was performed CD15+ MPs were not 
significantly different between 26 patients with active vasculitis (median value 0.025 x 
10
6
 MPs/ml) and child controls (3 febrile, median value 0.03 x 10
6
 MPs/ml and 20 
healthy, median value 0.04 x 10
6
 MPs/ml).  There was no significant difference between 
18 patients with inactive vasculitis (median value 0.02 x 10
6
 MPs/ml) and these control 
groups (Figure 4.17a).  When paired data between active and inactive vasculitis was 
excluded (the first observation made in each individual patient was used in this analysis) 
there was no significant difference between 26 patients with active disease and 4 
patients in remission (median value 0.045 x 10
6
 MPs/ml, data not shown). Paired 
analysis in 14 individuals showed no significant difference between active and inactive  
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Figure 4-16 MPs of platelet origin – P-selectin 
 
 
 
 Figure 4.16a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.06). When individual analysis was performed P-selectin+ MPs were not significantly 
different between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  
There were no significant differences between inactive vasculits and these control groups.Figure 4.16b:  
In 14 individual patients paired analysis revealed P-selectin+ MPs were significantly higher during 
remission than active disease (p=0.01, median time to remission 6 months). Figure 4.16c:  13 individual 
patients were followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines).  At median 
followup of 3 and 12 months from disease onset (n=10) P-selectin+ MPs were not significantly different 
from pretreatment levels. Rx = treatment.  
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Figure 4-17: MPs of neutrophil origin – CD15 
 
Figure 4.17a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.3). When individual analysis was performed CD15+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also no significant differences between inactive vasculits and these control groups (AAV patients – red 
dots). Figure 4.17b:  In 14 individual patients paired analysis revealed there was no significant 
differences between active and inactive disease, subgroup analysis of 7 patients with AAV (red lines) also 
showed no significant difference Figure 4.17c:: 13 individual patients were followed from disease onset 
(n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 12 months from disease 
onset (n=10) CD15+ MPs were not significantly different from pretreatment levels, analysis of 4 patient 
with AAV(red lines) also demonstrated no significant difference at these timepoints. Rx = treatment. 
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disease  (Figure 4.17b).   Subgroup  paired  analysis  of  7  individuals  with  AAV  also 
disease  (Figure 4.17b).   Subgroup  paired  analysis  of  7  individuals  with  AAV  also 
indicated no significant difference between active and inactive disease.  13 of these 17 
individuals were followed up for up to 18 months from disease onset and initiation of 
treatment (n=10, solid lines) or disease flare (n=3, dotted lines).  At median followup of 
3 and 12 months from disease onset (n=10) there was no significant difference from 
pretreatment levels of CD15+ MPs (Figure 4.15c), there was also no differences 
observed in the AAV subgroup (Figure 4.17c, AAV – red lines, n=4). 
 
CD11b+ NMPs 
CD11b+ MPs were not significantly different between 26 patients with active vasculitis 
(median value 0.27 x 10
6
 MPs/ml) and child controls (3 febrile, median value 0.37 x 10
6
 
MPs/ml and 20 healthy, median value 0.18 x 10
6
 MPs/ml).  There was no significant 
difference between 18 patients with inactive vasculitis (median value 0.15 x 10
6
 
MPs/ml) and these control groups (Figure 4.18a).  When paired data between active and 
inactive vasculitis was excluded (the first observation made in each individual patient 
was used in this analysis) there was no significant difference between 26 patients with 
active disease and 4 patients in remission (median value 0.26 x 10
6
 MPs/ml, data not 
shown). Paired analysis in 14 individuals showed no significant difference between 
active and inactive disease (Figure 4.18b).  Subgroup paired analysis of 7 individuals 
with AAV also indicated no significant difference between active and inactive disease.    
13 of these 17 individuals were followed up for up to 18 months from disease onset and 
initiation of treatment (n=10, solid lines) or disease flare (n=3, dotted lines).  At median 
followup of 3 and 12 months from disease onset (n=10) there was no significant 
difference from pretreatment levels of CD11b+ MPs (Figure 4.15c), there was also no 
differences observed in the AAV subgroup (Figure 4.18c, AAV – red lines, n=4). 
198 
 
Figure 4-18: MPs of neutrophil origin – CD11b 
 
Figure 4.18a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.2). When individual analysis was performed CD11b+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also no significant differences between inactive vasculitis and these control groups (AAV patients – red 
dots).. Figure 4.18b:  In 14 individual patients paired analysis revealed there was no significant 
differences between active and inactive disease, subgroup analysis of 7 patients with AAV (red lines) also 
showed no significant difference Figure 4.18c: : 13 individual patients were followed from disease onset 
(n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 12 months from disease 
onset (n=10) CD11b+ MPs were not significantly different from pretreatment levels subgroup analysis of 
4 patients with AAV (red lines) also demonstrated no significant difference at these timepoints.. Rx = 
treatment.  
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L-selectin+ NMPs 
L-selectin+ MPs were not significantly different between 26 patients with active 
vasculitis (median value 0.05 x 10
6
 MPs/ml) and child controls (3 febrile, median value 
0.08 x 10
6
 MPs/ml and 20 healthy, median value 0.02 x 10
6
 MPs/ml).  There was no 
significant difference between 18 patients with inactive vasculitis (median value 0.025 x 
10
6
 MPs/ml) and these control groups (Figure 4.19a).  When paired data between active 
and inactive vasculitis was excluded (the first observation made in each individual 
patient was used in this analysis) there was no significant difference between 26 patients 
with active disease and 4 patients in remission (median value 0.035 x 10
6
 MPs/ml, data 
not shown). Paired analysis in 14 individuals showed no significant difference between 
active and inactive disease (Figure 4.19b).  Subgroup paired analysis of 7 individuals 
with AAV also indicated no significant difference between active and inactive disease.    
13 of these 17 individuals were followed up for up to 18 months from disease onset and 
initiation of treatment (n=10, solid lines) or disease flare (n=3, dotted lines).  At median 
followup of 3 and 12 months from disease onset (n=10) there was no significant 
difference from pretreatment levels of L-selectin+ MPs (Figure 4.19c), there was also 
no differences observed in the AAV subgroup (Figure 4.19c, AAV – red lines, n=4). 
 
CD66b+ NMPs 
CD66b+ MPs were not significantly different between 26 patients with active vasculitis 
(median value 0.005 x 106 MPs/ml) and child controls (3 febrile, median value 0 x 106 
MPs/ml and 20 healthy, median value 0 x 106 MPs/ml).  There was no significant 
difference between 18 patients with inactive vasculitis (median value 0 x 106 MPs/ml) 
and these control groups (Figure 4.20a).  When paired data between active and inactive 
vasculitis was excluded (the first observation made in each individual patient was used 
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Figure 4-19: MPs of neutrophil origin – L-selectin 
 
Figure 4.19a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.4). When individual analysis was performed L-selectin+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also no significant differences between inactive vasculits and these control groups (AAV patients – red 
dots).. Figure 4.19b:  In 14 individual patients paired analysis revealed there was no significant 
differences between active and inactive disease, subgroup analysis of 7 patients with AAV also showed no 
significant difference (red lines). Figure 4.19c: 13 individual patients were followed from disease onset 
(n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 12 months from disease 
onset (n=10) L-selectin+ MPs were not significantly different from pretreatment levels, subgroup 
analysis of 4 patient with AAV (red lines) also demonstrated no significant difference at these timepoints.. 
Rx = treatment.  
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in this analysis) there was no significant difference between 26 patients with active 
disease and 4 patients in remission (median value 0.005 x 106 MPs/ml, data not shown). 
Paired analysis in 14 individuals showed no significant difference between active and 
inactive disease (Figure 4.20b).  Subgroup paired analysis of 7 individuals with AAV 
also indicated no significant difference between active and inactive disease (although 
6/7 patients did have higher CD66b+ MPs during active disease).  
 
13 of these 17 individuals were followed up for up to 18 months from disease onset and 
initiation of treatment (n=10, solid lines) or disease flare (n=3, dotted lines).  At median 
followup of 3 and 12 months from disease onset (n=10) there was no significant 
difference from pretreatment levels of L-selectin+ MPs (Figure 4.19c), there was also 
no differences observed in the AAV subgroup (Figure 4.19c, AAV – red lines, n=4).   
When 10 individuals were followed from disease onset, there were no significant 
differences from pre-treatment to median followup of 3 and 12 months, there was also 
no differences observed in the AAV subgroup (Figure 4.20c, AAV – red lines, n=4). 
 
TF+ MMPS 
TF+ MPs were only observed in a small number of individuals (2 patients with active 
vasculitis, 5 in remission, 1 febrile control and 3 healthy controls).  Hence no significant 
differences were observed between 26 patients with active vasculitis, or 18 patients with 
inactive disease and child controls (3 febrile, 20 healthy, median value for all groups 0 x 
10
6
 MPs/ml, Figure 4.21a).  Paired analysis in 14 individuals showed no significant 
differences between active and inactive disease (Figure 4.21b) and when 13 individuals 
were followed from disease onset prior to treatment (n=10, solid lines) or disease flare 
(n=3, dotted lines), only 4 individuals had any detectable TF+ MPs (Figure 4.21c).   
202 
 
Figure 4-20:MPs of neutrophil origin – CD66b 
 
 
Figure 4.20a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.8). When individual analysis was performed CD66b+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also no significant differences between inactive vasculits and these control groups (AAV- red dots). 
Figure 4.20b:  In 14 individual patients paired analysis revealed there was no significant differences 
between active and inactive disease, subgroup analysis of 7 patients AAV (red lines) also showed no 
significant difference (although 6/7 patients had a increased CD66b+ MPs during active disease) Figure 
4.20c: : 13 individual patients were followed from disease onset (n=10, solid lines) or flare (n=3, dotted 
lines).  At median followup of 3 and 12 months from disease onset (n=10) CD66b+ MPs were not 
significantly different from pretreatment levels, subgroup analysis of 4 patients with AAV also revealed 
no differences at these timepoints. Rx = treatment.  
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Figure 4-21: MPs of monocyte origin – TF 
 
 
Figure 4.21a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.2). When individual analysis was performed TF+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also no significant differences between inactive vasculits and these control groups.  The majority fo 
individuals had no detectable TF+ MPs. Figure 4.21b:  In 14 individual patients paired analysis 
revealed there was no significant differences between active and inactive disease Figure 4.21c: 13 
individual patients were followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines).  TF+ 
MPs were only detected in 4 individuals. Rx = treatment.  
CD14+ MMPs 
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MPs expressing CD14, were significantly higher in 30 patients with active vasculitis 
(median value 0.51 x 10
6 
MPs/ml) compared to 20 healthy child controls (median value 
0.24 x 10
6 
MPs/ml, p=0.037) or 20 healthy adult controls (median value 0.17 x 10
6 
MPs/ml, p=0.02), although not 10 febrile controls (median value 0.25 x 10
6 
MPs/ml).  
There were no significant differences in CD14+ MPs between 27 patients with inactive 
disease (median value 0.23 x 10
6 
MPs/ml) and these control groups (Figure 4.22a).  
When paired data between active and inactive vasculitis were excluded (the first 
observation made in each individual patient was used in this analysis) there was no 
significant difference between 30 patients with active disease and 10 patients in 
remission (median value 0.23 x 10
6
 MPs/ml, data not shown).   
 
In 17 individual patients paired analysis also revealed no significant difference between 
active vasculitis and remission (Figure 4.22b)  Of these 17 patients, 13 were followed 
up for up to 18 months, from disease onset (n=10, solid lines) or disease flare (n=3, 
dotted lines) at median followup of 3 and 12 months from disease onset, there was no 
signficant difference from pretreatment levels of CD14+ MPs (Figure 4.22c).    
 
CD3+ LMPs 
CD3+ MPs were only observed in a small number of individuals (3 patients in 
remission and 1 healthy child controls), hence no significant differences were observed 
between 26 patients with active vasculitis, or 18 patients with inactive disease and child 
controls (3 febrile, 20 healthy, median value for all groups 0 x 10
6
 MPs/ml, Figure 
4.23a).  Paired analysis, demonstrated only 2/14 individuals had any change in their 
CD3+ MPs  (Figure 4.23b)  and when 13 individuals were followed from disease onset  
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Figure 4-22: MPs of monocyte origin – CD14 
 
Figure 4.22a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.2). However when individual analysis was performed CD14+ MPs were significantly higher 
in 30 patients with active disease compared to 20 healthy child controls (p=0.038) or 20 adult controls 
(p=0.02), although not 3 febrile controls.  There no significant differences between inactive vasculits and 
these control groups.  Figure 4.22b:  In 14 individual patients paired analysis revealed there was no 
significant differences between active and inactive disease. Figure 4.22c: 13 individual patients were 
followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines).  At median followup of 3 and 
12 months from disease onset (n=10) CD14a+ MPs were not significantly different from pretreatment 
levels. Rx = treatment.  
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Figure 4-23: MPs of lymphocyte origin – CD3 
 
Figure 4.23a: Kruskall Wallis testing indicated that there was no overall significant difference between 
groups (p=0.1). When individual analysis was performed CD3+ MPs were not significantly different 
between 26 patients with active disease and 20 healthy child controls or 3 febrile controls.  There were 
also no significant differences between inactive vasculits and these control groups.  The majority of 
individuals had no detectable CD3+ MPs. Figure 4.23b:  In 14 individual patients paired analysis 
revealed there was no significant differences between active and inactive disease Figure 4.21c: 13 
individual patients were followed from disease onset (n=10, solid lines) or flare (n=3, dotted lines). 
CD3+ MPs were only detected in 4 individuals. Rx = treatment.  
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 (n=10, solid lines) or flare (n=3, dotted lines), only 4 individuals had any detectable 
CD3+ MPs (Figure 4.23c).   
 
4.5.3 Correlation between MPs and disease activity 
Spearman Rank correlation coefficiant analysis was performed between all the 
phenotypes of MPs assessed and BVAS, CRP, ESR, CEC, white cell count, neutrophil 
count, platelet count and serum albumin levels, Table 4.1 summarises the results – 
significant correlations are highlighted in blue.   Table 4.2 shows the corrected P-values 
obtained from a post-hoc Holm-Bonferroni correction.  The significant correlations 
observed on individual tests did not withstand the rigours of multiple comparison 
correction and thus no significant correlations were observed between different MP 
phenotypes and other markers of disease activity.     
 
When 16 patients were followed up in detail over time from first initiation of treatment 
a number had periods of disease flare.  While different populations of MPs may not be 
significantly different from healthy controls they did change over time in individual 
patients.  Figures 4.24 - 4.26 highlights some of the changes seen in MP populations 
over time from disease onset and initiation of treatment in the same 3 patients that were 
described earlier in this thesis in the context of CECs. In the two patients who flared 
(Figure 4.24 – systemic flare and figure 4.25, localized granulomatous flare) E-selectin+ 
MPs rose before the flare and prior to CD144 becoming elevated.  In the same patients, 
CD14 MPs also rose prior to flare and were followed by CD15, suggesting that different 
MPs may reflect different stages of disease activity and underlying pathology.  In the 
patient who did not have a flare, but a UTI, there was no rise in EMPs or NMPs and 
MMPS.  These data are very preliminary but warrants further study in a large cohort of 
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patients.  Further examples of changes in MPs and CECs in individual patients are given 
in Appendix 6. 
 
Table 4-1: Spearman Rank correlation coefficiant analysis between different 
MP phenotypes and other markers of disease activity 
 
 
MP  
population 
BVAS ESR CRP WCC 
Neutrophil 
count 
Platelet 
count 
Albumin 
CEC 
count 
Total AnV 
MP 
r = -0.015 
p = 0.89 
n = 88 
r = -0.072 
p = 0.52 
n = 83 
r = 0.005 
p = 0.97 
n = 88 
r = 0.065 
p = 0.56 
n = 85 
r = 0.065 
p = 0.56 
n = 85 
r = 0.145 
p = 0.19 
n = 82 
r = -0.003 
p = 0.98 
n = 82 
r = 0.081 
p = 0.43 
n = 81 
CD144 r = 0.038 
p = 0.73 
n = 88 
r = -0.001 
p = 0.99 
n = 83 
r = 0.040 
p = 0.71 
n = 86 
r = 0.084 
p = 0.44 
n = 85 
r = -0.006 
p = 0.96 
n = 85 
r = 0.155 
p = 0.17 
n = 82 
r = -0.011 
p = 0.92 
n = 81 
r = 0.232 
p = 0.037 
n = 81 
CD105 r = -0.011 
p = 0.3 
n = 88 
r = -0.21 
p = 0.055 
n = 83 
r =- 0.132 
p = 0.23 
n = 86 
r = -0.111 
p = 0.31 
n = 85 
r = -0.092 
p = 0.40 
n = 85 
r =- 0.026 
p = 0.82 
n = 82 
r = 0.001 
p = 0.99 
n = 81 
r = 0.006 
p = 0.96 
n = 81 
E-selectin r = 0.121 
p = 0.26 
n = 88 
r = 0.070 
p = 0.53 
n = 83 
r = 0.02 
p = 0.84 
n = 86 
r = -0.001 
p = 0.99 
n = 85 
r = -0.009 
p = 0.94 
n = 85 
r = 0.155 
p = 0.17 
n = 82 
r = -0.051 
p = 0.65 
n = 81 
r = 0.092 
p = 0.41 
n = 81 
ICAM-1 r = -0.138 
p = 0.24 
n = 75 
r = 0.044 
p = 0.72 
n =  72 
r = 0.072 
p = 0.54 
n = 73 
r = 0.077 
p = 0.52 
n = 73 
r = 0.002 
p = 0.99 
n = 73 
r = 0.122 
p = 0.31 
n = 70 
r = -0.060 
p = 0.63 
n = 69 
r = -0.141 
p = 0.25 
n = 68 
CD42a r = -0.235 
p = 0.029 
n = 87 
r = -0.284 
p = 0.010 
n = 82 
r = -0.245 
p = 0.024 
n = 85 
r = -0.087 
p = 0.43 
n = 86 
r = -0.158 
p = 0.15 
n = 84 
r = 0.072 
p = 0.52 
n = 81 
r = 0.108 
p = 0.34 
n = 80 
r = -0.094 
p = 0.41 
n = 80 
P-selectin r = -0.136 
p = 0.25 
n = 75 
r = -0.063 
p = 0.60 
n =  72 
r = -0.082 
p = 0.50 
n = 73 
r = -0.29 
p = 0.013 
n = 73 
r = -0.25 
p = 0.033 
n = 73 
r = -0.030 
p = 0.81 
n = 70 
r = 0.181 
p = 0.63 
n = 69 
r = 0.028 
p = 0.82 
n = 68 
CD15 r = 0.073 
p = 0.53 
n = 75 
r = 0.061 
p = 0.61 
n =  72 
r = 0.048 
p = 0.69 
n = 73 
r=-0.217 
p = 0.07 
n = 73 
r = -0.110 
p = 0.354 
n = 73 
r = 0.008 
p = 0.94 
n = 70 
r = -0.075 
p = 0.54 
n = 69 
r = 0.010 
p = 0.93 
n = 68 
CD11b r = 0.071 
p = 0.54 
n = 75 
r = 0.145 
p = 0.22 
n =  72 
r = 0.176 
p = 0.14 
n = 73 
r= 0.097 
p = 0.42 
n = 73 
r = -0.004 
p = 0.98 
n = 73 
r = -0.026 
p = 0.83 
n = 70 
r = -0.150 
p = 0.22 
n = 69 
r = -0.044 
p = 0.72 
n = 68 
L-selectin r = 0.078 
p = 0.51 
n = 75 
r = -0.040 
p = 0.74 
n =  72 
r = 0.016 
p = 0.89 
n = 73 
r= 0.148 
p = 0.21 
n = 73 
r = 0.019 
p = 0.88 
n = 73 
r = -0.038 
p = 0.76 
n = 70 
r = -0.174 
p = 0.15 
n = 69 
r = 0.058 
p = 0.63 
n = 68 
CD66b r = 0.157 
p = 0.18 
n = 75 
r = 0.094 
p = 0.43 
n =  72 
r = 0.077 
p = 0.52 
n = 73 
r = 0.233 
p = 0.047 
n = 73 
r = 0.262 
p = 0.025 
n = 73 
r = -0.042 
p = 0.73 
n = 70 
r = -0.212 
p = 0.081 
n = 69 
r = 0.087 
p = 0.48 
n = 68 
TF r = 0.057 
p = 0.63 
n = 75 
r = -0.023 
p = 0.84 
n =  72 
r = -0.082 
p = 0.49 
n = 73 
r = -0.341 
p = 0.003 
n = 73 
r = -0.247 
p = 0.035 
n = 73 
r = 0.116 
p = 0.34 
n = 70 
r = 0.042 
p = 0.73 
n = 69 
r = 0.031 
p = 0.80 
n = 68 
CD14 r = -0.003 
p = 0.98 
n = 88 
r = -0.166 
p = 0.13 
n = 83 
r =- 0.096 
p = 0.38 
n = 86 
r = 0.005 
p = 0.96 
n = 85 
r = -0.049 
p = 0.66 
n = 85 
r = 0.161 
p = 0.15 
n = 82 
r = 0.076 
p = 0.50 
n = 81 
r = 0.111 
p = 0.33 
n = 81 
CD3 r = -0.166 
p = 0.16 
n = 75 
r = -0.150 
p = 0.21 
n =  72 
r = -0.049 
p = 0.68 
n = 73 
r = -0.114 
p = 0.34 
n = 73 
r = -0.182 
p = 0.12 
n = 73 
r = -0.061 
p = 0.62 
n = 70 
r = 0.106 
p = 0.39 
n = 69 
r = -0.241 
p = 0.048 
n = 68 
Significant correlations are highlighted in blue 
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Table 4-2: Holm-Bonferroni correction for multiple comparisons 
 
Significant test  P value Adjusted critical value (Holm-
Bonferroni) 
TF vs WCC 0.003 0.0004464 
CD42a vs ESR 0.01 0.0004505 
P-selectin vs WCC 0.013 0.0004545 
CD42a vs CRP 0.024 0.0004587 
CD66b vs neutrophil count 0.025 0.000463 
CD42a vs BVAS 0.029 0.0004673 
P-selectin vs neutrophil count 0.033 0.0004717 
TF vs neutrophil count 0.035 0.0004762 
CD144 vs CECs 0.037 0.0004808 
CD66b vs WCC 0.047 0.0004854 
CD3 vs WCC 0.048 0.0004902 
 
 
 
4.5.4 MPs in different vasculitic syndromes 
When the vasculitis cohort was classified into the different, there were no obvious 
differences in expression of the different MP populations in active or inactive disease 
between diseases as had been for CECs.  However, Figure 4.27 demonstrates the 
expression of EMPs (CD144+, CD105+, E-selectin+, ICAM-1+) during active disease.  
Interestingly, whereas CECs were all low in patients with KD (Figure 3.22), their EMPs 
were high.   
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Figure 4-24: Patient with WG - MPs and disease activity – predictive of 
flare?  
 
 
 
 
 
Figure 4.24a indicates the changes in BVAS anc CEC number over time from intitiation of treatment at 
disease onset in a 12 year old female with WG (ANCA+). Figure 4.24b indicates the changes in 
endothelial MPs (CD144+ and E-selectin+).  Figure 2.24c indicates changes in monocytes and 
neutrophil MPS (CD14+ and CD15+ respectively).  Notably in this individual, E-selectin+ MPs mirrored 
changes in CECs, whilst CD144+ MPs remained high despite clinical remission. 
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Figure 4-25:  Patient with WG - MPs and disease activity – localised flare 
 
 
 
Figure 4.25a indicates the changes in BVAS and CEC number over time from intitiation of treatment at 
disease onset in an 11 year old female with WG (ANCA+) who suffered a granulomatous orbital flare. 
Figure 4.25b indicates the changes in endothelial MPs (CD144+ and E-selectin+).  Figure 2.25c 
indicates changes in monocytes and neutrophil MPS (CD14+ and CD15+ respectively).  Notably in this 
individual, E-selectin+ MPs, CD14+ MPs and CD15+ MPs rose prior to the clinical flare, whilst 
CD144MPs and CEC rose at the time of clinical detection of flare.  
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Figure 4-26:   Patient with PAN – MPs and disease activity 
 
 
 
Figure 4.26a indicates the changes in BVAS and CEC number over time from intitiation of treatment at 
disease onset in an 12 year old female with PAN.  Figure 4.26b indicates the changes in endothelial MPs 
(CD144+ and E-selectin+).  Figure 2.25c indicates changes in monocytes and neutrophil MPS (CD14+ 
and CD15+ respectively).  Notably in this individual, while CD14+ and CD15+ were elevated prior to 
treatment and fell with treatment, CD144+ and E-selectin MPs rose after initiation of treatment, after 
this CD144+ closely tracked changes in CECs.  There was no elevation in any MP during the patients 
UTI. 
 
 
213 
 
Figure 4-27: EMPs in different vasculitis syndromes 
 
 
 
 
Figure 4.27a-d: When the patient cohort was divided into the different disease classifications,  although 
very preliminary, patients with KD had higher EMPs than other diseases.  This is in striking contrast to 
their CECs (Chapter 3). 
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4.6 Discussion  
Endothelial (CD144+) and monocyte derived microparticles (CD14+) are elevated at 
times of active vasculitic disease activity as assessed by BVAS score.  Although 
significant differences in a number of other MP populations between health and disease 
were not observed, preliminary data in individual patients demonstrated that different 
biomarkers altered with changes in disease activity. 
 
The finding that EMPs are elevated during active vasculitis is comparable to the other 
studies, performed in vasculitis which examined EMPs (Brogan et al., 
2004a,Erdbruegger et al., 2008).  However, these studies did not use CD144 as 
endothelial marker and the data presented herein did not reproduce these groups 
findings that CD105+ and E-selectin+ MPs were significantly elevated during active 
vasculitis.  Differences in methodology relating to the use of an FL1 threshold in this 
study to enhance sensitivity could account for this, as well as differences in patient 
populations.  Erdbruegger et al examined adults with AAV, whereas Brogan et al 
examined 29 children with active PSV, 15 of which had KD.  As can be seen in the 
preliminary data presented in Figure 4.27, in this study KD patients appeared to have 
higher EMPs (of all phenotypes) than other vasculitic syndromes which could have 
skewed this previous result.  
 
Both CD105 (endoglin) and CD144 are considered to be constitutive endothelial 
markers and it is interesting that they gave completely different results with peaks at 
different time points in some individual patients (appendix 6).  As discussed in the 
introduction to this chapter, these markers have very different roles, CD144 forms part 
of the intercellular EC-EC contact complex and thus its expression would require 
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significant cellular disruption to release it.  This could explain why this showed 
correlation with CEC levels (although this did not withstand the more stringent post-hoc 
testing for multiple comparisons).  CD105 is upregulated on proliferating/angiogenic 
cells and thus may be indicative of a more reparative phase of the disease rather than an 
activatory phase.  The finding that E-selectin+ and ICAM-1+ EMPs were not elevated 
in active disease is perhaps not surprising when the transient nature of their expression 
on activated endothelial cells is considered.   
 
Another possibility for the differences in EMPs between this and previous studies 
relates to the observation that of the patients studied there were a number with active 
vasculitis prior to treatment that had very low levels of endothelial derived MPs 
(examples are shown in Figures 4.25-26, and can also be observed in the longitudinal 
studies in Figure 4.11-14).  It may be that EMPs are sequestered out of the plasma by 
binding to activated endothelium, platelets and/or cells of the blood.  This situation has 
been observed in other diseases associated with severe endothelial injury including 
multiple organ dysfunction associated with sepsis (Joop et al., 2001).  Thus when 
patients are on treatment and the underlying inflammation is suppressed, MPs may be 
observed in greater numbers and perhaps could provide insightful information regarding 
the risk of relapse prior to overt clinical disease flare.  Although numbers are very 
preliminary, increases in E-selectin+ MPs occurred prior to and during flares in a small 
number of patients (Figure 4.25, and Appendix 6 patients 4, 8 and 12), whilst CD144+ 
MPs were elevated during active disease.  In some individuals EMPs were higher 
during disease flare than at onset (Figure 4.26, Appendix 6 patients 2,5,8,10 and 13).  
CD14+ and CD15+ MPs were also elevated during disease flare in individual patients 
(Figure 4.25-26, Appendix 6 patients 1,5,8,9,12 and 13)   
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The study by Daniel et al examined CD66b+ neutrophil MPs and CD41a+ platelet MPs 
in adults with AAV (WG, MPA, CSS) (Daniel et al., 2006).  Significant differences 
between healthy children and patients with active vasculitis for any of the NMPs or 
PMPs studied herein were not observed in this study, however there are number of 
differences between this study and the one performed by Daniel et al.   Primarily Daniel 
et al did not discriminate MPs based on phosphatidylserine (PS) expression using AnV 
and so may have included MPs that were excluded herein.  Also the clinical criteria for 
active vasculitis used by Daniel et al was patients prior to cytotoxic treatment with 
BVAS >7.5 - so adults with highly active systemic disease. Unfortunately the rarity of 
the vasculitides in children makes this exclusion criteria inappropriate for this cohort.  
In contrast to the data from Daniel et al, prior to correction for multiple comparisons 
PMPs in this study actually correlated negatively with disease activity, which if is a true 
finding rather than a false error could indicate that PMPs are sequestered from the 
plasma during active disease. 
 
MPs which were observed in very low levels in all cohorts included CD3, however 
other studies had not examined this T cell marker in patients before and it may be that 
this is not expressed on T-cell derived MPs. This finding is supported by an in vitro 
study (Fritzsching et al., 2002) where low levels of CD4 and CD3 were found in MPs 
derived from isolated T cells.  It may be that the MPs produced from activated T cells 
lack PS on their surface and are in the AnV negative fraction of MPs, which were not 
analysed in this study.  In this context another marker that was found in low levels was 
TF, no other study has examined this in vasculitis, however the presence of TF positive 
MPs are associated conditions which are often associated with vascular damage (Morel 
et al., 2006), so this is somewhat surprising, however the antibody was titrated with care 
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and worked well on activated parent cells so it may be a genuine finding within the 
parameters of the cohort analysed. 
 
Another factor which needs to be considered is that these parameters were being tested 
simultanously in the patient populations and therefore there is a risk of identifying false 
positives.  While correcting for multiple comparisons may prevent the investigator 
falsely finding significant results it is equally important that the investigator does not 
discredit true findings by over conservative correction of the data.  While the Holm 
Bonferroni is a less conservative variation of the Bonferroni test, it is not without its 
limitations and there are varying opinions on the validity of making such corrections.  
While some statisticians believe that a correction for multiple comparisons must be 
followed rigidly, others believe careful interpretation of the data is more crucial to 
understanding which results are likely to be true positives.  Especially when there are 
only small numbers in each test group.   In the case of the elevation of CD144+ EMPs 
in this patient population and correlation with other markers of disease activity,  as other 
studies performed have indicated elevation of EMPs in patients with vasculitis it is 
likely that this is a true result and not a false positive. 
 
What is apparent from this study of MPs is that in order to understand the role of 
different MP phenotypes in the context of vasculitis, their assessment at several 
timepoints over the disease course in order to examine the subtle changes may provide 
greater information relating to disease activity rather than large cross-sectional studies 
comparing groups of patients either in remission or with active disease. 
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As with all methods there are technical pitfalls and scope for further optimization.  One 
major confounder relating to FC for detection of MPs is that it is unlikely that the whole 
MP population is observed.  As MPs range in size from 0.1-2µm in diameter (Piccin et 
al., 2007) it is likely that the smaller MPs are beyond the limits of detection of FC.  
While ultimately it may not be as important in conditions where large elevations of MPs 
are observed, it may give an inaccurate representation of their phenotype and a skewed 
population profile.  For example some cells may have a tendency to produce smaller 
MPs and therefore where a population is not observed by FC, it doesn’t necessarily 
mean it was not present (e.g. CD3 MPs).   
 
If it were not for the time constraints of a PhD study, other methodologies could have 
been employed including pull down ELISA.  However only one parameter could be 
measured using this approach per well on the ELISA plate and thus would not be as 
simple to generate multi-parametric data.  ELISA plates are coated with Annexin V 
which MPs from platelet poor plasma samples bind to.  A secondary antibody to a cell 
surface marker associated with the MP of interest can then be used to enumerate the 
MPs in the sample (Jy et al., 2004a).  However, as the data presented herein indicates, 
MPs can express a wide varety of cell surface markers and thus choosing a single 
marker to base the assay around would not be as informative as the multiparamet 
approach that FC offers.   ELISA can however be used in a more functional capacity to 
investigate the behavior of MPs and in fact there are now commercially available kits to 
examine the prothrombotic potential of MPs (e.g. ZYMUPHEN MP-activity kit, 
Aniara). 
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While the current protocol described had been used previously within the group there is 
still much controversy regarding the centrifugation protocols used for MP enumeration 
within the literature and as yet no consensus has been reached (Enjeti et al., 2007).   
Some groups centrifuge at a lower speed but for longer to generate platelet poor plasma.  
Some do not pellet the MPs at all.  Feasibly all the spinning protocols particularly those 
associated with genreation of MP pellets could result in damage and loss of fragile MPs.  
Thus a protocol which involves a minimal amount of centrifugation and handling would 
be preferable.  Currently the widespread use of Annexin V for detection of PS on the 
surface and its’ reliance on Ca2+ for binding necessitates the high speed pelleting spin to 
remove anticoagulated plasma with low Ca
2+
 content.  However use of alternative stains 
for PS, such as monoclonal antibodies directed against it (Mourdjeva et al., 2005) may 
allow development of a potentially more robust methodology.   
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5.1 Summary 
As the endothelium is such a dynamic organ, it must be protected from the 
consequences of injury which could conceivably lead to loss of function.  As has been 
demonstrated in Chapters 3 and 4 during active vasculitis injury and activation of the 
endothelium is significant, thus it is possible that repair mechanisms would be activated 
in these patients.  The concept of endothelial repair in response to injury has rapidly 
gained credence in a number of human diseases, including coronary artery disease.  This 
chapter examines some of the important signals that could provide evidence of an 
attempt of endothelial repair in the face of vasculitic injury.   
 
Growth factors released from the endothelium and surrounding cells are pivotal in 
activating the mechanisms by which repair can be instigated, including recruitment of 
endothelial progenitor cells from the bone marrow (discussed in more detail in Chapter 
6) and activation of angiogenic pathways in the surrounding endothelium, smooth 
muscle and pericytes.  As well as reflecting a potential reparative response they could 
also reflect the extent of injury to the endothelium and as such could be used as a 
surrogate biomarker of disease activity.  This chapter details the assessment of a number 
of growth factors associated with angiogenic and vasculogenic responses in patients 
with vasculitis, and considers their potential for use as a biomarker of disease activity.  
 
 
5.2 Introduction 
Angiogenesis, the remodelling of existing blood vessels to form new ones has been well 
studied in the development of tumour vasculature and is regulated by an extremely 
sensitive interplay of growth factors and inhibitors.  A number of key signalling 
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pathways have been identified that play a role in the formation of new vessels including 
vascular endothelial growth factor (VEGF) and it’s receptor family; platelet derived 
growth factor (PDGF) and its receptor family; Delta-notch signalling and the 
angiopoietins (Ang-1-Ang-4) and their receptors Tie1 and Tie2 (Ferrara and Kerbel, 
2005).  Other signalling molecules that can impact on this system include peptides such 
as the thymosins and various cytokines and chemokines.  Vasculogenesis, the de novo 
formation of blood vessels has been studied predominantly in embryonic development 
and perhaps unsurprisingly the same regulatory pathways are involved.  
 
5.2.1 The VEGF family – the major angiogenic signalling pathway 
The mammalian VEGF family consists of five isoforms of VEGF (A-D and placental 
growth factor PlGF) and three tyrosine kinase receptors which are expressed 
predominantly in the vasculature (Olsson et al., 2006). VEGFR1 and VEGFR2 are 
highly expressed by vascular endothelial cells whereas VEGFR3 is prominently 
expressed in lymphatic endothelial cells, although it can also be expressed on activated 
vascular endothelial cells.  Other cell types that VEGFRs are found on include 
haematopoetic stem cells, monocytes,
 
osteoblasts and neurons (Tammela et al., 2005). 
 
The VEGF family is further complicated by the presence of splice variants of each of 
the different ligand isoforms which may have different functional effects depending on 
their ability to interact with VEGFR co-receptors, one variant of VEGF-A (VEGF-
A165b) for example is a negative regulator of VEGF activity (Woolard et al., 2004).   The 
VEGF-A165 isoform is the most abundant and widely studied of the VEGF isoforms and 
is principal effector
 
of VEGF action (others include VEGF-A189 and VEGF-A206 which 
are mostly bound to cell surface or extracellular matrix and VEGF-A121 which like 
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VEGF-A165 is a soluble secreted form) (Tammela et al., 2005).  VEGFR1 is bound by 
VEGF-A, VEGF-B and PlGF, VEGFR2 is bound by VEGF-A and cleaved forms of 
VEGF-C and VEGF-D, while VEGFR3 is bound by VEGF-C and VEGF-D.  
Experimental data implicates it is the interactions of VEGF-A with VEGFR1 and 
VEGFR2 that are most important in embryonic vascular development and postnatal 
angiogenesis and vasculogenesis (Karamysheva, 2008), and it is these pathways that 
most recent research studies have focused on.  A recent publication has implicated a 
novel role for VEGFR3 in the early vessel sprouting stages of vessel development 
(Tammela et al., 2008).  
 
Targeted deletions of all of the VEGF receptors (VEGFR1-3) in mice results in 
embryonic lethality associated with defective vasculogenesis and vessel development 
(Olsson et al., 2006).  Whilst VEGFR2
-/- 
is associated with deficiency in EC 
development and a lack of vessels (Shalaby et al., 1995), VEGFR1
-/-
 results in excessive 
endothelial proliferation and obstruction of vessel lumen (Fong et al., 1995).  Knock out 
(-/-) or depletion (+/-) of VEGF-A gives a similar phenotype to the VEGFR2
-/-
.  Mice 
which exclusively express individual splice variants of VEGF-A have wide variations in 
phenotype, and studies have implicated VEGF-A164 (Human equivalent is VEGF-A165 
as mice VEGF variants are one amino acid residue shorter than the corresponding 
human isoforms) as the most important isoform as these are normal and healthy (Maes 
et al., 2004).  Mice expressing only VEGF-A120 die soon after birth from impaired 
myocardial angiogenesis with reduced capillary branching (Carmeliet et al., 
1999,Ruhrberg et al., 2002) whilst those expressing VEGF-A188 have stunted growth 
due to defects in bone formation and vascularisation (Maes et al., 2004).  Conversely 
overexpression of VEGF-A also results in embryonic lethality (Miquerol et al., 2000), 
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highlighting the essential role of tightly regulated VEGF-A interactions in early 
developmental angiogenesis and vasculogenesis.   
 
Knockouts of other VEGF isoforms are viable, but with the exception of VEGF-D
-/-
 all 
have significant defects; VEGF-B
-/-
 have reduced heart size with dysfunctional coronary 
vasculature and an impaired recovery from induced myocardial infarction (Bellomo et 
al., 2000) although a later study suggested phenotype was less severe and limited to 
impaired atrial conduction (Aase et al., 2001).  PlGF
-/-
 which also interacts with 
VEGFR1 has a vascular phenotype with impaired angiogenesis and wound healing 
(Carmeliet et al., 2001).  VEGF-C
-/-
 mice have defective lymphatic development 
(Karkkainen et al., 2004). 
 
On ligand binding VEGFR form homo or heterodimers which allow their signal to be 
transduced via activation of receptor tyrosine kinases.  Activated tyrosine kinases recruit 
and activate an array of second messengers including the mitogen activated protein 
kinases (MAPK) phosphoinositide -3 kinases (PI3K) and phospholipase Cγ (PLCγ), 
which in turn activate numerous signaling cascades and complex crosstalk between 
them (Olsson et al., 2006).  Negative regulation of the signal is important for limiting 
the target cell responses and phosphotyrosine phosphatases such as src-homology 
phosphatases (SHP1 and 2) which dephosphorylate and deactivate the tyrosine kinase 
signaling are involved (Guo et al., 2000), as is receptor internalization and degradation 
(Singh et al., 2005).   
 
Neuropilins (NRP1 and NRP2), another family of transmembrane receptors can also 
interact with VEGF although their intracellular domain is short and they do not signal 
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(Takahashi and Shibuya, 2005).  Knockout studies indicate that while NRP1 is 
important in vascular development (Kawasaki et al., 1999) NRP2 is important in the 
lymphatic system (Yuan et al., 2002) and this reflects their expression profile 
(Karamysheva, 2008).  In vitro studies show that NRP1 complexes with VEGFR2, 
enhancing the proliferation and migration of cells in response to VEGF (Whitaker et al., 
2001).   
 
Pathways that VEGF signaling have been implicated in postnatally include endothelial 
cell proliferation, survival, motility and migration, vascular permeability and 
recruitment of bone marrow derived stem cells.  VEGFR signaling is dependent on the 
availability of the VEGF ligands, which can be released from a number of different cell 
types including epithelial cells, tumour cells and macrophages (Berse et al., 1992), 
smooth muscle cells (Ferrara et al., 1991), fibroblasts (Pertovaara et al., 1994), 
neutrophils (Gaudry et al., 1997) and from the endothelium itself (Lee et al., 2007).  
Interestingly the autocrine VEGF signal is necessary for endothelial cell survival 
although not for angiogenesis, demonstrated in endothelial specific VEGF knockout 
mice where marked endothelial apoptosis and thromboembolic events were observed, 
yet overall vascular branched structure was no different to wildtype (Lee et al., 2007).   
 
VEGF is upregulated by a variety of stimuli, including hypoxia, growth factors, 
cytokines, oestrogen, nitric oxide and mutations in its promoter associated with tumours 
(Takahashi and Shibuya, 2005).  Circulating VEGF is upregulated in pathological 
conditions associated with vascular injury and dysfunction including myocardial 
infarction (Seko et al., 1997), diabetes and sickle cell aneamia (Solovey et al., 1999) and  
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has previously been observed in active vasculitis in  HSP  (Topaloglu et al., 2001), 
Behçet’s disease (Shaker et al., 2007) and in KD (Terai et al., 1999).     
 
5.2.2 NOTCH-delta signaling – giving endothelial cells direction 
The Notch family consist of 4 transmembrane receptors (Notch 1-4) and their 
membrane bound ligands Delta-like-1, -3 and -4 and Jagged-1 and -2.  While VEGF 
directly stimulates the endothelium in angiogenesis and promotes the direction of 
migration, the response cannot be identical in all cells, otherwise new vessel formation 
would not be able to occur in the directional manner that it does.  So called “tip cells” 
which form the tip of the sprouting blood vessel are necessary and signaling between 
Delta-like ligand-4 (Dll4) and Notch receptors 1 and 4 have been shown to be important 
in their selection, allowing the VEGF gradient to direct new vessel formation (Thurston 
and Kitajewski, 2008).   
 
Notch signaling occurs in many cell types and has a fundamental role in determining the 
differentiation patterns of individual cells in close proximity.  One mechanism by which 
this occurs is lateral inhibition, whereby one cell presents a Notch ligand (Delta or 
Jagged) to an adjacent Notch receptor expressing cell, resulting in activation of the 
Notch pathway in one cell and suppression in the adjacent cell.  Notch 1 knockout is 
embryonically lethal in mice and is associated with defective angiogenic vascular 
remodeling.  Mice develop early vessels (the primary vascular plexus) suggesting it is 
not influencing vasculogenesis, however these do not develop further into a complex 
organized network of vessels (Krebs et al., 2000).  Mice lacking Notch 4 develop 
normally, however dual Notch 1/Notch 4 knockouts often have a more severe vascular 
phenotype (some can lack entire major vessels) than the Notch 1 knockout (Krebs et al., 
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2000) and overexpression of Notch 4 results in embryonic lethality (Uyttendaele et al., 
2001).  Thus appropriate Notch 4 signalling is also necessary.  Dll4 knockout is 
embryonic lethal and the majority of heterozygous knockouts do not survive (Gale et 
al., 2004).  
 
5.2.3 PDGF – stabilizing new vessels 
The PDGF family consists of 4 ligands (PDGFA-D) which form functional hetero or 
homodimers and 2 receptors (α and β).  PDGFs form part of the same receptor/ligand 
family as VEGFs, it is generally accepted that the PDGFs influence mesenchymal cells, 
whereas VEGFs influence endothelial cells and both PDGFS and VEGFS are selective 
for their own receptors.  However a recent publication has demonstrated that VEGF-A 
can bind
 
to and activate PDGF receptors in bone-marrow-derived mesenchymal
 
stem 
cells and thus this long held view that the growth factors do not cross-signal has become 
further complicated (Ball et al., 2007).   
 
PDGFs act in a paracrine manner, in angiogenesis PDGF-B is highly secreted by 
endothelial cells, particularly those in the tip region and influences the recruitment of 
pericytes and vascular smooth muscle (VSM) cell precursors expressing PDGFR-β 
(Hellstrom et al., 1999) which will stabilise the newly formed vessel.  Knockouts of 
both PDGF-B and PDGFR-β result in pericyte and VSM cell deficiency seen from early 
in embryonic development.  While the cells develop, they do not spread along newly 
developed vessels and the result is embryonic lethality due to vascular defects including 
endothelial hyperplasia, abnormal junctions, and excessive luminal membrane folds 
(Hellstrom et al., 2001).  The stabilization of newly formed vessels by pericytes 
involves their release of TGFβ which inhibits further endothelial proliferation and 
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migration, downregulates VEGFR2 expression and promotes differentiation of pericyte 
progenitors (Karamysheva, 2008). In vitro this occurs on contact between endothelial 
cells and pericytes (Sato and Rifkin, 1989). 
 
5.2.4 Angiopoietins 
The angiopoietin family (Angiopoietins-1,-2,-3 and -4 (Ang-1-4)), like the VEGF 
family, bind to receptor tyrosine kinases (RTK) – namely Tie-1 and Tie-2 (Fiedler and 
Augustin, 2006).  The Tie receptors are predominantly expressed within the vasculature 
and haematopoeitic stem cells, although Tie-2 expression can be detected on a subset of 
monocytes (Venneri et al., 2007).  The known functional effects of the angiopoietins are 
predominantly mediated via Tie-2, as yet Tie-1 signalling pathways have been poorly 
elucidated and it was considered an orphan receptor.  Yuan et al have recently 
demonstrated that Ang-1 can induce Tie1 signalling, although this is dependent on Tie2 
expression, its consequence is a down regulation of the Tie2 dependent EC survival 
(Yuan et al., 2007). 
 
Deletion of Tie-2 in mice results in embryonic lethality that is associated with reduction 
in vascular complexity and branching (Sato et al., 1995).  A similar phenotype is seen 
when Ang-1 (Suri et al., 1996) is deleted, or when Ang-2 is overexpressed 
(Maisonpierre et al., 1997), indicating that Ang-2 acts as an antagonist of Ang-1 
signalling via the Tie-2 receptor (at least in embryonic development).  Deletion of Ang-
2 gives a relatively mild phenotype at birth, although mice usually die within 2 weeks 
due to severe chylous ascites (lymph fluid leaking into the peritoneal cavity) due to 
defective lymphatic development (Gale et al., 2002).  Embryonic vascular development 
is relatively normal, however postnatal angiogenesis is defective, indiciating a key role 
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for Ang-2 in remodeling of the vasculature (Gale et al., 2002).  While Ang-1 is 
constitutively expressed by many cell types including smooth muscle, fibroblasts and 
some tumor cells, Ang-2 is expressed predominantly by endothelial cells (as well as 
some tumour cells and retinal cells) (Fiedler and Augustin, 2006).   
 
Ang-1 acting on Tie-2, induces phosphorylation of the receptor, resulting in activation 
of a complex cascade of second messengers, including PI3K and Akt (DeBusk et al., 
2004).  Akt promotes cell survival and inhibits the action of the forkhead transcription 
factor FKHR-1, which induces Ang-2 production (Daly et al., 2004).  Thus Ang-1 
signalling inhibits production of its antagonist Ang-2.  It also reduces vascular 
permeability, inhibits NFkB activation and thus suppresses inflammation (Hughes et al., 
2003) and promotes association between pericytes and the endothelium helping stabilize 
vessels.  The constitutive agonist action of Ang-1 on Tie-2 is considered to be crucial to 
maintaining the endothelium in a non-activated quiescent state (Fiedler and Augustin, 
2006).   
 
Stimulation of the endothelium results in release of Ang-2 from Weibel-palade bodies, 
resulting in disruption of the resting state of the endothelium and priming it for 
angiogenesis or inflammation (Fiedler and Augustin, 2006).  Ang-2 also enhances 
TNFα induced leukocyte endothelial interactions via increased upregulation of adhesion 
molecules (Fiedler et al., 2006).  The action of Ang-2 is altered by the presence of 
VEGF, in its absence Ang-2 contributes to vascular regression, but in its presence Ang-
2 stimulates angiogenesis (Maisonpierre et al., 1997).  In vitro, Ang-2 treatment of 
human microvascular endothelial cells (HMECs) disrupts barrier function, promoting 
actin stress fibre formation, resulting in intercellular gaps and increased permeability 
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(Parikh et al., 2006).  While antagonism of Ang-1 Tie2 signalling may explain some of 
these responses, it is also conceivable that Ang-2 may also signal by alternative as yet 
unknown pathways.   
 
Elevated Ang-2 is associated with conditions of inflammation and cardiovascular injury 
including sepsis (Siner et al., 2008), hypertension (Patel et al., 2008), diabetes (Lim et 
al., 2005) and acute coronary syndromes (Lee et al., 2004). After trauma Ang-2 can be 
elevated in circumstances when VEGF is not (Ganter et al., 2008).  At the time of study 
no groups had examined Angiopoietin levels in patients with vasculitis.  However a 
recent publication has indicated that Ang-2 levels are a potential biomarker of disease 
activity in adults with AAV (Kumpers et al., 2009). 
 
5.2.5 Thymosin β4 
The Thymosins are a family of peptides which were first isolated from the thymus 
(Hannappel, 2007).  They were originally thought to be thymic hormones, however it 
has become apparent that they are ubiquitously expressed.  The β-thymosins sequester 
G-actin, regulating its phosphorylation and thus cytoskeletal remodeling (Hannappel, 
2007).  Thymosin β4 (Tβ4) is the most abundant member in most cell types, 
representing approximately 70–80% of total beta thymosins and has been implicated in 
angiogenic and vasculogenic pathways (Smart et al., 2007b). 
 
Tβ4 has been shown to influence VEGF levels, act as an endothelial chemoattractant 
and regulate a number of genes which can influence angiogenesis and cell motility, 
including matrix metalloproteinases, adhesion molecules and cytoskeletal related 
peptides (Smart et al., 2007b).  In tissues with high Tβ4, VEGF levels are also elevated 
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(Cha et al., 2003), correspondingly in tissues where Tβ4 has been knocked out, VEGF 
expression is also low (Smart et al., 2007a).  Whether this is a direct interaction between 
Tβ4 and VEGF or whether Tβ4 influences an upstream inducer of VEGF such as 
hypoxia inducible factor (HIF) remains unknown.  Another member of the thymosin 
beta family, Tβ10 which has anti-angiogenic effects reduces VEGF levels (Mu et al., 
2006).  A small number of studies have examined plasma or serum levels of  Tβ4 in 
humans, Tβ4 increases in rhinovirus infection (Hsia et al., 1989), interestingly is lower 
in serum extracted from umbilical cords than from adults (Weller et al., 1988) and a 
recent study has indicated it is elevated in patients with psoriasis (Plavina et al., 2008).  
 
In this chapter the growth factors which have been shown to directly drive angiogenesis 
(VEGF, Ang-1, Ang-2 and Tβ4) as opposed to those described which are more 
important in influencing direction and vessel stabilisation have been measured in 
patients with vasculitis.  Many of these studies (Ang-1, Ang-2 and Tβ4) represent data 
which have hitherto not been reported in paediatric vasculitis.  At the time of writing, of 
these 3 growth factors only Ang-2 has been reported in adults with AAV (Kumpers et 
al., 2009). 
 
 
 
  
232 
 
5.3 Evaluation of growth factors in vasculitis 
5.3.1 Patients and methods 
5.3.1.1 Patients 
40 children with primary systemic vasculitis were studied. The majority of these 
patients (n=36) were the same individuals described in Chapters 3 and 4, allowing GFs 
to be compared with CECs and MPs.  These included 16 males and 24 females of 
median age 9.8 years (range 0.1 -19.0 years). The vasculitis type (using the Chapel Hill 
Consensus Criteria) (Jennette et al., 1994) was polyarteritis nodosa (PAN) n=17, 
Wegener’s granulomatosis (WG) n=9, microscopic polyangiitis (MPA) n=1, 
Kawasaki’s disease (KD) n=5, Takayasu’s arteritis (TD) n=2, Beçhets disease (BD) n=1 
and unclassified n=6.  Disease activity was assessed using a modified paediatric 
Birmingham Vasculitis Activity Score (BVAS), as described previously.  18 healthy 
child controls (4 males, 14 females), 14 febrile controls (6 males, 8 females with a 
variety of autoimmune or other inflammatory disorders without the presence of 
vasculitis) and 20 healthy adult controls were also recruited (2 males, 18 females, age 
range 24-40 years). As with the vasculitis patients, the control individuals were the 
same as those studied in Chapters 3 and 4.    
 
5.3.1.2 Methods 
Platelet poor plasma and serum were collected and stored as described in section 2.4.  
Platelet poor plasma was used in ELISA for Ang-1 and Ang-2, using ELISA kits from 
R&D as per manufacturer’s instructions (as described in section 2.6.1).  Serum was 
used in ELISA for detection of VEGF-A165 using an ELISA kit from R&D as described 
in section 2.6.1  Serum was also used for detection of Tβ4 using an ELISA kit from 
immunodiagnostik (as described in section 2.6.1).  Samples were defrosted at room 
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temperature while the ELISA kit reagents were being prepared.  Ang-1 required a 1 in 
15 dilution of sample, Ang-2 required a 1 in 5 dilution of samples (as per manufacturers 
instructions). VEGF serum was used neat and Tβ4 was diluted 1 in 5 before addition to 
the test plate.    As Ang-1 levels were frequently falling below the detection limit of the 
kit and the high level of dilution was necessary to prevent Ang-1 complex formation 
(R&D, technical support, personal communication) fewer samples had their Ang-1 
detected than Ang-2.  Examples of calibration curves are given in Appendix 5.   
  
5.3.1.3 Statistics 
Median growth factor levels were compared between groups using the Kruskall Wallis 
test to check for overall differences.  Individual Mann Whitney U tests for non 
parametric data were performed to compare between specific groups.  The Wilcoxon 
signed rank test was performed to compare medians of paired samples.  Spearman Rank 
correlation coefficiants were performed to assess correlation between growth factors 
and other markers of disease activity, including CECs.  In all data graphs patient 
classification was denoted using colour coding as indicated below: 
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5.3.2 Results 
5.3.2.1 VEGF 
Kruskall Wallis testing indicated there were significant differences between test groups 
(p=0.04). Individual analysis between groups revealed VEGF was significantly higher 
in 20 patients with active vasculitis (median value 579pg/ml) compared to 22 healthy 
child controls (median value 194pg/ml, p=0.02) and 9 healthy adult controls (median 
value 231pg/ml, p=0.03).  There were no significant differences between patients with 
active vasculitis and 9 febrile controls (median value 395 pg/ml) or 17 patients with 
inactive disease (median value 241pg/ml) and these control groups.  The data presented 
in Figure 5.1a represents the overall vasculitis cohort and when tested a significant 
difference between patients with active and inactive vasculitis (p=0.04) was observed, 
however this analysis includes paired data. When  paired data between active and 
inactive vasculitis was excluded (the first observation made in each individual patient 
was used in this analysis) the difference between 18 patients with active disease 
(median value 578 pg/ml) and 6 patients in remission (median value 137pg/ml) was no 
longer significant (p=0.07).  As before the colour of symbols and lines indicates disease 
classification of individual patients. 
 
In 13 individual patients VEGF levels were significantly higher during active disease 
than when patients were in remission (p=0.013) (median time to remission 3 months) 
(Figure 5.1b).  10 patients were followed over time from initiation of treatment at 
disease onset, at median follow up of 3 and 12 months VEGF was significantly lower 
than at onset than at followup (p=0.02 and p=0.047 respectively, Figure 5.1c).  
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Figure 5-1: Serum levels of VEGF in vasculitis 
 
 
Figure 5.1a:VEGF was significantly higher in 20 patients with active vasculitis compared to 22 healthy 
child controls (p=0.02), 9 healthy adult controls (p=0.03) and 17 patients with inactive disease (p=0.04).  
There were no significant differences between patients with active disease and 9 febrile controls or 17 
patients with inactive disease and any of the control groups. Figure 5.1b: In 13 individual patients VEGF 
levels were significantly higher during active disease compared to remission (p=0.025, median time to 
remission 3 months). Figure 5.2c:  13 individual patients were followed from initiation of treatment , at 
median followup of 3 months VEGF was significantly lower than at onset (p=0.015) although not at 12 
months (p=0.06).  Symbol and line colours reflect individual patients disease classification.  
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5.3.2.2 Angiopoietin-1 
Kruskall Wallis testing indicated there were no overall significant differences between 
test groups (p=0.07).  When test groups were considered individually Ang-1 was not 
significantly different in 13 patients with active vasculitis (median value 2670 pg/ml) 
compared to 14 healthy child controls (median value 835pg/ml, p=0.1) and 3 healthy  
adult controls (median value 0pg/ml, not enough data to compare statistically).  There 
were no significant differences between 12 patients with inactive vasculitis (median 
value 1051pg/ml) and these control groups (Figure 5.2a.  Ang-1 was comparable with 
reference ranges for the kit in adult controls. The data presented in Figure 5.2a 
represents the overall vasculitis cohort, when tested no significant difference was 
observed between patients with active and inactive vasculitis (p=0.5).  There were not 
enough samples to exclude paired data between the two test groups.  As before the 
colour of symbols and lines indicates disease classification of individual patients. 
 
In 12 individual patients Ang-1 levels were not significantly different between active 
disease and remission (p=0.6) (median time to remission 3.5 months, Figure 5.2b).  12 
individual patients were followed from initiation of treatment at disease onset or flare 
(dotted lines indicate flare).  In 11 patients followed over time from initiation of 
treatment, at median follow up of 3 and 12 months Ang-1 was not significantly different 
to levels at onset (p=0.3 and p=0.2 respectively, Figure 5.2c). 
 
5.3.2.3 Angiopoeitin-2  
Kruskall Wallis testing indicated there were no overall significant differences between 
the test groups (p=0.2).  When test groups were considered individually Ang-2 was not  
significantly different between 23 patients with active vasculitis (median value 1739 pg/  
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Figure 5-2:Plasma Angiopoeitin-1 levels in vasculitis 
 
 
Figure 5.2a: Ang-1 levels were not significantly different in 12 patients with active vasculitis compared 
to 14 healthy child controls (p=0.07), 11 patients with inactive vasculitis (p=0.5) and 3 healthy adult 
controls (not enough data to compare).  There were no significant differences between patients with 
inactive vasculitis and these control groups. Figure 5.2b: In 13 individual patients Ang-1 levels were not 
significantly different between active disease and remission (p=0.44) (median time to remission 3.5 
months). Figure 5.2c: 12 patients were followed over time from initiation of treatment, at median follow 
up of 3 and 12 months Ang-1 was not significantly different to levels at onset (p=0.3 and p=0.2 
respectively).  Symbol and line colours reflect individual patients disease classification. 
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ml) compared to 12 febrile controls (median value 1798pg/ml, p=0.27), 19 healthy child 
controls (median value 1512 pg/ml, p=0.15) and 20 healthy adult controls (median 
value 1382pg/ml, p=0.167, comparable with reference ranges for the kit).  There were 
no significant differences between 25 patients with inactive vasculitis and healthy child 
controls or adult controls however Ang-2 was significantly higher in febrile controls 
(p=0.04).  The data in figure 5.3a represents the whole vasculitis cohort, on testing no 
significant differences were observed between active and inactive disease.  When paired 
samples between these groups were excluded there remained no significant difference 
between 23 patients with active vasculitis and 10 in remission (p=0.2). As before the 
colour of symbols and lines indicates disease classification of individual patients. 
 
In 17 individual patients Ang-2 was significantly higher during active disease than in 
remission (p=0.045, median time to remission 5.5 months, Figure 5.3b).  13 patients 
were followed over time from initiation of treatment at disease onset (solid lines) or 
during flare  (dotted lines), at median follow up of 3 and 12 months from  disease  onset  
and initiation of treatment Ang-2 was significantly lower than at onset (p=0.001 and 
p=0.04 respectively,  Figure 5.3c). 
 
5.3.2.4   Thymosin β4 
Kruskall Wallis  testing indicated no overall significant differences between the test 
groups (p=0.2).  When test groups were considered individually Tβ4 was not 
significantly different between 17 patients with active vasculitis (median value 5.87 
µg/ml) compared to 5 febrile controls (median value 6.7µg/ml p=0.56), 9 healthy child 
controls (median value 8.61µg/ml p=0.78) or 8 healthy adult controls (median 
value3.84µg/ml, p=0.07).  There were no significant differences between patients with 
inactive vasculitis and any of these controls groups or with patients with active disease  
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Figure 5-3: Plasma Angiopoeitin-2 levels in vasculitis 
 
 
Figure 5.3a: Ang-2 was not significantly different between 23 patients with active vasculitis compared to 
12 febrile controls, 19 healthy child controls and 20 healthy adult controls.  There were no significant 
differences between patients with inactive disease and healthy child controls or adult controls however 
Ang-2 was significantly higher in febrile controls (p=0.04). Figure 5.3b: In 17 individual patients, Ang-2 
was significantly higher during active disease than in remission (p=0.045, median time to remission 5.5 
months)  Figure 5.2c: In 12 patients followed over time from initiation of treatment, at median follow up 
of 3 and 12 months Ang-2 was significantly lower than at disease onset (p=0.001 and p=0.04 
respectively). Symbol and line colours reflect individual patients disease classification. 
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(this analysis included paired data between active and inactive disease as there was not 
enough data for statistical analysis otherwise).  Healthy child controls had significantly 
higher levels of Tβ4 than healthy adult controls (p=0.022, Figure 5.4a).     
 
In 12 individual patients there were no significant differences in Tβ4 between active and 
inactive disease (p= 0.7, median time to remission 3 months) (Figure 5.4b).  11 patients 
were followed over time from initiation of treatment at disease onset (solid line) or flare 
(dotted line).  In 10 patients at median follow up of 3 and 12 months from disease onset 
there were no significant differences from initiation of treatment (p=0.8 and p=0.19, 
Figure 5.4c). 
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Figure 5-4: Serum levels of Thymosin Beta 4 in vasculitis 
 
 
Figure 5.4a: Tβ4 was not significantly different between 17 patients with active vasculitis and 5 febrile 
controls, 9 healthy child controls or 8 healthy adult controls.  There were no significant differences 
between patients with inactive vasculitis and any of these controls groups.  Healthy child controls had 
significantly higher levels of Tβ4 compared to healthy adult controls (p=0.022). Figure 5.4b: In 12 
individual patients there were no significant differences in Tβ4 between active and inactive disease 
(median time to remission 3 months) Figure 5.4c: 11 patients were followed over time from initiation of 
treatment at disease onset (solid lines) or flare (dotted lines).  At median follow up of 3 and 12 months 
there were no significant differences from initiation of treatment. Symbol and line colours reflect 
individual patients disease classification.  
242 
 
5.3.3 Correlation between growth factors and disease activity 
Spearman Rank correlation coefficiant analysis was performed between the 4 growth 
factors assessed and the traditional markers of active disease; BVAS, CRP, ESR, 
platelet count, albumin, white cell count as well as the previously demonstrated novel 
markers of endothelial injury and cellular activation CEC count, EMPs and PMPs in 
patients with vasculitis.  Table 5.1 summarises the results.  Table 5.2 shows the 
corrected P-values obtained from a post-hoc Holm-Bonferroni correction.  In this 
instance a number of the significant correlations observed on individual tests withstood 
the rigours of multiple comparison correction and therefore are likely to be true 
significant results and not false positives. 
 
Serum VEGF and Plasma Ang-2 both correlated significantly with the inflammatory 
markers ESR and CRP, as well as the BVAS score of disease activity. Interestingly 
neither growth factor correlated with circulating endothelial cells.  Although the 
following did not withstand correction for multiple comparisons Ang-2 correlated 
inversely with EMPs (CD105+) Ang-1 correlated with platelet count and TB4 only 
correlated with VEGF.  Importantly VEGF did not correlate with platelet count or 
PMPS.  Both can act as stores of VEGF and thus platelet degranulation may influence 
serum levels (Jelkmann, 2001), however this did not appear to affect this result.    
 
5.3.4 Influence of treatment on growth factor responses 
The result that growth factors did not correlate with endothelial injury as assessed by 
CECs or EMPs was unexpected, especially as both VEGF and Ang-2 correlated with 
the inflammatory markers ESR and CRP and the clinical score of disease activity.  As 
immunosuppression influences the release of chemokines and cytokines from a number 
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Table 5-1: Spearman Rank correlation coefficiants of growth factors and 
markers of disease activity in vasculitis. 
 
 
Marker of 
disease activity 
VEGF ANG-1 ANG-2 TB4 
BVAS r = 0.329 
p = 0.018* 
n = 51 
r = 0.158 
p = 0.34 
n = 38 
r = 0.344 
p = 0.002* 
n = 76 
r = 0.22 
p = 0.2 
n = 33 
ESR r = 0.529 
p<0.001* 
n = 48 
r = 0.035 
p = 0.83 
n = 38 
r = 0.432 
p <0.001* 
n = 74 
r = 0.140 
p = 0.45 
n = 31 
CRP r = 0.460 
p = 0.001* 
n = 49 
r = 0.086 
p = 0.6 
n = 38 
r = 0.503 
p <0.001* 
n = 75 
r = 0.27 
p = 0.14 
n = 32 
WCC r = 0.508 
p <0.001* 
n = 50 
r = 0.034 
p = 0.84 
n = 39 
r = 0.137 
p = 0.24 
n = 75 
r = 0.337 
p = 0.055 
n = 33 
Platelet count r = 0.274 
p = 0.06 
n = 47 
r = 0.44 
p = 0.006* 
n = 37 
r = -0.015 
p = 0.9 
n = 72 
r = 0.215 
p = 0.245 
n = 31 
Albumin r = -0.502 
p <0.001* 
n = 46 
r = -0.190 
p = 0.266 
n = 36 
r = -0.370 
p = 0.001* 
n = 72 
r = -0.027 
p = 0.09 
n = 31 
CEC count r = 0.150 
p = 0.35 
n = 41 
r = 0.182 
p = 302 
n = 34 
r = 0.016 
p = 0.89 
n = 70 
r = 0.058 
p = 0.765 
n = 29 
EMP (CD144+) r = 0.061 
p = 0.69 
n = 44 
r = 0.127 
p = 0.428 
n = 41 
r = -0.148 
p = 0.2 
n = 76 
r = 0.109 
p = 0.55 
n = 32 
EMP (CD105+) r = 0.047 
p = 0.76 
n = 44 
r = -0.62 
p = 0.7 
n = 41 
r = -0.308 
p = 0.007* 
n = 76 
r = -0.22 
p = 0.23 
n = 32 
EMP (eselectin+) r = 0.217 
p = 0.16 
n = 44 
r = 0.025 
p = 0.88 
n = 41 
r = -0.103 
p = 0.378 
n = 76 
r = 0.132 
p = 0.47 
n = 32 
PMP (CD42a+) r = -0.235 
p = 0.13 
n = 43 
r = -0.056 
p = 0.73 
n = 41 
r = -0.214 
p = 0.066 
n = 75 
r = 0.137 
p = 0.46 
n = 32 
Total MP r = -0.111 
p = 0.473 
n = 44 
r = -0.129 
p = 0.42 
n = 41 
r = -0.067 
p = 0.566 
n = 76 
r = -0.022 
p = 0.9 
n = 32 
VEGF  r = 0.315 
p = 0.09 
n = 30 
r = 0.306 
p = 0.039* 
n = 46 
r = 0.369 
p = 0.023* 
n = 38 
ANG-1 r = 0.315 
p = 0.09 
n = 30 
 r = 0.032 
p = 0.84 
n = 30 
r = 0.178 
p = 0.38 
n = 26 
ANG-2 r = 0.306 
p = 0.039* 
n = 46 
r = 0.032 
p = 0.84 
n = 30 
 r = 0.269 
p = 0.13 
n = 33 
TB4 r = 0.369 
p = 0.023* 
n = 38 
r = 0.178 
p = 0.38 
n = 26 
r = 0.269 
p = 0.13 
n = 33 
 
Significant correlations are highlighted in blue 
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Table 5-2: Holm-Bonferroni correction for multiple comparisons relating to 
correlations of growth factors and other markers of disease activity 
 
Significant Test P value Adjusted critical value 
(Holm-Bonferroni) 
WCC vs VEGF <0.001 0.000925926 
Albumin vs VEGF <0.001 0.000943396 
ESR vs ANG-2 <0.001 0.000961538 
CRP vs ANG-2 <0.001 0.000980392 
ESR vs VEGF 0.001 0.001 
CRP vs VEGF 0.001 0.001020408 
Albumin vs ANG-2 0.001 0.001041667 
BVAS vs ANG-2 0.002 0.00106383 
Platelet count vs ANG-1 0.006 0.001086957 
EMP (CD105+) vs ANG-2 0.007 0.001111111 
BVAS vs VEGF 0.018 0.001136364 
TB4 vs VEGF 0.023 0.001162791 
ANG-2 vs VEGF 0.039 0.001190476 
 
of cell types, we hypothesised that treatment might be influencing the release of growth 
factors and thus the data was reanalysed to take this into account.  29 individual patients 
whose  growth factors had been measured and had active disease as defined via clinical  
scores (BVAS) were then divided into two subgroups: those who were treatment naive 
 (i.e. had received no treatment, n= 13), and those who had flared while on 
immunosuppressive treatment (n=16).  In those individuals who had had repeated 
measurements taken while disease was still active, it was the first sample that was used 
in this analysis.    
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There were no significant differences in markers of endothelial injury/activation (CECs 
and EMPs) between 9 patients who were treatment naive and 12 patients who were on 
immunosuppressive treatment (Figures 5.5a and b).  Patients who were treatment naive 
had significantly higher BVAS scores (p=0.03) and CRP (p=0.01) although not ES). 
(Figures 5.5c-e)  Correspondingly the treatment naive patients also had significantly 
higher levels of VEGF (p=0.007), Ang-1 (p=0.03) and Ang-2 (p=0.0003), than those 
who were on immunosuppressive therapy. This may indicate that immunosuppressive 
treatment influences release of these growth factors in response to disease activity.   
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Figure 5-5: Influence of treatment on endothelial injury markers and 
clinical parameters  
 
 
 
Figure 5.5a-e: When patients with active disease had their treatment status considered (treatment naive 
or on treatment), there was no significant differences in CECs or EMP between patients who were 
treatment naive (no Rx) or on immunosuppressive therapy (on Rx) when they flared (Figure 5.5a and b).  
There were significant differences between the two groups when clinical parameters were considered: 
BVAS (p=0.01, Figure 5.5c) and the inflamamotry markers CRP (p=0.005, Figure 5.5d) and ESR 
(p=0.02, Figure 5.5e) were significantly higher in patients who had not yet received treatment Rx = 
treatment.  Symbol and line colour reflect individual patients disease classification (colour coded as in 
previous figures) 
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Figure 5-6: Influence of treatment on growth factors 
 
 
Figure 5.6a-d:When patients with active vasculitis had their treatment status considered  there were 
significant differences in growth factor levels between patients who were treatment naïve (Rx naïve) and 
those who were on immunosuppressive therapy (on Rx) when they flared. Figure 5.6a:  VEGF was 
significantly higher in 12 treatment naive patients compared to 7 on immunosuppression (p=0.03) Figure 
5.6b Ang-1 was not significantly different between 10 treatment naive patients compared to 4 on 
immunosuppression (p=0.1), however this comparison was underpowered  Figure 5.6c Ang-2 was 
significantly higher in 12 treatment naive patients compared to 13 on immunosuppression (p=0.002) .  
Figure 5.6d: there were no signficant differences in Tβ4 between treatment naïve and those on 
immunosuppression. Symbol and line colour reflect individual patients disease classification (colour 
coded as in previous figures) 
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5.4 Discussion 
Growth factors regulate the angiogenic and vasculogenic pathways that are necessary 
for vascular repair and thus monitoring of their levels may provide insight into potential 
reparative response.  Like CECs and EMPs, they can be expressed as a consequence of 
endothelial injury and it was with this in mind that this study was undertaken, to assess 
their potential as an indicator of active disease in vasculitis.   
 
The preliminary observations made are interesting and warrant further investigation, 
however it is difficult to draw firm conclusions from them since patient numbers are 
small.  Although VEGF and Ang-2 in particular correlate with a number of markers of 
disease activity, responses may be influenced by treatment.  Thus their use as 
biomarkers in a highly heterogenous cohort on widespread immunosuppression may not 
be appropriate.  The complexity of the results is perhaps not surprising when it is 
considered that growth factors form part of extensive regulatory networks and could 
conceivably be contributing to the pathological processes involved in vascular 
inflammation as well as promoting repair.   
 
None of the growth factors examined herein correlated with CECs or EMPs.  VEGF and 
Ang-2 did however correlate with clinical scores of disease activity (BVAS) as well as 
non specific markers of inflammatory disease activity such as ESR and CRP.  This 
could be indicative of the upstream signalling required to release them: VEGF is 
produced by monocytes which are integral to the inflammatory process and although 
Ang-2 is relatively endothelial specific, it is released from the Weibel-palade bodies in 
response to inflammatory stimuli.  Perhaps these growth factors are upregulated in 
reponse to inflammatory stimuli that are not sufficient to induce EC detachment 
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(forming CECs).  VEGF also correlated with Tβ4 levels (although this did not withstand 
the rigours of correction for multiple comparisons), corresponding with previously 
published reports that in animal models high Tβ4 in isolated organs is associated with 
elevated VEGF (Cha et al., 2003).  
 
The concept that growth factors may be more closely linked with inflammation than as 
a direct consequence of endothelial injury was further reinforced by the effect of 
therapy on levels of VEGF, Ang-2 and Ang-1 (although this latter observation was 
underpowered and lacked statistical significance).  Routine maintenance therapy (in the 
majority of cases corticosteroids, with azathioprine) dampened down the elevations seen 
in these growth factors when patients had flares of their disease.  While it would be easy 
to suggest that patients on maintenance therapy do not have such extensive disease 
activity in flare and that is why their response is dampened, CECs and EMPS (which 
reflect the extensiveness of EC injury and activation) were unaffected by treatment 
status in patients with active disease.   The pathways upstream of VEGF and ANG-2 are 
complicated, a number of mediators can influence their production and thus it is 
conceivable that inhibition of several immune pathways by treatment such as 
corticosteroids and cytotoxic immunosuppressants could impact on growth factor 
release.   
 
The recently published data from Kumpers et al on Ang-2 levels in adults with AAV, is 
similar to that described herein, Ang-2 levels were elevated at disease onset, declined 
with therapy and correlated strongly with BVAS and (in contrast to the data presented 
herein) CEC number (Kumpers et al., 2009).  Their interpretation of the usefulness of 
Ang-2 as a biomarker of disease activity in vasculitis is more optimistic than the 
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conclusion reached in this study as they did not observe that immunosuppressive 
treatment could be influencing the growth factor responses.  While this could be due to 
differences between adult and child physiology, it may be that the inclusion criteria of 
the patients studied is the cause.  Of the 15 patients with active disease studied by 
Kumpers et al, 8 were treatment naive and the remainder were off immunosuppressive 
therapy or on <7.5mg/day prednisolone (exact numbers were not stated).  If the majority 
of patients were in fact not on any immunosuppressive therapy then this interesting 
observation may well have gone undetected in their cohort. Regardless of the status of 
patients included in these studies, both remain preliminary as the datasets are small and 
a larger scale study is necessary to assess the potential of Ang-2 as a biomarker of 
disease activity, and if indeed its levels are influenced by treatment status.  
 
The implications of the apparent growth factor suppression by treatment in children 
may not necessarily be a bad thing. VEGF is a well known mediator of vascular 
permeability and elevations of this could be contributing to oedema formation often 
associated with inflammation (Mehta and Malik, 2006).  Furthermore, as discussed in 
the introduction to this chapter, newly formed vessels may amplify and target vascular 
inflammation.  Indeed, one line of argument has regarded angiogenic signals as a means 
of amplifying vasculitic injury (Cid, 2002).   In healthy individuals growth factors act in 
a localised manner to control angiogenesis and vasculogenesis, processes reliant on 
concentration gradients to direct tightly regulated changes in vessel behaviour.  
Therefore large changes in growth factors could in fact be pathological and not 
indicative of a reparative response but of a “growth factor storm” propagating further 
disruption of endothelial cells and injury.     
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In conclusion, children with active vasculitis demonstrate significant angiogenic and 
vasculogenic signals in peripheral blood at a time when their vasculitis is most active.  
Although routine clinical testing of growth factors in vasculitis would be a simple 
clinical test, the influence of treatment, the inconsistent results observed (particularly 
for Ang-1 and Tβ4) and the complexity associated with growth factor responses and 
effects suggest that the growth factors assessed in this study may not be an appropriate 
biomarker of disease activity for clinical monitoring of disease activity.  These 
observations, particularly in relation to the finding of elevated VEGF and Ang-2 in 
active vasculitis (albeit influenced by treatment), do however, provide impetus for 
further study of endothelial progenitor cell reponses in relation to vasculitis disease 
activity.  EPCs are the subject of Chapter 6. 
  
252 
 
6 Endothelial Progenitor Cells 
 
6.1. Summary  
 
6.2. Introduction 
 
6.3. Optimisation of flow cytometric for detection of EPCs 
 
6.4. EPCs in vasculitis 
 
6.5. Detection of EPCs using cell culture 
 
6.6. Discussion  
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6.1 Summary 
Endothelial progenitor cells (EPCs) are bone marrow derived cells which migrate to 
sites of endothelial injury and assist in repair.  Whether this occurs is via EPCs 
differentiating down an endothelial lineage or by orchestrating a localised 
proangiogenic environment is unclear.  As has been discussed in Chapter 5, growth 
factors which promote angiogenesis have been implicated in recruitment of EPCs from 
the bone marrow and I previously demonstrated elevations of VEGF and Ang-2 in 
children with active vasculitis.  This chapter describes EPCs in children with vasculitis 
and changes with treatment.  
 
 
6.2 Introduction 
Endothelial repair is integral to maintaining health, however the exact mechanisms by 
which this occurs remain as yet unclear. As mentioned in the introduction to this thesis, 
angiogenesis was considered to be the mechanism by which the endothelium repaired 
itself until relatively recently, when Asahara et al introduced the concept of postnatal 
vasculogenesis and endothelial progenitor cells (EPCs) (Asahara et al., 1997).    
 
The EPCs described by Asahara et al were a population of CD34+ cells.  CD34+ cells 
are routinely used in stem cell transplantation and can reconstitute all blood cell 
lineages (Cheng et al., 1996).  CD34 is found on mature endothelium and 
haematopoietic progenitor cells (of myeloid and lymphoid lineages) although is lost 
during the latters maturation.  Vasculogenesis studies in embryonic development, 
indicate that both the cells forming the vasculature and those that form the cells of the 
blood are derived from a common progenitor – known as the haemangioblast (Vogeli et 
254 
 
al., 2006).  Haematopoeitic cells are continually repopulated throughout life and thus 
the concept that EPCs also remain involved in vascular repair and remodeling is an 
attractive hypothesis.   
 
While the work of Asahara et al may have been the first description of EPCs, evidence 
had accumulated for many years previously that circulating cells could repopulate the 
endothelium.  As early as 1932 Hueper and Russell had found capillary like tubule 
formations in cultures of leukocytes and continuation of their work by Parker in 1934 
demonstrated that leukocytes require a base of red blood cells and platelets in order to 
form these structures (Parker, 1934).  By 1963 the concept of fallout endothelialisation 
had been described, whereby synthetic grafts implanted into animals showed re-
endothelialisation which was not derived from infiltrating surrounding endothelium (Shi 
et al., 1994,Stump et al., 1963).  In 1998 Shi et al demonstrated that these circulating 
cells originated from bone marror as donor derived cells were found to be the 
predominant endothelial cell on reendothelialised grafts implanted after transplantation 
in dogs (Shi et al., 1998).   
 
6.2.1 EPCs influence in vivo endothelial repair 
Since the discovery of EPCs by Asahara et al numerous studies involving animal 
models of acute vascular injury, transplantation and atherosclerosis have been 
described, indicating a role for EPCs in reparative responses.  The exact phenotype of 
EPCs is a controversial subject and as yet no specific combination of markers 
conclusively defines the EPC population (Hirschi et al., 2008).  Most in-vivo studies 
where EPCs have been perfused into subjects (animals and human) have used mixed 
populations of cells which include EPCs; some studies have used CD34+ or whole 
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mononuclear fractions of freshly isolated peripheral blood.  In animal models culture 
modified mononuclear cells have also been used.  In a number of studies 
pharmacological agents such as G-CSF have been used to mobilise bone marrow 
progenitors.  These will now be discussed in more detail. 
 
6.2.1.1  EPCs in animal models 
In a series of vein graft transplant studies in transgenic mice, Xu et al demonstrated that 
circulating cells from the recipient rapidly repopulate the vein graft endothelium, about 
a third of which are bone marrow derived cells (Xu et al., 2003).  In apolipoprotein E
−/−
 
(ApoE-/-) knockout mice, which have reduced circulating EPCs, regeneration of the 
endothelium is delayed and development of atherosclerotic lesions in the vein graft 
accelerated (Xu et al., 2003).   ApoE1-/- are a well established model of atherosclerosis 
and develop spontaneous disease, the progression of which can be decreased with the 
infusion of EPCs  from younger mice, not yet exhibiting atherosclerotic changes, but 
not EPCs from older sick mice (Rauscher et al., 2003).  In this study cells isolated from 
bone marrow and cultured for up to 2 weeks were used.  Interestingly other studies have 
demonstrated that EPC infusion is detrimental in this model when combined with an 
ischaemic injury possibly due to an inflammatory role.  Although EPC infusion 
improved ischaemia reperfusion injury in 2 studies, it also accelerated atherosclerotic 
plaque development and instability (Silvestre et al., 2003), which was associated with 
higher serum IL-6 and MCP-1 (George et al., 2005).  However both these latter studies 
used uncultured cells isolated from bone marrow. 
  
In  arterial  balloon injury  models in rats, mobilization of  EPCs using G-CSF enhances  
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repair and reduces associated hyperplasia of the intima and smooth muscle (Kong et al., 
2004a).  The same group demonstrated that in a similar model in rabbits, modification 
of cultured autologous EPCs to overexpress eNOS further enhanced the reparative 
response and suppression of hyperplasia (Kong et al., 2004b).  While in these models of 
vascular injury, EPCs suppressed hyperplasia, the opposite effect was observed when 
experimental stents coated with anti-CD34 to promote EPC recruitment were implanted 
in pigs.  While endothelialisation of coated stents was more rapid than in controls, it 
was also associated with excessive intimal hyperplasia  (Rotmans et al., 2005). 
 
In induced myocardial infarction in both mice and rats, transplantation of bone marrow 
mononuclear cells into the heart improves recovery and function, associated with 
enhanced angiogenesis (Zhang et al., 2004) with increased IL-10 production and 
reduced T cell infiltration, indicating a possible anti-inflammatory role for EPCs 
(Burchfield et al., 2008).  Similarly enhanced angiogenic responses and improved 
function are also seen in hindlimb ischaemia models by injection of autologous and 
donor animal bone marrow mononuclear cells (Asahara et al., 1997) and even human 
circulating PBMCs (into athymic rats) (Iba et al., 2002). 
 
While there is wide variation in the methods employed in these animal studies, 
particularly relating to the phenotype of cells considered to be EPCs and their isolation 
and culture (in some studies), it is apparent that EPCs do promote neovascularisation.  
The extent of incorporation of EPCs into the newly formed vasculature is extremely 
variable (0-90%, (Ward et al., 2007) and recently there has been much interest in 
understanding the paracrine effects of these cells.   Some in vivo studies have implied 
that EPC recruitment to the site of injury is a transient response and hypothesise that the 
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major role of EPCs is to provide a localized pro-angiogenic environment facilitating 
repair (Fazel et al., 2006).   
 
6.2.1.2 EPCs in human clinical trials   
Despite many unanswered questions relating to function, phenotype and possible 
detrimental effects of EPC infusions, there have been a small number of groundbreaking 
studies that have taken EPC therapy into humans.  The majority of studies have 
involved patients with myocardical infarction and while safety has not been an issue in 
the studies performed, efficacy has been questionable (Jujo et al., 2008).   
 
The majority of studies undertaken have used infusions of freshly isolated mononuclear 
cells, from either blood (Assmus et al., 2002,Wollert et al., 2004) or bone marrow 
(Lunde et al., 2008,Janssens et al., 2006) rather than a selected population.  A small 
number of studies have examined the effects of isolated CD34+(Balogh et al., 2007) or 
CD133+ populations (Bartunek et al., 2005).  Overall it appears that localized infusion 
into the coronary arteries or myocardium during bypass surgery of either mononuclear 
cells, CD133+ or CD34+ cells can result in a mild to moderate improvement in cardiac 
function and/or reduction in infarct size, although these are inconsistent findings, with 
some studies indicating no improvement (Jujo et al., 2008).  This is in contrast to the 
promising and significant differences seen in the aforementioned animal models.  
However, the small human studies so far performed have been underpowered, and the 
methodologies variable, particularly the timing of EPC infusions post injury; the 
harvesting of cells and types of cell populations infused (Jujo et al., 2008).  Thus it is 
not surprising that the results obtained so far are inconsistent.  Only a longer clinical 
trial  or  metanalaysis of similar trials with common  treatment  protocols, will  establish  
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whether this is truly a therapeutic option for the future.   
 
Clinical trials of G-CSF mobilisation of autologous bone marrow stem cells have so far 
demonstrated no efficacy, and concerns have been raised over the risk associated with 
mobilization of inflammatory cells using this approach (Ward et al., 2007).  In the 
context of vasculitis, G-CSF has been implicated in experimental models of 
glomerulonephritis; mice in which GM-CSF or G-CSF has been knocked out are 
protected from a neutrophil driven glomerulonephritis (although not T-cell driven 
disease) (Kitching et al., 2002) and when rats with glomerulonephritis were treated with 
G-CSF, the condition was exacerbated (Futamura et al., 2002).  
 
6.2.2 Detecting EPCs 
Alongside the studies that implicate EPCs in endothelial reparative responses, there has 
been much interest in assessing their levels and functional capacity in different human 
diseases.  In various conditions it has been demonstrated that EPCs may be impaired or 
reduced in number, which in the context of vasculitis could conceivably be contributing 
to the disease.  As mentioned above, the exact phenotype of EPCs is unclear, however 
there are several methodologies by which putative EPCs have been enumerated, and in 
many studies these do appear to correlate with parameters relating to endothelial health.  
To date putative EPCs have been enumerated using cell culture techniques and flow 
cytometry.  Both techniques will now be described in detail.  
 
6.2.2.1 Cultured EPCs 
There are a number of different protocols described that use cell culture techniques to 
evaluate EPCs.  A number of studies have evaluated EPC colonies, which can be 
259 
 
derived from PBMCs or CD34+ enriched populations.  Colonies are clusters of cells, 
consisting of a central core of small rounded cells surrounded by spindle-like 
outgrowths (examples of which can be seen in section 2.6) and are formed after 5-7 
days of culture in media optimised for endothelial cell growth.  Cells are grown on an 
attachment scaffold such as fibronectin or collagen, and protocols may or may not 
involve a pre-plating step, whereby the non-adherent population is removed after 1-2 
days and replated (in order to remove possible contamination by mature endothelial 
cells (Hill et al., 2003)).  
 
Although colonies derived using different protocols look similar (Section 2.6, Figure 
2.4ab), their phenotype and cellular composition may well vary.  This is highlighted by 
two large studies from Hill et al and Xiao et al which have compared EPC colonies with 
cardiovascular risk factors.  The EPC colonies in these studies were grown using 
different culture media -  Hill et al used Medium 199 (Gibco) supplemented with 20% 
fetal calf serum (FCS) and antiobiotics, whilst Xiao et al used the commercially 
available endothelial optimised culture media EGM-2.  While Hill et al counted 
colonies derived from non-adherent pre-plated cells, Xiao et al did not pre-plate their 
EPCs.  Hill et al, demonstrated an inverse correlation with Framingham risk factors of 
cardiovascular disease and a positive correlation with flow mediated dilatation (FMD) 
(Hill et al., 2003), whilst Xiao et al in contrast observed no correlation with 
cardiovascular risk factors (Xiao et al., 2007b).     
 
The methodology described by Hill et al, has led to a commercially available colony 
counting media – EndocultTM which has been widely used to study putative EPC colony 
forming units (known henceforth as Hill-CFU).  The colonies formed consist of a 
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central core of haematopoeitic cells, which includes myeloid
 
progenitor cells, 
monocytes, and T lymphocytes and macrophage/monocyte derived outgrowths (Yoder 
et al., 2007).  While the outgrowths have been shown to express endothelial markers, 
produce nitric oxide and angiogenic growth factors they also have the ability to ingest 
bacteria – reflective of their myeloid lineage.  Moreover, when implanted in vivo they 
do not incorporate in de novo vessels, they have low proliferative capacity and if 
continued in culture after colony formation do not form endothelial-like monolayers, 
thus it is hypothesized that these colonies are not endothelial progenitors per se but pro-
angiogenic cells of a myeloid lineage (Yoder et al., 2007).  Regardless of which cell 
population Hill-CFUs represent, it is apparent that they are a reflection of endothelial 
health (Hill et al., 2003), in a more recent study by Werner et al in individuals with 
coronary artery disease increased levels of Hill-CFUs were accompanied by decreasing 
risk of death from cardiovascular cause (Werner et al., 2005). 
 
Whilst Hill-CFUs may reflect endothelial health, the colonies described by Xiao et al 
which did not reflect cardiovascular risk may in fact contain the elusive EPC 
population.  Longer term continuation (20+ days) of (non pre-plated) adherent colony 
cultures in EGM-2 can lead to the development of endothelial-like monolayers, known 
as late outgrowth EPCs (Lin et al., 2000,Ingram et al., 2004), although not in all 
individuals.  In contrast to Hill-CFUs this population of cells is highly proliferative, do 
not express haematopoetic markers such as CD45, CD14, or CD115 and do not ingest 
bacteria.  More importantly when implanted in mice this population spontaneously
 
forms blood vessels that incorporate with murine vessels (Yoder et al., 2007).   
 
Using  cell  sorted  umbilical cord blood, it has been  demonstrated  that  late  outgrowth  
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EPCs derive from a CD14 negative (Gulati et al., 2003) small CD34+ CD45 negative 
subset that expresses VEGFR2 but not CD133 (Timmermans et al., 2007), whereas the 
early colonies that form prior to late-outgrowth EPCs (the population examined by Xiao 
et al) are derived from a haematopoeitic source including CD34+CD45+ (Timmermans 
et al., 2007) and CD14+ cells (Gulati et al., 2003). 
 
Other cell culture techniques that have been used to examine EPC number and function, 
include the counting of cells staining for both DiI-acetylated
 
low-density lipoprotein and 
Ulex europaeus (endothelial markers) after 4-5 days in EGM-2 culture; the assessment 
of cultured cells ability to adhere to endothelial cells (such as HUVEC); or their 
incorporation into HUVEC tubules in extracellular matrix formulations (Matrigel
TM
).  
As with colony cultures a number of protocols are described and the exact cell 
populations which orchestrates these observations is unknown.  Most experiments 
relating to EPCs adherence/incorporation with HUVEC have used the aforementioned 
adherent cell colonies cultured in EGM-2.  As described above, despite the study by 
Xiao et al demonstrating that these colonies do not reflect cardiovascular risk factors, 
this is the culture which can go on to form late-outgrowth EPCs. 
 
The major restriction relating to EPC cell culture assays in children is the large volumes 
of blood required to obtain enough PBMCs for culture.  As described in the methods 
chapter the initial cultures require a minimum of 5 x 10
6
 cells per well for the Hill-CFU 
assay (preferably in duplicate) and 5 x 10
6
 cells per well for culturing of outgrowth 
monolayers or for Matrigel
TM
.  To perform each assay in triplicate would require 30 x 
10
6
 cells or a minimum of 30mls of blood (conceivably more in an immunosuppressed 
patient).   Thus for the purposes of this thesis it was decided to focus on development of 
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flow cytometric assays for detection of EPCs in vasculitis patients and to examine the 
culture methods in healthy adults to determine if it was possible to reduce blood volume 
required for these assays to ultimately apply to the vasculitis cohort. 
 
6.2.2.2 Flow cytometry of EPCs 
The flow cytometric markers used for EPC enumeration are based on the hypothesis 
that a putative circulating endothelial progenitor (adult angioblast) would share a 
combination of cell surface markers found on both embryonic angioblasts and 
haematopoeitic cells (Asahara et al., 1997).  The most commonly used are combinations 
of CD34 (found on angioblasts, haematopoietic progenitors and mature endothelium), 
VEGFR2 (found on angioblasts and mature endothelium) and CD133 (found on 
angioblasts and haematopoietic progenitors), with or without other endothelial markers 
such as CD31, CD144 or CD146 (Hirschi et al., 2008).  Some groups have defined 
EPCs as cells which stain for CD34, VEGFR2 and CD133 (Kondo et al., 2004)while 
others have used combinations of only 2 markers as these represent a larger cell 
population: CD34+CD133+ (Allanore et al., 2007), CD34+VEGFR2+ (George et al., 
2006), CD34+CD144+ (Redondo et al., 2008), CD133+VEGFR2+ (Brunner et al., 
2008) and CD133+CD144+(Rehman et al., 2004) have all been called EPCs.  While it is 
apparent that these populations do indeed correlate with a wide number of conditions 
associated with vascular injury or cardiovascular disease, it is unclear whether they 
reflect a true EPC population, and use of these different EPC definitions means that 
direct comparison between studies is problematic.   
 
When CD34+VEGFR2+CD133+ cells are isolated and cultured they do not form 
colonies or late outgrowth endothelial-like cells (Case et al., 2007) and neither do they 
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correlate with Hill-CFUs in healthy individuals (George et al., 2006).  However, as 
colonies have been shown to primarily consist of haematopoeitic cells, it is unsurprising 
that these methods are not comparable and that isolated populations do not form 
colonies alone.  The work of Timmermans et al indicates that late outgrowth EPCs may 
derive from the CD34+ VEGFR2+ population and so this combination of cell surface 
markers may be indicative of a true EPC.  However as these markers are both expressed 
on mature endothelium they cannot be used alone to define EPC populations and further 
phenotypic clarification is still required (Timmermans et al., 2007).   For the purposes 
of this thesis, as both in vivo and in vitro evidence indicate that the CD34+ population 
contains true EPCs, subpopulations of CD34+ cells were examined using flow 
cytometry. 
 
To date putative EPCs have been enumerated using flow cytometry from either whole 
blood or isolated PBMCs.  While using whole blood has the benefit that only small 
volumes of sample are necessary, the assay must be performed on the day of sampling; 
requires lysis which may remove fragile cell populations; and has a much higher level 
of non specific antibody binding.  In contrast isolated PBMCs can be stored (-80
o
C) 
allowing batch analysis, and as well as having overall less background noise neutrophils 
and red blood cells are removed without the need for lysis, thereby further increasing 
the signal to noise ratio.  Putative EPCs are rare events in the circulation and therefore 
careful consideration of the flow cytometric methodology is required to optimize their 
detection. Optimisation of flow cytometry for rare event analysis has been described in 
detail in Chapters 3 and 4, the principles of which remain the same when considering 
EPCs. 
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6.2.3 EPCs in health and disease 
While the exact phenotype of EPCs remains unclear, the field of EPC research has 
expanded rapidly since the early publications and much work has been done examining 
these putative EPC populations in health and disease.  As previously described care 
must be taken when comparing different studies as there is much heterogeneity in 
methods employed including cell surface markers examined.  In general, EPC numbers 
(as defined by both colony formation and by flow cytometry) appear to be lower in 
conditions associated with vascular risk and dysfunction including rheumatoid arthritis 
(Egan et al., 2008a), SLE (Moonen et al., 2007), acute stroke (Chu et al., 2008), 
diabetes mellitus (Egan et al., 2008b), hypertension (Umemura et al., 2008) and in the 
presence of cardiovascular risk factors such as smoking (Kondo et al., 2004).  EPCs can 
be mobilized using GM-CSF (granulocyte macrophage colony stimulating 
factor)(Takahashi et al., 1999), on exercise (Laufs et al., 2005) and in response to acute 
vascular injury such as acute myocardial infarction (Shintani et al., 2001) or in burns 
victims (Fox et al., 2008). 
 
EPC number and function declines with age (Heiss et al., 2005,Vasa et al., 2001) and 
children have higher levels of EPCs and haematopoeitic stem cells (CD34+) than adults 
(Jie et al., 2008).  This observation may explain in part why EPC therapy in young 
healthy animal models has proved more effective than in older, sick human patients. 
 
6.2.4 EPCs in vasculitis 
In adults with PR3-ANCA+ WG the number of Hill-CFUs is lower in active disease 
than in remission or in healthy controls (Holmen et al., 2005).  In a recent study in  
AAV, Hill-CFUs were again found to be decreased in patients compared to healthy 
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controls, although not compared to patients on hemodialysis (without vasculitis) or with 
peripheral arterial occlusive disease (Zavada et al., 2008) and in contrast to the work of 
Holmen et al, in this study remission inducing treatment did not increase Hill-CFUs 
(perhaps due to the more heterogeneic population studied).  In a recent flow cytometric 
study, de Groot et al demonstrated that adults with active AAV have comparable 
haematopoietic progenitor cells (CD34+) to healthy controls, however treatment 
increased numbers (de Groot et al., 2007).  As discussed above changes in CD34+ cells 
are not necessarily representative of an EPC response, but could indicate repopulation 
of a number of haematopoetic lineages (perhaps not surprising after cytotoxic 
immunosuppression).      
 
EPCs have only been examined in children with KD, although the study performed used 
a bead based isolation protocol, from which no EPCs were observed in healthy controls 
and only 11 out of 20 KD patients had measurable EPCs.  It was therefore concluded 
that EPCs were higher in KD both in the acute and aubacute phase compared to healthy 
child controls (Nakatani et al., 2003).  
 
 
6.3 Optimisation of flow cytometry for detection of 
EPCs  
6.3.1 Optimisation of antibody staining 
3 colour flow cytometry, as described in section 2.6.2 was used to evaluate expression 
of combinations of the most commonly studied EPC markers: VEGFR2, CD133 and 
CD34, with a variety of other cell surface markers.  These included the constitutive 
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endothelial markers CD144 and CD146 (used in CEC enumeration), the monocyte 
marker, the pan leukocyte marker CD45 and the T cell marker CD3. 
 
As EPCs are found in low levels in the circulation, there were a number of important 
considerations relating to rare event analysis which had to be taken into account when 
setting up this assay.  Non-specific antibody binding was minimized via use of FC-
receptor blocking agents.  Non stained samples and fluorochrome matched isotype 
controls were used to define positivity.  Antibodies were carefully titrated to determine 
optimum concentrations.  In the case of cell surface markers found on the endothelium 
(VEGFR2, CD144,CD146) the antibodies were titrated using HUVEC.  All other 
antibodies were titrated using umbilical cord PBMCs as cord blood contains higher 
numbers of haematopoeitic progenitor cells than adult blood (Watt and Contreras, 
2005).     
 
6.3.2 Sample storage - fresh/frozen PBMCS vs whole blood   
To further reduce non-specific antibody binding, isolated PBMCs as opposed to whole 
blood could be used – removing the need for red cell lysis.  Another advantage of this 
approach is that it would allow sample collection and storage (-80
o
C) while the 
techniques were being optimized.  In order to determine if EPC enumeration was 
dramatically affected by the freeze-thaw process, or was considerably different between 
whole blood samples and isolated PBMCs, blood was obtained from 5 healthy adult 
controls and the percentage of mononuclear cells which expressed CD34, CD133 and 
VEGFR2 was determined (Figure 6.1a-d).  As indicated in Figure 6.1 there were no 
significant differences in the proportion of mononuclear cells expressing CD34, CD133 
or the combined triple positive cells, when whole blood, fresh PBMCs and frozen 
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PBMCs were compared.  While there were some wide differences in values observed in 
individual patients, there were no overall directional trends observed.  Interestingly 
VEGFR2 staining was higher (although not significantly) in whole blood compared to 
PBMCs (frozen or fresh, Figure 6.1c) however this did not influence the triple positive 
population of interest and was presumably due to non-specific binding of this antibody.  
A larger study may have revealed significant differences, however as all samples from 
patients and controls were to be treated the same, the study examining EPCs in children 
with vasculitis was performed using isolated PBMCs, frozen and stored at -80
o
C.  
Storage was frequently necessary as it was often not practical to assay EPCs on the 
same day as sampling, and this also allowed convenient batch analysis.   
 
6.3.3 Flow cytometry – instrument settings and gates 
6.3.3.1 FSC/SSC of CD34+CD133+VEGFR2+ cells  
PBMCs isolated from umbilical cord blood were used to determine the FSC/SSC profile 
of cells expressing CD34, CD133 and VEGFR2 in order to determine the most 
appropriate gating strategy for enumeration of EPCs in isolated PBMCs.  Previous 
studies have used FSC/SSC gates for viable cells based on the lymphocyte population 
alone (Vasa et al., 2001),  an “extended lymphocyte gate” (Laufs et al., 2005) or both 
lymphocytes and monocytes combined (Rustemeyer et al., 2006) and therefore it was 
decided to investigate which strategy would include all putative EPCs  
  
As Figure 6.2 indicates, when cells positive for CD34, VEGFR2 or CD133 were back-
gated their FSC/SSC profiles fell within a similar region to lymphocytes (Figure 6.2a-f).  
However it was notable that both the CD34 and CD133 populations extended beyond 
  
268 
 
Figure 6-1: % of mononuclear cells expressing EPC markers in whole 
blood, fresh or frozen isolated PBMCs 
 
 
 
Figure 6.1a: Blood was obtained from 5 healthy adult controls.  The percentage of mononuclear cells 
(monocytes and lymphocytes expressing of CD34 (figure 6.1a), CD133 (Figure 6.1b), VEGFR2 (Figure 
6.1c) and the combination of all three markers (figure 6.1d) was determined in whole blood, fresh 
PBMCs and frozen PBMCs.  There were no overall significant differences between fresh and frozen 
PBMCs for expression for these markers and only VEGFR2 appeared higher (although not significantly) 
in whole blood from PBMCs (paired analysis vs fresh p=0.12, vs frozen p=0.14)  
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the lymphocyte population (highlighted in Figure 6.2g and h).  Thus an “extended 
lymphocyte gate” might be most appropriate to detect these cells.   
 
However this may be difficult to reproduce between different samples, particularly in 
vasculitis when the populations gated on may be activated or apoptotic which can 
influence their FSC/SSC profile (Darzynkiewicz et al., 1992).  Of particular concern 
was defining the upper limit of the gate, between the lymphocyte and monocyte 
populations.  Thus it was decided that a gate encompassing all PBMCs allowing EPCs 
to be expressed as a percentage of PBMCs would be a more standardized measure in 
this cohort (bold outline in Figure 6.2f).   
 
6.3.3.2 CD34+ cell gating 
Using a large viable cell gate has disadvantages, however, as cells from different 
populations may have slightly different staining intensities and there is a greater risk of 
non specific binding.  As can be seen in Figures 6.2a and b CD34+ and CD133+ 
PBMCs isolated from cord blood formed discrete populations.  The same was true for 
the CD34+ population in adult blood (data not shown).   In some individuals while the 
VEGFR2 staining was a much greater percentage of the PBMC gate than the percentage 
of CD34+ cells, there was much variability and discrete populations were not observed.  
It was decided that in order to allow identification of the different populations of CD34+ 
cells, PBMCS could be gated first on their FSC SSC and then on CD34 positivity, to 
further reduce background noise.  The staining of other putative EPC markers can then 
be examined in this population as demonstrated in Figure 6.3a-d.  
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Figure 6-2: FSC SSC characteristics of CD34+, CD133+ and VEGFR+ cells 
 
 
 
Figure 6.2a-h: PBMCs isolated from umbilical cord blood were stained for CD34, CD133 and VEGFR2. 
Cells positive for these markers (Figure 6.2a-c) were gated on, and the FSC/SSC characteristics of these 
populations determined by back-gating (Figure 6.2d-f).  Figures 6.2g - h indicates the combined regions 
that these populations fall in (thin lines) as well as  FSC SSC gate for EPC enumeration, both an 
extended lymphocyte gate (thick line, Figure 6.2g) and a broad mononuclear cell gate (thick line, Figure 
6.2h). 
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Figure 6-3: EPC gating strategy 
 
 
 
 
Figure 6.3: PBMCs were obtained from umbilical cord blood and stained for CD34, CD133 and 
VEGFR2.  Figure 6.3a: PBMCs were gated initially on their FSC SSC characteristics (R1); a large 
mononuclear cell gate incorporating the regions of high staining for CD34 and CD133 as described in 
Figure 6.2. Figure 6.3b: Cells were then gated on CD34 as this marker formed a discrete cell population 
(R2). Figure 6.3c: R1 and R2 were combined in order to determine the proportion of CD34 cells 
expressing CD133 and VEGFR2.   The triple positive population could then be calculated.  Figure 6.3d 
demonstrates the low nonspecific binding of the isotype control for CD34. CD34/VEGFR2/CD133 EPC 
count for this individual would be (0.69-0.04)% x 5.58/100 =  0.036% 
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6.3.3.3 How best to express EPC numbers? 
In the majority of published studies EPCs have been enumerated as a percentage of a 
viable cell gate as described above.  However, as previously discussed this will give 
varying results dependent on the size of the gate, making it difficult to compare 
different studies.  Of perhaps more relevance in the vasculitis cohort though is the 
possibility that the total number of cells within the gated population is changed in 
disease – for example there may be increased white cell count at disease onset which 
may decrease with immunosuppressive cytotoxic treatment and thus using a percentage 
of this gate may no longer be representative of absolute EPC number (giving falsely 
elevated results in patients with low mononuclear cells). 
 
Absolute enumeration of EPCs using counting beads in whole blood would be one way 
of avoiding this potential pitfall.  However as a number of precious samples had already 
been stored prior to establishing the assay, and rare event analysis in whole blood 
requires extensive optimization (due to increased background noise and the possibility 
of lysis removing some of the cells of interest) it was decided to investigate this 
phenomena concurrently to the aforementioned widely used methodology.  This was 
done by estimating absolute EPC number and evaluating an alternative enumeration 
strategy which may reduce the effect of this potential error as described below 
(summarized in Table 6.1). 
 
Estimating absolute EPC number 
As research bloods were taken from vasculitis patients in the study at the same time as 
routine clinical tests, full blood count as determined by the hospital laboratory could be 
used to estimate absolute EPC number.  The dual platform ISHAGE (International 
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Society of Hematotherapy and Graft Engineering) protocol for enumeration of CD34+ 
cells is routinely performed in hospital laboratories.  This utilizes the leukocyte count 
determined using an automated haematology analyzer and the % of nucleated white 
blood cells (CD45+, including CD45dim cells) expressing CD34, to determine absolute 
CD34 count in a sample, either of peripheral blood, bone marrow or leukapheresis 
product (Gajkowska et al., 2006).  It is important to note that applying this principle to 
the patient samples in  his study (as these have undergone density gradient separation to 
isolate PBMCs) does not give an exact measure of CD34+ cells, but can be used as a 
crude tool to estimate EPC levels and determine if trends observed using a percentage of 
the mononuclear gate are reflected when the absolute number of leukocytes is taken into 
account.  Thus validating the use of a percentage of a viable cell gate as an expression 
of EPC number in this cohort. 
 
Alternative gating 
Expressing EPCs as a percentage of the large mononuclear cell gate, gives a very small 
value (in healthy adult controls values were <0.1%, Figure 6.1d), which as discussed 
above could be influenced by changes in cell numbers.  Another approach which has 
been utilized in T cell biology when examining rare populations is to express the 
population of interest as a percentage of a much more defined, relevant population.  For 
example, the IL-17 producing T cell subset (Th17 cells) is expressed as a percentage of 
CD4+ T cells (Nistala et al., 2008), not as an absolute number or as a percentage of the 
larger total T cell population.  As the CD34+ population can reconstitute all blood cell 
lineages (Cheng et al., 1996) and is thought to contain the “true EPC” population, 
changes in expression of EPC markers in this cell population, may be an informative 
indicator of a reparative responses -  reflecting changes in haematopoetic progenitor 
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differentiation.  As can be seen in Figure 6.3, while cells expressing CD34, CD133 and 
VEGFR2 are only 0.036% of the mononuclear cell gate, they make up 5.68% of the 
CD34 population.  The advantages and disadvantages associated with each of the 
aforementioned methodologies for EPC enumeration is summarised in Table 6.1. 
 
Table 6-1: How best to enumerate and express EPC number 
 
Method Advantages Disadvantages 
Whole blood – absolute 
enumeration, using counting 
beads or ISHAGE dual 
platform protocols 
(Gajkowska et al., 2006) 
Only a small volume of blood 
required (<1ml) 
 
Can get an absolute value for 
EPCs per ml of blood 
Much background noise 
 
Lysis is necessary - may 
remove fragile cell 
populations 
 
Samples must be processed 
quickly, cannot be stored 
PBMC – expressing EPCs as 
% of viable cell gate. 
PBMCs can be isolated and 
stored for batch analysis 
 
If same gate is used, studies 
can be easily compared 
 
Variable gating strategy has 
been described in literature 
 
Changes in total 
mononuclear cell number 
with therapeutic intervention 
could influence results 
PBMCs – expressing EPCs 
as a % of CD34 cells 
PBMCs can be isolated and 
stored for batch analysis 
 
Gate is less variable 
 
Changes in total mononuclear 
cell number will have less of 
an affect on population of 
interest 
This methodology has not 
been described in the 
literature for EPC 
enumeration 
 
 
 
 
 
For the purposes of this thesis EPCs were enumerated from PBMCs isolated from 
patient using the two enumeration methodologies described in the above table.  
Absolute EPC number was also estimated from the values obtained in PBMCs to 
determine if either of these two enumeration methodologies mirrored the trends 
observed in absolute number. 
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6.4 EPCs in vasculitis 
6.4.1 Patients and Methods 
6.4.1.1 Patients 
15 children with primary systemic vasculitis were studied.  These patients were the 
same individuals described in Chapters 3, 4 and 5, allowing EPCs to be compared with 
CECs, MPs and growth factors involved in angiogenic/vasculogenic responses.  The 
patients studied included 6 males and 9 females of median age 9.7 years (range 1.0.-
15.3 years). The vasculitis type was polyarteritis nodosa (PAN) n=6, Wegener’s 
granulomatosis (WG) n=4, Kawasaki disease (KD) n=1, unclassified n=3. Disease 
activity was assessed using a modified paediatric BVAS as previously described.  18 
healthy child controls (4 males, 14 female, median age 8.4, range 1.5-14.6), 4 febrile 
controls (1 male, 3 females with a variety of autoimmune or other inflammatory 
disorders without the presence of vasculitis, median age 7.8, range 1.5-12) and 5 healthy 
adult controls were also recruited (1 male, 4 females, age range 24-30 years). As with 
the vasculitis patients, the control individuals were the same as those studied in 
Chapters 3 and 4.    Blood was processed immediately after collection as described in 
Chapter 2.6.   
 
6.4.1.2 Methods 
FC was performed as described previously and in section 2.6.2.  In order to allow 
enough flow cytometric cell events for accurate rare event analysis, the number of 
markers examined was varied so that in individuals where only small numbers of cells 
were obtained, meaningful data could still be acquired (Flow cytometric staining plans 
are listed in Appendix 3).  Putative EPCs were enumerated as a % of total PBMC 
population and as a % of CD34+ cells to determine which was the most appropriate 
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measure in this cohort.  Absolute EPC number was estimated from whole blood counts 
obtained from the hospital laboratory, to determine if trends observed in individual 
patients were reflective of absolute EPC number.  
  
6.4.1.3 Statistics 
The Mann-Whitney U test or Wilcoxon signed rank test (paired samples) were used to 
compare EPCs between patient groups (active vs inactive vasculitis – paired samples) 
and controls (unpaired analysis).  As only a small number of patients were studied – the 
majority of the active-inactive vasculitis data was paired and therefore there was not 
enough data to exclude paired events for comparative unpaired analysis between active 
and inactive disease. Spearman rank correlation coefficiants were used to determine 
correlation.  All statistical analyses were performed in SPSS version 15.0. Statistical 
significance was set at p<0.05.   In all data graphs patient classification was denoted 
using colour coding as indicated below: 
 
 
 
6.4.2 Results 
6.4.2.1 CD34+ cells 
Kruskall Wallis testing indicated no overall significant differences in the percentage of 
PBMCs expressing CD34 between test groups (p=0.3).  When individual analysis was 
performed the percentage of PBMCs expressing CD34, was not significantly different 
between 14 patients with active vasculitis (median value 0.198%) and 18 healthy child 
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controls (median value 0.161%) or 4 febrile controls (median value 0.18%).  The 
percentage of PBMCs expressing CD34 was however significantly lower in 5 healthy 
adult controls (median value 0.04%) compared to 18 healthy children (p=0.03) or 14 
children with active vasculitis (p=0.04). There were no significant differences between 
9 patients with inactive vasculitis (median value 0.11%) and any of the control groups.   
(Figure 6.4a).   
 
In 9 individual patients, there were no significant differences in the percentage of 
PBMCs expressing CD34 between active vasculitis and remission (median time to 
remission 4 months) (Figure 6.4b).  When 10 individual patients were followed up 
longitudinally from disease onset and initiation of treatment for up to 15 months there 
were no significant differences in CD34+ cells between onset and median followup of 3 
and 12 months (Figure 6.4c).   
 
In order to determine if the % of PBMCs expressing CD34 was comparable to the 
absolute numbers of CD34+ cells the changes in absolute CD34+ cell number was 
estimated as described above in section 6.6.3.  (Figure 6.5a and b).  Line colour reflects 
individual patients disease classification and the different line styles 
(solid/dashed/dotted) represent individual patients.  Notably, whilst a number of 
patients’ changes in absolute CD34 number reflected the changes in % of PBMCs 
expressing CD34, in some individuals the trends went in different directions (3/10, 
although only 1 – the red dashed line was considerably different), indicating that % of 
PBMCs may not be the most appropriate way of expressing EPC count in this cohort.  
At median followup of 3 and 12 months, there were no significant differences observed 
for either of these measures of CD34 count from pretreatment levels. 
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Figure 6-4:CD34+ cells in vasculitis 
 
 
 
 
 
Figure 6.4a: Kruskall Wallis testing indicated no overall significant differences between test groups 
(p=0.3).  Individual analysis revealed there were no significant differences in the % of PBMCs 
expressing CD34 between 15 patients with active vasculitis and 4 febrile controls or 18 healthy child 
controls.   However 5 adults had significantly lower CD34% compared to 15 children with active 
vasculitis (p=0.04) and 18 healthy child controls (p=0.03).  There were no significant differences 
between 9 patients in remission and these controls groups.  Figure 6.4b:  In 9 individual patients, there 
were no significant difference in CD34+ PBMCs during active or inactive disease, median time to 
remission 4 months (p=0.08).  
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Figure 6-5: CD34+ cells in vasculitis – responses to treatment 
 
 
Figure 6.5a-b: Changes in the % of PBMCs expressing CD34 over time from disease onset was 
compared to changes in estimated absolute numbers of CD34+ cells.  Line colour reflects individual 
patients disease classification (as before) and the different line styles (solid/dashed/dotted) represent 
individual patients.  Of the 10 patients followed longitudinally, the changes observed in 7 individuals 
were the same using both enumeration methods.  At median followup of 3 and 2 months, there were no 
significant differences using either technique when compared to pretreatment levels. 
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6.4.2.2 CD34+CD133+ cells 
PBMCs expressing both CD34 and CD133, could be indicative of an early progenitor 
population (although not necessarily one of endothelial lineage).  Kruskall Wallis 
testing indicated no overall significant differences in the percentage of PBMCs 
expressing both CD34 and CD133 between test groups (p=0.13).  Individual analysis, 
however revealed that the percentage of CD34+CD133+ PBMCs were significantly 
higher in 15 patients with active vasculitis (median value 0.099%) compared to 18 child 
controls (median value,0.037%, p=0.017), although not 4 febrile controls (median value 
0.056%) or 5 healthy adult controls (median value 0.05%).  There were no significant 
differences between 9 patients in remission (median value 0.057%) and these control 
groups, nor was there any difference using unpaired analysis (although paired data was 
included in this due to small numbers) between active and inactive vasculitis (p=0.08, 
Figure 6.6a).  In 9 individual patients, there appeared to be a trend towards a higher % 
of PBMCs expressing CD34+CD133+ during active disease compared to remission, 
although this had not reached statistical significance (p=0.054, median time to remission 
4 months) (Figure 6.6b).   
 
When the CD34+CD133+ population was expressed as the percentage of CD34+ cell 
expressing CD133, Kruskall Wallis testing indicated an overall significant difference 
between populations (p=0.006).  Individual analysis revealed that the percentage of 
CD34+ cells expressing CD133 was significantly higher in patients with active 
vasculitis (median value 53.5%) compared to 18 child controls (median value 28%, 
p=0.005), although not 4 febrile controls (median value 39%) or 4 healthy adult controls 
(median value 27.5%).  There was no significant difference between 9 patients in 
remission (median value 39%) and these control groups. Unpaired analysis (again 
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paired data was included in this due to small numbers) between active and inactive 
vasculitis revealed significantly higher CD133+CD34+ cells in patients with active 
disease (p=0.03, Figure 6.6c).  This finding was also true when paired analysis in 9 
individual patients was performed (p=0.04, median time to remission 4 months). 
 
In order to determine if the % of PBMCs expressing CD34 and CD133 was comparable 
to the proportion of CD34+ PBMCs expressing CD133 or the absolute numbers of 
CD34+ CD133+ cells, the changes observed in individual patients using these methods 
of expressing EPC are shown in figure 6.7a-c.   Of the 10 patients followed up from 
disease onset, the changes in the % of PBMCs expressing CD34 and CD133 were 
mirrored in 7/10 individuals by the changes in the % of CD34+ expressing CD133 and 
8/10 individuals by changes in the estimate of absolute number.  The changes in the 
estimate of absolute number were mirrored in 9/10 individuals by the proportion of 
CD34+ cells expressing CD133. 
 
When 10 patients were followed up from disease onset, the only significant difference 
observed was between pretreatment levels and median followup of 12 months for the 
absolute estimate of CD34+CD133+ cells.  There were no other significant differences 
in CD34+CD133+ between onset and median followup of 3 and 12 months for any of 
the three ways of expressing cell numbers (Figure 6.5c).  P values for percentage of 
PBMCs were p=0.25 and p= 0.22, for the percentage of CD34+ cells p = 0.054 and p = 
0.16 and for the estimate of absolute number p=0.1, p=0.03 respectively. 
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Figure 6-6: CD34+CD133+ cells in vasculitis 
 
Figure 6.6a: Kruskall Wallis testing indicated no overall significant differences in the percentage of PBMCs 
expressing CD34 and CD133 between test groups (p=0.13).  Individual analysis however revealed that 
CD133+CD34+ PBMCs were significantly higher in 15 patients with active disease compared to 18 healthy child 
controls (p=0.017) although not 4 febrile controls or 5 healthy adult controls.  There were no significant differences 
between 9 patients in remission and these controls groups.  Figure 6.6b:  In 9 individual patients, there were no 
significant difference in CD34+CD133 PBMCs during active or inactive disease, median time to remission 4 months 
(p=0.054).  Figure 6.6c: Kruskall Wallis testing indicated significantly different proportions of CD34+ cells 
expressing CD133 between test groups (p=0.006).  Individual analysis revealed that the CD133+ proportion of 
CD34+ PBMCs was significantly higher in 15 patients with active disease compared to 18 healthy child controls 
(p=0.005) and 9 patients in remission (p=0.03) although not 4 febrile controls or 18 healthy adult controls.  There 
were no significant differences between 9 patients in remission and these controls groups.  Figure 6.6d:  Paired 
analysis in 9 individual patients, showed that the CD133+ proportion of CD34+ PBMCs was significantly higher 
during active compared to remission (p=0.04, median time to remission 4 months).   
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Figure 6-7:  CD34+CD133+ cells in vasculitis – responses to treatment 
 
Figure 6.7a-c: Changes in the % of PBMCs expressing CD34 and CD133 (Figure 6.7a), the proportion 
of CD34 cells expressing CD133 (Figure 6.7b) and the estimated absolute numbers of CD34+CD133+ 
cells (Figure 6.7c) were observed over time from disease onset in individual patients.   Line colour 
reflects individual patients disease classification (as before) and the different line styles 
(solid/dashed/dotted) represent individual patients.  Of the 10 patients followed longitudinally, the 
changes in the % of PBMCs expressing CD34 and CD133 were mirrored by 7/10 individuals in the 
changes in the proportion of CD34+ expressing CD133 and 8/10 individuals in changes in the estimate of 
absolute number.  The changes in the estimate of absolute number were mirrored in 9/10 individuals by 
changes in the proportion of CD34+ cells expressing CD133.   When values at median followup of 3 and 
12 months, were compared to disease onset, a significant difference was only observed at 12 months 
when the estimate of absolute number was considered (p=0.03).    
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6.4.2.3 CD34+CD133+VEGFR2+ cells 
PBMCs which express CD34, VEGFR2 and CD133, has been the most widely 
published description of EPCs.  In this study Kruskall Wallis testing indicated no 
overall significant differences in the percentage of PBMCs expressing CD34, VEGFR2 
and CD133 between test groups (p=0.19).  Individual analysis, however revealed that 
the percentage of CD34+VEGFR2+CD133+ PBMCs was significantly higher in 15 
patients with active vasculitis (median value 0.027%) compared to 18 child controls 
(median value 0.016%, p=0.04), although not 4 febrile controls (median value 0.027%) 
or 5 healthy adult controls (median value 0.017%).  There were no significant 
differences between 9 patients in remission (median value 0.023%) and these control 
groups nor was there any difference using unpaired analysis (although paired data was 
included in this due to small numbers) between active and inactive vasculitis (p=0.3, 
Figure 6.8a).  In 9 individual patients, paired analysis also revealed no significant 
difference in the percentage of CD34+VEGFR2+CD133+ PBMCs between active 
vasculitis and remission (p=0.4, median time to remission 4 months, Figure 6.8b).   
 
When the CD34+VEGFR2+CD133+ population was expressed as the percentage of 
CD34+ cell expressing VEGFR2 and CD133, Kruskall Wallis testing failed to reach 
significance (p=0.052).  Individual analysis however revealed that the proportion of 
CD34+ cells expressing VEGFR2 and CD133 was significantly higher in patients with 
active vasculitis (median value 28.5%) compared to 18 child controls (median value 
11%, p=0.007), although not 4 febrile controls (median value 12%) or 5 healthy adult 
controls (median value 20%).  There was no significant difference between 9 patients in 
remission (median value 15%) and these control groups.  Unpaired analysis  (again  
paired   data   was   included   due   to   small   numbers)   between  active  and  inactive 
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Figure 6-8: CD34+VEGFR2+CD133+ cells in vasculitis 
 
Figure 6.8a: Kruskall Wallis testing indicated no overall significant differences in the percentage of PBMCs 
expressing CD34, VEGFR2 and CD133 between test groups (p=0.2).  Individual analysis however revealed that 
CD34+VEGFR2+CD133+ PBMCs were significantly higher in 15 patients with active disease compared to 18 
healthy child controls (p=0.04) although not 4 febrile controls or 5 healthy adult controls.  There were no significant 
differences between 9 patients in remission and these control groups.  Figure 6.8b:  In 9 individual patients, there 
were no significant difference in CD34+VEGFR2+CD133+ PBMCs during active or inactive disease, median time 
to remission 4 months (p=0.4).  Figure 6.8c: Kruskall Wallis testing indicated a significantly higher proportion of 
CD34+ cells expressing VEGFR2 and CD133 between test groups (p=0.05).  Individual analysis revealed that the 
VEGFR2+CD133+ proportion of CD34+ PBMCs was significantly higher in 15 patients with active disease 
compared to 18 healthy child controls (p=0.004) although not 9 patients in remission, 4 febrile controls or 18 healthy 
adult controls.  There were also no significant differences between 9 patients in remission and any control group.  
Figure 6.8d:  Paired analysis in 9 individual patients, showed that the VEGFR2+CD133+ proportion of CD34+ 
PBMCs was not significantly different between active vasculitis and remission (p=0.5, median time to remission 4 
months).   
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Vasculitis revealed no significant differences (p=0.3, Figure 6.8c). This finding was also 
true when paired analysis in 9 individual patients was performed (p=0.5, median time to 
remission 4 months, Figure 6.8d). 
 
In order to determine if the % of PBMCs expressing CD34, VEGFR2 and CD133 was 
comparable to the proportion of CD34+ PBMCs expressing VEGFR2 and CD133 or the 
absolute numbers of CD34+ VEGFR2+CD133+ cells, the changes observed in 
individual patients using the methods of expressing EPC are shown in Figure 6.9a-c.   
Of the 10 patients followed up form disease onset, the changes in the % of PBMCs 
expressing CD34, VEGFR2 and CD133 were mirrored in 5/10 individuals by the 
changes in the % of CD34+ expressing VEGFR2 and CD133 and 7/10 individuals by 
changes in the estimate of absolute number.  The changes in the estimate of absolute 
number were mirrored in 6/10 individuals by the proportion of CD34+ cells expressing 
VEGFR2 and CD133.    
 
When 10 patients were followed up from disease onset, no significant differences were 
observed between pretreatment levels and median followup of 3 or 12 months for for 
any of the three ways of expressing cell numbers (Figure 6.9a-c).  P values for the 
percentage of PBMCs were p = 0.6 and p = 0.3, for the percentage of CD34+ cells were 
p=0.2 and p=0.3 and for the estimate of absolute number p=0.1, p=0.15 respectively. 
 
6.4.2.4 CD34+ VEGFR2+ cells 
As discussed in the introduction to this chapter some groups consider only the 
CD34+VEGFR2+ population when describing EPCs using flow cytometry.  Using 
Kruskall  Wallis  testing  revealed that the percentage of PBMCs expressing  CD34  and 
VEGFR2 was not significantly different between test groups (p=0.5).   
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Figure 6-9: CD34+VEGFR2+CD133+ cells in vasculitis 
 
Figure 6.9a-c: Changes in the % of PBMCs expressing CD34,VEGFR2 and CD133 (Figure 6.9a), the proportion of 
CD34 cells expressing VEGFR2 and CD133 (Figure 6.7b) and the estimated absolute numbers of 
CD34+VEGFR2+CD133+ cells (Figure 6.7c) were observed over time from disease onset in individual patients.   
Line colour reflects individual patients disease classification (as before) and the different line styles 
(solid/dashed/dotted) represent individual patients.  Of the 10 patients followed longitudinally, the changes in the % 
of PBMCs expressing CD34, VEGFR2 and CD133 were mirrored by 5/10 individuals in the changes in the 
proportion of CD34+ expressing CD133 and 7/10 individuals in changes in the estimate of absolute number.  The 
changes in the estimate of absolute number were mirrored in 6/10 individuals by changes in the proportion of 
CD34+ cells expressing VEGFR2 and CD133.   When values at median followup of 3 and 12 months, were compared 
to disease onset, no significant differences were observed for any of the methods of enumeration. 
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On individual analysis no significant differences were observed between 15 patients 
with active vasculitis (median value 0.04%)  compared to 18 child controls (median 
value 0.05%), 4 febrile controls (median value 0.09%) or 5 healthy adult controls 
(median value 0.03%).  There was no significant difference between 9 patients in 
remission (median value 0.05%) and these control groups. Unpaired analysis between 
active vasculitis and patients in remission also revealed no significant differences 
(Figure 6.10a).  A finding repeated when data pairing was considered in the analysis 
(Figure 6.10b).   
 
When CD34+VEGFR2+ cells were expressed as the proportion of CD34+ cells 
expressing VEGFR2, Kruskall Wallis testing also revealed no overall significant 
differences between tesr groups (p=0.3).  Individual analysis again revealed no 
significant differences between patients with active vasculitis (median value 43%) or 
those in remission (median value 18%) and any of the control groups (median values 
adults = 21%, healthy children = 29%, febrile controls = 37%) .  Unpaired analysis 
between active vasculitis and patients in remission also revealed no significant 
differences, however when paired analysis was performed although not yet significant 
there appeared to be a trend with 7/9 patients having lower levels in disease remission 
(p=0.07).   
 
In order to determine if the % of PBMCs expressing CD34 and VEGFR2 was 
comparable to the proportion of CD34+ PBMCs expressing VEGFR2 or the absolute 
numbers of CD34+ VEGFR2+ cells, the changes observed in individual patients using 
the methods of expressing EPCs are shown in Figure 6.11a-c.   Of the 10 patients 
followed up form disease onset, the changes in the % of PBMCs expressing CD34 and  
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Figure 6-10: CD34+VEGFR2+ cells in vasculitis  
 
Figure 6.10a: Kruskall Wallis testing indicated no overall significant differences in the percentage of PBMCs 
expressing CD34 and VEGFR2 between test groups (p=0.5).  Individual analysis also revealed no significant 
differences between 14 patients with active vasculiits and 18 healthy child controls, 4 febrile controls or 5 healthy 
adult controls.  There were no significant differences between 9 patients in remission and these control groups.  
Figure 6.10b:  In 9 individual patients, there was a trend towards a decrease in CD34+VEGFR2+ PBMCs during 
remission, however this had not reached significance (p=0.07, median time to remission 4 months).  Figure 6.10c: 
Kruskall Wallis testing indicated no overall significant difference in the proportion of CD34+ cells expressing 
VEGFR2 between test groups (p=0.3).  Individual analysis also revealed no significant differences between 14 
patients with active vasculiits and 18 healthy child controls, 4 febrile controls or 5 healthy adult controls.  There 
were no significant differences between 9 patients in remission and these control groups.  Figure 6.10:  Paired 
analysis in 9 individual patients, showed that the VEGFR2+ proportion of CD34+ PBMCs expressing VEGFR2 was 
not significantly different between active vasculitis and remission (p=0.15, median time to remission 4 months).   
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VEGFR2 were mirrored in 6/10 individuals by the changes in the % of CD34+ 
expressing VEGFR2 and in 8/10 individuals by changes in the estimate of absolute 
number.  The changes in the estimate of absolute number were mirrored in 8/10 
individuals by the proportion of CD34+ cells expressing VEGFR2.   When 10 patients 
were followed up from disease onset, no significant differences were observed between 
pretreatment levels and median followup of 3 or 12 months for any of the three ways of 
expressing cell numbers (Figure 6.11a-c).  P values for the percentage of PBMCs were 
p = 0.5 and p = 0.3, for the percentage of CD34+ cells were p = 0.1 and p= 0.5 and for 
the estimate of absolute number p=0.2, p=0.15 respectively. 
 
6.4.2.5 CD34+CD144+ cells  
Another putative EPC combination described in a number of studies is CD34+CD144+ 
cells.  Using Kruskall Wallis testing revealed that the percentage of PBMCs expressing 
CD34 and CD144 was not significantly different between test groups (p=0.13).  
However, individual analysis revealed that 14 patients with active vasculitis (median 
value 0.05%) had significantly higher CD34+CD144+ PBMCs compared to 17 child 
controls (median value 0.019%, p=0.013), although not 4 febrile controls (median value 
0.09%) or 5 healthy adult controls (median value 0.03%).  There was no significant 
difference between 8 patients in remission (median value 0.05%) and these control 
groups. Unpaired analysis between active vasculitis and patients in remission also 
revealed no significant differences, a finding repeated when data pairing was considered 
in the analysis (Figure 6.12b).  When CD34+CD144+ cells were expressed as the 
proportion of CD34+ cells expressing CD144, Kruskall Wallis testing also revealed no 
overall significant differences between test groups (p=0.17).   
 
291 
 
Figure 6-11: CD34+VEGFR2+cells in vasculitis – responses to treatment 
 
Figure 6.11a-c: Changes in the % of PBMCs expressing CD34 and VEGFR2 (Figure 6.11a), the 
proportion of CD34 cells expressing VEGFR2 (Figure 6.11b) and the estimated absolute numbers of 
CD34+VEGFR2 cells (Figure 6.11c) were observed over time from disease onset in individual patients.   
Line colour reflects individual patients disease classification (as before) and the different line styles 
(solid/dashed/dotted) represent individual patients.  Of the 10 patients followed longitudinally, the 
changes in the % of PBMCs expressing CD34, and VEGFR2 were mirrored by 6/10 individuals in the 
changes in the proportion of CD34+ expressing VEGFR2 an in 8/10 individuals in changes in the 
estimate of absolute number.  The changes in the estimate of absolute number were mirrored in 8/10 
individuals by changes in the proportion of CD34+ cells expressing VEGFR2 and CD133.   When values 
at median followup of 3 and 12 months, were compared to disease onset, no significant differences were 
observed for any of the methods of enumeration. 
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Individual analysis revealed no significant differences between patients with active 
vasculitis (median value 38%) and any of the control groups (median values adults = 
35%, healthy children = 34%, febrile controls = 9%) or those in remission (median 
value 16%) (Figure 6.12c).  Unpaired analysis between active vasculitis and patients in 
remission revealed a significantly higher proportion of CD144+ cells during active 
disease (p=0.026), however when paired analysis was performed on 9 individual 
patients, the data was no longer significant (p=0.19, Figure 6.12d). 
 
In order to determine if the % of PBMCs expressing CD34 and CD144 was comparable 
to the proportion of CD34+ PBMCs expressing CD144 or the absolute numbers of 
CD34+ CD144+ cells, the changes observed in individual patients using the methods of 
expressing EPCs are shown in Figure 6.13a-c.   Of the 9 patients followed up form 
disease onset, the changes in the % of PBMCs expressing CD34 and CD144 were 
mirrored in 6/9 individuals by the changes in the % of CD34+ expressing CD144 and in 
6/9 individuals by changes in the estimate of absolute number.  The changes in the 
estimate of absolute number were mirrored in 7/9 individuals by the proportion of 
CD34+ cells expressing CD144.    
 
When 9 patients were followed up from disease onset, no significant differences were 
observed between pretreatment levels and median followup of 3 or 12 months for any of 
the three ways of expressing cell numbers (Figure 6.13a-c).  P values for the percentage 
of PBMCs were p = 0.6 and p = 0.7, for the percentage of CD34+ cells were p = 0.5 and 
p= 0.8 and for the estimate of absolute number p=0.3, p=0.8 respectively. 
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Figure 6-12:  CD34+CD144+ cells in vasculitis 
 
Figure 6.12a: Kruskall Wallis testing indicated no overall significant differences in the percentage of PBMCs 
expressing CD34 and CD144 between test groups (p=0.13).  However individual analysis revealed that 14 patients 
with active vasculitis had significantly higher CD34+CD144+ cells compared to 17 healthy child controls (p=0.013), 
although not 4 febrile controls or 5 healthy adult controls.  There were no significant differences between 9 patients 
in remission and these control groups.  Figure 6.12b:  In 8 individual patients, there was no significant difference 
between active vasculitis and remission (p=0.07, median time to remission 4 months).  Figure 6.12c: Kruskall Wallis 
testing indicated no overall significant difference in the proportion of CD34+ cells expressing CD144 between test 
groups (p=0.17).  However individual analysis revealed that 14 patients with active vasculitis had significantly 
higher CD34+CD144+ cells compared to 8 patients in remission, although not 17 healthy child controls, 4 febrile 
controls or 5 healthy adult control.   Figure 6.10: In 8 individual patients, there was no significant difference 
between active vasculitis and remission (p=0.19, median time to remission 4 months).  
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Figure 6-13: CD34+CD144+ cell in vascultis – response to treatment 
 
  
Figure 6.13a-c: Changes in the % of PBMCs expressing CD34 and CD144 (Figure 6.13a), the proportion of CD34 
cells expressing CD144 (Figure 6.13b) and the estimated absolute numbers of CD34+CD144+ cells (Figure 6.13c) 
were observed over time from disease onset in individual patients.   Line colour reflects individual patients disease 
classification (as before) and the different line styles (solid/dashed/dotted) represent individual patients.  Of the 9 
patients followed longitudinally, the changes in the % of PBMCs expressing CD34 and CD144 were mirrored by 6/9 
individuals in the changes in the proportion of CD34+ expressing VEGFR2 an in 6/9 individuals in changes in the 
estimate of absolute number.  The changes in the estimate of absolute number were mirrored in 7/9 individuals by 
changes in the proportion of CD34+ cells expressing VEGFR2 and CD133.   When values at median followup of 3 
and 12 months, were compared to disease onset, no significant differences were observed for any of the methods of 
enumeration. 
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6.4.2.6 CD34+CD144+CD133+ cells  
As CD34 and CD144 are both found on mature ECs, further discrimination is necessary 
and thus this population was examined in combination with the progenitor marker 
CD133.  Using Kruskall Wallis testing revealed that the percentage of PBMCs 
expressing CD34 and CD144 was not significantly different between test groups 
(p=0.17).  Individual analysis also revealed no significant differences between 14 
patients with active vasculitis (median value 0.03%) and any of the control groups (17 
healthy children, median value = 0.01%, 4 febrile controls, median value 0.01%, 5 
healthy adult controls, median value 0.02%).  8 patients in remission (median value 
0.01%) appeared to have lower CD34+CD144+CD133+ cells than patients with active 
vasculitis (unpaired analysis, p=0.07) and healthy child controls although this had not 
reached significance (p=0.051, Figure 6.14a).  When paired analysis was performed 
between active and inactive vasculitis in 8 individual patients there was no significant 
difference observed (p=0.1, Figure 6.14b).   
 
When CD34+CD144+CD133+ cells were expressed as the proportion of CD34+ cells 
expressing CD144 and CD133, Kruskall Wallis testing also revealed no overall 
significant differences between test groups (p=0.12).  Individual analysis revealed no 
significant differences between patients with active vasculitis (median value 18.6%) and 
any of the control groups (median values adults = 17%, healthy children = 14%, febrile 
controls = 9%).  There was also no significant difference between patients in remission 
(median value 8.5%) and these control groups, although values appeared lower in 
patients in remission compared to healthy child controls, this failed to reach significance 
(p=0.07, Figure 6.14c).  Unpaired analysis between active and inactive disease revealed 
patients with active disease had significantly higher CD34+CD144+CD133+ cells than 
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Figure 6-14 :CD34+CD144+CD133+ cells in vasculitis  
 
Figure 6.14a: Kruskall Wallis testing indicated no overall significant differences in the percentage of PBMCs 
expressing CD34, CD144 and CD133 between test groups (p=0.17).  Individual analysis also revealed no significant 
difference between 14 patients with active vasculitis and 17 healthy child controls, 4 febrile controls or 5 healthy 
adult controls.  There were no significant differences between 8 patients in remission and these control groups.  
Figure 6.14b:  In 8 individual patients, there was no significant difference between active vasculitis and remission 
(p=0.1, median time to remission 4 months).  Figure 6.14c: Kruskall Wallis testing indicated no overall significant 
difference in the proportion of CD34+ cells expressing CD144 and CD133 between test groups (p=0.12).  However 
individual analysis revealed that 14 patients with active vasculitis had significantly higher CD34+CD144+CD133+ 
cells compared to 8 patients in remission, although not 17 healthy child controls, 4 febrile controls or 5 healthy adult 
control.  There were no significant differences between 8 patients in remission and these control groups  Figure 
6.14d: In 8 individual patients, there was no significant difference between active vasculitis and remission (p=0.1, 
median time to remission 4 months).  
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patients in remission (p=0.023), although when paired analysis was performed on 8 
individual patients, the data was no longer significant (p=0.1, Figure 6.14d). 
 
In order to determine if the % of PBMCs expressing CD34, CD144 and CD133 was 
comparable to the proportion of CD34+ PBMCs expressing CD144 and CD133 or the 
absolute numbers of CD34+ CD144+CD133+ cells, the changes observed in individual 
patients using these methods of expressing EPCs are shown in Figure 6.13a-c.   Of the 9 
patients followed up from disease onset, the changes in the % of PBMCs expressing 
CD34 CD144 and CD133 were mirrored in 5/9 individuals by the changes in the % of 
CD34+ expressing CD144 and CD133 and in 8/9 individuals by changes in the estimate 
of absolute number.  The changes in the estimate of absolute number were mirrored in 
6/9 individuals by the proportion of CD34+ cells expressing CD144 and CD133 (Figure 
6.15a-c)    
 
When 9 patients were followed up from disease onset, no significant differences were 
observed between pretreatment levels and median followup of 3 or 12 months for any of 
the three ways of expressing cell numbers (Figure 6.15a-c).  P values for the percentage 
of PBMCs were p = 0.5 and p = 0.9, for the percentage of CD34+ cells were p = 0.3 and 
p= 0.25 and for the estimate of absolute number p=0.4, p=0.4 respectively. 
 
6.4.2.7 Other EPC related CD34 subpopulations 
In a small number of individuals, the EPC markers CD34, CD133, VEGFR2 and 
CD144 were examined in combination with CD14, CD45, CD3 and CD146 to further 
establish the origins of CD34+ progenitor cells.   
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Figure 6-15: CD34+CD144+CD133+ cells in vasculitis – response to 
treatment 
 
 
 
Figure 6.15a-c: Changes in the % of PBMCs expressing CD34 CD144 and CD133 (Figure 6.15a), the proportion of 
CD34 cells expressing CD144 and CD133 (Figure 6.15b) and the estimated absolute numbers of 
CD34+CD144+CD133+ cells (Figure 6.15c) were observed over time from disease onset in individual patients.   
Line colour reflects individual patients disease classification (as before) and the different line styles 
(solid/dashed/dotted) represent individual patients.  Of the 9 patients followed longitudinally, the changes in the % of 
PBMCs expressing CD34,CD144 and CD133 were mirrored by 5/9 individuals in the changes in the proportion of 
CD34+ expressing CD144 and CD133 in 8/9 individuals in changes in the estimate of absolute number.  The 
changes in the estimate of absolute number were mirrored in 6/9 individuals by changes in the proportion of CD34+ 
cells expressing CD144 and CD133.   When values at median followup of 3 and 12 months, were compared to 
disease onset, no significant differences were observed for any of the methods of enumeration. 
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The discrete CD34+ population gated on was frequently negative for CD45 or had only 
dim CD45 staining (Figure 6.16a).  Only a small proportion of CD34 cells expressed 
CD14 (Figure 6.16b) or the EC marker CD146 (Figure 6.16c).  CD146 as often at >1% 
in the blood, the majority of cells expressing it however were CD3+ T cells (Figure 
6.16d). In the small number of patients who were examined for CD34+CD14+CD133+ 
PBMCs, 6 patients with active vasculitis had a significantly higher percentage of this 
monocytic lineage cell expressing progenitor markers, compared to 16 healthy child 
controls (p=0.035) (Figure 6.17a).  There were no significant differences for 
CD14+CD34+ (figure 6.17b) or CD146+CD34+ (Figure 6.17c) compared to healthy 
child controls.   Figure 6.17a-c only expresses these cell populations as percentage of 
PBMCs, other ways of expressing cell populations were also not significant. 
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Figure 6-16:Further CD34+ staining 
 
 
 
 
 
Figure 6.16a and b: The discrete CD34+ population, was frequently negative for CD45 (Figure 
6.16a) and CD14 (Figure 6.16b) or only exhibited dim staining of either of these markers. Figure 
6.16c: The discrete CD34 population was also predominantly negative for the endothelial marker 
CD146.  The majority of CD146+ cells were CD3 positive T cells. (Figure 6.16d).   
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Figure 6-17: CD34+CD14+CD146+ cells in vasculitis 
 
Figure 6.17a: The % of PBMCs expressing CD34, CD14 and  CD133 were significantly higher in 6 
patients with active vasculitis compared to 16 healthy child controls, although not 4 healthy adult 
controls (not enough data for comparison with febrile controls (n=2)). 6 patients in remission were 
not significantly different from these control groups Figure 6.17b: The % of PBMCs expressing 
CD34 and CD14 were not significantly different between 6 patients with active vasculitis or 6 
patients in remission compared  to16 healthy child controls or 4 healthy adult controls (not enough 
data for comparison with febrile controls (n=2)). Figure 6.17c:  The % of PBMCs expressing CD34 
and CD146 were not significantly different between 4 patients with active disease or 4 patients in 
remission compared to 4 healthy child controls. 
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6.4.3 Correlation of EPCs with disease activity 
Spearman Rank correlation coefficiant analysis was performed between the different 
combinations of EPCs markers (measured as % of PBMCs and % of the CD34+ 
population) and the traditional markers of active disease; BVAS, CRP, ESR, platelet 
count, albumin, white cell count as well as the previously demonstrated novel markers 
of endothelial injury and cellular activation CEC count, EMPs and PMPs and the 4 
growth factors assessed in Chapter 5, in patients with vasculitis.  Tables 6.1 and 6.2 
summarises the results.   Table 6.3 shows the Holmn-Bonferroni critical values to 
correct for multiple comparisons. 
 
When EPCs were expressed as a percentage of PBMCs, correlations were observed 
between CD34+CD133+ PBMCs and white cell count (r = 0.444, p = 0.012), 
CD34+VEGFR2+ PBMCs and E-selectin +ve MPs (r = -0.516, p = 0.007) and total MP 
count (r = -0.460, p = 0.018) and CD34+ VEGFR2+CD133+ PBMCs and E-selectin 
+ve MPs (r = -0.496, p = 0.010).  When EPCs were expressed as a percentage of 
CD34+ cells, correlations were observed between CD34+CD133+ PBMCs and white 
cell count (r = 0.364, p=0.044),  CD34+ VEGFR2+ CD133+ PBMCs and CD144 +ve 
MPs  (r = -0.233, p = 0.022*), CD34+VEGFR2+ PBMCs and CD144 +ve MPs (r = -
0.556, p = 0.003), CD14+ MMPs (r = -0.418, p = 0.034) and total MP population (r = -
0.529, p = 0.005).   CD34+CD144+ PBMCs correlated with levels of Ang-1 (r = 0.464, 
p = 0.046).  Interestingly all significant correlations for both methods of expressing 
putative EPC populations with MPs were negative.   
 
When correction for multiple comparisons were taken into account non of the 
correlations observed remained significant (Table 6.3). 
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Table 6-2: Spearman rank correlation coefficiants of putative EPC populations 
– expressed as percentage of PBMCs.  
 
 
Significant correlations highlighted in blue 
Marker of 
disease 
activity/ 
growth 
factors 
% of 
PBMCs 
expressing 
CD34 
% of PBMCs 
expressing 
CD34/CD133 
% of PBMCs 
expressing 
CD34/CD133/ 
VEGFR2 
% of 
PBMCs 
expressing 
CD34/ 
VEGFR2 
% of 
PBMCs 
expressing 
CD34/ 
/CD144 
% of PBMCs 
expressing 
CD34/CD133/ 
CD144 
BVAS r = 0.18 
p = 0.39 
n = 30 
r = 0.266 
p = 0.149 
n = 31 
r = 0.152 
p = 0.42 
n = 30 
r = 0.080 
p = 0.68 
n = 30 
r = 0.131 
p = 0.515 
n = 27 
r = 0.164 
p = 0.40 
n = 28 
ESR r = 0.229 
p = 0.231 
n = 29 
r = 0.296 
p = 0.112 
n = 29 
r = 0.221 
p = 0.25 
n = 29 
r = 0.186 
p = 0.34 
n = 29 
r = 0.118 
p = 0.57 
n = 26 
r = 0.152 
p = 0.42 
n = 27 
CRP r = 0.335 
p = 0.075 
n = 29 
r = 0.325 
p = 0.080 
n = 30 
r = 0.090 
p = 0.64 
n = 29 
r = 0.177 
p = 0.58 
n = 29 
r = 0.025 
p = 0.90 
n = 26 
r = 0.177 
p = 0.38 
n = 27 
WCC r = 0.274 
p = 0.113 
n = 30 
r = 0.444 
p = 0.012* 
n = 31 
r = 0.256 
p = 0.17 
n = 30 
r = 0.168 
p = 0.37 
n = 30 
r = -0.035 
p = 0.863 
n = 27 
r = 0.331 
p = 0.085 
n = 28 
Platelet 
count 
r =-0.04 
p = 0.83 
n = 29 
r = 0.118 
p = 0.53 
n = 30 
r = 0.053 
p = 0.79 
n = 29 
r = -0.121 
p = 0.53 
n = 29 
r = -0.093 
p = 0.63 
n = 27 
r = 0.088 
p = 0.67 
n = 24 
Albumin r = -0.160 
p = 0.436 
n = 26 
r = -0.213 
p = 0.29 
n = 27 
r = -0.162 
p = 0.43 
n = 26 
r = -0.011 
p = 0.96 
n = 26 
r = -0.024 
p = 0.65 
n = 23 
r = -0.165 
p = 0.44 
n = 24 
CEC count r = 0.209 
p = 0.34 
n = 23 
r = 0.340 
p = 0.113 
n = 23 
r = 0.232 
p = 0.29 
n = 23 
r = 0.160 
p = 0.47 
n = 23 
r = -0.026 
p = 0.91 
n = 20 
r = -0.014 
p = 0.96 
n = 20 
EMP 
(CD144+) 
r = 0.083 
p = 0.68 
n = 27 
r = 0.122 
p = 0.545 
n = 27 
r = -0.258 
p = 0.20 
n = 26 
r = -0.236 
p = 0.25 
n = 26 
r = -0.174 
p = 0.43 
n = 23 
r = -0.110 
p = 0.61 
n = 24 
EMP 
(CD105+) 
r = 0.003 
p = 0.988 
n = 27 
r = -0.084 
p = 0.68 
n = 27 
r = -0.233 
p = 0.25 
n = 26 
r = -0.234 
p = 0.25 
n = 26 
r = 0.167 
p = 0.45 
n = 23 
r = -0.220 
p = 0.92 
n = 24 
EMP 
(eselectin+) 
r = -0.184 
p = 0.359 
n = 27 
r = -0.261 
p = 0.188 
n = 27 
r = -0.496 
p = 0.010* 
n = 26 
r = -0.516 
p = 0.007* 
n = 26 
r = -0.303 
p = 0.159 
n = 23 
r = -0.186 
p = 0.39 
n = 24 
PMP 
(CD42a+) 
r = -0.816 
p = 0.354 
n = 27 
r = -0.127 
p = 0.528 
n = 27 
r = -0.120 
p = 0.56 
n = 26 
r = -0.342 
p = 0.087 
n = 26 
r = -0.060 
p = 0.79 
n = 23 
r = -0.007 
p = 0.97 
n = 24 
MMP 
(CD14+) 
r = -0.014 
p = 0.95 
n = 27 
r = -0.009 
p = 0.963 
n = 27 
r = -0.359 
p = 0.072 
n = 26 
r = -0.352 
p = 0.078 
n = 26 
r = -0.044 
p = 0.84 
n = 23 
r = -0.220 
p = 0.30 
n = 24 
Total MP r = 0.217 
p = 0.32 
n = 23 
r = -0.007 
p = 0.96 
n = 27 
r = -0.296 
p = 0.141 
n = 26 
r = -0.460 
p = 0.018* 
n = 26 
r = 0.093 
p = 0.67 
n = 23 
r = -0.257 
p = 0.23 
n = 24 
VEGF r = 0.1 
p = 0.62 
n = 26 
r = -0.029 
p = 0.89 
n = 26 
r = -0.068 
p = 0.75 
n = 25 
r = -0.068 
p = 0.748 
n = 25 
r = 0.039 
p = 0.86 
n = 22 
r = 0.299 
p = 0.17 
n = 23 
ANG-1 r = -0.357 
p = 0.112 
n = 21 
r = -0.196 
p = 0.394 
n = 21 
r = -0.050 
p = 0.83 
n = 21 
r = -0.050 
p = 0.830 
n = 21 
r = 0.027 
p = 0.91 
n = 19 
r = 0.012 
p = 0.96 
n = 19 
ANG-2 r = -0.101 
p = 0.61 
n = 28 
r = -0.003 
p = 0.989 
n = 28 
r = -0.204 
p = 0.31 
n = 27 
r = -0.204 
p = 0.308 
n = 27 
r = -0.276 
p = 0.19 
n = 24 
r = -0.117 
p = 0.58 
n = 25 
TB4 r = -0.205 
p = 0.387 
n = 20 
r = -0.015 
p = 0.95 
n = 20 
r = -0.228 
p = 0.35 
n = 19 
r = 0.1 
p = 0.63 
n = 25 
r = -0.382 
p = 0.14 
n = 16 
r = 0.042 
p = 0.87 
n = 17 
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Table 6-3: Spearman rank correlation coefficiants of putative EPC populations 
– expressed as percentage of CD34+ PBMCs. 
 
Marker of 
disease 
activity/ 
growth 
factors 
% of CD34+ 
cells expressing 
CD133 
% of CD34+ 
cells expressing 
CD133/VEGFR2 
% of CD34+ 
cells expressing 
VEGFR2 
% of CD34+ 
cells expressing 
CD144 
% of CD34+ 
cells expressing 
CD133/CD144 
BVAS r = 0.139 
p = 0.456 
n = 31 
r = 0.013 
p = 0.95 
n = 30 
r = 0.013 
p = 0.94 
n = 30 
r = 0.263 
p = 0.17 
n = 27 
r = 0.177 
p = 0.36 
n = 28 
ESR r = 0.285 
p = 0.126 
n = 29 
r = 0.051 
p = 0.79 
n = 29 
r = 0.104 
p = 0.59 
n = 29 
r = 0.139 
p = 0.49 
n = 26 
r = 0.129 
p = 0.52 
n = 27 
CRP r = 0.113 
p = 0.554 
n = 30 
r = -0.116 
p = 0.55 
n = 29 
r = -0.104 
p = 0.59 
n = 29 
r = 0.236 
p = 0.24 
n = 26 
r = 0.063 
p = 0.75 
n = 27 
WCC r = 0.364 
p = 0.044* 
n = 31 
r = -0.105 
p = 0.58 
n = 30 
r = 0.216 
p = 0.25 
n = 30 
r = -0.259 
p = 0.18 
n = 27 
r = -0.133 
p = 0.50 
n = 28 
Platelet count r = 0.290 
p = 0.12 
n = 30 
r = -0.001 
p = 0.99 
n = 29 
r = -0.164 
p = 0.40 
n = 29 
r = -0.181 
p = 0.34 
n = 27 
r = -0.076 
p = 0.70 
n = 24 
Albumin r = -0.103 
p = 0.61 
n = 27 
r = 0.048 
p = 0.81 
n = 26 
r = 0.043 
p = 0.83 
n = 26 
r = -0.277 
p = 0.19 
n = 23 
r = -0.210 
p = 0.32 
n = 24 
CEC count r = 0.146 
p = 0.51 
n = 23 
r = -0.174 
p = 0.42 
n = 23 
r = -0.282 
p = 0.19 
n = 23 
r = -0.276 
p = 0.24 
n = 20 
r = -0.229 
p = 0.33 
n = 20 
EMP 
(CD144+) 
r = -0.004 
p = 0.9 
n = 27 
r = -0.233 
p = 0.022* 
n = 26 
r = -0.556 
p = 0.003 
n = 26 
r = -0.239 
p = 0.26 
n = 24 
r = -0.262 
p = 0.22 
n = 24 
EMP 
(CD105+) 
r = -0.168 
p = 0.40 
n = 27 
r = -0.149 
p = 0.47 
n = 26 
r = -0.245 
p = 0.23 
n = 26 
r = 0.169 
p = 0.43 
n = 24 
r = -0.140 
p = 0.52 
n = 24 
EMP 
(eselectin+) 
r = -0.301 
p = 0.13 
n = 27 
r = -0.340 
p = 0.089 
n = 26 
r = -0.351 
p = 0.078 
n = 26 
r = 0.054 
p = 0.80 
n = 24 
r = 0.012 
p = 0.96 
n = 24 
PMP 
(CD42a+) 
r = -0.107 
p = 0.59 
n = 27 
r = 0.048 
p = 0.82 
n = 26 
r = -0.257 
p = 0.20 
n = 26 
r = -0.041 
p = 0.85 
n = 24 
r = -0.055 
p = 0.79 
n = 24 
MMP 
(CD14+) 
r = 0.007 
p = 0.98 
n = 27 
r = -0.26 
p = 0.2 
n = 26 
r = -0.418 
p = 0.034 
n = 26 
r = -0.074 
p = 0.26 
n = 24 
r = -0.377 
p = 0.069 
n = 23 
Total MP r = 0.004 
p = 0.98 
n = 27 
r = -0.201 
p = 0.32 
n = 26 
r = -0.529 
p = 0.005* 
n = 26 
r = -0.179 
p = 0.40 
n = 24 
r = -0.336 
p = 0.11 
n = 23 
VEGF r = -0.245 
p = 0.23 
n = 26 
r = -0.245 
p = 0.24 
n = 25 
r = -0.139 
p = 0.51 
n = 25 
r = 0.333 
p = 0.12 
n = 23 
r = 0.328 
p = 0.099 
n = 23 
ANG-1 r = -0.083 
p = 0.72 
n = 21 
r = 0.204 
p = 0.28 
n = 21 
r = 0.284 
p = 0.21 
n = 21 
r = 0.464 
p = 0.046 
n = 19 
r = 0.489 
p = 0.034 
n = 19 
ANG-2 r = 0.310 
p = 0.109 
n = 28 
r = 0.252 
p = 0.21 
n = 27 
r = 0.098 
p = 0.63 
n = 27 
r = 0.228 
p = 0.27 
n = 24 
r = 0.227 
p = 0.27 
n = 25 
TB4 r = -0.180 
p = 0.45 
n = 20 
r = -0.170 
p = 0.23 
n = 19 
r = -0.205 
p = 0.40 
n = 25 
r = 0.145 
p = 0.58 
n = 17 
r = -0.042 
p = 0.87 
n = 17 
 
Significant correlations highlighted in blue 
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Table 6-4:  Holm-Bonferroni critical values for significant correlations between 
EPCs and markers of disease activity 
Test P value Adjusted critical value 
(Holm-Bonferroni) 
EMP (eselectin+) vs % of 
PBMCs expressing CD34 0.007 0.00049 
EMP (eselectin+) vs % of 
PBMCs expressing CD34 0.01 0.000495 
WCC vs % of PBMCs 
expressing CD34/CD133 0.012 0.0005 
Total MP vs % of PBMCs 
expressing CD34/CD133 0.018 0.000505 
   
EMP (CD144+) vs % of CD34+ 
cells expressing VEGFR2 0.003 0.000588 
Total MP vs % of CD34+ cells 
expressing VEGFR2 0.005 0.000595 
EMP (CD144+) vs % of CD34+ 
cells expressing 
CD133/VEGFR2 0.022 0.000602 
MMP vs % of CD34+ cells 
expressing VEGFR2 0.034 0.00061 
ANG-1 vs % of CD34+ cells 
expressing CD133/CD144 0.034 0.000617 
WCC vs % of CD34+ cells 
expressing CD133 0.044 0.000625 
ANG-1 vs % of CD34+ cells 
expressing CD144 0.046 0.000633 
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6.5 Detection of EPCs using cell culture 
While the main focus of this chapter has been on using flow cytometry to detect 
populations of EPCs, culture methodologies may give some insight into the functional 
capacity of EPCs, and although time limitations (and blood volume limitations as 
previously mentioned) of this project did not permit extensive assessment of the 
vasculitis cohort, the preliminary observations relating to methodology performed in 4 
adult controls and 2 patients bears mention.   
 
As discussed in the introduction to this chapter, many groups have used a colony 
counting methodology to assess EPCs in vitro.  While the non-adherent population 
isolated after 1-2 days in culture gives rise to a colony phenotype which correlates with 
endothelial function (Hill et al., 2003) and mortality (Werner et al., 2005), as yet the 
colonies derived from the non-adherent cells have not shown such a clear cut 
relationship (Xiao et al., 2007b), yet this population contains a cell population which 
can go on to form endothelial-like monolayers after 2-3 weeks in culture (notably the 
non-adherent population has not been documented to do this).    The aim of these 
preliminary studies was to develop a methodology where it would be possible to analyse 
both adherent and non-adherent colonies as well as using the non-adherent population in 
matrigel tubule experiments, based on techniques previously established in our group 
but minimizing the volume of blood necessary.  As has been apparent throughout this 
study, it is frequently a problem to obtain greater than 10-15mls total volume of 
research blood from small children.  In the following series of preliminary experiments 
blood was obtained from 4 healthy adult controls and 2 children with vasculitis (one 
individual had PAN, the other an unclassified small vessel vasculitis, both were on 
immunosuppressive treatment and disease was in remission). 
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6.5.1 Colony counting 
The protocol for enumeration of colonies derived from the non-adherent culture 
population as described in the section 2.6.3 was based on the protocol described by Hill 
et al (Hill et al., 2003).  Briefly 2.5 x 10
6
 cells were added per well on a 12 well 
fibronectin coated plate and cultured for 48hrs in RPMI with 20% FCS and antibiotics.  
After 48hrs the supernatant was removed and the  non-adherent cells contained in it 
were counted and replated at a concentration of 1 x10
6
 cells per well on a second 12 
well fibronectin coated plate and cultured in EPC media for 7 days (section 2.6.3).  The 
remaining adherent populations on the original culture plate were also cultured 
concurrently in EPC mix to see if the two populations differed considerably when 
colonies were counted.   
 
In 5 individuals (2 patients, 3 adult controls) each initial culture well gave enough non-
adherent cells for 1 well of second stage non-adherent culture.  In 1 healthy control, 
however, 3 wells only gave sufficient non-adherent cells for 2 wells.  Thus in order to 
get a minimum of 2 non-adherent cultures for enumeration of colonies, at least 3 initial 
wells would be necessary using this methodology (a total of 7.5x10
6
 cells, 
approximately 7-10mls of blood).  Figure 6.18a-d demonstrates the typical phenotype of 
both the non-adherent and adherent colonies observed in this experiment and the 
number of colonies counted for both the patients and controls.   As can be seen from 
Figure 6.18, more colonies were formed in non-adherent cell cultures and both patients 
had less colonies than 3 of 4 healthy adults studied.   
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Figure 6-18: EPC colony culture 
 
 
Figure 6.18a and b: When PBMCs were cultured in EPC mix the non-adherent colonies were often 
large (formed after 5-9 days) (figure 6.18a) and in 6 individuals (4 healthy adult controls and 2 
vasculitis patients – one with PAN, one with an unclassified small vessel vasculitis, both on 
immunosuppressive treatment) colony count at day 9 ranged from 0-86 colonies per well. Figure 
6.18c and d: When the non-adherent population was removed after an initial 48 hours in culture and 
replated, colonies formed after 5-7 days in culture (figure 6.18c) and in 6 individuals (4 healthy 
adult controls and 2 vasculitis patients as before) colony count at day 7 ranged from 0-42 colonies 
per well. 
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6.5.2 Matrigel 
When endothelial cells such as HUVEC are grown on the extracellular matrix scaffold - 
Matrigel
TM
, they form tubule networks (Figure 6.19a).  In this system, the ability of 
EPCs to incorporate and influence EC growth (and repair) can be assessed.  As 
mentioned above, culturing of PBMCs in EGM-2 can lead to the development of late-
outgrowth EC-like monolayers.  Thus earlier cultures must include the putative EPC 
population, thus EGM-2 cultures in which colonies have formed (herein described as 
EPC enriched) are used in these in vitro assays.  
 
In order to generate sufficient adherent cells for matrigel assays (as described in section 
2.6.4) 5 x 10
6 
cells per well were cultured on fibronectin coated 12 well plates in EGM-
2 for 9 days. Cells from these EPC enriched cultures were then lifted and 40,000 cells 
were combined with 40,000 HUVEC in EGM-2 on a Matrigel
TM
 coated 12 well plate 
and cultured for a further 18 hours.  In all of the 6 individuals studied (4 adult controls, 
2 patients), 1 well of initial culture was more than sufficient to generate enough cells for 
1 well of Matrigel
TM
 culture.  However even in the small numbers studied it was 
immediately apparent that the cultures obtained from patients grew poorly compared to 
the adults.  After 9 days, all of the healthy adult cultures were confluent with cells, 
making it impossible to distinguish colonies (Figure 6.19b).  In both patients, however, 
there were much fewer cells and neither culture appeared confluent, individual colonies 
could be readily counted (Figure 6.19d).  Thus in order to generate enough cells for a 
Matrigel
TM
 assay using this methodology, at least 2 wells would be necessary (10 x 10
6 
cells, approximately 10-15mls of blood). 
 
The  extent  of  incorporation  and the influence that EPC enriched cultures can  have on  
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endothelial cells, can be readily assessed in this system.  EPC enriched culture cells can 
be distinguished from HUVEC by using a metabolic dye such as diI labeled-acetylated 
low density lipoprotein as described in section 2.6.5 (Figure 6.19d) to determine the 
extent of incorporation.  Growth characteristics such as total tubule length and number 
of branch point in a random field can also be readily determined (highlighted in Figure 
6.19a).   
 
The changes in growth characteristics attributable to EPC enriched cells were 
determined by comparing mixed EPC enriched/HUVEC cultures to a control well 
containing only 40,000 HUVEC.  This is an important comparison as it controls for 
variations in HUVEC growth between different experiments.  Figures 6.20a-c 
demonstrate the preliminary results obtained in the individuals studied.  In this series of 
experiments 5 out of the 6 EPC enriched cultures studied (3 healthy adults and 2 
patients) exerted a slightly negative effect on HUVEC tubule length (Figure 6.20a) and 
number of branch points (Figure 6.20b) when compared to the control well of HUVEC 
alone.  The range of tubule length (expressed as a ratio of HUVEC cultured with EPC 
enriched cells to HUVEC alone) was 0.75 – 1.25 in healthy adults and 0.3-0.75 in the 
two patients.  When branch points were considered the range (as before expressed as a 
ratio) was 0.4-1.25 in healthy adults and 0.4-0.5 in the two patients.  Incorporation of 
EPC enriched cultures was low in all cultures (5-14 cells per random field, Figure 
6.20c).  
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Figure 6-19: Matrigel EPC culture 
 
 
 
 
Figure 6.19a: When HUVEC were cultured on Matrigel
TM
, they formed tubule networks.  Growth of 
these tubules were assessed by counting of branch points (arrowed) and measuring total tubule 
length within a random field.  Figure 6.19b:  To assess how EPC enriched cells could influence 
HUVEC tubule formation, PBMCs were cultured for 9 days in EGM-2 before combining with 
HUVEC in Matrigel
TM
.  All of the EPC enriched cultures from healthy adults were confluent with 
cells making it impossible to count colonies (figure 6.19b).  In the 2 patients studied both had much 
fewer cells (Figure 6.19c). Figure 6.19d: DiI-acetylated LDL could be used to stain cultured 
PBMCs to allow them to be distinguished from the HUVEC they incorporated into.  
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Figure 6-20: Matrigel assay results 
 
 
 
Figure 6.20a-c: 40,000 PBMCs cultured for 9 days in EGM-2 were lifted and mixed with 40,000 HUVEC 
and cultured on Matrigel
TM
 for 18 hours.  These were compared to HUVEC cultured alone.  Figure 
6.20a: In 6 individuals (4 healthy adult controls and 2 patients on treatment) the ratio of total tubule 
length between mixed cultures and HUVEC alone ranged from 0.3 to 1.25.  Figure 6.20b: In 6 
individuals (4 healthy adult controls and 2 patients on treatment) the ratio of total branch points between 
mixed cultures and HUVEC alone ranged from 0.4 to 1.2.  Figure 6.20c: Incorporation of cells was low 
in all cultures, ranging from 2-14 cells per random field.  
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6.6 Discussion 
EPCs have been enumerated in a number of different ways and as yet no consensus has 
been reached as to which culture techniques or flow cytometric protocols best describes 
this population of cells.  In this chapter flow cytometry was used to investigate the 
different CD34+ populations within which EPCs are thought to reside and some 
preliminary data relating to optimization of culture methodologies for detection of EPCs 
was also presented.  The latter are important, but were not applied widely to the 
paediatric vasculitis cohort because the blood volumes required were too great to obtain 
from children concurrently with the other tests described in this thesis.    
 
Using flow cytometry the proportion of PBMCs expressing a number of combinations 
of EPC markers (CD34+CD133+, CD34+CD133+VEGFR2+ and CD34+CD144+) 
were significantly higher in patients with active disease compared to healthy child 
controls.  Two different combinations of cell surface markers which other groups have 
used to define EPCs (CD34+VEGFR2+ and CD34+CD144+CD133+) were not. 10 
individual patients were studied from disease onset and no significant differences were 
observed in any of the combinations of cell surface markers between active and inactive 
disease (although CD133+CD34+ was close to significance with p=0.054) or at median 
followup of 3 or 12 months from disease onset.  This is undoubtedly influenced by the 
small numbers studied.  
 
As described earlier in this chapter, concerns were raised as to whether enumeration of 
putative EPCs as a proportion of a viable cell gate (a protocol which is frequently 
described within EPC literature) was appropriate in this cohort.  While this is an 
acceptable definition of an EPC for some studies, and has been widely published, in the 
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context of vasculitis, immunosuppressive treatment might be skewing the population by 
reducing the absolute number of cells within the gate.   In order to determine if this was 
a major limitation of this study, putative EPC populations were enumerated in 3 
different ways.  Firstly using the widely published percentage of the broad PBMC gate, 
secondly as a percentage of a smaller more defined population (CD34+ cells).  Both of 
these were compared to an estimate of absolute number in individual patients followed 
up from disease onset.  In order to estimate the absolute number of EPCs, the leukocyte 
count derived from the routine bloods taken in the vasculits patients was utilized in a 
methodology adapted from the dual platform ISHAGE protocol for enumeration of 
CD34+ cells (Gajkowska et al., 2006).    
 
For each combination of putative EPC markers, when these 3 enumeration methods 
were compared, the majority of changes in EPC number over time in individual patients 
was comparable.  However in a small number of patients, there were obvious 
differences; for example where EPCs enumerated as a percentage of PBMCs had 
increased, absolute number may have declined.  Enumerating EPCS as a proportion of 
CD34+ cells did not mirror the changes occurring in the estimate of absolute number 
any better than enumerating them as a percentage of the PBMC gate.  However when 
differences between active disease and controls groups for this method of enumeration 
were examined, p values for the groups where a significant difference was observed 
were smaller (for CD34+CD133+ and CD34+VEGFR2+CD133+ populations).  The 
exception to this was the CD34+CD144+ population which was significantly different 
between active disease and controls when expressed as a percentage of PBMCs, but not 
when expressed as a percentage of CD34+ cells.      
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While this could be consided over-interpretation of the available data, it raises an 
interesting question relating to what is the most appropriate way to quantify an EPC 
population.  When considered alone absolute number seems to a more intuitive 
measure, however when the relationship between EPCs and haematopeotic cells is 
considered matters become more complicated.  The measure of EPCs which has been 
shown to most closely reflect endothelial function (non-adherent colonies) is actually a 
measure of the interaction between haematopoeitic cells and presumanbly EPCs (the 
majority of cells making up these colonies staining postiviely for CD3 or CD14).  
Therefore the ratio (or percentage) of EPCs within this population may actually be more 
informative.  For future studies, it would be important to consider both, thus 
optimization of whole blood flow cytometry from which both an absolute number and a 
% of the mononuclear cells expressing these markers could be derived would be an 
obvious future direction of this work.  It would also allow a much smaller amount of 
blood to be used, allowing culture work to be carried out in parallel on these samples. 
 
Despite questions relating to the best way to enumerate EPCs, significant increases were 
observed during active disease in CD34+VEGFR2+CD133+ and CD133+CD34+ 
populations in the two methods that could be compared with healthy child controls.  
This is comparable with the study by Nakatani et al who observed increased EPC 
number in patients with active  KD compared to healthy controls, with highest levels 
being found in patients with coronary artery lesions (Nakatani et al., 2003).   The 
increase in EPCs number seen in these children with vasculitis also corresponds with 
the findings from Chapter 5, where it was determined that growth factors associated 
with vasculogenesis are also elevated in active disase, particularly at disease onset, and 
decline with remission inducing therapy.   
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When the putative EPC populations observed in this chapter with correlated with other 
markers of disease activity, including growth factors, no striking correlations were 
observed, however numbers were small (>30 events) and a larger study population may 
be needed, also the large number of tests performed meant the significant correlations 
observed did not withstand multiple comparison corrections.  Interestingly the majority 
of EPC markers studied actually correlated negatively with endothelial microparticles, 
perhaps this is indicative of EPCs being targeting towards activated endothelium, hence 
being at lower levels.       
 
In adults however, the situation is in contrast to that observed in children.  Adults with 
active AAV have comparable levels of CD34+ PBMCs to healthy controls, which 
increase on treatment (de groot et al., 2007).  This interesting observation indicates that 
perhaps children have a different response to vasculitic injury than adults.  Further study 
will however be necessary to clarify this.  While increases in EPC number may well be 
relevant to attempted reparative responses, the function of these EPCs in children, could 
conceivably be impaired.  Studies which have utilized colony formation assays  in 
adults with active AAV have demonstrated decreased formation of colonies which may 
(Holmen et al., 2005) or may not improve with treatment (Zavada et al., 2008) .  
 
Considering the underwhelming differences in the different EPC populations between 
disease and the various controls, and the lack of consistency within the literature as to 
what constitutes an EPC, EPC functional assays in this cohort may indeed give more 
informative data and is an avenue of considerable future interest.   Using the EPC 
culture methodologies that have been previously established within the group (Arrigoni 
F & Haliday N, personal communication), it was immediately apparent that the volume 
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of blood necessary for generating informative data was prohibitive in the vasculitis 
cohort, particularly if any of the other assays described in this thesis were to be carried 
out in parallel. Thus further optimization would be necessary.  Currently performing 
assays to assess non-adherent colonies and Matrigel
TM
 would require a minimum of 15-
20mls of blood (to obtain 17.5x10
6
 PBMCs in total).  This is too much blood to obtain 
from small children, especially when a further 5-10mls is required for the other assays 
described in this thesis.  The methodologies for these assays described in this chapter 
were preliminarily investigated because they are based on techniques previously 
published which have provided the most informative data relating to endothelial health 
(in the case of the non-adherent colonies which correlate with FMD) or in the case of 
the EPC enriched population which can integrate into endothelium (the matrigel 
experiments).  The first obvious optimization would be to combine the two above 
mentioned culture assays in order to generate one culture from which both the non-
adherent culture and the adherent cells for Matrigel
TM
 could be derived.  This would 
require extensive investigation into the effects that slight changes to culture media, 
number of cells plated and protocols may make however and time restraints meant that 
this could not be done within the remit of this thesis.   
 
In order to examine both adherent and non-adherent colonies, one possible protocol 
would be to establish the EGM-2 matrigel cultures, removing the non-adherent cells at 
day 2.   In order to ascertain whether changes to methodology (including media used, 
number of cells initially plated) influences the colonies formed, cultures using the 
different protocols must be grown in parallel and compared.  Phenotypic 
characterization using flow cytometry would be one way of doing this, however 
comparing colony counts between cultures would also be necessary.  While this may be 
318 
 
time consuming, if the end result was a robust assay, which could use a small volume of 
blood (<10mls) to enumerate both the non-adherent colonies which correlate with 
endothelial function and to investigate the interaction of EPC cultures with HUVEC the 
effort would be rewarded.   
 
In conclusion, this chapter has described the different CD34+ subpopulations that may 
constitute a population of cells which are involved in vascular repair.  A number of 
these populations are elevated at disease onset, corresponding with a time when growth 
factors involved in their recruitment are also elevated.  Thus children with vasculitis in 
contrast to adults with the disease may be instigating a reparative response, whether this 
is of functional significance remains unknown and is an avenue of future work. 
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7 Discussion and concluding remarks  
 
7.1.  Discussion 
 
7.2.  Concluding remarks 
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Discussion 
The vasculitides are a rare and heterogeneous group of disorders that are characterized 
by the presence of inflammation in blood vessel walls.  As has been discussed 
previously, robust classification of the vasculitides has proven difficult; to date there are 
no specific diagnostic tests and patients frequently exhibit complex and overlapping 
symptoms.  Consequently the most commonly used classification criteria (CHCC) is 
based on the size of the vessels predominantly affected.  In relation to children however, 
these criteria have now been formally shown to have poor sensitivity and specificity 
(Ozen, Brogan et al, manuscript in preparation 2009), highlighting the need to consider 
children differently to adults.  A number of the vasculitides are also associated with the 
risk of disease recurrence and patients require careful monitoring long term to allow 
detection of flaring disease.   
 
It was with these concepts in mind that this thesis was undertaken, to investigate assays 
which could indicate the presence of active systemic vasculitis irrespective of causal 
pathology and disease classification and would be of relevance in adults, but more 
importantly in children, where small sample volumes are an issue.  Although causal 
pathology remains poorly defined in many conditions, one common downstream 
consequence of inappropriate inflammation within the vasculature, which may be 
relevant to virtually all of the vasculitides, is injury to the endothelium.  This concept 
underlies all of the work described within this thesis.  Moreover, the damaged 
endothelium releases factors into the blood, thus allowing testing in a relatively non 
invasive manner from small volumes of peripheral blood. 
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The first putative biomarkers of disease activity described within this thesis were 
circulating endothelial cells (CECs, Chapter 3).  At the time of establishing the assay it 
was apparent that two techniques were being interchangeably used within the literature 
for enumeration of CECs, namely flow cytometry (FC) and immunomagnetic bead 
extraction (IBE).  It had even been reported that the two techniques gave comparable 
results in adult controls and patients with breast cancer or acute coronary syndromes 
(Goon et al., 2006).  Thus initially both techniques were utilised within the GOSH 
cohort to determine which was the most appropriate method for examining CECs in this 
population (Section 3.5).  In contrast to the study by Goon et al, it was soon apparent 
that IBE and FC did not give comparable results in children with vasculitis, although the 
IBE data obtained was comparable with previous studies in adults with vasculitis which 
had utilized the IBE methodology (Woywodt et al., 2003b).   
 
Subsequently a number of experiments were performed in order to determine why the 
FC protocol, as described by Goon et al, was not appropriate for enumeration of CECs 
in children with vasculitis.  The following conclusions were reached: firstly that size 
matters – whilst Goon et al had gated on a mononuclear cell FSC SSC region, light 
microscopy had indicated that CECs were of comparable sizes to HUVEC and PAEC 
which exhibited a different FSC SSC profile. Thus a much larger gate was necessary to 
include this; secondly, factors that are inherent to FC also limited CEC recovery.  These 
included sensitivity of detection of rare events and the ability of the flow cytometer to 
resolve individual events.  Most importantly it was found that the lysis necessary for 
removal of red cells significantly limited recovery of CECs (Clarke et al., 2008).   
 
The  published findings from this series of experiments have added to what  is  currently 
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an ongoing area of debate within the CEC literature – how best to quantify CECs 
(Shantsila and Lip, 2008).  Currently new methodologies utilizing IBE and automated 
microscopy (Rowand et al., 2007) or IBE enriched FC (Widemann et al., 2008) have 
now been described which may provide a more automated approach to CEC 
enumeration, bringing it closer to clinical utilization.  It is also likely that an approach to 
FC based around previously published protocols for detection of apoptotic and necrotic 
cells may also provide another methodology by which FC could be utilized to detect 
CECs in patients with vasculitis and would be an obvious future direction of this study 
(discussed in Chapter 3).   However, as demonstrated herein any techniques developed 
for CEC enumeration need to be carefully validated in individuals where CECs may be 
fragile in nature.  While data was not presented in this thesis to indicate why CECs may 
be less robust on handling than in other conditions, Woywodt et al had already 
convincingly demonstrated in adults with AAV that 84% of cells obtained from patients 
with active disease stained positive for annexin V/propidium iodide indicating a 
necrotic phenotype (Woywodt et al., 2003b).  Whilst repeating this work in children 
would be an important next step, the limiting blood volumes and rarity of patients meant 
this was not possible during this project.    
 
Despite the methodological controversies IBE enumeration of CECs proved robust in 
this particular cohort (Section 3.7) and demonstrated significantly higher CECs in 
patients with active vasculitis than in all control groups studied (healthy and disease 
control children, and adults) as well as compared to patients in remission.  Of 
considerable interest was the indication that CECs were elevated during active disease 
irrespective of treatment status, declined with remission inducing therapy and were 
highest in individuals with more widespread disease.  CECs also correlated strongly 
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with clinical scores of disease activity but not with inflammatory markers such as ESR 
and CRP (which are influenced by treatment).  Therefore in this context CECs are a 
particularly useful biomarker of disease activity, although the current methodology 
limits use to a research tool. 
 
In a number of individuals, when CECs were enumerated, small ULEX-bright staining 
particles were frequently seen alongside the larger CECs, which could be indicative of 
fragile CECs fragmenting or possibly of endothelial MPs.   Chapter 4 therefore went on 
to describe MPs in the same group of patients.  Because FC was utilized to enumerate 
MPs, several different populations could easily be studied within this project and these 
included MPs of endothelial, platelet, neutrophil, monocyte and lymphocyte origins.  As 
indicated in Chapter 3, FC for rare event analysis requires careful optimization and thus 
this chapter also contained a significant proportion of optimization work, particularly as 
MPs are at the lower limits of detection of the flow cytometer.  A major step in 
optimising the technique was limiting the background noise, which had been shown to 
adversely influence accuracy of detection of latex counting beads and thus presumably 
MPs themselves.  As the MPs of interest were AnV positive it was decided to utilize the 
AnV staining, by using a fluoresence threshold, below which events were not counted, 
thereby removing the majority of electrical noise and any debris in the fluidics, 
increasing the recovery of MP events.  Although this greatly improved sensitivity 
(Figure 4.7), the major downside to this approach was that post-hoc analysis of AnV 
negative populations could not be performed if required at a later date.   
 
The utilization of a threshold to reduce background noise has been widely used by 
Jimenez et al, although not by other groups, which makes comparison with the other 
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studies performed in vasculitis difficult.  Despite this the results obtained were similar 
to other studies.  The previous study from our group indicated higher EMPs (CD105+ 
and E-selectin+) during active disease compared to patients in remission and controls 
(Brogan et al., 2004a).  In the present study CD144+ EMPs were also significantly 
higher in patients with active vasculitis compared to controls and declined when 
individual patients entered remission, although CD105+ EMPs and E-selectin + EMPs 
were not.  Interestingly in this study CD105+ EMPs were significantly higher in 
patients in remission compared to controls.   Although this contrasts with the previous 
study from within our group it could be explained by the higher proportion of KD 
patients within the previously studied cohort - preliminary data indicates that patients 
with acute KD may have higher EMPs than other vasculitis patients (Figure 4.27).   As 
before PMPs were not significantly different between patients and controls, although 
they did correlate inversely with markers of disease activity (white cell count, BVAS, 
ESR and CRP) indicating that PMPs may indeed be lower during active disease.   MPs 
of monocytic origin (CD14+) were also found to be elevated during active disease.   
 
The differences in MP numbers between active disease and remission or the control 
groups were not particularly striking even when significant differences were observed 
and it may be that changes in individual patients provide more informative data than 
broad studies within a heterogenous population.  Whilst MPs may not be as robust a 
biomarker of disease activity as CEC, they may provide more informative data relating 
to cellular activation in individual patients, which could be of particular importance 
when predicting whether a patient is likely to enter disease flare.  Further prospective 
studies in larger cohorts will be required to truly clarify whether MPs could provide a 
way of monitoring patients cellular activation profiles.  
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Another interesting finding in this study (although preliminary) was that in a number of 
individual patients with active disease prior to treatment MPs were low (particularly 
apparent for EMPs and PMPs), suggesting that in active untreated disease there may be 
sequestering of MPs to activated cells within the blood or to the endothelium.  As MPs 
of a number of different phenotypes have been demonstrated to influence cell function 
(discussed in detail in the introduction Chapter 4), in this context they could be 
contributing to the pathogenesis of the disease and thus future studies concurrently 
investigating MP-cell complexes would also be an interesting direction to take this 
study.   
 
Whilst EMPs and CECs reflect the activation and injury of the endothelium, it is 
possible that reparative responses maybe underway in an attempt to repair the damaged 
vessels.  Thus the latter chapters of this thesis focused on possible repair mechanisms, 
firstly by measuring growth factors associated with angiogenesis and vasculogenesis  - 
the signals of repair and secondly by enumerating endothelial progenitor cells, the cells 
believed to play a key role in orchestrating repair.  As a downstream consequence of 
endothelial injury, these could also be utilized as biomarkers of disease activity.  
However as the results from these studies indicate, this highly controversial and 
complex field is likely influenced by treatment and thus although their use as 
biomarkers is limited, the data presented herein raises some interesting questions 
relating to the long term potential for damage repair in vasculitis.  
 
In Chapter 5, the relationship between the growth factors VEGF, Ang-1, Ang-2 and Tβ4 
and disease activity was considered.  Whilst Tβ4 was not significantly different between 
patients and controls, children (controls and patients) had higher levels than adults – a 
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previously unpublished finding, perhaps indicative of ongoing growth.  When patients 
with active disease prior to treatment were considered it was apparent that with the 
exception of Tβ4, growth factors were elevated, when compared to controls and patients 
in remission.  In individual patients, levels declined with treatment, however whether 
this is due to patients being in remission or due to therapy is unclear.  Growth factor 
levels appear to be influenced by treatment and preliminary data demonstrated that 
when patients had an active disease flare while on routine maintenance therapy 
(corticosteroids, with azathioprine) their levels of VEGF, Ang-1 and Ang-2 were lower 
when compared to treatment naive patients (Figure 5.6).  This finding could thus limit 
growth factors usefulness as biomarkers of disease activity and is in contrast to the 
conclusions reached in the recent publication by Kumpers et al, whereby Ang-2 was 
considered to be a good biomarker of disease activity in adults with AAV (Kumpers et 
al., 2009).  However as discussed in Chapter 5, the influence of treatment status was not 
studied in depth as in this study.   
 
Regardless of the usefulness of growth factors as putative biomarkers, these studies 
indicate that angiogenic and vasculogenic pathways are activated in patients with active 
disease and therefore there may be an attempted reparative response occurring.  
Conversely, when one considers the tightly regulated systems that control angiogenesis 
and vasculogenesis, these elevations in several interlinked growth factors (a “growth 
factor storm”) could also be of pathological consequence, propagating further 
dysfunction and injury to the endothelium.  Rather than viewing growth factors as 
targets for influencing repair, their double edged sword action could indeed make them 
novel therapeutic targets.  In this context a recent publication has indicated that PDGF 
receptor inhibition using imatinib (Gleevec
TM
, Novartis) may be effective in inhibiting 
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the cell responses necessary for the development of intimal hyperplasia characteristic of 
giant cell arteritis and TD using an in vitro system.  In vivo data is eagerly awaited 
(Lozano et al., 2008).  While an attractive hypothesis, this avenue of research would 
require extensive in vivo justification before clinical trials could be performed, 
particularly in children.    
 
While Chapter 5 indicated there may indeed be changes in reparative responses, Chapter 
6 went on to investigate the controversial topic of endothelial progenitor cells (EPCs).  
As discussed previously while this cell population has received much interest, as yet 
there is no consensus relating to cell surface marker expression or culture methodology 
for their detection.  As with the other FC techniques described in this thesis, technical 
difficulties associated with rare event analysis had to be considered, as did the gating 
strategy and way of enumerating EPCs.  What was apparent from the data obtained 
however, was that EPCs (defined as cells expressing CD34, CD133 and VEGFR2) and 
“early” progenitor cells not necessarily of endothelial lineage (expressing CD34 and 
CD133) were elevated at disease onset when compared to controls and declined with 
treatment in individual patients.  This is in striking contrast to the data published in 
adults (de Groot et al., 2007), whereby treatment increased EPC number, further 
hilighting the need to consider children as different from adults, particular when 
considering vascular growth and repair.   
 
Whilst EPC number may be elevated, function cannot be determined in FC assays and 
thus the latter part of the chapter described some preliminary data in order to establish 
culture assays.  While time constraints and the low blood volumes available meant that 
patients could not be studied concurrently with the other biomarkers in this thesis, even 
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preliminary data in 2 individuals on maintenance therapy indicated that cultured cell 
growth may be impaired when compared to healthy adults (Figures 6.18 and 6.19).  
Extensive study is required to determine whether EPC function as determined using 
these culture assays is impaired and whether this relates to EPC number.  However this 
is an avenue of ongoing work within the group, which on the basis of the preliminary 
data described in this thesis has now been funded by the Arthritis Research Campaign.   
 
Because of the nature of this study, one recurrent theme throughout related to the 
statistical interpretation of data, particularly when multiple comparisons were performed 
simultaneously.  The purpose of tests such as the Bonferroni is to correct for the 
familywise error that occurs when multiple statistical tests are performed 
simultaneously.  A test is considered significant when the likelyhood of it occurring by 
chance is less than 5%.  Conversely this means that the likelyhood of a rare event 
occurring randomly is thus 5% and therefore when multiple comparisons are performed 
5% of these could be occurring by chance.  Corrections such as the Holm Bonferroni 
have been developed to attempt to correct this.  However there remains much debate to 
the valididity of these rigid statistical tests particularly when relating to heterogenous 
patient populations such as those studied herein.  While interesting observations were 
made relating to the putative biomarkers studied in this project in order to clarify 
whether these are in fact truly significant effects rather than false positives resulting 
from multiple comparisons further study in more patients of those interesting 
observations is required.  This is work is ongoing within the group. 
  
The term biomarker was defined as an objectively measured characteristic which could 
be utilized as a clinical outcome or endpoint in trials.  Currently clinical outcomes 
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which can be utilized in clinical trials of vasculitis are limited and include parameters 
such as mortality, although in the short term and in children particularly this is not a 
useful outcome as it is so low.  In the three years of this study only one individual died, 
this individual had had preexisting TD for several years prior to enrolling in the study 
and at the time of study was considered to have inactive vasculitis, being well into the 
late “fibrotic” phase of this disease.   
 
Thus biomarkers such as those described herein must be utilized in the future to allow 
more realistic clinical endpoints in trials.  Alongside blood biomarkers, other possible 
endpoints could include more longterm responses to disease such as the assessment of 
structural changes in arteries and overall vascular function, using non invasive 
techniques such as assessment of flow mediated dilatation, pulse wave velocity or 
intima media thickness.  These changes ultimately would reflect the balance between 
extent of injury and the ability to repair and may not be as influenced by treatment as 
some of the rapidly changing blood biomarkers described herein.  Assessment of 
structure and function is an ongoing avenue of work within the group.   
 
Concluding remarks 
This study has been underlined by the common pathology of all the vasculitiides – 
endothelial injury.  By focusing on this pivotal consequence of innappropriate and 
sustained inflammation in the vessel wall, a number of putative biomarkers which have 
potential to be utilised clinically to assess disease activity, (particularly that which may 
not have overt clinical symptoms) have been assessed.  Of those studied CECs have 
proven the most robust to date, however methodological limitations restrict their use 
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clinically to a research tool.  During this study it also became apparent that children may 
have differences relating to vasculogenic responses when compared to adults and that 
therapy necessary to promote disease remission may be influencing pathways involved 
in reparitive responses and thus could impact on the long term health of the vasculature.  
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Appendix 1 - Classification and definitions of Vasculitis  
Chapel Hill Consensus Criteria  (Jennette et al., 1994) 
Large vessel vasculitis 
 
Giant cell 
(temporal) arteritis  
 
Granulomatous arteritis of the aorta and its major branches, with a 
predilection for the extracranial branches of the carotid artery. Often involves 
the temporal artery. Usually occurs in patients older than 50 and often is 
associated with polymyalgia rheumatica.  
 
Takayasu arteritis  
 
Granulomatous inflammation of the aorta and its major branches. Usually 
occurs in patients younger than 50.  
 
Medium-sized vessel vasculitis 
 
Polyarteritis 
nodosa (classic 
PAN)  
 
Necrotizing inflammation of medium-sized or small arteries without 
glomerulonephritis or vasculitis in arterioles, capillaries, or venules. 
 
Kawasaki disease  
 
Arteritis involving large, medium-sized, and small arteries, and associated 
with muco-cutaneous lymph node syndrome. Coronary arteries are often 
involved. Aorta and veins may be involved. Usually occurs in children.  
Small vessel vasculitis 
 
Wegener’s 
granulomatosis  
 
Granulomatous inflammation involving the respiratory tract, and necrotizing 
vasculitis affecting small to medium-sized vessels (e.g., capillaries, venules, 
arterioles, and arteries). Necrotizing glomerulonephritis is common.  
 
Churg-Strauss 
syndrome  
 
Eosinophil-rich and granulomatous inflammation involving the respiratory 
tract, and necrotizing vasculitis affecting small to medium-sized vessels, and 
associated with asthma and eosinophilia.  
 
Microscopic 
polyangiitis 
(microscopic 
polyarteritis) 
 
Necrotizing vasculitis, with few or no immune deposits, affecting small 
vessels (i.e., capillaries, venules, or arterioles). Necrotizing arteritis involving 
small and medium- sized arteries may be present. Necrotizing 
glomerulonephritis is very common. Pulmonary capillaritis often occurs.  
 
Henoch-Schönlein 
purpura  
 
Vasculitis, with IgA-dominant immune deposits, affecting small vessels (i.e., 
capillaries, venules, or arterioles). Typically involves skin, gut, and glomeruli, 
and is associated with arthralgias or arthritis.  
 
Essential 
cryoglobulinemic 
vasculitis  
 
Vasculitis, with cryoglobulin immune deposits, affecting small vessels (i.e., 
capillaries, venules, or arterioles), and associated with cryoglobulins in serum. 
Skin and glomeruli are often involved.  
 
Cutaneous 
leukocytoclastic 
angiitis  
 
Isolated cutaneous leukocytoclastic angiitis without systemic vasculitis or 
glomerulonephritis.  
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American College of Rheumatology (ACR) Criteria, 1990  
Polyarteritis nodosa  
(Lightfoot, Jr. et al., 1990) modified for children (Brogan et al., 2002). The presence of 3 
or more of the criteria defines a patient as having PAN. Arteriography or biopsy are mandatory 
criteria 
 Weight loss of 5% or more (not due to diet or other factors) or failure to thrive 
 Livedo reticularis 
 Testicular pain or tenderness 
 Myalgias, weakness, or leg tenderness 
 Mononeuropathy or polyneuropathy 
 Systemic hypertension 
 Elevated blood urea nitrogen or creatinine 
 Hepatitis B virus -  presence of hepatitis B surface antigen or antibody in serum 
 Arteriographic abnormality -  aneurysms or occlusions of the visceral arteries, 
not caused by arteriosclerosis, fibromuscular dysplasia, or other non-
inflammatory causes 
 Biopsy of small- or medium-sized artery containing granulocytes/mononuclear 
leukocytes in vessel wall 
 
Wegener’s Granulomatosis   (Leavitt et al., 1990) 
Diagnosis requires the presence of two of the four criteria. The presence of any two or more 
criteria has a sensitivity of 88.2% and a specificity of 92.0%.  
 Nasal or oral inflammation – ulcers, nasal discharge 
 Abnormal-appearing chest radiograph  - Nodules, fixed infiltrates or cavities 
 Abnormal urinary sediment -  Microhematuria (>5 RBC/hpf) or RBC casts 
(RBC- red blood cell) 
 Granulomatous inflammation within artery wall 
 
Takayasu’s disease  (Arend et al., 1990) 
The presence of 3 or more of these 6 criteria gives a sensitivity of 90.5% and a 
specificity of 97.8%. 
 Onset at less than 40 years of age 
 Claudication of an extremity 
 Decreased brachial artery pulse 
 > 10mm Hg difference in blood pressure between arms 
 A bruit over the subclavian arteries or the aorta  
 Arteriographic evidence of narrowing or occlusion of the entire aorta, its 
primary branches, or large arteries in the proximal upper or lower extremities 
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Hypersensitivity vasculitis   (Calabrese et al., 1990) 
For classification, hypersensitivity vasculitis is defined if at least three of these criteria 
are present. The presence of any three or more criteria yields a sensitivity of 71.0% and 
specificity of 83.9%.  
 Age at onset >16 yr  (not relevant for children) 
 Medication at disease onset (agents that may have been factor in disease 
development) 
 Palpable purpura – elevated rash over one of more areas of skin – does not 
blanch with pressure 
 Maculopapular rash – flat raised lesions 
 Biopsy (including arteriole and venule) - showing granulocytes in perivascular 
of extravascular location 
 
Henoch-Schönlein purpura  (Mills et al., 1990) 
For classification, Henöch- Schonlein purpura is defined  if at least two of these criteria 
are present. The presence of any two or more criteria yields a sensitivity of 87.1% and 
specificity of 87.7%.  
 Palpable purpura 
 Age </=20 yr at onset 
 Bowel angina - diffuse abdominal pain, worse after meals, or the diagnosis of 
bowel ischemia, usually including bloody diarrhoea 
 Wall granulocytes on biopsy 
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EULAR/PReS endorsed consensus criteria for the classification 
of childhood vasculitides (Ozen et al., 2006) 
 
Predominantly large vessel vasculitis 
Takayasu arteritis 
Predominantly medium sized vessel vasculitis 
 
Childhood polyarteritis nodosa 
Cutaneous polyarteritis 
Kawasaki disease 
Predominantly small vessel vasculitis 
 
Granulomatous 
 
 
Wegener’s granulomatosis 
 Churg-Strauss syndrome 
 
Non-Granulomatous 
 
Microscopic polyangiitis 
Henoch-Schönlein purpura  
Isolated cutaneous leucocytoclastic 
vasculitis 
Hypocomplementic urticarial vasculitis 
 
Other vasculitides 
 
Behçet disease 
Vasculitis secondary to infection (including hepatitis B associatedpolyarteritis nodosa), 
malignancies, and drugs, including hypersensitivity vasculitis 
Vasculitis associated with connective tissue diseases 
 Isolated vasculitis of the central nervous system 
Cogan syndrome 
Unclassified 
 
 
Classification criteria:  
 
Henoch-Schönlein purpura 
 
Palpable purpura (mandatory criterion) in the presence of at least one of the following four 
features: 
 Diffuse abdominal pain 
 Any biopsy showing predominant IgA deposition 
 Arthritis (acute any joint) or arthralgia 
 Renal involvement (any haematuria and/or proteinuria) 
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Kawasaki disease 
Fever persisting for at least five days (mandatory criterion) plus four of thefollowing five 
features: 
 Changes in peripheral extremities or perineal area 
 Polymorphous exanthema 
 Bilateral conjunctival injection 
 Changes of lips and oral cavity: injection of oral and pharyngeal mucosa 
 Cervical lymphadenopathy 
In the presence of coronary artery involvement (detected on echocardiography) and fever, fewer 
than four of the remaining five criteria are sufficient (the exact number of criteria 
 
Polyarteritis nodosa 
A systemic illness characterised by the presence of either a biopsy showing small and mid-size 
artery necrotising vasculitis OR angiographic abnormalities* (aneurysms or occlusions) 
(mandatory criteria), plus at least two of the following: 
 Skin involvement (livedo reticularis, tender subcutaneous nodules,other vasculitic 
lesions) 
 Myalgia or muscle tenderness 
 Systemic hypertension, relative to childhood normative data 
 Mononeuropathy or polyneuropathy 
 Abnormal urine analysis and/or impaired renal function (Glomerular filtration rate of 
less than 50% normal for age) 
 Testicular pain or tenderness 
 Signs or symptoms suggesting vasculitis of any other major organ system 
(gastrointestinal, cardiac, pulmonary, or central nervous system) 
*Should include conventional angiography if magnetic resonance angiography is negative. 
 
Wegener’s granulomatosis 
Three of the following six features should be present: 
 Abnormal urinalysis* (Haematuria and/or significant proteinuria.) 
 Granulomatous inflammation on biopsy_ 
 Nasal sinus inflammation 
 Subglottic, tracheal, or endobronchial stenosis 
 Abnormal chest x ray or CT 
 PR3 ANCA or C-ANCA staining 
*If a kidney biopsy is done it characteristically shows necrotising pauciimmune 
glomerulonephritis. 
 
Takayasu’s arteritis 
Angiographic abnormalities (conventional, CT, or MR) of the aorta or its main branches 
(mandatory criterion), plus at least one of the following four features: 
 Decreased peripheral artery pulse(s) and/or claudication of extremities 
 Blood pressure difference >10 mm Hg 
 Bruits over aorta and/or its major branches 
 Hypertension (related to childhood normative data) 
 CT, computed tomography; MR, magnetic resonance.
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Appendix 2 - The Birmingham Vasculitis Activity Score 
(Luqmani et al., 1994) 
Tick box only if abnormality is newly present or worsening within the previous 4 weeks 
and ascribable to vasculitis (changes from adult BVAS are in bold)  
 
1. SYSTEMIC      3 (maximum total)  
none       0 
malaise      1 
myalgia       1 
arthralgia/arthritis     1 
fever (<38.5°C)     1  
fever (>38.5°C)     2  
wt loss (1-2 kg) within past month  2  
wt loss (>2 kg) within past month   3  
 
2. CUTANEOUS     6 (maximum total)  
none      0  
infarct      2  
purpura       2 
other skin vasculitis     2 
ulcer       4 
gangrene      6 
multiple digit gangrene     6 
 
3. MUCOUS MEMBRANES/EYES   6 (maximum total)  
none       0 
mouth ulcers      1 
genital ulcers     1  
conjunctivitis      1 
episcleritis      2 
uveitis       6 
retinal exudates     6  
retinal haemorrhage     6 
 
 
4. ENT       6 (maximum total)  
nil       0 
nasal discharge/obstruction    2 
sinusitis      2 
epistaxis      4 
crusting       4 
aural discharge     4 
otitis media      4 
new deafness      6 
hoarseness/laryngitis     2 
subglottic involvement     6 
 
5. CHEST      6 (maximum total)  
none      0  
dyspnoea or wheeze     2 
nodules or fibrosis     2 
pleural effusion/pleurisy     4 
infiltrate      4 
haemoptysis/haemorrhage    4 
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massive haemoptysis     6 
 
6. CARDIOVASCULAR    6 (maximum total) 
none       0 
bruits       2 
new loss of pulses     4 
aortic incompetence     4 
pericarditis      4 
new coronary artery lesions   4 
new myocardial infarct     6 
CCF/cardiomyopathy     6 
 
7. ABDOMINAL     9 (maximum total) 
none      0  
abdominal pain      3 
bloody diarrhoea      6 
gall bladder perforation     9 
gut infarction      9 
pancreatitis     9 
 
8. RENAL      12 (maximum total)  
none      0  
hypertension (systolic >95
th
 centile)   4 
proteinuria (>1 + or >20mmol/mg)   4 
haematuria (> 1 + or >10 rbc/ml)     8 
cGFR 50-80 mls/min/1.73m2   8 
cGFR 15-49 mls/min/1.73m2   10 
cGFR <15 mls/min/1.73m2     12 
rise in creatinine >10%     12 
 
9. NERVOUS SYSTEM    9 (maximum total) 
none      0         
organic confusion/dementia   3  
seizures (not hypertensive)   9  
stroke      9  
cord lesion      9      
peripheral neuropathy     6 
motor mononeuritis multiplex    9 
 
MAXIMUM SCORE    63 
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Appendix 3 – Flow cytometry plans 
Microparticles tube plan 
 
22 tube plan – samples >200ul 
1. Unstained MPs 
2. AnV (beads) 
3. AnV + IgG PE (BD) 
4. AnV + IgG PE (Serotec) 
5. AnV + IgG PE (ebiosciences) 
6. AnV + IgG PE (Biolegend) 
7. AnV + IgG CY5 (BD) 
8. AnV + IgG PerCP (BD) 
9. AnV + E-selectin PE (BD) 
10. AnV + P-selectin PE (BD) 
11. AnV + CD15 PE (Biolegend) 
12. AnV + CD144 PE (BD) 
13. AnV + CD105 PE (BD) 
14. AnV + CD66b PE (BD) 
15. AnV + CD42a PerCP (BD) 
16. AnV + ICAM-1 CY5 (BD) 
17. AnV + CD11b CY5 (BD) 
18. AnV + L-selectin PE (BD) 
19. AnV + TF PE (BD) 
20. AnV + CD14 PE (BD) 
21. AnV + CD3 CY5 PE (BD) 
22. AnV (beads) 
12 tube plan – samples 
<200ul 
1. Unstained MPs 
2. AnV (beads) 
3. AnV + IgG PE (BD) 
4. AnV + IgG PE (Serotec) 
5. AnV + IgG PE (ebiosciences) 
6. AnV + IgG PerCP (BD) 
7. AnV + E-selectin PE (BD) 
8. AnV + CD144 PE (BD) 
9. AnV + CD105 PE (BD) 
10. AnV + CD42a PerCP (BD) 
11. AnV + CD14 PE (BD) 
12. AnV (beads) 
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EPC tube plan for frozen PBMCs 
23 tube plan 
1. Unstained PBMCs 
2. VEGFR2 isotype control 
3. VEGFR2 
4. CD144 isotype controls 
5. CD144 
6. CD45 isotype control 
7. CD45 
8. CD14 isotype contro*l 
9. CD14* 
10. CD133 PE control 
11. CD133 
12. CD146 PE control 
13. CD146 
14. CD34 controls 
15. CD34  
16. CD3 control* 
17. CD3* 
18. VEGFR2/CD133/CD34 
19. CD144/CD133/CD34 
20. CD14/CD133/CD34* 
21. CD144/CD146/CD34* 
22. CD45/CD146/CD34 
23. CD45/CD146/CD3*
12 tube plan  
1. Unstained PBMCs 
2. VEGFR2 isotype control 
3. VEGFR2 
4. CD144 isotype controls 
5. CD144 
6. CD133 PE control 
7. CD133 
8. CD34 controls 
9. CD34  
10. VEGFR2/CD133/CD34 
11. CD144/CD133/CD34 
 
 
 
The 23 tube plan was used when samples have large numbers of PBMCs 
The 16 tube plan (same as the 23 plan, excluding tubes with *) was used for samples 
with between 5x10
6
 and 10x10
6
 frozen PBMCs  
The 11 well tube plan was used for samples with less than 5x10
6
 frozen PBMCs 
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Appendix 4 – MP generation  
MPs were generated from paternt cells as described in section 4.3.2. 
 
Neutrophil MP generation – activation of parent cells 
 
341 
 
Neutrophil MP generation – phenotype of MPs 
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MPs generated from TNFα stimulated PBMCS - 
phenotype
 
Nb. PBMC samples isolated were lymphoprep often had platelet contamination, hence 
the high CD42a and P-selectin expression in this individual.  
343 
 
MPs generated from TNFα stimulated endothelial cells -
activation of parent cells 
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MPs generated from TNFα stimulated endothelial cells 
– phenotype 
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Appendix 5 –  Standard graphs for ELISAs 
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Appendix 6 – Changes in CECs and MPs with disease 
activity in individual patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 1 – A 13 year old male with PAN, patient was not treatment naïve at onset of 
study and was followed from a flare (t=0). 
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Patient 2 – A 9 year old male with systemic vasculitis and colitis.  Patient was treatment 
naïve at onset of study. 
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Patient 3 – A 10 year old male with PAN, patient was treatment naïve at start of study, 
at first presentation of disease. Notably this individual entered a period of disease flare 
at 23 months from disease onset. 
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Patient 4 - A 12 year old female with ANCA+ WG, this patient was treatment naïve at 
onset of study at disease presentation. Changes in this individual relating to CECs and 
MPS were highlighted in Figures 3.19 and 4.24.  Notably this individual entered a 
period of systemic flare 12 months into their disease. 
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Patient 5 - An 11 year old female with WG. This patient was treatment naïve at onset of 
study at disease presentation. Changes in this individuals CECs and MPs were 
highlighted in figures 3.20 and 4.25.  Notably this patient had an episode of localized 
granulomatous flare 28 months into their disease (orbital). 
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Patient 6 – A 2 year old female with PAN who suffered a stroke at disease onset. Patient 
was treatment naïve at onset of study at presentation of disease. 
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Patient 7 -  A 6 year old male with PAN, this patient was treatment naïve at onset of 
study at disease presentation.   
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Patient 8 – A 15 year old male with WG, patient was treatment naïve at onset of study.  
15 months into treatment patient exhibited localized nasal symptoms.  By 19 months 
symptoms were more systemic, although CECs remained low. 
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Patient 9 – a 6 year old female with PAN. Patient was treatment naïve at onset of study 
at disease onset. 
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Patient 10 – a 1 year old female with PAN.  Patient was treatment naïve  at onset of 
study at disease onset. 
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Patient 11 – a 10 year female with PAN, presented with gastrointestinal inflammation. 
Patient was undergoing immunosuppression for this at onset of study. 
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Patient 12 – a 14 year old female with WG. Treatment had been instigated prior to 
study, although patient was observed at first presentation of disease. 
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Patient 13 -  a 12 year old male with PAN, patient was followed from a disease flare. 
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